

Standards for Oncology Registry Entry

STandards for Oncology Registry Entry STORE 2026

Effective for Cases Diagnosed
January 1, 2026

Posted 12/15/2025

Cancer
PROGRAMS

QUALITY PROGRAMS
of the AMERICAN COLLEGE
OF SURGEONS



AMERICAN COLLEGE OF SURGEONS
*Inspiring Quality
Highest Standards. Better Outcomes.*

STORE

STandards for **O**ncology **R**egistry **E**ntry

Effective for cases diagnosed January 1, 2026



© 2025 AMERICAN
COLLEGE OF SURGEONS
All Rights Reserved

[Table of Contents for NH-specific data items available here](#)

Table of Contents

STORE 2026 Summary of Changes	1
2026 Source References	9
Section One: Case Eligibility and Overview of Coding Principles	10
Case Eligibility	11
Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Database (NCDB)	11
Reportable-by-Agreement Cases	12
Ambiguous Terms at Diagnosis	12
Ambiguous Terminology Lists: References of Last Resort	13
Class of Case	14
Analytic Cases	14
Nonanalytic Cases	14
Date of First Contact	14
Overview of Coding Principles	16
Unique Patient Identifier Codes	16
National Provider Identifier	16
Coding Dates	16
Cancer Identification	17
Primary Site	17
Occult Cervical Lymph Node	17
Cutaneous Carcinoma of the Head and Neck	18
Hematopoietic and Lymphoid Cancers	18
Kaposi Sarcoma	18
Melanoma	18
Specific Tissues with Ill-Defined Sites	18
Patient Address and Residency Rules	19
Rules for Persons with Ambiguous Residences	19
Coding Country and State	20
In Utero Diagnosis and Treatment	20
Secondary Diagnoses	21
Stage of Disease at Initial Diagnosis	21
AJCC Prognostic Staging	21
First Course of Treatment	22

Treatment Plan	22
Time Periods for First Course of Treatment	23
All Malignancies except Leukemias	23
Leukemias	23
Surgery	23
Relationships among Surgical Items	24
Radiation Therapy	26
Radiation Treatment Phase-specific Data Items.....	27
Relationships among Radiation Items	27
Systemic Therapy	28
Relationships Among Systemic Therapy Items	30
Other Treatment	30
Palliative Care.....	31
Treatment, Palliative, and Prophylactic Care.....	31
Embolization	32
Outcomes	32
Follow-up items that are required to be in the facility's database	32
Recurrence Definition	33
Case Administration.....	33
Administrative Tracking	34
EDITS Overrides.....	34
Code Versions Used	34
Section Two: Instructions for Coding.....	36
Patient Identification	37
Accession Number[550]	38
Sequence Number[560]	39
Name—Last[2230]	41
Name--Birth Surname[2232].....	42
Name – First[2240]	43
Name—Middle[2250]	44
Name—Alias[2280]	45
City/Town at Diagnosis (City or Town)[70]	46
State at Diagnosis (State)[80]	47
Postal Code at Diagnosis (Zip Code)[100]	49
Address at Dx—Country[102]	50

County at Diagnosis[90]	51
Birthplace—State[252]	52
Birthplace—Country[254]	53
Date of Birth[240]	54
Age at Diagnosis[230]	55
Race 1[160]	56
Spanish Origin—All Sources (Spanish/Hispanic Origin)[190]	58
Sex Assigned at Birth[225]	59
Primary Payer at Diagnosis[630]	60
Tobacco Use Status[344]	63
Secondary Diagnosis #1[3780]	64
Secondary Diagnosis #2-10[3782-3798]	66
NPI—Primary Surgeon[2485]	67
NPI—Physician #3 (Radiation Oncologist—CoC Preferred)[2495]	68
NPI—Physician #4 (Medical Oncologist—CoC Preferred)[2505]	69
Cancer Identification	70
Class of Case[610]	71
NPI—Institution Referred From[2415]	75
NPI—Institution Referred To[2425]	76
Date of First Contact[580]	77
Date of Initial Diagnosis[390]	79
Primary Site[400]	81
Method of Detection -Breast[10110]	83
Laterality[410]	85
Histology[522]	87
Behavior Code[523]	88
Grade Clinical[3843]	90
Grade Pathological[3844]	91
Diagnostic Confirmation[490]	92
Stage of Disease at Diagnosis	96
Date of Surgical Diagnostic and Staging Procedure[1280]	97
Surgical Diagnostic and Staging Procedure[1350]	98
Surgical Diagnostic and Staging Procedure at This Facility[740]	100
Lymphovascular Invasion[1182]	102
Macroscopic Evaluation of the Mesorectum[3950]	108

Sentinel and Regional Lymph Nodes	109
Date of Sentinel Lymph Node Biopsy[832]	110
Sentinel Lymph Nodes Examined[834]	111
Sentinel Lymph Nodes Positive[835]	113
Date Regional Lymph Node Dissection[682]	115
Regional Lymph Nodes Examined[830]	116
Regional Lymph Nodes Positive[820]	118
Tumor Size and Mets	120
Tumor Size Summary[756].....	121
Mets at Diagnosis – Bone[1112]	125
Mets at Diagnosis – Brain[1113]	127
Mets at Diagnosis – Distant Lymph Nodes[1114]	129
Mets at Diagnosis – Liver[1115].....	131
Mets at Diagnosis – Lung[1116].....	133
Mets at Diagnosis – Other[1117]	135
AJCC TNM Stage, Current Edition	137
AJCC TNM Clin T[1001]	138
AJCC TNM Clin T Suffix[1031].....	139
AJCC TNM Clin N[1002]	140
AJCC TNM Clin N Suffix[1034]	141
AJCC TNM Clin M[1003]	142
AJCC TNM Clin Stage Group[1004]	143
AJCC TNM Post Therapy Clin (yc) T[1062].....	144
AJCC TNM Post Therapy Clin (yc) T Suffix[1063].....	145
AJCC TNM Post Therapy Clin (yc) N[1064]	146
AJCC TNM Post Therapy Clin (yc) N Suffix[1065]	147
AJCC TNM Post Therapy Clin (yc) M[1066]	148
Grade Post Therapy Clin (yc)[1068]	149
AJCC TNM Path T[1011]	150
AJCC TNM Path T Suffix[1032]	151
AJCC TNM Path N[1012]	152
AJCC TNM Path N Suffix[1035].....	153
AJCC TNM Path M[1013].....	154
AJCC TNM Path Stage Group[1014]	155
AJCC TNM Post Therapy Path (yp) T[1021].....	156

AJCC TNM Post Therapy Path (yp) T Suffix[1033]	157
AJCC TNM Post Therapy Path (yp) N[1022]	158
AJCC TNM Post Therapy Path (yp) N Suffix[1036]	159
AJCC TNM Post Therapy Path (yp) M[1023]	160
AJCC TNM Post Therapy Path (yp) Stage Group[1024].....	161
Grade Post Therapy Path (yp)[3845]	162
Site-Specific Data Items	163
First Course of Treatment	165
Date of First Course of Treatment[1270].....	166
Rx Summ – Treatment Status[1285].....	167
Surgery Data Items.....	169
Date of First Surgical Procedure[1200].....	170
Date of Most Definitive Surgical Resection of the Primary Site[3170].....	171
Rx Hosp-- Surg 2023[671]	172
Rx Summ—Surg 2023[1291]	174
Rx Hosp—Recon Breast[751]	176
Rx Summ—Recon Breast[1335]	178
Approach -Surgery of the Primary Site at this Facility(RxHospSurgApp2010)[668]	180
Surgical Margins of the Primary Site[1320]	182
Scope of Regional Lymph Node Surgery[1292]	184
Scope of Regional Lymph Node Surgery at this Facility[672]	190
Surgical Procedure/Other Site[1294].....	195
Surgical Procedure/Other Site at this Facility[674].....	197
Date of Surgical Discharge[3180].....	199
Readmission to the Same Hospital within 30 Days of Surgical Discharge[3190].....	200
Reason for No Surgery of Primary Site[1340]	202
Radiation Data Items.....	204
Date Radiation Started[1210]	205
Location of Radiation Treatment[1550]	206
Phase I-II-III Radiation Primary Treatment Volume[1504, 1514, 1524].....	208
Phase I-II-III Radiation to Draining Lymph Nodes[1505, 1515, 1525].....	214
Phase I-II-III Radiation Treatment Modality[1506, 1516, 1526]	216
Phase I-II-III External Beam Radiation Planning Technique[1502, 1512, 1522].....	218
Phase I-II-III Dose per Fraction[1501, 1511, 1521]	222
Phase I-II-III Number of Fractions[1503, 1513, 1523].....	224

Phase I-II-III Total Dose[1507, 1517, 1527]	226
Number of Phases of Radiation Treatment[1532]	228
Radiation Treatment Discontinued Early[1531]	229
Radiation Course Total Dose[1533]	231
Radiation/Surgery Sequence[1380]	233
Date Radiation Ended[3220]	235
Reason for No Radiation[1430]	236
Systemic Therapy Data Items.....	238
Date Systemic Therapy Started[3230]	239
Chemotherapy	240
Date Chemotherapy Started[1220]	241
Chemotherapy[1390]	242
Chemotherapy at this Facility[700].....	245
Hormone Therapy	247
Date Hormone Therapy Started[1230]	248
Hormone Therapy (Hormone/Steroid Therapy)[1400]	249
Hormone Therapy at this Facility (Hormone/Steroid Therapy)[710]	251
Immunotherapy	253
Date Immunotherapy Started[1240]	254
Immunotherapy[1410]	255
Immunotherapy at this Facility[720]	257
Hematologic Transplant and Endocrine Procedures[3250]	259
Systemic/Surgery Sequence[1639]	261
Other Treatment	263
Date Other Treatment Started[1250]	264
Other Treatment[1420]	265
Other Treatment at this Facility[730]	267
Palliative Care (Palliative Procedure)[3270]	269
Palliative Care at this Facility (Palliative Procedure at this Facility)[3280]	271
Outcomes.....	272
Date of First Recurrence[1860]	273
Type of First Recurrence[1880]	274
Date of Last Cancer (tumor) Status[1772]	277
Cancer Status[1770]	278
Date of Last Contact or Death[1750]	280

Vital Status[1760].....	281
Follow-Up Source[1790]	282
Next Follow-Up Source (Next Follow-Up Method)[1800]	283
Case Administration.....	284
Abstracted By[570]	285
Facility Identification Number (FIN)[540]	286
NPI–Reporting Facility[545]	287
Archive FIN[3100]	288
NPI–Archive FIN[3105]	289
Date Case Completed – CoC[2092]	290
Override Site/TNM-Stage Group[1989]	291
Override Site/Type[2030]	292
TNM Edition Number[1060]	293
APPENDIX A: Current Site-Specific Surgery Codes for 2024+	294
Oral Cavity.....	295
Parotid and Other Unspecified Glands	296
Pharynx	297
Esophagus	298
Stomach	299
Colon	301
Rectosigmoid.....	303
Rectum	304
Anus	305
Liver and Intrahepatic Bile Ducts	306
Pancreas.....	307
Larynx.....	308
Lung.....	309
Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease	310
Bones, Joints, and Articular Cartilage	311
Peripheral Nerves and Autonomic Nervous System.....	311
Connective, Subcutaneous, and Other Soft Tissues	311
Spleen.....	312
Skin.....	313
Breast	314
Cervix Uteri	316

Corpus Uteri	318
Ovary	320
Prostate.....	321
Testis	322
Kidney, Renal Pelvis, and Ureter.....	323
Bladder	324
Brain	326
Thyroid Gland.....	327
Lymph Nodes	328
All Other Sites	329
Unknown and Ill-Defined Primary Sites	330
APPENDIX B: ICD-O-3 Eligibility Reporting Table for diagnosis year 2026+	331
APPENDIX C: Country and State Codes	340
APPENDIX M: Case Studies for Coding Melanoma in STORE	352
Introduction	353
Case Studies: 1 Punch Biopsy Followed by WLE with SLN Biopsy and LN Dissection Performed on the Same Day	354
2 Shave Biopsy followed by WLE	355
3 Elliptical Biopsy Followed by WLE with SLN Biopsy and Lymph Node Dissection Performed on the Same Day.....	356
4 Case Study Slow Mohs	357
5 Core Biopsy followed by WLE with SLN Biopsy	358
6 Biopsy followed by MOHs followed by WLE with SLN Biopsy	359
7 Excisional Biopsy followed by WLE, SLN and LAD performed on different days	360
8 Excisional Biopsy Followed by WLE with SLN Biopsy	361
Appendix M Summary of Coding Rules.....	362
APPENDIX R: CTR Guide to Coding Radiation Therapy Treatment in the STORE.....	363
Introduction	366
Case Studies:	370
1 No Radiation Therapy	370
2 Radiation Given – Details Unknown.....	371
3 Bladder Cancer – Patient Takes a Flyer.....	372
4 Single Target Volume – Single Phase	373
5 Thyroid Cancer Treated with Radioiodine	374
6 Prostate Cancer, Boost First, Elsewhere	375
7 Breast and Regional Nodes with Breast and Axillary Boost.....	376
8 Prostate Cancer: Concurrent Prostate and SV Boost.....	377

9 Multiple Metastatic Sites Treated Concurrently.....	378
10 Lung: How Many Phases?	379
11 Prophylactic Cranial Irradiation (PCI): How Many Phases?	380
12 Total Body Irradiation for Transplant.....	381
13 Head and Neck: Simultaneous Integrated Boost (SIB).....	382
14 Lung: Off-line Adaptive Re-plan	383
15 Bladder: On-line Adaptive Therapy with an MR-Linac.....	385
16 Gyn-Brachytherapy + External Beam Radiotherapy (EBRT).....	386
17 Multiple Brain Mets: Treated with Gamma Knife	387
18 Prostate and Rectal: Treated with One Plan.....	388
19 Unknown Primary, Head and Neck: with Simultaneous Integrated Boost	390
20 Head and Neck: Unknown Primary with Staged Boost.....	391
21 Breast: Simultaneous Integrated Boost (SIB).....	392
22 Prostate and Seminal Vesicles with IMRT	393
23 Cervical Cancer: HDR Brachytherapy with Variable Dose per Fraction	394
24 Pelvis, Prostate and Seminal Vesicles with VMAT	395
25 Breast: Treatment Interrupted – Big Time.....	396
26 Prostate: VMAT to Pelvis with SBRT Boost	397
27 Lung: Brain and Bone Metastases.....	398
28 Breast: Lumpectomy, External Beam, Accuboot™	399
STORE Radiation Data Field Items	401
Phase Fields.....	402
Coding Modality for the Heavy Equipment of Modern Radiation Therapy.....	403
Radiation Therapy Useful Abbreviations	404
Summary of Radiation Coding Rules.....	406

Table of Contents

(For NHSCR-required data items NOT included in *STORE 2026*)

Foreword from NHSCR.....	ii
NHSCR Preface 2026.....	iii-a
Introduction.....	iii-a
NHSCR Data Collection Manual and STORE.....	iii-a
Reportable Cases.....	iii-b
Casefinding.....	iii-b
Data Collection.....	iii-b
Data Transmissions.....	iii-c
2026 Changes.....	iii-c

SECTION TWO: Coding Instructions

Patient Identification

Medical Record Number.....	40a
Social Security Number.....	40b
Name--Prefix.....	45a
Name--Suffix.....	45a
Patient Address (Number and Street) at Diagnosis.....	45b
Patient Address at Diagnosis—Supplemental.....	45c
Race 2, 3, 4, 5.....	57a
Marital Status at DX.....	59a
Height at DX.....	62a
Weight at DX.....	62b
Text--Usual Occupation.....	63a
Text--Usual Industry.....	63b
NPI--Physician--Managing.....	66a
NPI--Physician--Following.....	66b

Cancer Identification

Type of Reporting Source.....	70a
Casefinding Source.....	70b
Text--Place of Diagnosis	78a
Text--Primary Site Title.....	86a
Text--Histology Title.....	87a

Cancer Identification, cont.

Text--DX Proc--PE.....	95a
Text--DX Proc--Lab Tests.....	95c
Text--DX Proc--Path.....	95e
Text--Remarks.....	95g

Stage of Disease at Diagnosis

Summary Stage 2018.....	136a
Text--Staging.....	162a
Text--DX Proc--X-ray/Scan.....	164a
Text--DX Proc--Op.....	164c
Text--DX Proc--Scopes.....	164e

First Course of Treatment

RX Text--Surgery.....	203a
RX Text Radiation (Beam).....	237a
RX Text Radiation Other.....	237c
RX Text--Chemo.....	246a
RX Text--Hormone.....	252a
RX Text--BRM.....	258a
RX Text--Other.....	268a
Neoadjuvant Therapy.....	268c
Neoadjuvant Therapy--Clinical Response.....	268d
Neoadjuvant Therapy--Treatment Effect.....	268e

Outcomes

Cause of Death.....	281a
Place of Death--State.....	281b
Place of Death--Country.....	281c

Case Administration

Override Age/Site/Morph.....	291a
Override Surg/DXConf.....	291b
Override Histology.....	292a
Override Leuk, Lymphoma.....	292d
Override Site/Behavior.....	292e
Override Site/Lat/Morph.....	292g

APPENDIX D: New Hampshire Town/County & Zip Codes

APPENDIX E: NHSCR Supplement to STORE 2026

APPENDIX F: New Hampshire Rules & Regulations

APPENDIX G: NHSCR Non-Analytic Tracking Form

APPENDIX H: Casefinding Lists

APPENDIX I: Table of Required Data Items

Foreword

NHSCR Data Collection Manual

In an ongoing effort to facilitate the data collection of cancer cases by reporting facilities, the New Hampshire State Cancer Registry (NHSCR) has developed the *NHSCR Data Collection Manual*. With permission from the American College of Surgeons and the Commission on Cancer, the NHSCR used the *Standards for Oncology Registry Entry (STORE 2026)*¹ manual as the basis for the *NHSCR Data Collection Manual*. Per copyright law, the content of the *STORE 2026* information itself is not altered in any way. Instead, sections of *STORE 2026* are highlighted and notations added that reference NHSCR-specific requirements. NHSCR has also been granted permission by SEER to reference sections from the *SEER Program Coding and Staging Manual 2026*². Definitions for required data items that are not included in *STORE 2026* are taken from the *NAACCR Data Standards and Data Dictionary*³.

NHSCR thanks the CoC, SEER, and NAACCR for allowing the use of the STORE¹, SEER², and NAACCR³ coding manuals as a basis for the NHSCR Data Collection Manual.

NHSCR provides additional definitions and coding instructions for data items not included in *STORE 2026*. These are listed in the [NHSCR Table of Contents](#). NHSCR differences with items in *STORE 2026* are noted with NH and hyperlinked throughout *STORE 2026* for easy reference to the corresponding notations located in [Appendix E: NHSCR Supplement to STORE 2026](#).

This data collection manual is formatted for electronic use; it is not intended for printing in paper form. NHSCR is using the most current version of *STORE 2026* available online and will update it as changes to *STORE 2026* are made available.

References

1. *Standards for Oncology Registry Entry (STORE 2026)*. Chicago: American College of Surgeons Commission on Cancer; 2025. Available at <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-data-submission/>. (Accessed February 18, 2026.)
2. Sanchez P, Groves C, Adamo M. (September 2025). SEER Program Coding and Staging Manual 2026. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Available at: <https://seer.cancer.gov/tools/codingmanuals/>. (Accessed February 18, 2026.)
3. Thornton ML, (ed). *Data Standards and Data Dictionary*, Version 26, 27th ed. Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025). Available at: <https://apps.naaccr.org/data-dictionary/>. (Accessed February 18, 2026.)

Acknowledgement

The NHSCR is supported by the Centers for Disease Control (CDC) and Prevention's National Program of Cancer Registries (NPCR) through cooperative agreement NU58DP007115 awarded to the New Hampshire Department of Health and Human Services, Division of Public Health Services, Bureau of Disease Control and Health Statistics, Health Statistics and Data Management Section. The contents of this manual are solely the responsibility of the NHSCR and do not necessarily represent the official views of the Centers for Disease Control and Prevention. Strict policies and procedures have been developed to maintain confidentiality in disclosure of data.

Preface 2026

NHSCR Data Collection Manual

Introduction

Cancer became a reportable disease in New Hampshire in 1985, and since 1986, the New Hampshire State Cancer Registry (NHSCR) has been charged to collect incidence data on all cancer cases seen and/or treated in New Hampshire. As required by NH Administrative Rules ([Appendix F](#)), the NHSCR currently collects reports from hospital registrars operating in all the large hospitals in NH. Hospitals with relatively smaller caseloads of cancer (fewer than 105 cases per year) generally do not have their own cancer registry, and NHSCR staff help these hospitals with their abstracting duties. NHSCR also receives reports of cases from physician practices, free standing radiation oncology centers, pathology laboratories, and other sources. In addition, the NHSCR receives reports for cases diagnosed and treated in other states who are NH residents at diagnosis, based on agreements of information exchange with other states.

The NHSCR has an innovative, two-phase reporting system. An initial *rapid* report that provides the most elemental aspects of case identification is reported within 45 days of diagnosis. A *definitive* case report is reported 180 days from the date of diagnosis and includes more specific information, such as treatment and staging information. The timeliness of the receipt of information is essential to the ability of the NHSCR to provide meaningful data.

NHSCR Data Collection Manual and STORE 2026

Continued efforts by standard-setting organizations, facility-based registries and population-based central registries now follow nearly identical standards for determining reportable tumors that are to be included in the registry; however, some differences in reportability remain.¹ The Commission on Cancer (CoC) stipulates the tumors that must be included in accredited facility registries to meet their standards.^{2,3} Most population-based registries, such as the NHSCR, follow the standards set by NPCR⁴ and enforce these standards on the facilities that report data to them under state cancer reporting laws ([Appendix F](#)).

To ensure the integrity of cancer data that are collected and submitted by reporting facilities, the NHSCR has developed the *NHSCR Data Collection Manual*. This manual is a combination of the *STandards for Oncology Registry Entry (STORE 2026)* with additional material pertaining to NHSCR-specific requirements and clarifications (see NHSCR Foreword). This manual is effective for cases diagnosed **January 1, 2026 and forward**.

NHSCR specific notations can be found in [Appendix E: NHSCR Supplement to STORE 2026](#). The main differences between NHSCR requirements and *STORE 2026* are as follows:

- All cases seen with evidence of cancer or for cancer-directed treatment since the NHSCR reference date of June 1986 are reportable to the NHSCR.
- Non-analytic cases ARE reportable IF the case has not been reported by the diagnosing or treating facility (see [Appendix G: NHSCR Non-Analytic Tracking Form](#)). For example, patients receiving transient care, with active cancer admitted for medical conditions other than cancer, and with a history of cancer that are now undergoing cancer-directed treatment **ARE** reportable. NHSCR does not require the reporting of historical cases when they do not have active disease. Place of diagnosis, residence, and class of case are **NOT** determining factors for reportability.

- Intraepithelial neoplasia, grade III, are reportable, EXCEPT carcinoma in situ of cervix (CIS, CIN III) and of the prostate (PIN III).
- Reportable-by-agreement cases that fall outside the NHSCR's reportable list should not be transmitted to the NHSCR. Only count NHSCR reportable cancers when assigning sequence numbers.
- Effective with cases diagnosed on or after January 1, 2010, the recording of Comorbidities and Complications or Secondary Diagnosis is required by NHSCR.
- NHSCR requires directly coded AJCC and SEER Summary Stage on all cases diagnosed prior to 2004 and 2015 forward, regardless of Class of Case. Collaborative Stage is to be used for cases diagnosed 2004-2015.
- The NHSCR is a population-based incidence registry only. NHSCR does not conduct annual follow-up on cases once initial diagnosis and complete first-course treatment has been reported. If a completed definitive case is revised as a result of additional information becoming available, submit a revised abstract to the NHSCR with a notation indicating the revision. (See note NH-25 in Appendix E)
- Descriptions and coding instructions of additional data items that are not included in *STORE 2026*, but required by NHSCR, are provided throughout *Section Two* (e.g., marital status, text fields). These pages are marked and noted to be NH-specific. (See Table of Contents for NHSCR-specific pages)

Reportable Cases

Section One: Case Eligibility and Appendix F: NH Rules and Regulations of this manual provide detailed criteria of cancers that are reportable by the NHSCR.

Casefinding

To successfully identify reportable cancers, reporting facilities should have casefinding procedures in place to confirm whether a case is required. While there are many sources for the identification of cancer cases, the principal sources are **pathology reports** (histology, cytology, bone marrow, and autopsy) and **medical disease indices**. Appendix H: Casefinding Lists provides a list of ICD-10-CM codes used to screen for prospective cases and identify reportable cancers. Note that this casefinding list is **not** the same as a reportable list. Casefinding lists are intended for searching a variety of cases so as not to miss any reportable cases. Some codes contain conditions that are not reportable; however, these diagnoses may indicate a reportable condition. Casefinding should include both primary and up to four (4) secondary diagnoses. The patient medical record will need to be reviewed to verify whether or not the case is reportable. Facilities are encouraged to keep record of casefinding efforts, especially of non-reportable cases, in case the NHSCR requests these as part of a casefinding audit.

Data Collection

Appendix I: NHSCR Table of Required Data Items lists the data items required to be collected; *Section Two* provides coding definitions of individual data items. In the case where NHSCR and CoC requirements differ, NHSCR requirements take precedence over the CoC.

NHSCR participated in CDC's Enhancing Cancer Registries for Comparative Effectiveness Research (CER) project. This project aimed to collect more detailed cancer registry data beyond SEER, CoC and NAACCR standards. As part of this project, facilities were required to collect additional variables for cases diagnosed in year 2011. These data items are defined in *Comparative Effectiveness Research Data Dictionary* and *Patient-Centered Outcomes Data Dictionary* available at <https://geiselmed.dartmouth.edu/nhscr/reporting/registrars/>.

Data Transmissions

Reporting facilities should have an agreement with the NHSCR for the submission of both rapid and definitive cancer reports. Appendix F: NHSCR Rules and Regulations of this manual specifies the methods of cancer case reporting. Cases must be retransmitted to the NHSCR if a change is made *after* the completed cases have already been transmitted. (See note NH-25 in Appendix E)

Records sent from reporting facilities to central cancer registries must use the NAACCR XML Data Exchange Standard starting in 2021. Central cancer registries are already required to submit their NAACCR Call for Data cases using the XML standard.⁵ The [NAACCR XML website](#) provides links to resources as well as CDC and SEER XML software products. The XML NAACCR ID for each data item can be found in the [NAACCR Data Standards and Data Dictionary Version 2026](#).

2026 Changes

Effective with 2026, there are a number of changes to national data standards that affect multiple aspects of cancer reporting. Changes related to cancer coding and staging include updates to the following:

- [ICD-O-3.2 Histology Code and Behavior Update](#) (effective January 1, 2026)
- [Solid Tumor Rules \(STR\)](#)
- [Grade Manual](#)
- [Site-Specific Data Items \(SSDI\) Manual](#)
- [NAACCR Version 26](#)

Appendix E: NHSCR Supplement to STORE 2026 includes additional major NHSCR-specific changes that are not included in STORE 2026 Summary of Changes.

References

1. Thornton ML, (ed). *Data Standards and Data Dictionary*, Version 26, 27th ed. Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025). Available at: <https://apps.naaccr.org/data-dictionary/>. (Accessed April 16, 2026.)
2. Optimal Resources for Cancer Care (2020 Standards). Effective January 2020; updated October 2025. American College of Surgeons Commission on Cancer. Available at: <https://www.facs.org/quality-programs/cancer-programs/education/optimal-resources-2020/>. (Accessed April 16, 2026.)
3. *Standards for Oncology Registry Entry (STORE 2026)*. Chicago: American College of Surgeons Commission on Cancer; 2025. Available at: <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdstandards-manuals-download/>. (Accessed April 16, 2026.)
4. Centers for Disease Control and Prevention. National Program of Cancer Registries. *NPCR Standards*. Available at: <https://www.cdc.gov/national-program-cancer-registries/about/npcr-standards.html>. (Accessed April 16, 2026.)
5. *2026 Implementation Guidelines and Recommendations*. (For NAACCR Data Standards and Data Dictionary, Version 26, effective with cases diagnosed on or after January 1, 2026). Available at: <https://www.naaccr.org/implementation-guidelines/>. (Accessed April 16, 2026.)

STORE 2026 Summary of Changes

Data Items not required for cases with diagnosis year 2026+

STORE 2025 Page Number	NAACCR Number	Data Item Name
58	220	Sex
63	3110 3120 3130 3140 3150 3160 3161 3162 3163 3164	Comorbidities and Complications #1 – 10 (Secondary Diagnoses)
158	3905 3906 3908 3919	SSDI: Oncotype DX Risk Level DCIS Oncotype DX Risk Level Invasive Percent Necrosis Post Neoadjuvant EOD Prostate Pathologic Extension

New Data Items optional for cases with diagnosis year 2026+

STORE 2026 Page Number	NAACCR Number	Data Item Name
41	2230	Name--Last
42	2232	Name--Birth Surname
43	2240	Name--First
44	2250	Name--Middle
45	2280	Name--Alias

New Data Items required for cases with diagnosis year 2026+

STORE 2026 Page Number	NAACCR Number	Data Item Name
59	225	Sex Assigned at Birth
83	10110	Method of Detection for Breast Primary (NCDB Custom Data Item)
163	1176 1178 1179	New SSDIs: Spread Through Air Spaces (STAS) Residual Cancer Burden (RBC) Residual Cancer Burden (RBC) Class
164	3890	New primary site collected for MSI: Added Corpus Carcinoma & Carcinocarcinoma

Data Items Allowable Value Corrected

STORE 2026 Page Number	NAACCR Number	Data Item Name	
118	820	Regional Lymph Nodes Positive	Corrected the Allowable Values from 00-99 to 00-90, 95, 97-99

The table below includes clarifications added to data items in STORE v26 by the page number

STORE 2026 Page Number	Section or NAACCR Data Item Number	Data Item Name	Changes/Comments/Clarifications
11	Case Eligibility	Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Database (NCDB)	Added: The acronym SIN III after squamous intraepithelial neoplasia (<i>SIN III</i>)
12		Ambiguous Terms at Diagnosis	Added: Report cases that use the words on the list even if the suffix is different such as favor(ed) rather than favor(s). Added parenthesis around optional suffixes.
14		Modifications to Class of Case in 2010	Removed: Treatment in staff physician offices is now coded “treated elsewhere” because the hospital has no more responsibility over this treatment than it would if the patient were treated in another hospital.
17	Overview of Coding Principles	Coding Dates	Added: use 1st for the beginning of the month, 15th for the mid-month and the last day for the end of month
19		Laterality	Moved coding information and Paired Organ Sites under the data item, Laterality [410] coding instructions
20		Coding Country and State	Removed: The third section is a list of obsolete codes that may have been assigned when the registry data were upgraded from former codes. This information is provided to assist registries in interpreting their historic data, but the obsolete codes must not be assigned for current abstracting
20		In Utero Diagnosis and Treatment	Removed: Last sentence in section. The exact date may be used for cases diagnosed prior to 2009.
21		Comorbidities and Complications	Removed Comorbidities and Complications from paragraph title Removed outdated ICD 9 CM information below: All are secondary diagnoses. Prior to 2018, the information was recorded in the International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9-CM or ICD-10-CM) code form

			Most hospitals in the United States were expected to implement use of ICD-10-CM in 2015. Separate data item series were used to record the two series. ICD-10-CM codes can have up to 7 characters, whereas ICD-9-CM codes only have 5 characters or fewer. Both the specific codes and the rules for recording them differ. The underlying meanings of the codes are similar. That is, the concepts originally described as “comorbidities and complications” are also known as “secondary diagnoses”; in this instance, the separate names are given to distinguish the separate registry data items Beginning with cases diagnosed in 2018, the following data items are no longer required: The items describing patient comorbid conditions and complications ICD-9-CM codes are: Comorbidities and Complications #1-10 [3110, 3120, 3130, 3140, 3150, 3160, 3161, 3162, 3163, or 3164]
23		Time Periods for First Course of Treatment	Added to 2 nd bullet: <i>was the only treatment</i>
23		Surgery	Added: Most invasive in the first sentence
24-26		Relationships among Surgical Items	Added to third paragraph: (most invasive) procedure is usually but not always the last performed Word change in seventh paragraph: Extensive changed to invasive Added to the end of the seventh paragraph: The numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed. Outdated paragraph removed: To the extent possible, codes and their definitions are the same as those previously assigned in ROADS/FORDS to accommodate analysis in registries that maintain unconverted data. As a result of added and modified codes, however, the numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed. Added to ninth paragraph: evaluate for possible malignant involvement. Added to the fifth bullet point under last section paragraph: inpatient
30		Other Treatment	Added:

			First course treatment does not necessarily end due to the managing physician changing an agent or agents in a combination regimen, to an agent of a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous). Changes in an agent or agents may occur due to reasons other than disease progression. A change to the regimen does not automatically represent subsequent therapy. Removed: If a patient has an adverse reaction, the managing physician may change one of the agents in a combination regimen. If the replacement agent belongs to the same subcategory as the original agent, there is no change in the regimen. However, if the replacement agent is of a different subcategory than the original agent, the new regimen represents the start of subsequent therapy, only the original agent or regimen is recorded as first course therapy. This rule does not apply for hormone therapy. If a change is made from Tamoxifen to Arimidex this is still all first course of treatment.
32		Follow-up items that are required to be in the facility's database	Added: (most invasive) and (surgical procedure recorded in the data item, Rx Summ-Surg 2023 [1291]).
56	160	Race 1	Added: clarification to bullet 3 and 4. (surgical procedure recorded in the data item, Rx Summ-Surg 2023 [1291]).
58	190	Spanish Origin—All Sources (Spanish/Hispanic Origin)	Removed: Outdated information from code 8
60	630	Primary Payer at Diagnosis	Removed: Outdated coding instructions removed (previously the fourth bullet point)
64	3780	Secondary Diagnosis #1	Clarified the first bullet point: Surgically treated patients: following the most definitive (most invasive) surgery of the primary site(procedure recorded in the data item, Rx Summ-Surg 2023 [1291])
67	2485	NPI—Primary Surgeon	Clarified description by adding: (most invasive) Clarified first bullet point: Record the 10-digit NPI for the physician who performed the most definitive (most invasive) surgical procedure (surgical procedure recorded in the data item, Rx Summ-Surg 2023 [1291])
71	610	Class of Case	Added to sixth bullet point: and squamous intraepithelial neoplasia (SIN III)
81	400	Primary Site	Removed:

			Topography codes are indicated by a “C” preceding the three-digit code number
85	410	Laterality	Moved: The coding instructions and paired organ site table previously in the Overview of Coding Principles chapter under the data item’s coding instructions
98	1350	Surgical Diagnostic and Staging Procedure	Added to fifth bullet point: except for lymphoma as described above
100	740	Surgical Diagnostic and Staging Procedure at this Facility	Added to ninth bullet point: invasive after more extensive
102	1182	Lymphovascular Invasion	Added: list of LVI synonyms
115	682	Date Regional Lymph Node Dissection	Removed since not applicable for coding this data item: Use the AJCC N suffix to designate sentinel node procedures for ALL sites
163	3864 3903 3957 3958 3959	Invasion Beyond Capsule Oncotype DX Recurrence DCIS Lymph Node Status Pelvic Lymph Node Status Para-Aortic LN Status Femoral-Inguinal	Data items were already being collected however were inadvertently not included in the SSDI table.
164	3938	Alk Rearrangement	Added full name to acronym: Anaplastic Lymphoma Kinase
164	3939	EGFR Mutational Analysis	Added full name to acronym: Epidermal Growth Factor Receptor
167	1285	Rx Summ-Treatment Status	Added clarification: Assign code 2 when Active Surveillance is the only treatment administered.
171	3170	Date of Most Definitive Surgical Resection of the Primary Site	Added: (most invasive) after most definitive as described in Rx Summ-Surg 2023 [1291].
172	671	Rx Hosp-- Surg 2023	Added to twelfth bullet point: invasive after more extensive
174	1291	Rx Summ—Surg 2023	Added to twelfth bullet point: invasive after more extensive
176	751	Rx Hosp—Recon Breast	Added to fifth bullet point: most invasive after definitive
178	1335	Rx Summ—Recon Breast	Added to fifth bullet point: most invasive after definitive
180	668	Approach -Surgery of the Primary Site at this Facility(RxHospSurgApp2010)	Added to second bullet point: (procedure recorded in the data item, Rx Summ-Surg 2023 [1291]) after definitive surgery Removed: This item should not be confused with the obsolete item published in Registry Operations and Data Standards (ROADS), Surgical Approach [1310].
184	1292	Scope of Regional Lymph Node Surgery	Added to second bullet point to align with statement in overview of coding principles: treat

190	672	Scope of Regional Lymph Node Surgery at this Facility	Added to second bullet point to align with statement in overview of coding principles: treat
200	3190	Readmission to the Same Hospital within 30 Days of Surgical Discharge	Added to Description: inpatient Removed: examples from code 2
202	1340	Reason for No Surgery of Primary Site	Changed word in sixth bullet point: Definitive to specific
234	1380	Radiation/Surgery Sequence	Removed from code 4: At least two phases of radiation therapy are given before and at least two more after surgery Added to code 4: At least one phase of radiation therapy was given before and at least one more phase after a surgical procedure
236	1430	Reason for No Radiation	Changed word in sixth bullet point: Definitive to specific
242 245	1390 700	Chemotherapy Chemotherapy at this Facility	Added: The managing physician may change a chemotherapy agent or one of the agents in a combination regimen, to an agent belonging to a different subcategory (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous). First course treatment would not necessarily end due to these changes and does not automatically represent subsequent therapy. Changes in an agent or agents may occur due to reasons other than disease progression. Refer to the SEER*Rx Interactive Drug Database (https://seer.cancer.gov/tools/seerrx/) to determine whether the drugs used are classified as chemotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as a chemotherapeutic agent should be coded as chemotherapy regardless of primary sites listed in SEER*RX for that agent. This would not be coded under the data item, Other Treatment [1420]. Removed: If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different subcategory (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and only the original agent or regimen is recorded as first course therapy.
249 251	1400 710	Hormone Therapy Hormone Therapy at this Facility	Added Refer to the SEER*Rx Interactive Drug Database (https://seer.cancer.gov/tools/seerrx/) to determine whether the drugs used are classified as hormonal agents.

			A drug administered to a patient for treatment, listed in SEER*Rx as a hormonal agent should be coded as Hormone Therapy regardless of primary sites listed in SEER*RX for that agent. This would not be coded under the data item, Other Treatment [1420].
255 257	1410 720	Immunotherapy Immunotherapy at this Facility	Added: Refer to the SEER*Rx Interactive Drug Database (https://seer.cancer.gov/tools/seerrx/) to determine whether the drugs used are classified as immunotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as an immunotherapeutic agent should be coded as Immunotherapy regardless of primary sites listed in SEER*RX for that agent. This would not be coded under the data item, Other Treatment [1420].
321	671/1291	Appendix A Prostate	Note was added to surgical code to Assign code A220 for a tumor destruction procedure or other minimally invasive procedure when cancer is an incidental finding during surgery/procedure for benign disease (such as ablation [aqua, cold, heat, laser] HoLEP, TURP) Changed: Any combination of A200–A230 WITH A240 Cryosurgery A250 Laser A260 Hyperthermia to Any combination of A200, A210 and A230 WITH (excludes incidental findings) A240 Cryosurgery A250 Laser A260 Hyperthermia
331	n/a	Appendix B	Updated to include new terminologies reportable to NCDB
353	n/a	Appendix M	Added to Introduction: most invasive after definitive
	580 1280 832 682 1270 1200 3170 3180	Date of First Contact Date of Surgical Diagnostic and Staging Procedure Date of Sentinel Lymph Node Biopsy Date Regional Lymph Node Dissection Date of First Course of Treatment Date of First Surgical Procedure Date of Most Definitive Surgical Resection of the Primary Site Date of Surgical Discharge	Removed outdated date information from multiple data items: Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of First Contact is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of First Contact transmits in

	1210 3220 3230 1220 1230 1240 1250 1860	Date Radiation Started Date Radiation Ended Date Systemic Therapy Started Date Chemotherapy Started Date Hormone Therapy Started Date Immunotherapy Started Date Other Treatment Started Date of First Recurrence	CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date.
	1220 1230 1240	Date Chemotherapy Started Date Hormone Therapy Started Date Immunotherapy Started	Removed statement: This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field
		Examples throughout STORE 2026	Dates in existing examples were updated to reflect a more current date. Additional examples were provided for selected data items.

2026 Source References

The 2026 Source Reference Document will be located on the NAACCR website once available at:

<https://www.naaccr.org/implementation-guidelines/>

Section One: Case Eligibility and Overview of Coding Principles

Case Eligibility **NH-1**

The American College of Surgeons Commission on Cancer (CoC) requires registries in accredited programs to accession, abstract, and conduct follow-up activities for required tumors diagnosed and/or initially treated at the abstracting facility. The tumors must meet the criteria for analytic cases (*Class of Case* 00-22), and pathologically and clinically diagnosed inpatients and outpatients must be included.

Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Database (NCDB) **NH-2**

Nonmalignant primary intracranial and central nervous system tumors diagnosed on or after January 1, 2004, with an ICD-O-3* behavior code of 0 or 1 are required for the following sites: meninges (C70._), brain (C71._), spinal cord, cranial nerves, and other parts of central nervous system (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3). Any other benign or borderline disease is not reportable to the CoC. **NH-3**

[See also Appendix E for reportable and non-reportable examples](#)

Malignancies with an ICD-O-3 behavior code of 2 or 3 are required to be reported to CoC for all primary sites except for the scenarios below (however may be required by other standard setters). **NH-4**

Pilocytic astrocytoma/juvenile pilocytic astrocytoma:

For cases diagnosed prior to 1/1/2023, these neoplasms are reportable in North American as malignant 9421/3 for all CNS sites with the exception of the optic nerve:

- WHO Classification Tumors of the Central Nervous System and IARC designate pilocytic astrocytoma as a synonym for optic glioma
- When the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma, the behavior is non-malignant and coded 9421/1
- Beginning with cases diagnosed 1/1/2023 forward, pilocytic astrocytoma/juvenile pilocytic astrocytoma are to be reported as 9421/1 for all CNS sites.

Effective in 2015, code 8240/1 for Carcinoid tumor, NOS, of appendix (C18.1) becomes obsolete. Carcinoid tumors of the appendix (C18.1) must be coded to 8240/3, effective with 2015. This is *required* and must be coded with a behavior 3. Prior appendix primaries coded 8240/1 are converted to 8240/3 by the implementation conversions for 2015.

Malignant primary skin cancers (C44._) with histology codes 8000–8110 *are not required* by the CoC. Skin primaries with those histologies diagnosed prior to January 1, 2003, were required to be accessioned and followed if the AJCC stage group at diagnosis was II, III, or IV. Those cases should remain in the registry data and continue to be followed.

Carcinoma in situ of the cervix (CIS), intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), anus (AIN III), larynx (LIN III), and squamous intraepithelial neoplasia (SIN III) *are not required* by CoC. **NH-5**

Effective diagnosis January 1, 2022 these codes and histologies *are not required* by the CoC: 8210/2 Adenomatous polyp, high grade dysplasia (C160 – C166, C168-C169, C170-C173, C178-C179); 8211/2 Tubular adenoma, high grade; 8261/2 Villous adenoma, high grade; 8263/2 Tubulovillous adenoma, high grade; 8483/2 Adenocarcinoma in situ, HPV-associated (C530-C531, C538-C539); 8484/2 Adenocarcinoma in situ, HPV-independent, NOS (C530-C531, C538-C539). [\(See Appendix B\)](#) **NH-6**

All gastro-intestinal stromal tumors (GIST) and thymomas with a Behavior Code of 3 are reportable effective January 1, 2021. Thymomas noted to have multiple foci, metastasis or positive lymph nodes must be abstracted and assigned a Behavior Code of 3.

Effective January 1, 2023, low grade appendiceal mucinous neoplasms (LAMN) (8480) are reportable. LAMN is a distinctive histologic subtype of mucinous appendiceal neoplasm and can be in-situ or invasive. Please reference the AJCC Appendix Protocol Version 9 for further information.

NH-7

Lobular Carcinoma In Situ (8520/2) alone is not reportable to CoC. The decision not to collect LCIS was made to align STORE with the AJCC 8th Edition. Please see the AJCC 8th Edition for complete details. Please note: SEER and NPCR require reporting of LCIS. If LCIS is reportable for your state registry, follow your state registry requirements.

NH-8

PI Rads, BI Rads, LI Rads alone are not reportable for CoC. PI Rads, BI Rads, LI Rads confirmed with biopsy or physician statement are reportable to CoC. Date of diagnosis is the date of the positive biopsy or definitive statement from physician.

NH-9

Reportable-by-Agreement Cases

Registries may be requested to collect information about tumors that are not required to be abstracted by the CoC for accredited programs. Ordinarily, such requests will come from the facility's cancer committee or the central registry. The CoC does not require that reportable-by-agreement cases be accessioned, abstracted, followed, or submitted, but the requestor may identify the extent of information needed.

NH-10

Examples of Reportable-by-Agreement Cases:

- The cancer committee requests abstracting and follow-up of Class of Case 30 cases.
- The state central registry requests abstracting and reporting of pathology-only cases.

NH-11

Ambiguous Terms at Diagnosis

NH-12

[See also How to Use Ambiguous Terminology for Case Ascertainment in Appendix E](#)

As part of the registry casefinding activities, all diagnostic reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included. Words or phrases that appear to be synonyms of these terms but do not use the term(s) listed does not constitute a diagnosis. Report cases that use the words on the list even if the suffix is different such as favor(ed) rather than favor(s). For example, "likely" alone does not constitute a diagnosis. Words in parenthesis are optional.

Ambiguous Terms that Constitute a Diagnosis		NH-12
Apparent(ly)	Presum(ed)	
Appear(s)	Probable	
Comparable (with)	Suspect(ed)	
Compatible (with)	Suspicious (for)	
Consistent (with)	Tumor* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)	
Favors	Typical (of)	
Malignant appear(ing)		
Most likely		
Neoplasm* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)		

*Additional terms for nonmalignant primary intracranial and central nervous system tumors only

- **EXCEPTION:** If cytology is identified only with an ambiguous term, do not interpret it as a diagnosis of cancer. The case would be abstracted only when a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.

NH-13

Examples of Diagnostic Terms:

- The inpatient discharge summary documents a chest x-ray *consistent with carcinoma* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with carcinoma* is indicative of cancer.
- The pathology report states *suspicious for malignancy*. *Suspicious for malignancy* is indicative of cancer.

Ambiguous Terms That <i>Do Not</i> Constitute a Diagnosis <i>without additional information</i>	
Cannot be ruled out	Questionable
Equivocal	Rule out
Possible	Suggests
Potentially malignant	Worrisome

NH-14

Examples of Nondiagnostic Terms:

- The inpatient discharge summary documents a chest x-ray *consistent with neoplasm* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with neoplasm* is not indicative of cancer. While “consistent with” can indicate involvement, “neoplasm” without specification of malignancy is not diagnostic except for non-malignant primary intracranial and central nervous system tumors.
- Final diagnosis is reported as *possible carcinoma* of the breast. *Possible* is not a diagnostic term for cancer.

Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

Ambiguous Terminology Lists: References of Last Resort

This section clarifies the use of Ambiguous Terminology as listed in STORE 2018 for case reportability in Commission on Cancer (CoC)-accredited programs. When abstracting, registrars are to use the [“Ambiguous Terms at Diagnosis”](#) list with respect to case reportability, however, the list needs to be used correctly.

The first and foremost resource for the registrar for questionable cases is the physician who diagnosed and/or staged the tumor. The ideal way to approach abstracting situations when the medical record is not clear is to follow up with the physician. If the physician is not available, the medical record, and any other pertinent reports (e.g., pathology, etc.) should be read closely for the required information. The purpose of the Ambiguous Terminology list is so that in the case where wording in the patient record is ambiguous with respect to reportability or tumor spread and no further information is available from any resource, registrars will make consistent decisions. When there is a clear statement of malignancy or tumor spread (i.e., the registrar can determine malignancy or tumor spread from the resources available), they should not refer to the Ambiguous Terminology lists. Registrars should only rely on these lists when the situation is not clear and the case cannot be discussed with the appropriate physician/pathologist.

The CoC recognizes that not every registrar has access to the physician who diagnosed and/or staged the tumor, as a result, the Ambiguous Terminology list delineated above must be used in CoC-accredited programs as “references of last resort.”

Class of Case

[Coding instructions for Class of Case](#)

All accessioned cases are assigned a *Class of Case* [610] based on the nature of involvement of the facility in the care of the patient.

Analytic Cases

Cases diagnosed and/or administered any of the first course of treatment at the accessioning facility are analytic (*Class of Case* 00-22). The CoC is aligned with the Federal Employer Tax ID (FEIN) for your hospital/facility. Any services or facility covered under your FEIN would then be covered under your CoC accreditation and you would be responsible for reporting the associated data that is reportable as defined in the STORE Manual. Generally, any facility/service included in your FEIN is included within your accreditation and therefore reportable to NCDB. You may also submit data from associated physician offices, outpatient or ambulatory centers/clinics, or other entities that share a FEIN, are owned and operated by your accredited facility, or are otherwise covered by your facility's American College of Surgeons Business Associate/Data Use Agreement.

Analytic cases *Class of Case* 10-22 are included in treatment and survival analysis.

Analytic cases *Class of Case* 00 are not required to be staged or followed, regardless of the year of diagnosis. *Class of Case* 00 is reserved for patients who are originally diagnosed by the reporting facility and receive all of their treatment elsewhere or a decision not to treat is made elsewhere. If the patient receives no treatment, either because the patient refuses recommended treatment or a decision is made not to treat, the *Class of Case* is 14. If there is no information about whether or where the patient was treated, the *Class of Case* is 10.

NH-15

Nonanalytic Cases

Nonanalytic cases (*Class of Case* 30-99) are not usually included in routine treatment or survival statistics. The CoC does not require registries in accredited programs to accession, abstract, or follow these cases, but the program or central registry may require them. Please follow the guidelines of the standard setter requiring the collection of the nonanalytic cases.

NH-16

Modifications to Class of Case in 2010

Class of Case was redefined for use beginning in 2010. The codes in this manual allow differentiation between analytic and nonanalytic cases and make additional distinctions. For analytic cases, the codes distinguish cases diagnosed in a staff physician's office from those diagnosed initially by the facility and patients fully treated at the facility from those partially treated by the reporting facility. Nonanalytic cases are distinguished by whether the patient received care at the facility or did not personally appear there. Patients who received care from the facility are distinguished by the reasons a case may not be analytic: type of cancer that is not required by CoC to be abstracted, consultation, in-transit care, and care for recurrent or persistent disease. Patients who did not receive care from the reporting facility are distinguished by care given in one or more staff physician offices, care given through an agency whose cancer cases are abstracted by the reporting facility but are not part of it, pathology only cases, and death certificate only cases.

Date of First Contact

[Coding instructions for Date of First Contact](#)

The *Date of First Contact* [580] is the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of the cancer. For analytic cases, the *Date of First Contact* is the date the patient qualifies as an analytic case *Class of Case* 00-22. Usually, the *Date of First Contact* is the date of admission for diagnosis or for treatment. If the patient was admitted for noncancer-related reasons, the *Date of First Contact* is the date the cancer was first suspected during the hospitalization. If the patient's diagnosis or treatment is as an outpatient of the facility, the *Date of First Contact* is the date the patient first appeared at the facility for that purpose.

If the patient was initially diagnosed at the facility and went elsewhere for treatment (*Class of Case* 00), but then returned for treatment that was initially expected to occur elsewhere, the *Class of Case* is updated to 13 or 14 but the *Date of First Contact* is not changed because it still represents the date the patient became analytic. If the *Class of Case* changes from nonanalytic (for example, consult only, *Class of Case* 30) to analytic (for example, part of first course treatment administered at the facility, *Class of Case* 21), the *Date of First Contact* is updated to the date the case became analytic (the date the patient was admitted for treatment).

When a pathology specimen is collected off site and submitted to the facility to be read (and the specimen is positive for cancer), the case is not required by the Commission on Cancer to be abstracted unless the patient receives first course treatment from the facility. **NH-17**

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment; and the *Class of Case* [610] is 11 or 12 if the diagnosing physician is a staff physician at the reporting facility or 20 or 21 for any other physician. A staff physician is one who is employed by the facility, is under contract with it, or has routine admitting privileges there.

When a staff physician performs a biopsy off site, and the specimen is not submitted to the facility to be read, the case is not required to be abstracted unless the patient receives some first course care at the facility. **NH-18**

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment and the *Class of Case* is 11 or 12.

For nonanalytic cases, the *Date of First Contact* is the date the patient's nonanalytic status begins with respect to the cancer. For example, for a patient diagnosed and treated entirely in a staff physician's Office (*Class of Case* 40), the date the physician initially diagnosed the cancer is the *Date of First Contact*. For autopsy only cases, the *Date of First Contact* is the date of death.

If the state or regional registry requires pathology-only cases to be abstracted and reported, the *Date of First Contact* is the date the specimen was collected, and the *Class of Case* is 43. If a patient whose tumor was originally abstracted as a *Class of Case* 43 receives first course treatment subsequently as an inpatient or outpatient at the facility, update both *Class of Case* and *Date of First Contact* to reflect the patient's first in-person contact with the facility. **NH-17**

NHSCR additional notes on reportable cases: **NH-19 and **NH-20****

Overview of Coding Principles

Unique Patient Identifier Codes

[Coding instructions for Accession Number](#)

Accession Number [550] and *Sequence Number* [560] uniquely identify the patient and the tumor. Each cancer patient in a registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The accession number *never* changes.

- Accession numbers are never reassigned, even if a patient is removed from the registry.
- Once cases are submitted to RCRS or the NCDB, accession numbers are not to be changed for any reason. Even if there is a clerical error, or if cases are found in an out-of-order fashion when casefinding (i.e., find an old case after abstraction of a newer one), the accession number serves as a permanent identifier for a patient at your facility. NCDB does not accommodate any requests for accession number changes for cases already submitted.
- The sequence number is the sequence of all tumors over the lifetime of a patient and is counted throughout the patient's lifetime. [Coding instructions for Sequence Number](#)
- Only tumors that would have been reportable at the time of diagnosis for CoC or by agreement with a central registry or the program's cancer committee are required to be counted when assigning sequence numbers. A registry may contain a single abstract for a patient with a sequence number of 02, because the first tumor was not cared for by the program or was not otherwise required to be accessioned. Because of differences in requirements, it is possible for two registries with dissimilar eligibility requirements (for example, a facility registry and a state central registry) to assign different sequence numbers to the same tumor, even though the sequence number codes and instructions applied are the same. **NH-21**

National Provider Identifier

[See also Appendix E: Determining Multiple Primaries](#)

The National Provider Identifier (NPI) is a unique identification number for health care providers that was implemented in 2007 and 2008 by the Centers for Medicare and Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008. Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions.

The NPI data items are:

NH-22

NPI—Archive FIN [3105]
NPI—Institution Referred From [2415]
NPI—Institution Referred To [2425]
NPI—Physician #3 [2495]
NPI—Physician #4 [2505]
NPI—Primary Surgeon [2485]
NPI—Reporting Facility [545]

Coding Dates

Beginning in 2010, the way dates are transmitted between facility registries and central registries or the National Cancer Database (NCDB) was changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format. Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown

date. Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. The following table illustrates the relationship among these items for *Date of Most Definitive Surgical Resection of the Primary Site*, where each lower case ‘b’ represents a blank space.

Description	<u>Traditional Date of Most Definitive Surgical Resection of the Primary Site</u>	<u>Interoperable Date of Most Definitive Surgical Resection of the Primary Site</u>
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces) indicated as ‘b’; omit the date if the date is completely unknown or not applicable.
Full date known	MMDDCCYY (example: 02182024)	CCYYMMDD (example: 20240218)
Month and year known	MM99CCYY (example: 02992024)	CCYYMMbb (example: 202402bb)
Year only known	9999CCYY (example: 99992024)	CCYYbbbb (example: 2024bbbb)
Full date unknown	99999999	bbbbbbbb (blank)

When the date is an approximation, use the 1st for the beginning of the month, 15th for mid- month, the last day of the month for end of month, April for “spring”, July for “summer” or “mid-year”, October for “fall” or “autumn”. In winter, attempt to determine whether the diagnosis was “late in the year” (use December with the applicable year) or “early in year” (use January with the applicable year).

Cancer Identification

The following instructions apply to *Primary Site* [400], *Laterality* [410], *Histology* [522], *Behavior Code* [523] and *Grade Clinical* [3843], *Grade Pathological* [3844], *Grade Post Therapy Clin* (yc) [1068] and *Grade Post Therapy Path* (yp) [3845].

[Coding instructions for Primary Site](#)

Primary Site **NH-23**

The instructions for coding primary site are found in the “Topography” section of the ICD-O-3 “Coding Guidelines for Topography and Morphology” (ICD-O-3 pp. 23–26). The following guidelines should be followed for consistent analysis of primary sites for particular histologies.

Occult Cervical Lymph Node

Beginning with cases diagnosed 1/1/2018 and later, for a head and neck primary lymph node involvement with no head and neck tumor found or specified by a physician (i.e., Occult Head and Neck Lymph Node), the primary site will be coded:

- C76.0 if the neck node has not been tested or is negative for both HPV and EBV. The AJCC Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck will be used.
- C10.9 if the neck node is p16 positive indicating human papillomavirus (HPV). The AJCC HPV-Mediated (p16+) Oropharyngeal Cancer will be used.
- C11.9 if the neck node is EBER positive, or both EBER and p16 positive, indicating Epstein Barr Virus (EBV). The AJCC Nasopharynx will be used.

Please refer to the SSDI Manual schema discriminators for further information and follow the instructions provided within the SSDI Schema Discriminator to assign the final primary site.

Cutaneous Carcinoma of the Head and Neck

Beginning with cases diagnosed 1/1/2018 and later, for skin cancers overlapping sites in the head and neck ONLY, assign the primary site code for the site where the bulk of the tumor is or where the epicenter is. These cases will be staged with AJCC Cutaneous Carcinoma of the Head and Neck. Do not use code C44.8 Overlapping lesion of skin. Cases coded to C44.8 will represent skin lesions overlapping between head and neck sites AND/OR skin in other parts of the body. These cases will not be staged with AJCC 8th Edition.

Hematopoietic and Lymphoid Cancers

The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual is to be used for coding primary site and histology of hematopoietic and lymphoid tumors (M-9590-9993) and to determine whether multiple conditions represent one or more tumors to be abstracted.

Kaposi Sarcoma

- Code Kaposi sarcoma to the site in which it arises.
- Code to Skin, NOS (C44.9) if Kaposi sarcoma arises simultaneously in the skin and another site or the primary site is not identified.

Melanoma

- Code to Skin, NOS (C44.9) if a patient is diagnosed with metastatic melanoma and the primary site is not identified.

Specific Tissues with Ill-Defined Sites

- If any of the following histologies appears only with an ill-defined site description (e.g., “abdominal” or “arm”), code it to the tissue in which such tumors arise rather than the ill-defined region (C76._) of the body, which contains multiple tissues. Use the alphabetic index in **ICD-O-3** to assign the most specific site if only a general location is specified in the record.

Histology	Description	Code to This Site
8720–8790	Melanoma	C44._, Skin
8800–8811, 8813–8830, 8840–8921, 9040–9044	Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
8990–8991	Mesenchymoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9120–9170	Blood vessel tumors, lymphatic vessel tumors	C49._, Connective, Subcutaneous and Other Soft Tissues
9580–9582	Granular cell tumor and alveolar soft part sarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9240–9252	Mesenchymal chondrosarcoma and giant cell tumors	C40._, C41._ for Bone and Cartilage C49._, Connective, Subcutaneous and Other Soft Tissues
8940–8941	Mixed tumor, salivary gland type	C07._ for Parotid Gland C08._ for Other and Unspecified Major Salivary Glands

Revising the Original Diagnosis **NH-24**

Data are gathered from multiple sources using the most recent and complete information available. Over time, the patient's records may contain new information such as tests, scans, and consults. Change the primary site, laterality, histology, grade and stage as the information becomes more complete. If the primary site or histology is changed, it may also be necessary to revise site-specific staging and treatment codes. There is no time limit for making revisions that give better information about the original diagnosis or stage. However, if staging information is updated, it is important to adhere to the staging timeframe and criteria for the respective staging system applicable at the time of the original diagnosis. Most cases that require revision are unknown primaries.

Example 1

The institution clinically diagnoses a patient with carcinomatosis. The registry enters the case as an unknown primary (C80.9), carcinoma, NOS (8010/3), stage of disease unknown. Nine months later, a paracentesis shows serous cystadenocarcinoma. The physician says that the patient has an ovarian primary. Change the primary site to ovary (C56.9), histology to serous cystadenocarcinoma (8441/3), and diagnostic confirmation to positive cytologic study, no positive histology (code 2). If enough information is available that meets the AJCC time frame requirements for staging, change the stage from not applicable (88) to the appropriate staging classification, TNM categories, and stage group, or to unknown. If first course surgery was performed, the surgery codes should be reviewed. For cases diagnosed 2004-2015, update the Collaborative Stage input items and rerun the derivation program.

Example 2

A physician decides a previously clinically diagnosed malignancy is a benign lesion. The patient is referred from a nursing home to the facility. The chest x-ray shows a cavitory lesion in the right lung. The family requests that the patient undergo no additional workup or treatment. Discharge diagnosis is "probable carcinoma of right lung." The registry abstracts a lung primary (C34.9). Two years later a chest x-ray shows an unchanged lesion. The physician documents "lung cancer ruled out." Delete the case from the database. Adjust the sequence number(s) of any other primaries the patient may have. If the deleted case is the patient's only primary, do not reuse the accession number.

Patient Name, Address and Residency Rules

Patient names are optional for CoC collection. This would include Name-Last [2230], Name-Birth Surname [2232], Name-First [2240], Name-Middle [2250], and Name-Alias [2280].

Although the name fields are optional for CoC facilities, sharing of these data items would allow for internal linkage which will result in deduplication and enrichment of the program's NCDB data.

The patient's address at diagnosis is the patient's place of residence at the time of original diagnosis. It does not change if the patient moves. If the patient has more than one primary tumor, the address at diagnosis may be different for each primary. The current address initially is the patient's residence at the time the patient was first seen at the accessioning facility for this primary. The current address is updated if the patient moves. If the patient has more than one primary tumor, the current address should be the same for each primary. Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau whenever possible. The registry can resolve residency questions by using the Census Bureau's definition, "the place where he or she lives and sleeps most of the time or the place the person considers to be his or her usual home." State Vital Statistics rules may differ from Census rules. Do not record residence from the death certificate. Review each case carefully.

NH-25**NH-26**

Rules for Persons with Ambiguous Residences

Persons with More than One Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

NH-27

Persons with No Usual Residence (transients, homeless): Use the address of the place the patient was staying when the cancer was diagnosed. This location may be a shelter or the diagnosing facility.

Persons Away at School: College students are residents of the school area. Boarding school students below the college level are residents of their parents' homes.

Persons in Institutions: The Census Bureau states, "Persons under formally authorized, supervised care or custody" are residents of the institution.

This classification includes the following:

- *Incarcerated persons*
- *Persons* in nursing, convalescent, and rest homes
- *Persons* in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or mentally ill
- *Long-term residents of other hospitals*, such as Veterans Affairs (VA) hospitals

Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community's address. The Census Bureau has detailed residency rules for Navy personnel, Coast Guard, and maritime ships. Refer to Census Bureau publications for the detailed rules.

Coding Country and State

Beginning in 2013, "country" fields accompany "state" fields in addresses. The following state and country address data items are found in FORDS/STORE:

State at Diagnosis (not changed)

[Coding instructions for State at Diagnosis](#)

Addr at Diagnosis--Country (associated with State at Diagnosis)

State—Current (not changed)

Address Current – Country (associated with State—Current)

Place of Birth (discontinued, replaced by Birthplace—State and Birthplace—Country)

Birthplace—State (coded similarly to the other two "state" fields) Birthplace—Country (associated with Birthplace—State)

[Appendix C](#) has a list of all country codes and corresponding state codes. State codes for all U.S. states and possessions and all Canadian provinces are included in [Appendix C](#). State codes for the United States and its possessions are those used by the United States Postal Service. Canadian province or territory codes are from Canada Post sources. Country codes are based on the International Standards Organization (ISO) 3166-1 Country Three Character Codes. State and country codes also include some custom codes, which are included in [Appendix C](#).

The list in [Appendix C](#) is divided into two parts:

[Appendix D has a list of NH Town/County & Zip Codes](#)

- The first part is the preferred codes to use when sufficient detail is known to identify the U.S. state, Canadian province, or other country to assign precise codes.
- The second part consists of codes for more general regions for use when a precise code cannot be assigned (for example, "Near East"). If there is no indication at all of location in the patient record, the country is coded ZZU and the state will be ZZ.

In Utero Diagnosis and Treatment

NH-28

Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born.

[Coding instructions for Secondary Diagnosis](#)**Secondary Diagnoses** **NH-29**

The CoC requires the registry record include up to 10 comorbid conditions, factors influencing the health status of the patient, and treatment complications, to be copied from the patient record typically located on the patient's discharge abstract or face sheet of the medical/billing record.

Beginning with cases diagnosed in 2018, the following data items are required:

Secondary Diagnosis #1-10[3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798].

Three general categories of information are collected within the data item(s), Secondary Diagnosis represented by ICD-10-CM codes found in the patient record: comorbidities, complications, and factors influencing the health status of patients.

Comorbidities are preexisting medical conditions or conditions that were present at the time the patient was diagnosed with this cancer (for example, chronic conditions such as COPD, diabetes, and hypertension).

Complications are conditions that occur during the hospital stay, while the patient is being treated for the cancer (for example, postoperative urinary tract infection or pneumonia). Complications may also occur following the completion of therapy and be a cause for readmission to the hospital. Complications are identified by codes which classify environmental events, circumstances, and conditions as the cause of injury, poisoning, and other adverse effects. Only complication codes that describe adverse effects occurring during medical care are collected in this data item. They include misadventures to patients during surgical and medical care, and drugs and medicinal and biologic substances causing adverse effects in therapeutic use.

Factors influencing the health status of patients are circumstances or problems that are not themselves a current illness or injury (for example, women receiving postmenopausal hormone replacement therapy, or a history of malignant neoplasm). Only specific codes which describe health characteristics are collected in this data item. They include prophylactic measures, personal health history, pregnancy, contraception, artificial opening and other postsurgical states, and prophylactic organ removal.

Stage of Disease at Initial Diagnosis **NH-30****AJCC Prognostic Staging**

AJCC Prognostic Stage is determined at key time points in a patient's care based on criteria including the clinical examination, imaging, operative procedures, and pathologic assessment of the anatomic extent of disease – plus additional prognostic factors as required – and is used to make appropriate treatment decisions, determine prognosis, and measure end results. Use the rules in the current *AJCC Cancer Staging System* to assign AJCC T, N, M, required prognostic factor(s), and Stage Group values.

The following general rules apply to AJCC staging of all sites.

- Clinical staging includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is shorter, as long as the cancer has not clearly progressed during that time frame. This stage classification is designated as cTNM.
- Pathological staging includes any information obtained about the extent of cancer through completion of definitive surgery as part of first course treatment or identified within 4 months after the date of diagnosis, whichever is longer, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame. This stage classification is designated as pTNM.

- Post therapy clinical staging (post-neoadjuvant therapy staging) includes any information obtained about the extent of cancer after completion of neoadjuvant therapy and before the planned surgery, and the time frame should be such that the post neoadjuvant therapy staging occurs within a time frame that accommodates disease specific circumstances. This stage classification is designated as ycTNM. Registrars are only required to complete yc staging when the planned surgery following neoadjuvant therapy has been cancelled.
- Post therapy pathological staging (post-neoadjuvant therapy staging) includes any information obtained about the extent of cancer after completion of neoadjuvant therapy followed by surgery, and the time frame should be such that the post neoadjuvant surgery and staging occur within a time frame that accommodates disease specific circumstances. This stage classification is designated as ypTNM.
- If a patient has multiple primaries, stage each primary independently.
- If the stage group cannot be determined from the recorded categories, then record it as unknown.
- When a patient with multiple primaries develops metastases, a biopsy may distinguish the source of distant disease. Stage both primaries as having metastatic disease if the physician is unable to conclude which primary has metastasized. If, at a later time, the physician identifies which primary has metastasized, update the stage(s) as appropriate.
- If pediatric staging is used and AJCC staging is not applied, code 88 for clinical and pathological T, N, and M as well as stage group. If either clinical, pathological or post therapy staging was applied for a pediatric tumor, enter the appropriate codes and do not code 88.
- If a site/histology combination is not defined in the current AJCC Cancer Staging System code 88 for clinical, pathological and post therapy T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the current AJCC Cancer Staging System code 88 for clinical and pathological T, N, and M as well as stage group.
- For additional information on AJCC’s general staging rules, visit the [American Joint Committee on Cancer](#) webpage.

First Course of Treatment

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. “Active surveillance” is a form of planned treatment for some patients; its use is coded in the *RX Summ–Treatment Status* [1285]. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, the physician recommends no treatment be given or the physician recommends palliative care for pain management only. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities. Maintenance treatment given as part of the first course of planned care (for example, for leukemia) is first course treatment, and cases receiving that treatment are analytic. If the first course of treatment plan changes due to an improvement in the tumor burden, the added treatment would still be considered first course. An example is palliative chemotherapy/radiation is recommended and administered per the first course treatment plan. Initially resection of primary tumor was contraindicated due to tumor size and location. Follow up imaging shows an improvement in tumor burden and treatment plan changed since tumor is now resectable to include surgery. Even though the primary tumor resection was not noted in the first course of treatment plan, the resection would be captured as first course of treatment since there was no progression of tumor.

Treatment Plan

A treatment plan describes the type(s) of therapies intended to modify, control, remove, or destroy proliferating cancer cells. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records.

- All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient and before disease progression.

- A discharge plan must be a part of the patient's record in the hospital's EHR and may contain part or all of the treatment plan.
- An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle: "initial treatment must begin within four months of the date of initial diagnosis."

Time Periods for First Course of Treatment

If first course treatment was provided, the *Date of First Course of Treatment* [1270] is the earliest of *Date of First Surgical Procedure* [1200], *Date Radiation Started* [1210], *Date Systemic Therapy Started* [3230], or *Date Other Treatment Started* [1250].

- If no treatment is given, record the date of the decision not to treat, the date of patient refusal, or the date the patient expired if the patient died before treatment could be given.
- If active surveillance ("watchful waiting") was the only treatment selected, record the date of that decision.
- Additional data items further define the parameters for specific treatments and treatment modalities, as described in the following sections.
- Data item, *RX Summ–Treatment Status* [1285], summarizes whether the patient received any first course treatment, no treatment, or is being managed by active surveillance.

All Malignancies except Leukemias

The first course of treatment includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Any therapy administered after the discontinuation of first course treatment is subsequent treatment.

Leukemias NH-31

The first course of treatment includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

Surgery

First course surgery items describe the most definitive (most invasive) type of surgical treatment the patient received from any facility, when it was performed, and its efficacy. When no surgical treatment is given, the reason is recorded. Major aspects of surgical care provided by the individual facility are also recorded so that hospital cancer programs can evaluate local patient care. NH-32

Individual item descriptions in [Section Two: Instructions for Coding](#) of this manual should be consulted for specific coding instructions. The paragraphs below describe how the surgery items fit together.

The following summary items apply to all surgical procedures performed at this facility and at other facilities:

Rx Summ – Surg 2023 [1291]

Radiation/Surgery Sequence [1380]

Scope of Regional Lymph Node Surgery [1292]

[Coding instructions for Surgery data items](#)

Date of Regional Lymph Node Dissection [682]

Date of Sentinel Lymph Node Biopsy (for breast and melanoma only) [832]

Sentinel Lymph Nodes Examined (for breast and melanoma only) [834]

Sentinel Lymph Nodes Positive (for breast and melanoma only) [835]
Surgical Procedure/Other Site [1294]
Surgical Margins of the Primary Site [1320]
Reason for No Surgery of Primary Site [1340]
Date of First Surgical Procedure [1200]
Date of Most Definitive Surgical Resection of the Primary Site [3170]
Date of Surgical Discharge [3180]
Readmission to the Same Hospital Within 30 Days of Surgical Discharge [3190]

The following items apply to surgical procedures performed at this facility:

Rx Hosp – Surg 2023 [671]
RX Hosp–Surg App 2010 [668]
Scope of Regional Lymph Node Surgery at This Facility [672]
Surgical Procedure/Other Site at This Facility [674]

Relationships among Surgical Items

Date of First Surgical Procedure [1200] is the date that the first *Rx Summ – Surg 2023* [1291], *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1), or *Surgical Procedure/Other Site* [1294] is performed as part of first course treatment.

- If surgery was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date of First Surgical Procedure* [1200] is the same as *Date of First Course of Treatment* [1270]. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Rx Summ – Surg 2023 [1291], *Scope of Regional Lymph Node Surgery* [1292], and *Surgical Procedure/Other Site* [1294] record three distinct aspects of first course therapeutic surgical procedures that may be performed during one or multiple surgical events. If multiple primaries are treated by a single surgical event, code the appropriate surgical items separately for each primary.

When multiple first course procedures coded under the same item are performed for a primary, the most definitive (most invasive) procedure is usually but not always the last performed.

Rx Summ-Surg 2023 [1291] represents the cumulative effect of the separate procedures. Do not rely on your registry software to accumulate separate surgeries into the correct code.

- *Rx Summ – Surg 2023* [1291] is a site-specific item that describes the most invasive extent of local tumor destruction or surgical resection of the primary site and of surrounding tissues or organs that are removed in continuity with the primary site.
- *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1) describes the removal, biopsy, or aspiration of sentinel nodes and other regional lymph nodes that drain the primary site and may include surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease as well as removal of nodes for treatment of the disease.
- *Surgical Procedure/Other Site* [1294] describes first course resection of distant lymph node(s) and/or regional or distant tissue or organs beyond the *Surgical Procedure of the Primary Site* range.

If surgery of the respective type was performed, the code that best describes the surgical procedure is recorded whether or not any cancer was found in the resected portion. Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.

The code ranges and corresponding descriptions for site-specific Surgical Procedure of Primary Site code are grouped according to the general nature of the procedure:

- Codes A/B100 through A/B190 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.
- Codes A/B200 through A/B800 are site-specific descriptions of resection procedures.
- The special code A980 applies to specific tumors that cannot be clearly defined in terms of primary/nonprimary site. Surgical Procedure of Primary Site should be coded A980 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for Unknown and Ill-Defined Primary Sites and Hematopoietic/ Reticuloendothelial/ Immunoproliferating/ Myeloproliferative Disease. The item Surgical Procedure/Other Site is used to indicate whether surgery was performed for these tumors.
- For codes A/B000 through A/B790, the descriptions of the surgical procedures are hierarchical. Last-listed Responses take precedence over earlier-listed responses (regardless of the code or numeric value).

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more invasive forms of resection. The numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

Example: A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed *after* polypectomy alone, is coded A220.

A200 Local tumor excision, NOS
 A260 Polypectomy
 A270 Excisional biopsy
 Combination of A200 or A260–A270 WITH
 A220 Electrocautery

Scope of Regional Lymph Node Surgery [1292] distinguishes between sentinel lymph node biopsy and removal of other regional lymph nodes and distinguishes removal of regional lymph nodes during the same surgical procedure as a sentinel node biopsy from subsequent removal.

- One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment to previously published treatment based on the former codes, or to data still unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. The compromise incorporated in the *Scope of Regional Lymph Node Surgery* [1292] codes separates removal of one to three nodes (code 4) from removal of four or more nodes in the response categories (code 5). It is very important to note that this distinction is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than four nodes was not reflected in surgery codes. The distinction between fewer than four nodes and four or more nodes removed is not intended to reflect clinical significance when applied to a particular surgical procedure.

Surgical Procedure/Other Site [1294] describes surgery performed on tissue or organs other than the primary site or regional lymph nodes to evaluate for possible malignant involvement. It is also used to describe whether surgery was performed for tumors having unknown or ill-defined primary sites or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease morphologies. If any surgical treatment was performed on these cancers, *Surgical Procedure/Other Site* is coded 1.

Rx Hosp – Surg 2023 [671], *Scope of Regional Lymph Node Surgery at This Facility* [672], and *Surgical Procedure/Other Site at This Facility* [674] are identical to *Rx Summ – Surg 2023* [1291], *Scope of Regional Lymph Node Surgery* [1292], and *Surgical Procedure/Other Site* [1294], respectively, except they each refer solely to surgery provided by the respective facility.

Six surgery items augment the information recorded in *Rx Summ - Surg 2023* [1291]. The items *Date of Most Definitive Surgical Resection of the Primary Site* [3170], *Surgical Margins of the Primary Site* [1320], *Date of Surgical Discharge* [3180], and *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] apply to the most definitive (most invasive) first course primary site surgery performed, that is, to the event recorded under *Rx Summ – Surg 2023* [1291]. When no surgical procedure of the primary site is performed, the reason is recorded in the item *Reason for No Surgery of Primary Site* [1340].

- *Date of Most Definitive Surgical Resection* [3170] is the date on which the specific procedure recorded in *Rx Summ – Surg 2023* [1291] was performed. If only one first course surgical procedure was performed, then the date will be the same as that for *Date of First Surgical Procedure* [1200].
- *Surgical Margins of the Primary Site* [1320] records the pathologist’s determination of the presence of microscopic or macroscopic involvement of cancer at the margins of resection following the surgical resection described by *Rx Summ – Surg 2023* [1291].
- *RX Hosp–Surg App 2010* [668] distinguishes among open surgery, laparoscopic surgery, and robotic assisted surgery when it is performed by the reporting facility. If more than one surgical procedure is performed by the facility, this item refers to the most definitive (most invasive) first course primary site surgery performed.
- *Date of Surgical Discharge* [3180] is the date the patient was discharged following the procedure recorded in *Rx Summ – Surg 2023* [1291]. It is on or after the *Date of Most Definitive Surgical Resection* [3170].
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] distinguishes a planned from an unplanned hospital inpatient admission and is used as a quality of care indicator.
- *Reason for No Surgery of Primary Site* [1340] identifies why surgical therapy was not provided to the patient and distinguishes between a physician not recommending surgical therapy due to contraindicating conditions and a patient’s refusal of the recommended treatment plan.

Radiation Therapy

The radiation items in *STORE* are clinically relevant and reflect contemporary practice. These items record new “phase” terminology, replacing the traditional terms of “regional” and “boost.” The first phase (Phase I) of a radiation treatment may be commonly referred to as an initial plan and a subsequent phase (Phase II) may be referred to as a boost or cone down but modern radiotherapy allows phases to be delivered simultaneously so new terminology is needed. Each phase is meant to reflect a “delivered radiation prescription”. At the start of the radiation planning process, physicians write radiation prescriptions to treatment volumes and specify the dose per fraction (session), the number of fractions, the modality, and the planning technique. A phase simply represents the radiation prescription that has actually been delivered (as sometimes the intended prescription differs from the delivered prescription.)

The following summary items apply to all radiation therapy administered at this facility and at other facilities:

Date Radiation Started [1210]

Location of Radiation Treatment [1550]

Radiation/Surgery Sequence [1380]

Date Radiation Ended [3220]

Reason for No Radiation [1430]

[Coding instructions for Radiation data items](#)

The following are the new phase-specific data items Phase I [1501-1507], Phase II [1511-1517], Phase III [1521-1527]:

- Radiation Primary Treatment Volume*
- Radiation to Draining Lymph Nodes*
- Radiation Treatment Modality*
- Radiation External Beam Planning Technique*
- Dose per Fraction*
- Number of Fractions*
- Total Dose*

The details of the radiation course can typically be found in the radiation oncologist's radiation treatment summary.

Please see [Appendix R](#) for examples in coding radiation treatment data items.

Radiation Treatment Phase-specific Data Items

To promote consistency across the clinical and registry community, new “phase” terminology has been adopted, replacing the traditional terms of “regional” and “boost.” A course of radiation is made up of one or more phases and each phase includes a target volume and a delivered prescription. At the start of the radiation planning process, physicians write radiation prescriptions to treatment volumes and specify the dose per fraction (session), the number of fractions, the modality, and the planning technique. A phase represents the radiation prescription that has actually been delivered as sometimes the intended prescription differs from the delivered prescription. The first phase (Phase I) of a radiation treatment may be referred to as an initial plan and a subsequent phase (Phase II) may be referred to as a boost or cone down. Up to three phases of radiation treatment can now be documented.

Note that phases can be delivered sequentially or simultaneously. In sequential phases, a new phase begins when there is a change in the anatomic target volume of a body site, treatment fraction size, modality or technique.

When phases are delivered simultaneously, this is sometimes referred to as “dose painting” or “simultaneous integrated boost (SIB)”. If multiple phases start on the same date, then summarize in order from highest ‘Total Phase Dose’ to lowest ‘Total Phase Dose’. If multiple phases start on the same date and have the same Total Phase Dose, then any order is acceptable.

Typically, in each phase, the primary tumor or tumor bed is treated. However, radiation treatment also commonly includes draining lymph node regions that are associated with the primary tumor or tumor bed. Because of this, the historical *Radiation Treatment Volume* [1540] has been divided into the phase-specific data items of *Radiation Primary Treatment Volume* and *Radiation to Draining Lymph Nodes*.

Historically, the previously named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that were commonly utilized by radiation oncologists. The

implementation of separate phase-specific data items for the recording of radiation modality (*Radiation Treatment Modality*) and radiation treatment planning techniques (*Radiation External Beam Planning Technique*) clarify this information using mutually exclusive categories.

Relationships among Radiation Items

Date Radiation Started [1210] is the date that the first radiation therapy was delivered to the patient as part or all of the first course of therapy. This item in combination with *Date Radiation Ended* [3220]

allows the duration of treatment to be calculated.

- If radiation was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date Radiation Started* [1210] is the same as *Date of First Course of Treatment* [1270]. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Location of Radiation Treatment [1550] can be used to assess where therapy was provided. This item allows for the distinction between summary treatment and treatment given at the accessioning facility. Codes are provided that allow the description of where regional and boost dose therapy were provided, whether all the therapy was provided at the accessioning facility or if all or some of the radiation therapy was referred out to another treatment location.

The targeted anatomic region is described by *Phase I, II and III Radiation Primary Treatment Volume* [1504, 1514 and 1524, respectively]. The treatment volume may be the same as the primary site of disease; however, the available code values provide descriptions of anatomic regions that may extend beyond the primary site of disease and may be used to describe the treatment of metastatic disease. If two distinct volumes are radiated, and one of those includes the primary site, record the radiation involving the primary site for each phase in the applicable radiation data items.

In addition to knowing the duration of treatment and the modalities and doses involved, it is critical to know the number of treatments to be able to gauge the intensity of the dose delivered to the patient. The data item *Number of Phases of Radiation Treatment to This Volume* [1532] describes the total number of therapeutic treatments (phases) delivered to the anatomic volume coded in *Phase I, II and III Radiation Primary Treatment Volume* [1504, 1514, and 1524, respectively].

Two items augment the information recorded in the radiation modality, dose, volume, and number of treatment items.

- *Radiation/Surgery Sequence* [1380] identifies those instances where radiation therapy and the surgical management of the patient are not discrete and overlap with respect to time.
- Radiation therapy can precede the surgical resection of a tumor and then be continued after the patient's surgery, or radiation can be administered intraoperatively.
- *Reason for No Radiation* [1430] identifies why radiation therapy was not provided to the patient and distinguishes between a physician not recommending the therapy due to contraindicating conditions and a patient's refusal of the recommended treatment plan.

Systemic Therapy

Systemic therapy encompasses the treatment modalities captured by the items chemotherapy, hormone therapy, and immunotherapy. The systemic therapy items in *FORDS/STORE* separate the administration of systemic agents or drugs from medical procedures which affect the hormonal or immunologic balance of the patient.

The following summary items apply to all systemic therapy administered at this facility and at other facilities:

Date Systemic Therapy Started [3230]

Date Chemotherapy Started [1220]

Date Hormone Therapy Started [1230]

[Coding instructions for Systemic Therapy](#)

Date Immunotherapy Started [1240]
Systemic/Surgery Sequence [1639]
Chemotherapy [1390]
Hormone Therapy [1400]
Immunotherapy [1410]
Hematologic Transplant and Endocrine Procedures [3250]

The following items describe systemic therapy performed at this facility:

Chemotherapy at This Facility [700]
Hormone Therapy at This Facility [710]
Immunotherapy at This Facility [720]

Clarification of Systemic Therapy Terms	
Term	Definition
Chemotherapy	Cancer therapy that achieves its antitumor effect through the use of antineoplastic drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis. (i.e. gemcitabine, etoposide , capecitabine)
Hormone therapy	Cancer therapy that achieves its antitumor effect through changes in hormonal balance. This type of therapy includes the administration of hormones, agents acting via hormonal mechanisms, antihormones, and steroids. (i.e. leuprolide acetate, levothyroxine sodium, anastrozole)
Immunotherapy	Cancer therapy that achieves its antitumor effect by altering the immune system or changing the host's response to the tumor cells. (i.e. panitumumab, rituximab, ramucirumab)
Endocrine therapy	Cancer therapy that achieves its antitumor effect through the use of radiation or surgical procedures that suppress the naturally occurring hormonal activity of the patient (when the cancer occurs at another site) and, therefore, alter or affect the long-term control of the cancer's growth. (i.e. oophorectomy, orchiectomy performed for the purposes of hormonal suppression)
Hematologic transplants	Bone marrow or stem cell transplants performed to protect patients from myelosuppression or bone marrow ablation associated with the administration of high-dose chemotherapy or radiation therapy. (i.e. stem cell harvest, bone marrow autologous transplant, umbilical cord stem transplant)

Chemotherapy and hormone therapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more drugs. First course treatment does not necessarily end due to the managing physician changing an agent or agents in a combination regimen, to an agent of a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous). Changes in an agent or agents may occur due to reasons other than disease progression. A change to the regimen does not automatically represent subsequent therapy.

Refer to the SEER*RX Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) for a list of systemic therapy agents.

Systemic agents may be administered by intravenous infusion or given orally. Other methods of administration include the following:

Method	Administration
Intrathecal	Administered directly into the cerebrospinal fluid through a lumbar puncture needle into an implanted access device (for example, Ommaya reservoir).
Pleural/pericardial	Injected directly into pleural or pericardial space to control malignant effusions.
Intraperitoneal	Injected into the peritoneal cavity.
Hepatic artery	Injected into a catheter inserted into the artery that supplies blood to the liver.

Relationships Among Systemic Therapy Items

The data item *Date Systemic Therapy Started* describes the first date on which any first course systemic treatment was administered to the patient. Nine out of 10 patients treated with systemic therapy receive only a single class of drugs (chemotherapy, hormone therapy, or immunotherapy). Of the remaining patients who receive a combined regimen of systemic therapies, two-thirds begin these combined regimens simultaneously. For the purposes of clinical surveillance, the collection of multiple dates to describe the sequence of systemic therapy administration is not necessary.

The data items *Chemotherapy*, *Hormone Therapy*, and *Immunotherapy* describe whether or not each respective class of agent(s) or drug(s) were administered to the patient as part of first course therapy, based on *SEER*Rx*. In the case of chemotherapy, additional distinction is allowed for instances where single or multiagent regimens were administered. Each of these three items includes code values that describe the reason a particular class of drugs is not administered to the patient and distinguishes between physician not recommending systemic therapy due to contraindicating conditions and a patient's refusal of a recommended treatment plan.

Hematologic Transplant and Endocrine Procedures data captures two distinct types of treatment in the same data item.

- Hematologic procedures, such as bone marrow transplants or stem cell harvests, are typically employed in conjunction with administration of systemic agent(s), usually chemotherapy.
- Endocrine Procedures are medical, surgical, or radiation procedures performed infrequently to affect the hormonal or immunological balance of the patient.

Other Treatment

Other Treatment encompasses first course treatment that cannot be described as surgery, radiation, or systemic therapy according to the defined data items found in this manual.

This item is also used for supportive care treatment for reportable hematopoietic diseases that do not meet the usual definition in which treatment "modifies, controls, removes, or destroys proliferating cancer tissue." Treatments such as phlebotomy, transfusions, and aspirin are recorded in *Other Treatment* data item for certain hematopoietic diseases and should be coded 1. Consult the most recent version of the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual for instructions for coding care of specific hematopoietic neoplasms in this item.

The following items apply to all Other Treatment provided at this facility and at other facilities:

Date Other Treatment Started [1250]

Other Treatment [1420]

Other Treatment at This Facility [730]

[Coding instructions for Other Treatment](#)

Palliative Care

Palliative care is provided to prolong the patient's life by controlling symptoms, to alleviate persistent pain, or to make the patient comfortable. Palliative care provided to relieve symptoms may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy. Palliative care is not used to diagnose or stage the primary tumor.

The following items apply to all palliative care provided at this facility and at other facilities:

Palliative Care [3270]

Palliative Care at This Facility [3280]

[Coding instructions for Palliative Treatment](#)

Any surgical procedure, radiation therapy, and/or systemic therapy that is provided to modify, control, remove, or destroy primary or metastatic cancer tissue, is coded in the respective first course of treatment fields and also identified in the *Palliative Care* items. Refer to the preceding discussion of the surgery, radiation and systemic therapy data items for specific coding guidelines. Because these treatments are less aggressive when given for palliation than for treatment, the treatment plan or treatment notes will indicate when they are performed for palliative purposes.

- Record as palliative care any of the treatment recorded in the first course therapy items that was provided to prolong the patient's life by managing the patient's symptoms, alleviating pain, or making the patient more comfortable. This includes care received during hospice.
- Palliative care can involve pain management that may not include surgery, radiation or systemic treatment.
- It is possible for a patient to receive one or a combination of treatment modalities in conjunction with palliative care intended to reduce the burden of pain. For example, a patient with metastatic prostate cancer may receive an orchiectomy and systemic hormone therapy in combination with palliative radiation for bone metastasis.

Treatment, Palliative, and Prophylactic Care

Any first course radiation or systemic treatment that acts to kill cancer cells is to be reported as treatment. For example, when total body irradiation (TBI) is given to prepare the patient for a bone marrow transplant (BMT), the TBI acts in two ways. First, it suppresses the immune system to reduce the body's ability to reject the BMT. Second, it contributes to the patient's treatment by destroying cancer cells in the bone marrow, though its use alone would generally not be sufficient to produce a cure. Both the TBI and the BMT should be coded as treatment. The situation is analogous to the use of breast-conserving surgery and adjuvant radiation when the surgery or radiation alone may not be sufficient to produce a cure, though together they are more effective.

When first course surgery, systemic treatment, or radiation is undertaken to reduce the patient's symptoms, that treatment should be coded as palliative care. An example is radiation to bone metastases for prostate cancer to reduce bone pain, which is palliative when there is no expectation that the radiation will effectively reduce the cancer burden. Palliative care involving surgery, systemic treatment, or radiation is also coded as treatment. This treatment qualifies the patient as analytic if it is given as part of planned first course treatment.

The term "prophylactic" is used in medical practice in a variety of ways. An action taken to prevent cancer from developing (such as a double mastectomy for a healthy woman who has several relatives diagnosed with breast cancer when they were young) is not reportable; there is no cancer to report. Actions taken as part of planned first course treatment to prevent spread or recurrence of the cancer are sometimes characterized as "prophylactic" (for example, performing an oophorectomy or providing Tamoxifen to a breast cancer mastectomy patient). These treatments are to be coded as treatment.

Embolization

The term *embolization* refers to the intentional blocking of an artery or vein. The mechanism and the reason for embolization determine how and whether it is to be recorded.

Chemoembolization is a procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This procedure permits a higher concentration of drug to be in contact with the tumor for a longer period of time. Code chemoembolization as *Chemotherapy* when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term *chemoembolization* is used with no reference to the agent. Use *SEER*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents. Also, code as *Chemotherapy* when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as *Other Therapy*.

Radioembolization is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Assign *Radiation Modality* to code 13 Radioisotopes for radioembolization procedures (e.g. intravascular Yttrium-90) for cases diagnosed January 1, 2018, or later. For cases diagnosed prior to January 1, 2018, use code 07 Brachytherapy, NOS.

Embolization is coded as *Other Therapy* (code 1) if the embolizing agent is alcohol, or if the embolized site is other than the liver and the only information in the record is that the patient was given “embolization” with no reference to the agent.

Do not code presurgical embolization of hypervascular tumors with particles, coils or alcohol. These presurgical embolizations are typically performed to make the resection of the primary tumor easier. Examples where presurgical embolization is used include meningiomas, hemangioblastomas, paragangliomas, and renal cell metastases in the brain.

Outcomes **NH-33**

Coding instructions for Outcomes data items

The outcomes data items describe the known clinical and vital status of the patient. Follow-up information is obtained at least annually for all living *Class of Case* 10-22 patients included in a cancer registry’s database. Recorded follow-up data should reflect the most recent information available to the registry that originates from reported patient hospitalizations, known patient readmissions, contact with the patient’s physician, and/or direct contact with the patient. Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe the range of follow-up information that should be obtained.

Follow-up items that are required to be in the facility’s database

There may be times when first course treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the necessary treatment information is collected.

This includes:

- Complete first course of treatment information when *Rx Summ – Surg 2023* [1291] is delayed six months or more following the *Date of First Contact* [580].
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] following the most definitive (most invasive) surgery (surgical procedure recorded in the data item, *Rx Summ-Surg 2023* [1291]).
- Radiation, chemotherapy, hormone therapy, immunotherapy, hematologic transplant and endocrine procedures, or other treatment that had been indicated as being planned as part of first course of treatment but not been started or completed as of the most recent follow-up date. Use “reason for no” treatment codes of 88 or 8 as ticklers to identify incomplete treatment information.

- When all planned first course treatment has been recorded, first course treatment items no longer need to be followed.
- The CoC does not require Class 00 cases to be followed.
- Follow-up for disease recurrence should be conducted until (a) evidence of disease recurrence is reported, or (b) the patient dies. If the *Type of First Recurrence* [1880] is coded 70 (never cancer free), when the patient was last seen, but treatment was still underway, then check at follow-up to see whether the patient subsequently became cancer-free. Occasionally, if first course treatment ends due to disease progression, it may be the second course or subsequent treatment that results in a cancer-free status. If the *Type of First Recurrence* is coded 00 (became cancer-free and has had no recurrence), then continue to follow for recurrence and record the type and date when it occurs.

In order to facilitate research on cancer recurrence, two new follow-up data items have been added for 2018 that allow for the recording of the last date on which the patient's cancer status has been updated.

Unlike the *Date of Last Contact or Death* [1750], which is a patient-specific data item, these new data items are tumor-specific to better document tumor recurrence/no evidence of disease (NED).

- Date of Last Cancer (Tumor) Status [1772]
- Cancer Status [1770]

Recurrence Definition

Local recurrence: recurs in initial primary organ

Trocar recurrence: organ removed, recurs in scar tissue from removal

Regional recurrence: recurs in adjacent organ or lymph nodes draining the organ

Distant recurrence: recurs in a location beyond regional

Once the first recurrence has been recorded, do not update recurrence items further.

While the patient is alive, be sure that contact information is kept current. Contact information includes:

Date of Last Contact or Death [1750]

Follow-Up Source, [1790]

Next Follow-Up Source [1800]

Follow-up for *Vital Status* [1760] and *Cancer Status* [1770] should be conducted annually for all analytic cases in the cancer program's registry. *Class of Case* 00 patients that are not followed will have the most recent information as of the *Date of Last Contact or Death* [1750].

Once the patient's death has been recorded and all care given prior to death is recorded, no further follow-up is performed.

Case Administration

[Coding instructions for Case Administration data items](#)

Correct and timely management of case records in a registry data set are necessary to describe the nature of the data in the cancer record and to facilitate meaningful analysis of data, and it is necessary to understand each item's respective purpose to ensure their accuracy and how to use them in facility analysis.

Administrative Tracking

The following administrative tracking items are required to be in the facility's database:

Abstracted By [570] **NH-34**
Facility Identification Number (FIN) [540]
NPI-Reporting Facility [545]
Archive FIN [3100]
NPI-Archive FIN [3105]

Abstracted By [570], *Facility Identification Number (FIN)* [540], and *NPI-Reporting Facility* [545] identify the individual and facility responsible for compiling the record. *Archive FIN* and *NPI-Archive FIN* store the identification numbers assigned to the original abstracting facility and are used to convey the original identity assigned to a facility that has since merged with another. In a registry with more than one abstractor or serving more than one facility, it will ordinarily be necessary to enter these three numbers only when they change. All of these items should be autocoded by the registry software.

Note: NPI numbers are available through the facility's billing or accounting department or at <https://nppes.cms.hhs.gov/#/>.

EDITS Overrides **NH-35**

Some of the CoC edits identify rare, but possible, code combinations. For these edits, an override flag can be set if, upon review, the unusual combination is verified as being correct. Once set, the error message will not be repeated on subsequent EDITS passes.

- When no error message is generated by an edit that uses an override item, no action by the registrar is needed.
- If an error message is generated, the problem can often be resolved by checking the accuracy of the entry for each item that contributes to the edit and correcting any problems identified. If correction of data entry errors resolves the problem, do not make an override entry. If the codes reflect the information in the patient record, check for physician notes indicating the unusual combination of circumstances (for example, a colon adenocarcinoma in a child) has been confirmed. Enter the override code according to the instructions for the data item.
- If no comment regarding the unusual circumstances can be found in the record, it may be necessary to check with the managing physician or pathologist to determine whether it is appropriate to override the edit.

The following override items are required to be in the facility's database:

Override Site/Type [2030]
Override Site/TNM-StgGrp [1989]

Code Versions Used

Fifteen items describe the version of codes applied to record information in the registry record. Because registries cover many years of cases, registry data will be recorded according to many different coding systems. These items are necessary for the analysis of registry data and for further conversions, so it is important that they be maintained accurately.

The following code version items are required to be in the facility's database:

TNM Edition Number [1060]
CS Version Input Original [2935; for cases diagnosed 2004-2017]
CS Version Input Current [2937; for cases diagnosed 2004-2017]
CS Version Derived [2936; for cases diagnosed 2004 through 2015]

All of these items are capable of being autocoded.

For newly abstracted cases, code version information will be applied both as the current and original code versions. When registry data are converted to an updated version for a coding system, the code for the current version should be updated automatically by the conversion.

It is not possible to convert from one version of AJCC TNM to another. The registrar should ascertain that the correct version number is recorded for autocoding.

Section Two: Instructions for Coding

NH-36

Patient Identification

Accession Number

Item #	Length	Allowable Values	Required Status	Date Revised
550	9	See Coding Instructions	All Years	01/04, 01/10

Description

Provides a unique identifier for the patient consisting of the year in which the patient was first seen at the reporting facility and the consecutive order in which the patient was abstracted.

Rationale

This data item protects the identity of the patient and allows cases to be identified on a local, state and national level.

Coding Instructions

- When a patient is deleted from the database, **do not** reuse the accession number for another patient.
- The first four numbers specify the year and the last five numbers are the numeric order in which the patient was entered into the registry database.
- Numeric gaps are allowed in accession numbers.
- A patient's accession number is never reassigned.

Code	Definition
(fill spaces)	Nine-digit number used to identify the year in which the patient was first seen at the reporting facility for the diagnosis and/or treatment of cancer.

Examples

Code	Reason
202300033	Patient enters the hospital in 2023, and is diagnosed with breast cancer. The patient is the thirty-third patient accessioned in 2023.
202300033	A patient with the accession number 202300033 for a breast primary returns to the hospital with a subsequent colon primary in 2024. The accession number will remain the same. <i>Sequence Number</i> [560] will distinguish this primary.
202300010	Patient diagnosed in November 2022 at another facility enters the reporting facility in January 2023, and is the tenth case accessioned in 2023.
202300012	Patient diagnosed in staff physician office in December 2022 enters the reporting facility in January 2023, and is the twelfth case accessioned in 2023.
202300001	First patient diagnosed and/or treated and entered into the registry database for 2023.
202300999	Nine hundred ninety-ninth patient diagnosed and/or treated and entered into the registry database for 2023.
202401504	One thousand five hundred fourth patient diagnosed and/or treated and entered into the registry database for 2024.

Sequence Number

Item #	Length	Allowable Values	Required Status	Date Revised
560	2	00-88, 99	All Years	06/05, 04/07, 01/10, 01/13

Description

Indicates the sequence of malignant and nonmalignant neoplasms over the lifetime of the patient.

Rationale

This data item is used to distinguish among cases having the same accession numbers, to select patients with only one malignant primary tumor for certain follow-up studies, and to analyze factors involved in the development of multiple tumors.

Coding Instructions

- Codes 00–59 and 99 indicate neoplasms of malignant (in situ or invasive) behavior (Behavior equals 2 or 3). Codes 60–88 indicate neoplasms of non-malignant behavior (Behavior equals 0 or 1).
- Code 00 only if the patient has a single malignant primary. If the patient develops a subsequent invasive or in situ primary tumor, change the code for the first tumor from 00 to 01, and number subsequent tumors sequentially.
- Code 60 only if the patient has a single non-malignant primary. If the patient develops a subsequent non-malignant primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent non-malignant primaries sequentially.
- If two or more invasive or in situ neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, do not reassign sequence numbers if one of those tumors becomes non-reportable later.
- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence.

Malignant or In Situ Primaries

Code	Definition
00	One malignant or <i>in situ</i> primary only in the patient's lifetime
01	First of two or more independent malignant or <i>in situ</i> primaries
02	Second of two or more independent or <i>in situ</i> primaries
...	(Actual sequence of this malignant or <i>in situ</i> primary)
59	Fifty-ninth of 59 or more independent malignant or <i>in situ</i> primaries
99	Unknown number of malignant or <i>in situ</i> primaries

Non-Malignant Primaries

Code	Definition
60	One nonmalignant primary only in the patient's lifetime
61	First of two or more independent nonmalignant primaries
62	Second of two or more independent nonmalignant primaries
...	(Actual sequence of this nonmalignant primary)
87	Twenty-seventh of 27 or more independent nonmalignant primaries
88	Unspecified number of independent nonmalignant primaries

Examples

Code	Reason
00	A patient with no previous history of cancer is diagnosed with in situ breast carcinoma. The in situ breast cancer would be accessioned as sequence 00, as this is the patient's first and single reportable malignant cancer.
01	The patient in the above example develops a second reportable malignancy, melanoma. The in situ breast cancer initially accessioned as sequence 00 is updated to sequence 01 representing the first of multiple malignancies.
02	The melanoma in the example above is accessioned as sequence 02, representing the second of multiple malignancies.
04	A patient is admitted for hemicolectomy for colon adenocarcinoma. The patient has a prior history of three reportable malignant cancers which were not initially diagnosed or received cancer directed treatment at the reporting hospital. No sequence numbers 01, 02 or 03 are accessioned for this patient. The colon adenocarcinoma would be accessioned as sequence 04 representing this is the fourth malignancy for this patient.
60	A patient has a history of breast carcinoma and melanoma. Patient had MRI of brain at reporting facility and is diagnosed with a new primary (meningioma). The meningioma is accessioned as sequence 60, representing the first and only benign brain or CNS primary for this patient.
63	The meningioma in the example above is initially accessioned as Sequence 60. Later it was discovered the patient had history of an earlier benign CNS tumor diagnosed and treated at an outside facility; the meningioma originally assigned to sequenced 60 (representing the first and only benign brain/CNS tumor) is updated to sequence 62 representing the meningioma is the second benign brain/CNS tumor for this patient.

Medical Record Number

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2300	15	medicalRecordNumber	Alphanumeric	All Years	2011, 2021

Description

Records medical record number used by the facility to identify the patient.

Rationale

This number identifies the patient in a facility. It can be used by a central registry to point back to the patient record, and it helps identify multiple reports on the same patient.

Coding Instructions

1. Record the medical record number.

Codes (in addition to the medical record number)

Code	Label
UNK	Medical record number unknown
RT	Radiation therapy department patient without HIM number
SU	1-day surgery clinic patient without HIM number

Note: Other standard abbreviations may be used to indicate departments within the facility for patients without HIM numbers assigned.

Social Security Number

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2320	9	socialSecurityNumber	001010001-899999999, 999999999. Invalid values in this range exist.	All Years	2021

Description

Records patient's social security number. The number is entered without dashes and without any letter suffix. This is not always identical to the Medicare claim number.

Rational

This data item can be used to identify patients with similar names.

Social Security Number is collected by NHSCR for identification and matching purposes. It is important to record the correct SSN for each patient so that cases reported by multiple sources are correctly merged and consolidated.

Code Instructions

1. Code the patient's Social Security number.
2. For missing parts of Social Security Number, enter 9s or leave blank depending on what the registry software allows.
3. Do not enter automatically enter a patient's Medicare claim number; it may not always be identical to the person's Social Security number.
4. Code Social Security numbers that end with "B" or "D" as 999999999. The patient receives benefits under the spouse's number and this is the spouse's Social Security number.
5. See <https://www.ssa.gov/> for more information.

Codes (in addition to social security number)

Code	Definition
(fill spaces)	Record the patient's Social Security number without dashes
999999999	Patient does not have a Social Security number; SSN is not available; unknown.

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed](#). Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

Source 3: Sanchez P, Groves C, Adamo M. (September 2025). [SEER Program Coding and Staging Manual 2026](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

Name--Last

Item #	Length	Allowable Values	Required Status	Date Revised
2230	40	See Coding Instructions	2026+	01/26

Description

Identifies the last name of the patient. The last name may also be referred to as surname. This data item is optional for CoC.

Rationale

Last name is collected for case matching purposes.

Coding Instructions

- If reporting names to CoC, and the patient's last name is unavailable, code as UNKNOWN.
- Mixed Case left justified.
- Truncate name if longer than 40 characters.
- Blank spaces, hyphens, and apostrophes are allowed; do not use other punctuation.
- Record the most current name and update this data item if the last name changes.
- Enter previous names in the Name--Alias data item [2280].

Examples

Code	Definition
Mc Farland	Record with space as Mc Farland
O'Reilly	Record with apostrophe as O'Reilly
Unknown	Last name is not known
Blank	Program is not reporting to CoC

Name--Birth Surname

Item #	Length	Allowable Values	Required Status	Date Revised
2232		See Coding Instructions	2026+	01/26

Description

Identifies the last name of the patient at birth regardless of gender or marital status. This data item is optional for CoC.

Rationale

Birth surname is collected for case matching purposes.

Coding Instructions

- Mixed Case left justified.
- Truncate name if longer than 40 characters.
- Record when known regardless of value in the Sex Assigned at Birth data item [225].
- Leave blank if the birth surname is not known or not applicable
- Blank spaces, hyphens, and apostrophes are allowed; do not use other punctuation

Examples

Code	Definition
Maiden name is Jones	Record Birth Surname as Jones
Blank	Birth Surname is not known

Name -- First

Item #	Length	Allowable Values	Required Status	Date Revised
2240	40	See Coding Instructions	2026+	01/26

Description

Identifies the first name of the patient. First name may also be referred to as given name. This data item is optional for CoC.

Rationale

First name is collected for case matching purpose.

Coding Instructions

- Mixed Case left justified
- Truncate if longer than 40 characters.
- Blank spaces, hyphens, and apostrophes are allowed; do not use other punctuation.
- Leave blank if first name is unknown.
- Record the most current name and update this data item if the first name changes.
- Enter previous names in Name--Alias data item [2280].
- Do not record nicknames in this data item. Record nicknames in Name--Alias data item [2280].

Examples

Code	Definition
John	Record as John
De Shandra	Record with space as De Shandra
Blank	First name is not known

Name—Middle

Item #	Length	Allowable Values	Required Status	Date Revised
2250	40	See Coding Instructions	2026+	01/26

Description

Identifies the middle name of the patient. This data item is optional for CoC.

Rationale

Middle Name is collected for case matching purposes.

Coding Instructions

- Mixed Case left justified
- Truncate middle name if longer than 40 characters.
- Blank spaces, hyphens, and apostrophes are allowed; do not use other punctuation.
- Record the middle initial if the full middle name is not known.
- Leave blank if the patient's middle name is unknown or patient has no middle name.
- Record the most current name and update this data item if the middle name changes.
Enter previous names in the Name--Alias data item [2280].

Examples

Code	Definition
Michael W. Smith	Record middle name as W
Blank	Middle name is not known

Name--Alias

Item #	Length	Allowable Values	Required Status	Date Revised
2280	40	See Coding Instructions	2026+	01/26

Description

Identifies the nickname of the patient. This data item is optional for CoC.

Rationale

Alias name is collected for case matching purposes.

Coding Instructions

- Mixed Case left justified
- Truncate middle name if longer than 40 characters.
- Blank spaces, hyphens, and apostrophes are allowed; do not use other punctuation.
- Leave blank if no known alias names.

Examples

Code	Definition
Robert Jones is also known as Bobby	Record alias as Bobby
Blank	No known alias names

Name--Prefix

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2260	3	namePrefix		All Years	

Description

Abbreviated title that precedes name in a letter (e.g., "Rev," "Ms").

Note: This data item is no longer supported by CoC (as of January 1, 2003).

Name--Suffix

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2270	3	nameSuffix		All Years	

Description

Title that follows a patient's last name, such as a generation order or credential status (e.g., "MD," "Jr.").

Note: This data item is no longer supported by CoC (as of January 1, 2003).

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and birth surname/maiden names.

Patient Address (Number and Street) at Diagnosis

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2330	60	addrAtDxNoStreet	Valid address or UNKNOWN	All Years	2010, 2012, 2021

Description

Identifies the patient's address (number and street) at the time of reportable cancer diagnosis. Residential street address should not include PO Boxes. For consolidated records, street address may be based on reported or corrected residential address information.

Rationale

The address is part of the patient's demographic data and has multiple uses. It can be used to evaluate referral patterns, allows for the analysis of cancer cluster concerns, and supports epidemiological studies that use area-based social measures.

Coding Instructions

- Record the number and street address or the rural mailing address of the patient's usual residence when the cancer was diagnosed.
- Record UNKNOWN when a PO Box or other non-physical, residential mailing address is the only address available, or when no other address information is available in the medical record and no other information sources are available. Record the PO Box or other non-physical, residential mailing address in *Addr At Dx—SupplementI* [2335].
- Additional address information such as facility, nursing home, name of apartment complex, or a PO Box used for mailing purposes, should be entered in *Addr At Dx—SupplementI* [2335].
- If the patient has multiple tumors, address at diagnosis may be different for each tumor.
- Do not update this item if the patient's residential address changes.
- U.S. addresses should conform to the U.S. Postal Service (USPS) Postal Addressing Standards. These standards are referenced in USPS Publication 28, Postal Addressing Standards. The current USPS Pub. 28 may be found and downloaded here: <http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Pub. 28, available at link above). Mixed case allowed.
- Punctuation marks should be avoided, except when punctuation is necessary to convey the meaning. Punctuation normally is limited to periods when the period carries meaning (e.g., 39.2 RD), slashes for fractional addresses (e.g., 101 1/2 Main St), and hyphens when the hyphen carries meaning (e.g., 289-01 Montgomery Ave). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 Main St Apt 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (e.g., 425 Flower Blvd # 72).
- Abbreviations should be limited to those recognized by USPS standard abbreviations. They include, but are not limited to the list below: A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.

APT	apartment	N	north
BLDG	building	NE	northeast
FL	floor	NW	northwest
STE	suite	S	south
UNIT	unit	SE	southeast
RM	room	SW	southwest
DEPT	department	E	east
		W	west

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

Patient Address at Diagnosis--Supplemental

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2335	60	addrAtDxSupplementI	Valid address or UNKNOWN	All Years	2006, 2010, 2012, 2021

Description

Provides the ability to store additional address information such as the name of a place or facility (for example a nursing home, apartment complex, jail or PO Box residential or other mailing address) at the time of diagnosis.

Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space.

The presence of a second street address field to hold additional address information also aids in follow-up. For instance, *Addr At DX--No & Street* [2330] should contain a street address only. However, it is important to retain any known PO Box information when linking for cohort studies or patient contact studies. Retaining facility name can also help correct errors in *Addr At DX--No & Street* [2330] or assist with geocoding or consolidation. Additionally, researchers can use this field to verify if geographic areas of high risk are driven by location of facilities, such as jails, nursing homes, or homeless shelters.

Coding Instructions

1. Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's usual residence when the tumor was diagnosed. Do not use this item for information stored in other address items such as *Addr At DX--NO & Street* [2330].
2. Record a full residential PO Box here (including city & zip code) or other non-physical, residential mailing address here.
3. Record HOMELESS here when the street address used is a shelter or diagnosing facility for persons with no usual residence.
4. Leave blank if this address space is not needed.
5. If the patient has multiple tumors, the address may be different for subsequent primaries.
6. Do not use this data item to record the number and street address of the patient.
7. Do not update this data item if the patient's address changes. Only update based on improved information on the residential address at time of diagnosis.
8. See Residency Rules in Section One for further instructions.

Source 1: Thornton ML, (ed). Data Standards and Data Dictionary, Version 26, 27th ed. Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: Standards for Oncology Registry Entry (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

City/Town at Diagnosis (City or Town)

Item #	Length	Allowable Values	Required Status	Date Revised
70	50	See Coding Instructions	1996+	01/10

Description

Identifies the name of the city or town in which the patient resides at the time the tumor is diagnosed and treated.

Rationale

The city or town is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Coding Instructions

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the city or town may be different for subsequent primaries.
- Do not update this data item if the patient's city or town of residence changes.
- See [Residency Rules](#) in Section One for further instructions.

Examples

Code	Reason
CITY NAME	Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary.
UNKNOWN	If the patient's city or town is unknown.

State at Diagnosis (State)

Item #	Length	Allowable Values	Required Status	Date Revised
80	2	See Coding Instructions	1996+	09/06, 01/10, 01/11, 01/12

Description

Identifies the patient's state of residence at the time of diagnosis.

Rationale

The state of residence is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

Coding Instructions

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the tumor is diagnosed and treated.
- If the patient has multiple tumors, the state of residence may be different for subsequent primaries.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Do not update this data item if the patient's state of residence changes.

Code	Label	Code	Label	Code	Label
AL	Alabama	MB	Manitoba	PW	Palau
AK	Alaska	MH	Marshall Islands	PA	Pennsylvania
AB	Alberta	MD	Maryland	PE	Prince Edward Island
AS	American Samoa	MA	Massachusetts	PR	Puerto Rico
AA	APO/FPO Armed Services America	MI	Michigan	QC	Quebec
AE	APO/FPO Armed Services Europe	FM	Micronesia	ZZ	Residence unknown.
AP	APO/FPO Armed Services Pacific	MN	Minnesota	XX	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>known</i> .
AZ	Arizona	MS	Mississippi	YY	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>unknown</i> .

Code	Label	Code	Label	Code	Label
AR	Arkansas	MO	Missouri	CD	Resident of Canada and the province is <i>unknown</i> .
BC	British Columbia	MT	Montana	US	Resident of the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i>
CA	California	NE	Nebraska	RI	Rhode Island
CD	Canada, province unknown	NV	Nevada	SK	Saskatchewan
CO	Colorado	NB	New Brunswick	SC	South Carolina
CT	Connecticut	NH	New Hampshire	SD	South Dakota
DE	Delaware	NJ	New Jersey	US	United States, state unknown
DC	District of Columbia	NM	New Mexico	TN	Tennessee
FL	Florida	NY	New York	TX	Texas
GA	Georgia	NL	Newfoundland and Labrador	UT	Utah
GU	Guam	NC	North Carolina	VT	Vermont
HI	Hawaii	ND	North Dakota	VI	Virgin Islands
ID	Idaho	NT	Northwest Territories	VA	Virginia
IL	Illinois	NS	Nova Scotia	WA	Washington
IN	Indiana	NU	Nunavut	WV	West Virginia
IA	Iowa	OH	Ohio	WI	Wisconsin
KS	Kansas	OK	Oklahoma	WY	Wyoming
KY	Kentucky	ON	Ontario	YT	Yukon
LA	Louisiana	OR	Oregon		
ME	Maine	UM	Outlying Islands		

Postal Code at Diagnosis (Zip Code)

Item #	Length	Allowable Values	Required Status	Date Revised
100	9	See Coding Instructions	All Years	01/04

Description

Identifies the postal code of the patient's address at diagnosis.

Rationale

The postal code is part of the patient's demographic data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies.

Coding Instructions

- For U.S. residents, record the patient's nine-digit extended postal code at the time of diagnosis and treatment.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple malignancies, the postal code may be different for subsequent primaries.
- Do not update this data item if the patient's postal code changes.
- See [Residency Rules](#) in Section One for further instructions.

Code	Definition
(fill spaces)	The patient's nine-digit U.S. extended postal code. Do not record hyphens.
60611_ _ _ _	When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks.
M6G2S8_ _ _	The patient's six-character Canadian postal code left justified, followed by three blanks.
88888_ _ _ _ or 8888888888	Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown.
99999_ _ _ _ or 9999999999	Permanent address in Canada, United States, or U.S. possession and postal code is unknown.

Address at Dx--Country

Item #	Length	Allowable Values	Required Status	Date Revised
102	3	See Coding Instructions	1996+	Added 01/13

Description

Identifies the country of the patient's residence at the time of diagnosis. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

Coding Instructions

- This item corresponds to the other Addr at DX items (state, postal code).
- Do not change if the patient moves to another country. Patients with more than one tumor may have different countries at diagnosis, however.
- See [Appendix C](#) for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

Examples

Code	Label
USA	United States
CAN	Canada

County at Diagnosis

Item #	Length	Allowable Values	Required Status	Date Revised
90	3	001-997, 998, 999	1996+	09/06, 01/10, 01/15

Description

Identifies the county of the patient's residence at the time the reportable tumor is diagnosed.

Rationale

This data item may be used for epidemiological purposes. For example, to measure the cancer incidence in a particular geographic area.

Coding Instructions

- For U.S. residents, use codes issued by the Federal Information Processing Standards (FIPS) publication Counties and Equivalent Entities of the United States, Its Possessions, and Associated areas. This publication is available in a reference library or can be accessed on the Internet through the U.S. EPA's Envirofacts Data Warehouse and Applications Web site at <https://www.epa.gov/>.
- If the patient has multiple tumors, the county codes may be different for each tumor.
- If the patient is a non-U.S. resident, use code 999.
- Do not update this data item if the patient's county of residence changes.

Code	Label	Definition
001–997	County at diagnosis	Valid FIPS code.
998	Outside state/county code unknown	Known town, city, state, or country of residence, but county code not known and a resident outside of the state of the reporting institution (must meet all criteria).
999	County unknown	The county of the patient is unknown, or the patient is not a United States resident. County is not documented in the patient's medical record.

Birthplace—State

Item #	Length	Allowable Values	Required Status	Date Revised
252	2	See Coding Instructions	2013+	01/13

Description

Records the patient's state of birth.

Rationale

This data item is used to evaluate medical care delivery to special populations and to identify populations at special risk for certain cancers.

Coding Instructions

- Use the most specific code.
- This item corresponds to [Birthplace—Country](#).
- See [Appendix C](#) for a list of state codes and their respective country codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software from the former Place of Birth.

Examples

Code	Reason
IL	The patient's place of birth is known as Illinois, assign the USPS code for the state of Illinois.
XX	State/province of <i>birth is unknown</i> however the country of birth is known and is <i>outside of the U.S.</i> (including its territories, commonwealths, or possessions) or Canada, assign XX for this data item and assign the code for the country of birth in the data item, Birthplace- Country [254].
YY	State/province and country of birth is unknown however it is known the patient was born outside of the U.S. (including its territories, commonwealths, or possessions) or Canada, assign YY for this data item and assign code ZZU in the data item, Birthplace- Country [254].
US	Born in the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i>
CD	Born in Canada and the province is <i>unknown</i> .
ZZ	Place of birth is <i>unknown</i> , not mentioned in patient record.

Birthplace—Country

Item #	Length	Allowable Values	Required Status	Date Revised
254	3	See Coding Instructions	2013+	01/13

Description

Identifies the country where the patient was born. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

Coding Instructions

- This item corresponds to [Birthplace—State](#).
- See [Appendix C](#) for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

Examples

Code	Reason
USA	United States
CAN	Canada
ZZU	Country of birth is unknown, not mentioned in patient record.

Date of Birth

Item #	Length	Allowable Values	Required Status	Date Revised
240	8	CCYYMMDD	All Years	01/10, 01/23

Description

Identifies the date of birth of the patient.

Rationale

This data item is useful for patient identification. It is also useful when analyzing tumors according to age cohort.

Coding Instructions

- Record the patient's date of birth as indicated in the patient record. For single-digit day or month, record with a lead 0 (for example, September is 09). Use the full four-digit year for year.
- For in utero diagnosis and treatment, record the actual date of birth. It will follow one or both dates for those events.
- If only the patient age is available, calculate the year of birth from age and the year of diagnosis and leave day and month of birth unknown (for example, a 60 year old patient diagnosed in 2025 is calculated to have been born in 1965).
- If month is unknown, the day is coded unknown. If the year cannot be determined, the day and month are both coded unknown.
- Blank is not allowed.

Age at Diagnosis

Item #	Length	Allowable Values	Required Status	Date Revised
230	3	000–120, 999	All Years	09/08

Description

Records the age of the patient at his or her last birthday before diagnosis.

Rationale

This data item is useful for patient identification. It may also be useful when analyzing tumors according to specific patient age.

Coding Instructions **NH-37**

- If the patient has multiple primaries, then the age at diagnosis may be different for subsequent primaries.

Code	Label
000	Less than one year old; diagnosed <i>in utero</i>
001	One year old but less than two years old
002	Two years old
...	Actual age in years
120	One hundred twenty years old
999	Unknown age

Race 1

Item #	Length	Allowable Values	Required Status	Date Revised
160	2	01–08, 10–17, 20–22, 25–28, 30–32, 96–99	All Years	01/04, 09/08, 01/10, 01/12, 01/23

Description

Identifies the primary race of the person.

Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

Coding Instructions

- Race 1 is the field used to compare with race data on cases diagnosed prior to January 1, 2000.
- “Race” is analyzed with Spanish/Hispanic Origin [190]. Both items must be recorded. All tumors for the same patient should have the same race code.
- If the person is multiracial and one of the races is white, assign the code representing the other race in this data item.
- If the person is multiracial and one of the races is Hawaiian, assign code 07 representing Hawaiian in this data item.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.

Code	Label	Code	Label
01	White	17	Pakistani
02	Black or African American	20	Micronesian, NOS
03	American Indian or Alaska Native	21	Chamorro
04	Chinese	22	Guamanian, NOS
05	Japanese	25	Polynesian, NOS
06	Filipino	26	Tahitian
07	Native Hawaiian	27	Samoan

Code	Label	Code	Label
08	Korean	28	Tongan
10	Vietnamese	30	Melanesian, NOS
11	Laotian	31	Fiji Islander
12	Hmong	32	Papua New Guinean
13	Cambodian	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian, NOS or Pakistani, NOS	98	Some other race
16	Asian Indian	99	Unknown by patient

Examples

Code	Reason
01	Patient has Mexican parentage, capture this data item as code 01 (white). Capture the Mexican parentage under data item, Spanish Origin–All Sources (Spanish/Hispanic Origin) [190] as code 1 (Mexican).
02	Patient is an African American female.
05	Patient has a Japanese father and a Caucasian mother. When a patient is multiracial and one of the races is white, assign the code for the other race in this data item.
07	Patient has a Hawaiian father and a Samoan mother. When patient is multiracial and one of the races is Hawaiian, code Hawaiian.

Race 2, 3, 4, 5

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
161 162 163 164	2	race2 race3 race4 race5	01-08, 10-17, 20-22, 25-28, 30-32, 88, 96-99, blank	2000+	2004, 2008, 2010, 2012, 2021

Description

Identifies the patient's race. Race and ethnicity are defined by specific physical, hereditary and cultural traditions or origins, not necessarily by birthplace, place of residence, or citizenship. 'Origin' is defined by the U.S. Census Bureau as the heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person's parents or ancestors before their arrival in the United States.

Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

Coding Instructions

The five race data items (Race 1 – Race 5) make it possible to code multiple races for one person, consistent with the 2000 Census. All resources in the facility, including the medical record, face sheet, physician and nursing notes, photographs, and any other sources, must be used to determine race. If a facility does not print race in the medical record but does maintain it in electronic form, the electronic data must also be reviewed.

1. "Race" is analyzed with *Spanish/Hispanic Origin* [190]. Both items must be recorded. All tumors for the same patient should have the same race code.
2. If *Race 1* [160] is coded 99, then Race 2-5 must be coded 99.
3. If *Race 2* [161] is coded 88 or 99, then Race 3-5 must be coded with the same value.
4. Codes 08–13 became effective with diagnoses on or after January 1, 1988.
5. Code 14 became effective with diagnoses on or after January 1, 1994.
6. In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
7. Codes 20–97 became effective with diagnoses on or after January 1, 1991.
8. See the instructions for *Race 1* [160] for coding sequences for entering multiple races.

Codes and Definitions

See the instructions for *Race 1* [160] for codes and code definitions.

Recommendation: Document how the race code(s) was (were) determined in a text field.

Source 1: Thornton ML, (ed). *Data Standards and Data Dictionary, Version 26, 27th ed.* Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

Source 3: Sanchez P, Groves C, Adamo M. (September 2025). *SEER Program Coding and Staging Manual 2026*. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

Spanish Origin–All Sources (Spanish/Hispanic Origin)

Item #	Length	Allowable Values	Required Status	Date Revised
190	1	0–7, 9	All Years	09/04

Description

Identifies persons of Spanish or Hispanic origin.

Rationale

This code is used by hospital and central registries to identify whether or not the person should be classified as “Hispanic” for purposes of calculating cancer rates. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the 01 (White category) of *Race 1*.

Coding Instructions

- Persons of Spanish or Hispanic origin may be of any race, but these categories are generally not used for Native Americans, Filipinos, or others who may have Spanish names.
- Code 0 (Non-Spanish; non-Hispanic) for Portuguese and Brazilian persons.
- If the patient has multiple tumors, all records should have the same code.

Code	Label
0	Non-Spanish; non-Hispanic
1	Mexican (includes Chicano)
2	Puerto Rican
3	Cuban
4	South or Central America (except Brazil)
5	Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic)
6	Spanish, NOS; Hispanic, NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1–5)
7	Spanish surname only (The only evidence of the person’s Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic)
8	Dominican Republic
9	Unknown whether Spanish or not; not stated in patient record

Sex Assigned at Birth

Item #	Length	Allowable Values	Required Status	Date Revised
225	1	1, 2, 9	All Years	01/26

Description

Identifies the sex of the patient assigned at birth.

Rationale

This data item is used to compare cancer rates and outcomes by site. The same sex code should appear in each medical record for a patient with multiple tumors.

Coding Instructions

- Record the sex of the patient assigned at birth.
- When the patient's sex is documented as male or female, and there is no other information to indicate the patient was assigned a different sex at birth, assign code 1 or 2, respectively.
- When sex is not known:
 - Assign code 1 when the primary site is C600-C639.
 - Assign code 2 when the primary site is C510-C589.
 - Assign code 9 for primary sites not included above.
- Assign code 9 when:
 - Sex is unknown and not within the listed ranges for primary site mentioned above.
 - Sex is not yet determined.
 - Patient is born with Disorders of Sexual Development (DSD) and sex is not clearly defined.
 - Patient's sex is documented as other than male or female (i.e., non-binary, transexual), and there is no additional information about sex assigned at birth.
- Do not assign code 9 when sex is documented as male or female and there is no other information about sex assigned at birth. Assign the respective code.

Code	Label
1	Male
2	Female
9	Not stated/Unknown

Marital Status at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
150	1	maritalStatusAtDx	1-6, 9	All Years	

Description

Code for the patient's marital status at the time of diagnosis for the reportable tumor. If the patient has multiple tumors, marital status may be different for each tumor.

Rationale

Incidence and survival with certain cancers vary by marital status. The item also helps in patient identification.

Coding Instructions

1. Assign code 2 [Married (including common law)] when the patient declares him/herself as married. Marriage is self-reported.
2. Assign code 6 when the patient is not married and is in a domestic partner relationship other than common law marriage.
3. Assign code 9 for death certificate only (DCO) cases when marital status at the time of diagnosis is unknown.

Codes

Code	Label
1	Single (never married)
2	Married (including common law*)
3	Separated
4	Divorced
5	Widowed
6	Unmarried or Domestic Partner (same sex or opposite sex, registered or unregistered, other than common law marriage) (effective for cases diagnosed 01/01/2011 and forward)
9	Unknown

**Definition Common Law Marriage:* A couple living together for a period of time and declaring themselves as married to friends, family, and the community, having never gone through a formal ceremony or obtained a marriage license.

Justification for Continued Collection

Marital Status at Diagnosis was evaluated for possible retirement (discontinuation of collection). It will not be retired at this time because it is readily available and provides important information not available from any other data item.

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: Sanchez P, Groves C, Adamo M. (September 2025). [SEER Program Coding and Staging Manual 2026](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

Primary Payer at Diagnosis

Item #	Length	Allowable Values	Required Status	Date Revised
630	2	01, 02, 10, 20, 21, 31, 35, 60–68, 99	All Years	06/05, 01/10, 1/23

Description

Identifies the patient's primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

Rationale

This item is used in financial analysis and as an indicator for quality and outcome analyses. It is required the patient admission page documents the type of insurance or payment structure that will cover the patient while being cared for at the hospital.

Coding Instructions **NH-38**

- If the patient is diagnosed at the reporting facility, record the payer at the time of diagnosis.
- If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known record the payer when the patient is initially admitted for treatment.
- Record the type of insurance reported on the patient's admission page.
- If more than one payer or insurance carrier is listed on the patient's admission page record the first.
- If the patient's payer or insurance carrier changes, do not change the initially recorded code.

Code	Label	Definition
01	Not insured	Patient has no insurance and is declared a charity write-off.
02	Not insured, self-pay	Patient has no insurance and is declared responsible for charges.
10	Insurance, NOS	Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68.
20	Private insurance: Managed Care, HMO, or PPO	An organized system of prepaid care for a group of enrollees usually within a defined geographic area. Generally formed as one of four types: a group model, an independent physician association (IPA), a network, or a staff model. "Gate-keeper model" is another term for describing this type of insurance.
21	Private insurance: Fee-for-Service	An insurance plan that does not have a negotiated fee structure with the participating hospital. Type of insurance plan not coded as 20.
31	Medicaid	State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35.

Code	Label	Definition
35	Medicaid administered through a Managed Care plan	Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
60	Medicare without supplement, Medicare, NOS	Federal government funded insurance for persons who are 65 years of age or older, or are chronically disabled (Social Security insurance eligible). Not described in codes 61, 62, or 63.
61	Medicare with supplement, NOS	Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare.
62	Medicare administered through a Managed Care plan	Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
63	Medicare with private supplement	Patient has Medicare and private insurance to pay costs not covered by Medicare.
64	Medicare with Medicaid eligibility	Federal government Medicare insurance with State Medicaid administered supplement.
65	TRICARE	Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military dependents, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).
66	Military	Military personnel or their dependents who are treated at a military facility.
67	Veterans Affairs	Veterans who are treated in Veterans Affairs facilities.
68	Indian/Public Health Service	Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service.
99	Insurance status unknown	It is unknown from the patient's medical record whether or not the patient is insured.

Examples

Code	Reason
01	An indigent patient is admitted with no insurance coverage.
20	A patient is admitted for treatment and the patient admission page states the primary insurance carrier is an HMO.
61	Patient is known to have Medicare with a supplement, but the type of Medicare supplement is unknown.
62	Patient has a Medicare managed plan (also known as Medicare C or Medicare Advantage). The Medicare managed care plan takes the place of original Medicare plan and will be listed as the first and usually only insurance as a HMO, PPO, etc.
63	Patient has Medicare A (inpatient) and B (outpatient and durable medical equipment) with a private supplement to cover costs outside of Medicare A and B. Medicare will be listed on the patient's face sheet as the first insurance with the commercial insurance (Medicare supplement) listed second
64	A patient has a Medicare plan listed first with Medicaid listed second, capture under code 64.
65	Patient is a military dependent and receiving treatment at a non-military facility. Expenses covered by TRICARE.
66	Soldier (active duty) treated at a military facility.
67	Retired veteran receiving treatment at VA facility or at an outside non-VA facility and the expenses are being covered by VA.
68	Patient's expenses are covered by Indian Health Service Facility at the reporting facility or at a referred outside facility.

Height at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
9960	2		00-99	2011+	

Description

Height of patient at the time of diagnosis for the reportable tumor. Different tumors for the same patient may have different values. It should be collected from source records once for each cancer. Height should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient's hospital medical record or physician office record. The height entered should be that listed at or around the time of diagnosis. If no height is listed on the date of diagnosis, please use the height recorded on the date closest to the date of diagnosis and before treatment was started.

Coding Instructions

- Entered as 2-digit numbers and measured in inches (note that 1 foot=12 inches).
- All inches values should be rounded to the nearest whole number; values with decimal place x .5 and greater should be rounded up (e.g., 62.5 inches would be 63 inches).
- When coding cases that include chemotherapy or other drugs, please exhaust all potential sources for height before using code "99" ("unknown").
- For all sites/histologies, "blanks" are not permitted and code "99" should be used to reflect unknown height. The CDC will use the volume of cases coded to "99" to help determine the availability of information related to height in the medical record.

Codes

Code	Label
01-97	Enter height in 2-digit numbers measured in inches
98	98 inches or greater
99	Unknown height

Weight at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
9961	3		000-999	2011+	

Description

Weight of patient at the time of diagnosis for the reportable tumor. Different tumors for the same patient may have different values. It should be collected from source records once for each cancer. Weight should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient's hospital medical record or physician office record. The weight entered should be that listed on the date of diagnosis. If no weight was listed on the date of diagnosis, please use the weight recorded on the date closest to the date of diagnosis and before treatment was started.

Coding Instructions

- Entered as 3-digit numbers and measured in pounds (note that 1 kg = 2.2 pounds).
- All pound values should be rounded to the nearest whole number; values with decimal place x.5 and greater should be rounded up (e.g., 155.5 pounds would be 156 pounds).
- Patients with a weight of less than 100 pounds should be recorded with a leading 0.
- When coding cases that include chemotherapy or other drugs, please exhaust all potential sources for weight before using code "999" ("unknown").
- For all sites/histologies, "blanks" are not permitted and code "999" should be used to reflect unknown weight. The CDC will use the volume of cases coded to "999" to help determine the availability of information related to weight in the medical record. (added July 2011)

Codes

Code	Label
001-998	Enter weight in 3-digit numbers measured in pounds
999	Unknown weight

Tobacco Use Status

Item #	Length	Allowable Values	Required Status	Date Revised
344	1	0- 3, 9	2023+	01/23

NH-39

Description

This variable indicates the patient's past or current smoking use of tobacco (cigarette, cigar and/or pipe).

Rationale

- Cigarette smoking is the leading preventable cause of death in the United States and a major risk factor for cancer.
- Reliable registry-based tobacco use data will help public health planners and clinicians target and assess tobacco control efforts.
- Tobacco use data at diagnosis may help health professionals better understand how tobacco use impacts cancer outcomes, prognosis, and effectiveness of treatment.
- Smoking status may be a useful covariate risk factor for cancer cluster investigations.

Coding Instructions

- Record cigarette, cigar and/or pipe use only. Tobacco Use Smoking Status does not include marijuana, chewing tobacco, e-cigarettes, or vaping devices.
- Tobacco smoking history can be obtained from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or Nursing Assessment section, or other available sources from the patient's hospital medical record or physician office record.
- Use code 1 (Current smoker) if there is evidence in the medical record that the patient quit smoking within 30 days prior to diagnosis. The 30 days prior information is intended to differentiate patients who may have quit recently due to symptoms that led to a cancer diagnosis.
- Use code 2 (Former smoker) if medical record indicates patient smoked tobacco in the past but does not smoke now. Patient must have quit 31 or more days prior to cancer diagnosis to be coded as 'Former smoker' (see above instruction).
- Use code 3 (Ever Smoked, current status unknown) if it cannot be determined whether patient currently smokes or formerly smoked. For example, the medical record only indicates "Yes" for smoking without further information.
- Use code 9 (Unknown if ever smoked) rather than code 0 (Never used):
 - if the medical record only indicates "No" for tobacco use
 - smoking status is not stated or provided
 - the method (cigarette, pipe, cigar) used cannot be verified in the chart.

Code	Label
0	Never smoker
1	Current smoker
2	Former smoker
3	Smoker, current status unknown
9	Unknown if ever smoked

Text--Usual Occupation

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
310	100	textUsualOccupation	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for information about the patient's usual occupation, also known as usual type of job or work.

Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies occupational groups in which cancer screening or prevention activities may be beneficial.

The data item "usual occupation" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.²⁵ See related materials in reference list, Chapter VII.

Abstracting Instructions

Record the patient's usual occupation (i.e., the kind of work performed during most of the patient's working life before diagnosis of this tumor). Do not record "retired." If usual occupation is not available or is unknown, record the patient's current or most recent occupation, or any available occupation.

If later documentation in the patient's record provides an occupation that is more likely to be the usual occupation than what was originally recorded, facility registrars are encouraged to update the abstract with the new information. However, it is not the responsibility of the facility registrars to update abstracts with occupation information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

If the patient was a homemaker and also worked outside the home during most of his/her adult life, record the usual occupation outside the home; if the patient was a homemaker and did not work outside the home for most of his/her adult life, record "homemaker." If the patient was not a student or homemaker and had never worked, record "never worked" as the usual occupation.

If no information is available, record "unknown."

This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

Text--Usual Industry

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
320	100	textUsualIndustry	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for information about the patient's usual industry, also known as usual kind of business/industry.

Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies industrial groups or worksite-related groups in which cancer screening or prevention activities may be beneficial.

The data item "usual industry" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.²⁵ See related materials in reference list, Chapter VII.

Abstracting Instructions

Record the primary type of activity carried on by the business/industry at the location where the patient was employed for the most number of years before diagnosis of this tumor. Be sure to distinguish among "manufacturing," "wholesale," "retail," and "service" components of an industry that performs more than one of these components.

If the primary activity carried on at the location where the patient worked is unknown, it may be sufficient for facility registrars to record the name of the company (with city or town) in which the patient performed his/her usual industry. In these situations, if resources permit, a central or regional registry may be able to use the employer name and city/town to determine the type of activity conducted at that location.

As noted in the *Text--Usual Occupation* [310] section, in those situations where the usual occupation is not available or is unknown, the patient's current or most recent occupation is recorded, if available. The information for industry should be based upon the information in occupation. Therefore, if current or most recent occupation rather than usual occupation was recorded, record the patient's current or most recent business/industry.

If later documentation in the patient's record provides an industry that is more likely to be the usual industry than what was originally recorded, facility registrars are encouraged to update the abstract with the new information. However, it is not the responsibility of the facility registrars to update abstracts with industry information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

There should be an entry for *Text--Usual Industry* if any occupation is recorded. If no information is available regarding the industry in which the reported occupation was carried out, record "unknown." If the patient was not a student or homemaker and had never worked, record "never worked" as the usual industry. This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Secondary Diagnosis #1

Item #	Length	Allowable Values	Required Status	Date Revised
3780	7	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996Z, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ	2015+	01/15, 02/21, 01/22

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Coding Instructions

[See Secondary Diagnosis rules in Section One for general overview.](#)

- Use this item to record ICD-10-CM codes.
- Only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
 - Surgically treated patients:
 - following the most definitive (most invasive) surgery of the primary site (procedure recorded in the data item, Rx Summ-Surg 2023 [1291])
 - following other non-primary site surgeries
 - Non-surgically treated patients:
 - following the first treatment encounter/episode
 - In cases of non-treatment:
 - following the last diagnostic/evaluative encounter
- If the data item Readmission to the Same Hospital within 30 Days of Surgical Discharge [3190] is coded 1, 2, or 3, report Secondary Diagnosis ICD-10-CM codes appearing on the "readmission" discharge abstract.
- If no ICD-10-CM secondary diagnoses were documented, then code 0000000 in this data item, and leave the remaining Secondary Diagnosis data items blank.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code Y63.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)
0000000	No applicable ICD-10-CM codes are recorded in this patient's record

Secondary Diagnosis #2-10

Item #	Length	Allowable Values	Required Status	Date Revised
3782 3784 3786 3788 3790 3792 3794 3796 3798	7	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996Z, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Coding Instructions

- Use these items to record ICD-10-CM codes.
- Only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code Y63.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

NPI--Physician--Managing

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2465	10	npiPhysicianManaging	10-digit NPI code (9-digit NPI integer plus 1 check digit), blank	2007+	2007, 2008, 2021

Description

The NPI (National Provider Identifier) that identifies the physician who is responsible for the overall management of the patient during diagnosis and/or treatment of this cancer.

NPI, a unique identification number for US health care providers, was scheduled for 2007-2008 implementation by the Centers for Medicare & Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008.

Rationale

Used to monitor patient care. The managing physician is responsible for the patient's work-up, plans the treatment, and directs the delivery of patient care in accordance with CoC Standards. In most cases, the managing physician is responsible for AJCC staging.

Coding Instructions

- Record the 10-digit NPI for the physician responsible for managing the patient's care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a managing physician for the patient, this item should not be changed even if a different managing physician is assigned.

Code	Label
(fill spaces)	10-digit NPI number for the managing physician.
(leave blank)	NPI for the managing physician is unknown or not available.

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

NPI--Physician--Follow-Up

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2475	10	npiPhysicianFollowUp	10-digit NPI code (9-digit NPI integer plus 1 check digit), blank	2007+	2007, 2008, 2011, 2021

Description

Records the NPI (National Provider Identifier) code for the physician currently responsible for the patient's medical care.

NPI, a unique identification number for US health care providers, was scheduled for 2007-2008 implementation by the Centers for Medicare & Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008.

Rationale

Used to monitor post-treatment patient care. The following physician is the first contact for obtaining information on a patient's status and subsequent treatment. This information may be used for outcomes studies.

Coding Instructions

- Record the 10-digit NPI for the physician currently responsible for the patient's medical care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Change this data item when patient follow-up becomes the responsibility of another physician.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the following physician.
(leave blank)	NPI for the following physician is unknown or not available.

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

NPI-Primary Surgeon

Item #	Length	Allowable Values	Required Status	Date Revised
2485	10	10 digits, Blank	2008+	04/07, 09/08, 01/11

Description

Identifies the physician who performed the most definitive (most invasive) surgical procedure.

Rationale

Administrative, physician, and service referral reports are based on this item.

Coding Instructions

- Record the 10-digit NPI for the physician who performed the most definitive (most invasive) surgical procedure (surgical procedure recorded in the data item, Rx Summ-Surg 2023 [1291]).
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/#/>.
- NPI should be recorded as available for cases diagnosed during 2007 and is required to be recorded for all applicable cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a primary surgeon for the patient, the information should not be changed or updated even if the patient receives care from another surgeon.

Code	Label
(fill spaces)	10-digit NPI number for the primary surgeon.
(leave blank)	The patient did not have surgery. NPI for the primary surgeon is unknown or not available. The physician who performed the surgical procedure was not a surgeon (for example, general practitioner).

NPI–Physician #3 (Radiation Oncologist–CoC Preferred)

Item #	Length	Allowable Values	Required Status	Date Revised
2495	10	10 digits, Blank	2008+	4/07, 9/08, 1/10, 1/11

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this item identify the physician who performed the most definitive radiation therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Coding Instructions

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/#/>.
- Do not update this item. If the registry has designated a primary radiation oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- NPI should be recorded as available for cases diagnosed during 2007 and is required to be recorded for all applicable cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the primary radiation oncologist.
(leave blank)	NPI for the primary radiation oncologist is unknown or not available.

NPI–Physician #4 (Medical Oncologist–CoC Preferred)

Item #	Length	Allowable Values	Required Status	Date Revised
2505	10	10 digits, Blank	2008+	4/07, 9/08, 1/10, 1/11, 1/12

Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who gives the most definitive systemic therapy.

Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

Coding Instructions

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/#/>.
- Do not update this item. If the registry has designated a primary medical oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another medical oncologist.
- NPI should be recorded as available for cases diagnosed during 2007 and is required to be recorded for all applicable cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the primary medical oncologist.
(leave blank)	NPI for the primary medical oncologist is unknown or not available.

Cancer Identification

Type of Reporting Source

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
500	1	typeOfReportingSource	1-8	All Years	

Description

This variable codes the source documents used to abstract the majority of information on the tumor being reported. This may not be the source of original case finding (for example, if a case is identified through a pathology laboratory report review and all source documents used to abstract the case are from the physician's office, code this item 4).

Rationale

The code in this field can be used to explain why information may be incomplete on a tumor. For example, death certificate only cases have unknown values for many data items, so one may want to exclude them from some analyses. The field also is used to monitor the success of non-hospital case reporting and follow-back mechanisms. All population-based registries should have some death certificate-only cases where no hospital admission was involved, but too high a percentage can imply both shortcomings in case-finding and that follow-back to uncover missed hospital reports was not complete.

Coding Instructions

Code in the following priority order: 1, 2, 8, 4, 3, 5, 6, 7. This is a change to reflect the addition of codes 2 and 8 and to prioritize laboratory reports over nursing home reports. The source facilities included in the previous code 1 (hospital inpatient and outpatient) are split between codes 1, 2, and 8.

This data item is intended to indicate the completeness of information available to the abstractor. Reports from health plans (e.g., Kaiser, Veterans Administration, military facilities) in which all diagnostic and treatment information is maintained centrally and is available to the abstractor are expected to be at least as complete as reports for hospital inpatients, which is why these sources are grouped with inpatients and given the code with the highest priority.

Sources coded with '2' usually have complete information on the cancer diagnosis, staging, and treatment.

Sources coded with '8' would include, but would not be limited to, outpatient surgery and nuclear medicine services. A physician's office that calls itself a surgery center should be coded as a physician's office. Surgery centers are equipped and staffed to perform surgical procedures under general anesthesia. If a physician's office calls itself a surgery center, but cannot perform surgical procedures under general anesthesia, code as a physician office.

Codes

Code	Label
1	Hospital inpatient; Managed health plans with comprehensive, unified medical records
2	Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent)
3	Laboratory only (hospital-affiliated or independent)
4	Physician's office/private medical practitioner (LMD)
5	Nursing/convalescent home/hospice
6	Autopsy only
7	Death certificate only
8	Other hospital outpatient units/surgery centers

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Casefinding Source

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
501	2	casefindingSource	10, 20-30, 40, 50, 60, 70, 75, 80, 85, 90, 95, 99	2006+	

Description

This variable codes the earliest source of identifying information. For cases identified by a source other than reporting facilities (such as through death clearance or as a result of an audit), this variable codes the type of source through which the tumor was first identified. This data item cannot be used by itself as a data quality indicator. The timing of the casefinding processes (e.g., death linkage) varies from registry to registry, and the coded value of this variable is a function of that timing.

Rationale

This data item will help reporting facilities as well as regional and central registries in prioritizing their casefinding activities. It will identify reportable tumors that were first found through death clearance or sources other than traditional reporting facilities. It provides more detail than "*Type of Reporting Source*."

Coding Instructions

This variable is intended to code the source that first identified the tumor. Determine where the case was first identified and enter the appropriate code. At the regional or central level, if a hospital and a non-hospital source identified the case independently of each other, enter the code for the non-hospital source (i.e., codes 30-95 have priority over codes 10-29). If the case was first identified at a reporting facility (codes 10-29), code the earliest source (based on patient or specimen contact at the facility) of identifying information.

If a death certificate, independent pathology laboratory report, consultation-only report from a hospital, or other report was used to identify a case that was then abstracted from a different source, enter the code for the source that first identified the case, not the source from which it was subsequently abstracted. If a regional or central registry identifies a case and asks a reporting facility to abstract it, enter the code that corresponds to the initial source, not the code that corresponds to the eventual reporting facility.

Codes

Code	Label
10	Reporting Hospital, NOS
20	Pathology Department Review (surgical pathology reports, autopsies, or cytology reports)
21	Daily Discharge Review (daily screening of charts of discharged patients in the medical records department)
22	Disease Index Review (review of disease index in the medical records department)
23	Radiation Therapy Department/Center
24	Laboratory Reports (other than pathology reports, code 20)
25	Outpatient Chemotherapy

Casefinding Source, cont.

Codes, cont.

Code	Label
26	Diagnostic Imaging/Radiology (other than radiation therapy, codes 23; includes nuclear medicine)
27	Tumor Board
28	Hospital Rehabilitation Service or Clinic
29	Other Hospital Source (including clinic, NOS or outpatient department, NOS)
30	Physician-Initiated Case
40	Consultation-only or Pathology-only Report (not abstracted by reporting hospital)
50	Independent (non-hospital) Pathology-Laboratory Report
60	Nursing Home-Initiated Case
70	Coroner's Office Records Review
75	Managed Care Organization (MCO) or Insurance Records
80	Death Certificate (case identified through death clearance)
85	Out-of-State Case Sharing
90	Other Non-Reporting Hospital Source
95	Quality Control Review (case initially identified through quality control activities such as casefinding audit of a regional or central registry)
99	Unknown

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Class of Case

Item #	Length	Allowable Values	Required Status	Date Revised
610	2	00, 10-14, 20-22, 30-38, 40-43, 49, 99	All Years	09/08, 01/10, 05/10, 01/11, 01/12, 01/14, 01/15

Description

Class of Case divides cases into two groups. Analytic cases (codes 00–22) are those that are required by CoC to be abstracted because of the program’s primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and first course of treatment. Nonanalytic cases (codes 30–49 and 99) may be abstracted by the facility to meet central registry requirements or in response to a request by the facility’s cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted.

NH-40

Rationale

Class of Case reflects the facility’s role in managing the cancer and whether the cancer is required to be reported by CoC.

Coding Instructions

[See *Class of Case* in Section One for further instructions.](#)

- Code the Class of Case that most precisely describes the patient’s relationship to the facility.
- Code 00 applies only when it is known the patient went elsewhere for treatment. If it is not known that the patient actually went somewhere else, code Class of Case 10.
- It is possible that information for coding Class of Case will change during the patient’s first course of care. If that occurs, change the code accordingly.
- Document NPI–Institution Referred To [2425] or the applicable physician NPI (NAACCR #s 2485, 2495, 2505) for patients coded 00 to establish that the patient went elsewhere for treatment
- Code 34 or 36 if the diagnosis benign or borderline (Behavior 0 or 1) for any site is diagnosed before 2004 or for any site other than meninges (C70._), brain (C71._), spinal cord, cranial nerves, and other parts of central nervous system (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3) that was diagnosed in 2004 or later.
- Code 34 or 36 for carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2 or 8148/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), anus (AIN III) and squamous intraepithelial neoplasia (SIN III). **NH-41**
- Physicians who are not employed by the hospital but are under contract with it or have routine admitting privileges there are described in codes 10-12 and 41 as physicians with admitting privileges. Treatment provided in the office of a physician with admitting privileges is provided “elsewhere”. That is because care given in the physician’s office is not within the hospital’s realm of responsibility.
- If the hospital purchases a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital’s) or not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physicians involved have routine admitting privileges or not, as with any other physician.

- “In-transit” care is care given to a patient who is temporarily away from the patient’s usual practitioner for continuity of care. If these cases are abstracted, they are Class of Case 31. Monitoring of oral medication started elsewhere is coded Class of Case 31. If a patient begins first course radiation or chemotherapy infusion elsewhere and continues at the reporting facility, and the care is not in-transit, then the case is analytic (Class of Case 21).
- First course maintenance treatment provided at the reporting facility prior to disease progression or recurrence is reportable IF the maintenance treatment is part of first course treatment plan and is provided by reported facility with documentation of prescription/administration. For example, if a patient is diagnosed and treated at another facility per the treatment plan was started on hormone therapy at the other facility then presents to your facility for continuation of hormone therapy the continuation of hormone therapy by your facility must be documented in medical record to assign class of case 21 (part of first course treatment elsewhere, part of first course of treatment at the reporting facility). This applies even if there is no longer active disease.

Code	Label
Analytic Classes of Case (Required by CoC to be abstracted by accredited programs)	
<i>Initial diagnosis at reporting facility or in a staff physician’s office</i>	
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
10	Initial diagnosis at the reporting facility or in an office of a physician with admitting privileges AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Initial diagnosis in an office of a physician with admitting privileges AND part of first course treatment was done at the reporting facility
12	Initial diagnosis in an office of a physician with admitting privileges AND all first course treatment or a decision not to treat was done at the reporting facility
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
<i>Initial diagnosis elsewhere</i>	
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
21	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.
22	Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility

Code	Label
Non-analytic Classes of Case (Not required by CoC to be abstracted by CoC accredited programs however may be required by program's Cancer Committee, state or regional registry, or other entity)	
<i>Patient appears in person at reporting facility</i>	
30	Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)
31	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care; or hospital provided care that facilitated treatment elsewhere (for example, stent placement)
32	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease)
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active)
34	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility
35	Case diagnosed before the program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility
36	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
37	Case diagnosed before the program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death
<i>Patient does not appear in person at reporting facility</i>	
40	Diagnosis AND all first course treatment given at the same staff physician's office
41	Diagnosis and all first course treatment given in two or more different offices of physicians with admitting privileges
42	Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)
43	Pathology or other lab specimens only
49	Death certificate only NH-43
99	Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases).

NH-42

Examples

Code	Reason
00	Leukemia was initially diagnosed at the reporting facility, and all care was administered at a known outside facility.
10	Reporting hospital found cancer in a biopsy but was unable to discover whether the homeless patient actually went somewhere else or received any treatment.
11	Patient was diagnosed by a physician with practice privileges, received neoadjuvant radiation at another facility, then underwent surgical resection at the reporting facility.
13	Patient was initially diagnosed, and first course resection of primary site was performed at the reporting hospital. The first course radiation was administered at an outside facility.
22	Patient was initially diagnosed at an outside facility. The patient was referred to the reporting facility's oncology clinic where it was determined no treatment due to patient's poor performance status.
31	Patient received chemotherapy while attending daughter's wedding in the reporting hospital's city, then returned to the originating hospital for subsequent treatments.
32	Patient was initially diagnosed and received first course treatment at outside facility, patient presents to reporting facility's ER with mets where it was decided to begin comfort measures only .
42	Patients from an unaffiliated, free-standing clinic across the street that hospital voluntarily abstracts with its cases because many physicians work both at the clinic and the hospital.

NPI—Institution Referred From

Item #	Length	Allowable Values	Required Status	Date Revised
2415	10	10 digits, Blank	2008+	04/07, 09/08, 01/11

Description

Identifies the facility that referred the patient to the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

Coding Instructions

- Record the 10-digit NPI for the referring facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all applicable cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search on <https://nppes.cms.hhs.gov/#/>.

Code	Label
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the referring facility is unknown or not available.
(leave blank)	If the patient was not referred to the reporting facility from another facility.

NPI—Institution Referred To

Item #	Length	Allowable Values	Required Status	Date Revised
2425	10	10 digits, Blank	2008+	04/07, 09/08, 01/11

Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

Coding Instructions

- Record the 10-digit NPI for the facility to which the patient was referred.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all applicable cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI or search on <https://nppes.cms.hhs.gov/#/>.

Code	Label
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility referred to is unknown or not available.
(leave blank)	If the patient was not referred to another facility.

Date of First Contact

Item #	Length	Allowable Values	Required Status	Date Revised
580	8	CCYYMMDD, Blank	All Years	09/06, 01/04, 01/10, 01/11, 01/23

Description

Date of first contact with the reporting facility for diagnosis and/or treatment of this cancer.

Rationale

This data item can be used to measure the time between first contact and the date that the case was abstracted. It can also be used to measure the length of time between the first contact and treatment for quality of care reports.

Coding Instructions

[See Date of First Contact in Section One for further instructions.](#)

- Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or first course treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, x-ray, or laboratory test, or the date a pathology specimen was collected at the hospital.
- For analytic cases (Class of Case 00-22), the Date of First Contact is the date the patient became analytic. For non-analytic cases, it is the date the patient first qualified for the Class of Case that causes the case to be abstracted.
- If this is an autopsy-only or death certificate-only case, then use the date of death.
- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.
- Blank is allowed.

Examples

Code	Label	Definition
20240914	September 14, 2024	Patient undergoes a biopsy in a staff physician's office on September 8, 2024. The pathology specimen was sent to the reporting facility and was read as malignant melanoma. The patient enters that same reporting facility on September 14, 2024 for wide re-excision.
20241207	December 7, 2024	Patient has an MRI of the brain on December 7, 2024, for symptoms including severe headache and disorientation. The MRI findings are suspicious for astrocytoma. Surgery on December 19, 2024 removes all gross tumor.
20241224	December 24, 2024	Patient presents to ER for flank pain on December 23, 2024 for right kidney stone. On December 24, 2024 a CT of Pelvis was performed and revealed a tumor suspicious for renal cell carcinoma.

Code	Label	Definition
20240499	April 2024	Information is limited to the description “Spring,” 2024.
20240799	July 2024	Information is limited to the description “The middle of the year,” 2024.
20241099	October 2024	Information is limited to the description “Fall,” 2024.
CCYY1299 or CCYY0199	December or January	If information is limited to the description “Winter,” try to determine if this means the beginning or the end of the year.

Text--Place of Diagnosis

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2690	60	textPlaceOfDiagnosis	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of the facility, physician office, city, state, or county where the diagnosis was made.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

Instructions

- Prioritize entered information in the order of the fields listed below.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- The complete name of the hospital or the physician office where diagnosis occurred. The initials of a hospital are not adequate.
- For out-of-state residents and facilities, include the city and the state where the medical facility is located.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item Numbers: 2410, 2420, 500, 540, 610, 670, 740

Date of Initial Diagnosis

Item #	Length	Allowable Values	Required Status	Date Revised
390	8	CCYYMMDD	All Years	09/04, 09/08, 1/10, 01/11, 01/23

Description

Records the date of initial diagnosis by a physician for the tumor being reported.

Rationale

The timing for staging and treatment of cancer begins with the date of initial diagnosis for cancer.

Coding Instructions

- Use the first date of diagnosis whether clinically or histologically established.
- If the physician states that in retrospect the patient had cancer at an earlier date, use the earlier date as the date of diagnosis.
- Refer to the list of [Ambiguous Terms](#) in Section One for language that represents a diagnosis of cancer.
- Do not consider cytology with ambiguous terms to be diagnostic. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.
- Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a diagnosis is documented.
- The date of death is the date of diagnosis for a Class of Case [610] 38 (diagnosed at autopsy) or 49 (death certificate only).
- Use the actual date of diagnosis for an in utero diagnosis, for cases diagnosed on January 1, 2009, or later. **NH-28**
- If the year of diagnosis cannot be identified, it must be approximated. In that instance, the month and day are unknown.
- Blanks are not allowed.

Examples

Code	Label	Definition
20100612	June 12, 2010	Cytology "suspicious" for cancer June 12, 2010; pathology positive July 2, 2010.
20100517	May 17, 2010	Pathology "suspicious" for cancer May 17, 2010; confirmed positive May 22, 2010
20240499	April 2024	Information is limited to the description "Spring," 2024, and day is unknown and cannot be approximated use 99 for day.
20240799	July 2024	Information is limited to the description "Summer or mid-year" 2024, and day is unknown and cannot be approximated use 99 for day.

Code	Label	Definition
20241099	October 2024	Information is limited to the description “Fall” 2024, and day is unknown and cannot be approximated use 99 for day.
CCYY1299 or CCYY0199	December or January	If information is limited to the description “Winter,” try to determine if this means the beginning or the end of the year and use either January for beginning of year and December for the end of the year. If the day cannot be approximate use 99 for day.
20240601	June 2024	If information is limited to the description of “beginning” of June 2024, use the 1st as an approximation.
20240915	September 2024	If information is limited to the description of “middle” of September 2024, use the 15th as an approximation.
20241031	October 2024	If information is limited to the description of “end” of October 2024, use the last day as an approximation.

Primary Site

Item #	Length	Allowable Values	Required Status	Date Revised
400	4	C+3 digits	All Years	01/04, 09/08, 01/10

Description

Identifies the primary site.

Rationale

Primary site is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Coding Instructions

[See Primary Site in Section One for further instructions.](#)

- Record the ICD-O-3 topography code for the site of origin.
- Consult the physician advisor to identify the primary site or the most definitive site code if the medical record does not contain that information.
- Do not record the decimal point.
- Follow the Instructions for Coding in ICD-O-3 and in the current SEER Multiple Primary and Histology Coding Rules to assign site for solid tumors. **NH-23**
- Refer to the instructions for [Occult Cervical Lymph Node](#) and [Cutaneous Carcinoma of the Head and Neck](#) found in the Overview of Coding Principles section.
- Follow the instructions in Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB) for assigning site for lymphomas, leukemia and other hematopoietic neoplasms.
- Use subcategory 8 for single tumors that overlap the boundaries of two or more sub-sites and the point of origin is not known.
- Use subcategory 9 for multiple tumors that originate in different subsites of one organ.

Examples

Code	Reason
C108	Overlapping lesion of oropharynx. Code overlapping lesion when a large tumor involves both the lateral wall of the oropharynx (C10.2) and the posterior wall of the oropharynx (C10.3) and the point of origin is not stated.
C109	Patient presented with enlarged cervical LNs. Biopsy taken and revealed SCC p16+.
C119	Patient presented with enlarged cervical LNs. Biopsy taken and revealed SCC EBER + (Epstein-Barr virus-encoded small RNAs) OR both EBER+ and p16 +.
C16–	Stomach (sub-site as identified). An extranodal lymphoma of the stomach is coded to C16. – (sub-site as identified).

Code	Reason
C189	Colon, NOS. Familial polyposis with carcinoma and carcinoma in situ throughout the transverse (C18.4) and descending colon (C18.6) would be one primary and coded to colon, NOS (C18.9). For a full explanation see the <i>SEER 2007 Multiple Primary and Histology Coding Rules</i> .
C449	Patient presents with persistent abdominal pain. EGD performed and biopsy taken. Pathology revealed Kaposi Sarcoma. It was noted the patient also had a purple skin lesion on right upper abdomen which was also biopsied and revealed Kaposi Sarcoma.
C449	Patient with liver lesion biopsied and biopsy revealed metastatic melanoma.
C678	Overlapping lesion of bladder. Code overlapping lesion of the bladder when a single lesion involves the dome (C67.1) and the lateral wall (C67.2) and the point of origin is not stated.
C760	Patient presented with enlarged cervical LNs. LN biopsy was performed and revealed squamous cell carcinoma but both HPV and EBV are negative.

Method of Detection -Breast

Item #	Length	Allowable Values	Required Status	Date Revised
10110	2	0-13, 99	2026+	01/26

Description

Method of Detection (MOD) refers to the first imaging test or symptom or clinical sign that prompted the subsequent workup and diagnosis of cancer. The diagnostic imaging report should include the descriptions/codes below indicating how the initial abnormality was detected. If the information is not available in the imaging report, the data item should be coded as unknown.

Rationale

MOD may be used to establish a baseline percentage of how all breast cancers were detected.

Coding Instructions

- Codes should only be assigned based on the MOD documented in the imaging report.
- Use code 03 when a distinction between code 01 or code 02 cannot be made.
- Use code 09 when the method of detection is an image-based screening but not otherwise specified.
- Use code 12 when a distinction between code 10 or code 11 cannot be made.
- Use code 13 when the first clinical sign was an incidental finding such as a non-breast imaging test or during a surgical procedure such as prophylactic mastectomy or reduction surgery, as documented on the diagnostic imaging report.
- Use code 99 when:
 - Diagnostic imaging report is not available.
 - MOD is not included in the imaging report.
 - MOD is documented as unknown in the diagnostic report.
 - MOD is only included in sources other than the imaging report (i.e. not included in the imaging report, but a physician makes a reference to the MOD in the history and physical).
- Please note this is a CoC user defined field.

Code	Label
01	Sma: screening full field 2D film or digital mammography (do not include synthetic views or Digital breast tomosynthesis (DBT))
02	Sdbt: screening with Digital breast tomosynthesis (DBT)with full field 2D or synthetic 2D
03	SmaNOS: screening full field 2D film or digital mammography; with or without synthetic views and/or Digital Breast Tomosynthesis (DBT), but not specified (corresponds to the basic Sma descriptor)
04	Scem: screening contrast enhanced mammography
05	Snuc: screening Positron Emission Mammography (PEM) or Molecular Breast Imaging (MBI)
06	Sus: screening ultrasound
07	Smri: screening MRI
08	So: other breast image-based screening modality (modality not covered by codes 01-07). (such as CT, etc)

Code	Label
09	Sunk: cancer was detected by image-based screening, but the specific modality is unknown.
10	Pat: patient reported self-examination finding and/or symptom
11	Pro: provider detected finding on physical examination of asymptomatic patient
12	Ppp: patient and/or the provider detected the cancer first; unknown whether it was patient or provider
13	N: Neither, An incidental finding, Not image-based screening, Not patient or provider detected
99	Unknown, NOS

Examples

Codes	Reason
04	Patient presents for diagnostic imaging of a mass detected on screening mammogram. The diagnostic imaging report indicates Method of Detection was: Scem: screening contrast enhanced mammography <i>Assign code 04</i>
09	Patient here for a diagnostic mammogram. Reason for exam documented suspicious mass found on imaging from outside facility, with no additional information. <i>Assign code 09 (image-based screening, NOS)</i>
12	Reason for exam is listed on the diagnostic imaging report as a palpable mass. It is unclear if the physician or the patient initially identified (palpated) the mass. <i>Assign code 12</i>
13	Patient presents for diagnostic imaging of a mass incidentally found on a chest CT. The diagnostic report indicates the Method of detection was N: Neither patient/provider nor screen detected. <i>Assign code 13</i>
99	Patient presents for diagnostic imaging of a mass. The history and physical note indicates patient identified lump, however the diagnostic imaging report does not indicate a Method of Detection. <i>Assign code 99. MOD must come from the diagnostic imaging report.</i>

Laterality

Item #	Length	Allowable Values	Required Status	Date Revised
410	1	0-5, 9	All Years	01/10, 05/10, 01/13

Description

Identifies the side of a paired organ or the side of the body on which the reportable tumor originated. This applies to the primary site only.

Rationale

Laterality supplements staging and extent of disease information and defines the number of primaries involved.

Coding Instructions

- Laterality [410] for sites listed in the Paired Organ Sites table must be recorded as code 1-5 or 9.
- Organs not paired, unless they are recorded “right” or “left” laterality, are assigned code 0.
- When the primary site is unknown (C80.9), assign code 0.
- Midline origins are coded 5. “Midline” in this context refers to the point where the “right” and “left” sides of paired organs come into direct contact and a tumor forms at that point. Most paired sites cannot develop midline tumors. For example, skin of the trunk can have a midline tumor, but the breasts cannot.
- Do not code metastatic sites as bilateral involvement.
- Non-paired sites may be coded right or left, if appropriate. Otherwise, code non-paired sites to code 0.
- Code 9 for Death Certificate Only

Code	Label
0	Organ is not a paired site.
1	Origin of primary is right.
2	Origin of primary is left.
3	Only one side involved, right or left origin not specified.
4	Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors; both breasts involved with diagnosis of bilateral inflammatory carcinoma at diagnosis; or diffuse bilateral lung nodules
5	Paired site: midline tumor
9	Paired site, but no information concerning laterality

Paired Organ Sites	
ICD-O-3	Site
C07.9	Parotid gland
C08.0	Submandibular gland
C08.1	Sublingual gland
C09.8	Overlapping lesion of tonsil
C09.9	Tonsil, NOS
C30.1	Middle ear
C31.0	Maxillary sinus
C31.2	Frontal sinus
C34.1–C34.9	Lung
C38.4	Pleura
C40.0	Long bones of upper limb and scapula
C40.1	Short bones of upper limb
C40.2	Long bones of lower limb
C40.3	Short bones of lower limb
C44.1	Skin of eyelid
C44.2	Skin of external ear
C44.3	Skin of other and unspecified parts of face
C44.4	Skin of Scalp and Neck
C44.5	Skin of trunk
C44.6	Skin of upper limb and shoulder
C44.7	Skin of lower limb and hip
C47.1	Peripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2	Peripheral nerves and autonomic nervous system of lower limb and hip
C49.1	Connective, subcutaneous, and other soft tissues of upper limb and shoulder
C49.2	Connective, subcutaneous, and other soft tissues of lower limb and hip
C50.0–C50.9	Breast
C56.9	Ovary
C57.0	Fallopian tube
C62.0–C62.9	Testis
C63.0	Epididymis
C63.1	Spermatic cord
C64.9	Kidney
C65.9	Renal pelvis
C66.9	Ureter
C69.0–C69.9	Eye and lacrimal gland
C70.0	Cerebral meninges
C71.0	Cerebrum
C71.1	Frontal lobe
C71.2	Temporal lobe
C71.3	Parietal lobe
C71.4	Occipital lobe
C72.2	Olfactory nerve
C72.3	Optic nerve
C72.4	Acoustic nerve
C72.5	Cranial nerve, NOS
C74.0–C74.9	Adrenal Gland
C75.4	Carotid body

Text--Primary Site Title

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2580	100	textPrimarySiteTitle	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding the primary site and laterality of the tumor being reported.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- State the specific location of the primary site, including subsite.
- Include available information on tumor laterality.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Primary site	400
Laterality	410

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Histology

Item #	Length	Allowable Values	Required Status	Date Revised
522	4	Four digits	2001+	09/06, 01/10, 03/10

Description

Identifies the microscopic anatomy of cells.

Rationale

Histology is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

Coding Instructions

- Record histology using the ICD-O-3, current edition (<https://seer.cancer.gov/icd-o-3/>) codes in the Numeric Lists/Morphology section and in the Alphabetic Index.
- Follow the coding rules outlined in ICD-O-3, current edition.
- Use the current Solid Tumor Rules (<https://seer.cancer.gov/tools/solidtumor/>) when coding the histology for all reportable solid tumors. These rules are effective for cases diagnosed January 1, 2007, or later. Do not use these rules to abstract cases diagnosed prior to January 1, 2007.
- Review all pathology reports.
- Code the final pathologic diagnosis for solid tumors.
- For lymphomas, leukemias and other hematopoietic tumors, follow the instructions in Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB)
- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are **not** interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).

Examples

Code	Label	Definition
8140	Adenocarcinoma	Final pathologic diagnosis is carcinoma, NOS (8010) of the prostate. Microscopic diagnosis specifies adenocarcinoma (8140) of the prostate.
9680	Diffuse large B-cell lymphoma	Diffuse large B-cell lymphoma, per the WHO Classification of Hematopoietic and Lymphoid Neoplasms.

Text--Histology Title

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2590	100	textHistologyTitle	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding the histologic type, behavior, and grade (differentiation) of the tumor being reported.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Information on histologic type and behavior
- Information on differentiation from scoring systems such as Gleason's Score, Bloom-Richardson Grade, etc.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Histology (92-00) ICD-O-2	420
Behavior (92-00) ICD-O-2	430
Histologic Type ICD-O-3	522
Behavior Code ICD-O-3	523
Grade Clinical	3843
Grade Pathological	3844
Grade Post Therapy	3845

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Behavior Code

Item #	Length	Allowable Values	Required Status	Date Revised
523	1	0–3	>2001	04/04, 01/10, 01/12, 01/13, 01/15

Description

Records the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code.

Rationale

The behavior code is used by pathologists to describe whether tissue samples are benign (0), borderline (1), in situ (2), or invasive (3).

Coding Instructions

- Code 3 if any malignant invasion is present, no matter how limited.
- Code 3 if any malignant metastasis to nodes or tissue beyond the primary is present.
- If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior.
- **Note:** The ICD-O-3 behavior code for juvenile astrocytoma (9421/1) is coded as 3 by agreement of North American registry standard-setters. Refer to “Case Eligibility” in Section One for information.

Code	Label	Definition
0	Benign	Benign
1	Borderline	Uncertain whether benign or malignant
		Borderline malignancy
		Low malignant potential
		Uncertain malignant potential
2	In situ and synonymous with in situ	Adenocarcinoma in an adenomatous polyp with no invasion of stalk
		Bowen disease (not reportable for C44._)
		Clark level 1 for melanoma (limited to epithelium)
		Comedocarcinoma, noninfiltrating (C50.–)
		Confined to epithelium
		Hutchinson melanotic freckle, NOS (C44.–)
		Intracystic, noninfiltrating.(carcinoma)

Code	Label	Definition
		Intraductal.(carcinoma)
		Intraepidermal, NOS (carcinoma)
		Intraepithelial, NOS (carcinoma)
		Involvement up to, but not including the basement membrane
		Lentigo maligna (C44.–)
		Noninfiltrating (carcinoma)
		Noninvasive (carcinoma only)
		No stromal invasion or involvement
		Papillary, noninfiltrating or intraductal (carcinoma)
		Precancerous melanosis (C44.–)
		Queyrat erythroplasia (C60.–)
3	Invasive	Invasive or microinvasive.

Examples

Code	Reason
1	Atypical meningioma (9539/1) invading bone of skull (the meninges, which line the skull, are capable of invading into the bone without being malignant; do not code as malignant unless it is specifically mentioned)
3	Patient had breast needle core biopsy which identified DCIS (/2) with focal areas of invasion (/3). Assign Behavior Code to 3 if any malignant invasion is identified, no matter how limited.
3	Patient experiencing abdominal pain and hematemesis. EUS with FNA of stomach lesion and suspicious regional LNs was performed, cytology revealed both positive for GIST involvement. STORE states gastro-intestinal stromal tumors (GIST) noted to have multiple foci, metastasis or positive lymph nodes must be abstracted and assigned a Behavior Code of 3.

Grade Clinical

Item #	Length	Allowable Values	Required Status	Date Revised
3843	1	1-5, 8, 9, A, B, C, D, E, L, H, M, S	2018+	01/18

Description

This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant). **NH-44**

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Pathological* [3844] and *Grade Post-Therapy* [3845], replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. **For some sites, grade is required to assign the clinical stage group.**

For those cases that are eligible for AJCC staging, the recommended grading system is specified in the current *AJCC Cancer Staging System*. The AJCC chapter -specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

Grade Pathological

Item #	Length	Allowable Values	Required Status	Date Revised
3844	1	1-5, 8, 9, A, B, C, D, E, L, H, M, S	2018+	01/18

Description

This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the current *AJCC Cancer Staging System*. This may include the grade from the clinical workup. Since all clinical information is used in pathological staging. Record the highest grade documented from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection.

NH-44

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Clinical* [3843] and *Grade Post Therapy Path (yp)* [3845], replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the pathological stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the current *AJCC Cancer Staging System*. The AJCC chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

Diagnostic Confirmation

Item #	Length	Allowable Values	Required Status	Date Revised
490	1	1–9	All Years	01/04, 01/10, 01/11, 01/12, 01/13, 01/23

Description

Records the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history. The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.

Rationale

This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases.

Coding Instructions – Solid Tumors (all tumors *except* 9590-9993)

- These instructions apply to “Codes for Solid Tumors” below. See the section following this one for “Coding Hematopoietic or Lymphoid Tumors (9590-9993)”.
- The codes are in **priority order**; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This data item must be changed to the lower (higher priority) code if a more definitive method confirms the diagnosis at any time during the course of the disease.
- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy or D&C or from aspiration of biopsy of bone marrow specimens.
- Assign code 2 when the microscopic diagnosis is based on cytologic examination of cells such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.
- Code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer.
- Code 6 when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy or from gross autopsy findings in the absence of tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Coding Instructions – Hematopoietic or Lymphoid Tumors (9590-9993)

- These instructions apply to “Codes for Hematopoietic and Lymphoid Neoplasms” below. See the preceding section for instructions “Coding Solid Tumors”.

- There is no priority hierarchy for coding Diagnostic Confirmation for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the Hematopoietic Database (DB) for information on the definitive diagnostic confirmation for specific types of tumors.
- Use code 2 when the microscopic diagnosis is based on cytologic examination of cells (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.
- Assign code 3 when there is a histology positive for cancer AND positive immunophenotyping and/or positive genetic testing results. Do not use code 3 for neoplasms diagnosed prior to January 1, 2010.
- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.
- Assign code 6 when the diagnosis is based only on the surgeon's report from a surgical exploration or endoscopy or from gross autopsy findings without tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Code	Label	Definition
1	Positive histology	Histologic confirmation (tissue microscopically examined).
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined).
3	Positive histology PLUS Positive immunophenotyping AND/OR Positive genetic studies	Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for acute myeloid leukemia. (9861/3) Genetic testing shows AML with inv(16)(p13.1q22) (9871/3). (Used only for hematopoietic and lymphoid neoplasms 9590/3-9993/3)
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology.
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer.
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from an imaging technique report only.
8	Clinical diagnosis only, other than 5, 6 or 7	The malignancy was reported by the physician in the medical record.
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic).

Examples for Solid Tumors

Code	Reason
1 Positive histology	FNA of liver was performed and was suspicious for HCC. A percutaneous liver biopsy was then performed which confirmed the FNA diagnosis of HCC. Assign code 1. The codes are in priority order; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods.
2 Positive cytology	Patient presented with severe shortness of air. CT scan revealed pleural effusion. Thoracentesis is performed which identified adenocarcinoma. Patient expired prior to additional workup.
3 Positive histology PLUS Positive immunophenotyping AND/OR Positive genetic studies	Code 3 cannot be used for Solid Tumors. Only use code 3 for hematopoietic and lymphoid neoplasms with histology 9590/3-9993/3)
4 Positive microscopic confirmation, method not specified	Patient initially diagnosed at an outside facility with proven cancer. It is unknown if malignancy was identified by cytology or histology.
5 Positive laboratory test/marker study	Physician states the patient has prostate cancer based on the patient's extremely elevated PSA level.
6 Direct visualization without microscopic confirmation	Elderly patient experiencing bloody stools presented for a colonoscopy. Scope was advanced to sigmoid colon where a 4.2 cm malignant appearing lesion was identified. No biopsies were taken due to patient's uncontrolled coagulation disorder.
7 Radiography and other imaging techniques without microscopic confirmation	Patient rushed to ER where CT chest/abdomen/pelvis showed widespread mets from unknown primary. No additional work up performed.
8 Clinical diagnosis only, other than 5, 6 or 7	Elderly patient presented to ER for hemoptysis, chest and abdominal pain. Patient refused additional work-up and admitted directly to hospice. Due to the initial presentation, the physician stated most likely has cancer.
9 Unknown whether or not microscopically confirmed	Patient diagnosed at outside facility with non-small cell lung cancer and presents at reporting facility for palliative radiation. Outside medical records are not available at time of abstracting and it is unknown how lung cancer was identified. Once additional information becomes available, the code should be reviewed and updated if possible.

Examples for Hematopoietic and Lymphoid Tumors

For additional coding information and examples, please review the [Hematopoietic and Lymphoid Manual](#)

Code	Reason
1 Positive histology	Patient had bronchoscopy with biopsy of hilar LN. Pathology identified DLBCL.
3 Positive histology PLUS Positive immunophenotyping AND/OR Positive genetic studies	Bone marrow examination is positive for acute myeloid leukemia. (9861/3) Genetic testing shows AML with inv(16)(p13.1q22) (9871/3).
5 Positive laboratory test/marker study	Patient had annual blood work which identified an elevated M protein. All other work up was negative. Physician diagnosed patient with smoldering myeloma.
8 Clinical diagnosis only, other than 5, 6 or 7	Patient presents with fatigue, night sweats and unexplained weight loss. Extensive work up performed including LN biopsy and all work up is negative or inconclusive. Physician made a clinical diagnosis based on patient symptoms/presentation.
9 Unknown whether or not microscopically confirmed	Patient diagnosed at outside facility and presented to reporting facility for chemotherapy. Outside medical records are not available, and it is unknown how the malignancy was initially identified. If additional information becomes available, the code should be reviewed and updated if possible.

Text--DX Proc--PE

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2520	4000	textDxProcPe	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation from the history and physical examination about the history of the current tumor and the clinical description of the tumor.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date of physical exam
- Age, sex, race/ethnicity
- History that relates to cancer diagnosis
- Primary site
- Histology (if diagnosis prior to this admission)
- Tumor location
- Tumor size
- Palpable lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Impression (when stated and pertains to cancer diagnosis)
- Treatment plan

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Text--DX Proc--PE, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
Primary Site	400
Laterality	410
Histologic Type ICD-O-3	522
Grade	440
Collaborative Stage variables	2800-2930
Diagnostic confirmation	490
RX Hosp--Surg Prim Site	670
RX Hosp--Scope Reg LN Sur	672
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Prim Site	1290
RX Summ--Scope Reg LN Sur	1292
RX Summ--Surg Oth Reg/Dis	1294
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Date Surgery	1200
Reason for No Surgery	1340
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Text--DX Proc--Lab Tests

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2550	4000	textDxProcLabTests	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information from laboratory examinations other than cytology or histopathology.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Type of lab test/tissue specimen(s)
- Record both positive and negative findings. Record positive test results first.
- Information can include tumor markers, serum and urine electrophoresis, special studies, etc.
- Date(s) of lab test(s)
- Tumor markers included, but are not limited to:
 - Breast Cancer – Estrogen Receptor Assay (ERA), Progesterone Receptor Assay (PRA), Her2/neu
 - Prostate Cancer – Prostatic Specific Antigen (PSA)\
 - Testicular Cancer – Human Chorionic Gonadotropin (hCG), Alpha Fetoprotein (AFP), Lactate Dehydrogenase (LDH)

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Text--DX Proc--Lab Tests, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Primary Site	400
Grade	440
Diagnostic Confirmation	490
Collaborative Stage variables	2800-2930
Date of Diagnosis	390
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Text--DX Proc--Path

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2570	4000	textDxProcPath	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information from cytology and histopathology reports.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date(s) of procedure(s)
- Anatomic source of specimen
- Type of tissue specimen(s)
- Tumor type and grade (include all modifying adjectives, i.e., predominantly, with features of, with foci of, elements of, etc.)
- Gross tumor size
- Extent of tumor spread
- Involvement of resection margins
- Number of lymph nodes involved and examined
- Record both positive and negative findings. Record positive test results first.
- Note if pathology report is a slide review or a second opinion from an outside source, i.e., AFIP, Mayo, etc.
- Record any additional comments from the pathologist, including differential diagnoses considered and any ruled out or favored

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Text--DX Proc--Path, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
Primary Site	400
Laterality	410
Histologic Type ICD-O-3	522
Grade	440
Collaborative Stage variables	2800-2930
Diagnostic confirmation	490
RX Hosp--Surg Prim Site	670
RX Hosp--Scope Reg LN Sur	672
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Prim Site	1290
RX Summ--Scope Reg LN Sur	1292
RX Summ--Surg Oth Reg/Dis	1294
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Date Surgery	1200
Reason for No Surgery	1340
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Text--Remarks

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2680	4000	textRemarks	Neither carriage return nor line feed characters allowed	All Years	2021

Description

Text area for information that is given only in coded form elsewhere or for which the abstract provides no other place. Overflow data can also be placed here. Problematic coding issues can also be discussed in this section.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

Instructions

- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments from other text fields can be continued in the Remarks field. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Smoking history
- Family and personal history of cancer
- Comorbidities
- Information on sequence numbers if a person was diagnosed with another primary out-of-state or before the registry's reference date
- Place of birth
- Justification of over-ride flags
- Information clarifying anything unusual such as reason for reporting a case seemingly not reportable for that facility or reason for coding numerous fields as "unknown."

Stage of Disease at Diagnosis

NH-45

Date of Surgical Diagnostic and Staging Procedure

Item #	Length	Allowable Values	Required Status	Date Revised
1280	8	CCYYMMDD, Blank	All Years	01/10, 01/11, 01/23

Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions

- Record the date on which the surgical diagnostic and/or staging procedure described in Surgical Diagnostic and Staging Procedure [1350] was performed at this or any facility.
- Blank is allowed.

Surgical Diagnostic and Staging Procedure

Item #	Length	Allowable Values	Required Status	Date Revised
1350	2	00–07, 09	All Years	09/06, 09/08, 01/12, 01/15

Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions

- Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Rx Summ – Surg 2023* [1291] to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this data item except for lymphoma as described above. Use the data item *Scope of Regional Lymph Node Surgery* [1292] to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure* [1280]. See instructions for *Scope of Regional Lymph Node Surgery* [1292].
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation* [490]. These are not considered surgical procedures and should not be coded in this item.
- Aspirations can be a biopsy (tissue) or cytology (cells).
 - Code tissue biopsy in *Surgical Diagnostic and Staging Procedure* [1350].
 - Code cytology cell aspiration in *Diagnostic Confirmation* [490].
- If there are negative or microscopically positive margins (visible with microscope only/not visible to the naked eye) then capture procedure as a *Rx-Summ-Surg 2023* [1291]. Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Rx Summ – Surg 2023* [1291] to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive (invasive) surgery, and upon the excisional biopsy or more extensive (invasive) surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] data item and the excisional biopsy or more extensive (invasive) surgery in the *Rx Summ – Surg 2023* data item [1291].

- If there are macroscopic positive margins (visible with the naked eye) then capture the procedure as a Surgical Diagnostic and Staging Procedure (SDSP) [1350].
- Do not code palliative surgical procedures in this data item. Use the data item Palliative Procedure [3270] to code these procedures.

Code	Label
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

Examples

Code	Reason
00	A lung cancer primary was diagnosed by CT scan. The patient expired. No surgical diagnostic or staging surgical procedure was performed.
00	A sputum sample is examined cytologically to confirm a diagnosis of suspected lung cancer. The procedure is not surgical.
01	A needle biopsy of a liver metastasis in a patient with suspected widespread colon cancer was done. Gross residual tumor is left at the biopsy site.
02	A liver needle core biopsy identified hepatocellular carcinoma.
03	During abdominal exploratory surgery, a gastric lesion and suspicious retroperitoneal lymph nodes were observed. No biopsy or treatment was done.
04	An abdominal exploration of a patient revealed pancreatic carcinoma with extension into surrounding organs and arteries. No attempt to treat. A bypass was performed to alleviate symptoms.
05	An exploratory procedure was performed for primary colon carcinoma with biopsy of suspicious liver lesions.
06	Esophagogastrectomy was performed for infiltrating gastric tumor following a biopsy of the primary site.
07	Stage III lung carcinoma was diagnosed and staged prior to admission.
09	A patient expires in the emergency room with recently diagnosed metastatic melanoma. It is unknown whether a diagnostic or staging procedure was done.

Surgical Diagnostic and Staging Procedure at This Facility

Item #	Length	Allowable Values	Required Status	Date Revised
740	2	00–07, 09	All Years	01/04, 09/08, 01/12

Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions

- Record the type of procedure performed as part of the initial diagnosis and workup at this facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item Rx Hosp–Surg 2023 [671] to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this data item except for lymphoma as described above. Use the data item Scope of Regional Lymph Node Surgery at This Facility [672] to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item Date of Surgical Diagnostic and Staging Procedure [1280]. See instructions for Scope of Regional Lymph Node Surgery at This Facility [672].
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item Diagnostic Confirmation [490]. These are not considered surgical procedures and should not be coded in this item.
- Aspirations can be a biopsy (tissue) or cytology (cells).
 - Code tissue biopsy in Surgical Diagnostic and Staging Procedure [1350].
 - Code cytology cell aspiration in Diagnostic Confirmation [490].
- If there are negative or microscopically positive margins (visible with microscope only/not visible to the naked eye) then capture procedure as a Rx-Hosp-Surg 2023 [671]. Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item Rx Hosp – Surg 2023 [671] to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive (invasive) surgery, and upon the excisional biopsy or more extensive (invasive) surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the Surgical Diagnostic and Staging Procedure at this Facility [740] data item and the excisional biopsy or more extensive (invasive) surgery in the Rx Hosp – Surg 2023 [671].

- If there are macroscopic positive margins (visible with a naked eye) then capture the procedure as a Surgical Diagnostic and Staging Procedure (SDSP) [1350].
- Do not code palliative surgical procedures in this data item. Use the data item Palliative Procedure at This Facility [3280] to code these procedures.

Code	Label
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

Lymphovascular Invasion

Item #	Length	Allowable Values	Required Status	Date Revised
1182	1	0-4, 8-9	2010+	01/11, 01/18, 01/22

Description

Indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

Rationale

Lymphovascular invasion is an indicator of prognosis.

Coding Instructions

- Codes have been updated to align with the current AJCC Cancer Staging System for appropriate disease sites. Additional clarifications implemented for thyroid and adrenal per suggestions from CAP.
 - Revised CAP Protocols and AJCC Cancer Staging System chapters will indicate which chapters will use the new codes (2, 3, and 4) and which will only use the existing codes (0, 1, 8, 9), as there are some disease sites where distinguishing between L and V is not medically appropriate.
 - Code 8, Not Applicable for benign/borderline brain and CNS tumors and Gastrointestinal Stromal Tumors (GIST).
 - For cases diagnosed January 1, 2018 and later, new codes indicating lymphatic, small vessel, and/or large vessel invasion were added.
1. Code from pathology report(s). Code the absence or presence of lymphovascular invasion as described in the medical record.
 - a. The primary sources of information about lymphovascular invasion are the pathology check lists (synoptic reports) developed by the College of American Pathologists. If the case does not have a checklist or synoptic report, code from the pathology report or a physician's statement, in that order.
 - b. Do not code perineural invasion in this field.
 - c. Information to code this field can be taken from any specimen from the primary tumor (biopsy or resection.)
 - d. If lymphovascular invasion is identified in any specimen, it should be coded as present/identified.
 - e. For cases treated with neoadjuvant therapy, refer to table below in order to code this field. However, if documentation in the medical record indicates information that conflicts with this table, code lymphovascular invasion with the documentation in the medical record.
 - i. If LVI was present prior to neoadjuvant therapy (codes 1-4) but LVI was not present after neoadjuvant therapy (codes 0 or 9), code the LVI to present (codes 1-4).
 - ii. If the LVI was not present prior to neoadjuvant therapy (codes 0 or 9), but LVI was present after neoadjuvant therapy (codes 1-4), code LVI to present (codes 1-4).

LVI on pathology report PRIOR to neoadjuvant therapy	LVI on pathology report AFTER neoadjuvant therapy	Code LVI to:
0 - Not present/Not identified	0 - Not present/Not identified	<i>0 - Not present/Not identified</i>
0 - Not present/Not identified	1 - Present/Identified	<i>1 - Present/Identified</i>
0 - Not present/Not identified	9 - Unknown/Indeterminate	<i>9 -Unknown/Indeterminate</i>
1 - Present/Identified	0 - Not present/Not identified	<i>1 - Present/Identified</i>
1 - Present/Identified	1 - Present/Identified	<i>1 - Present/Identified</i>
1 - Present/Identified	9 - Unknown/Indeterminate	<i>1 - Present/Identified</i>
9 - Unknown/Indeterminate	0 - Not present/Not identified	<i>9 -Unknown/Indeterminate</i>
9 - Unknown/Indeterminate	1 - Present/Identified	<i>1 - Present/Identified</i>
9 - Unknown/Indeterminate	9 - Unknown/Indeterminate	<i>9-Unknown/Indeterminate</i>

2. Use of codes.

- a. Use code 0 when the pathology report indicates that there is no lymphovascular invasion. This includes cases of purely in situ carcinoma, which biologically have no access to lymphatic or vascular channels below the basement membrane.
- b. Use code 1 when the pathology report or a physician's statement indicates that lymphovascular invasion (or one of its synonyms) is present in the specimen.

Synonyms include, but are not limited to:

Angiolymphatic invasion
 Blood vessel invasion
 Lymph vascular emboli
 Lymphatic invasion
 Lymphovascular invasion
 Vascular invasion
 Lymphovascular space invasion

Lymphovascular invasion must be coded 0, 1, 2, 3, 4, or 9 for the Schema IDs in the following list:

Ampulla Vater	00270
Appendix	09190
Bile Ducts Distal	00260
Bile Ducts Intrahepatic	00230
Bile Ducts Perihilar	00250
Bladder	00620
Buccal Mucosa	00076
Cervix	09520
Cervix Sarcoma	00528
Colon and Rectum	00200
Corpus Adenosarcoma	00542
Corpus Carcinoma	00530
Corpus Sarcoma	00541
Esophagus (incl GE Junct)(excl Squamous)	00169

Esophagus (incl GE Junction) Squamous	00161
Floor of Mouth	00074
Gum	00073
Hypopharynx	00112
Larynx Glottic	00132
Larynx Other	00130
Larynx Subglottic	00133
Larynx Supraglottic	00131
Lip	00071
Lung	09360
Major Salivary Glands	09081
Maxillary Sinus	00121
Melanoma Skin	00470
Merkel Cell Skin	00460
Mouth Other	00077
Nasal Cavity and Ethmoid Sinus	00122
NET Ampulla of Vater	09302
NET Appendix	09320
NET Colon and Rectum	09330
NET Duodenum	09301
NET Pancreas	09340
NET Stomach	09290
Oropharynx (p16-)	00111
Oropharynx HPV Associated (p16+)	09100
Palate Hard	00075
Pancreas	00280
Penis	00570
Placenta	00560
Small Intestine	00180
Stomach	00170
Testis	00590
Thymus	09350
Tongue Anterior	00072
Vagina	00510
Vulva	09500

- c. Lymphovascular invasion must be coded 0, 2, 3, 4, or 9 for the Schema IDs in the following list:

Adrenal Gland	00760
Thyroid	00730
Thyroid Medullary	00740

- d. Lymphovascular invasion may be coded any code (0, 1, 2, 3, 4, 8, or 9) for the remaining Schema IDs (shown in the following list):

Adnexa Uterine Other	00760
Anus	09210
Biliary Other	00278

Bone Appendicular Skeleton	00381
Bone Pelvis	00383
Bone Spine	00382
Brain	09721
Breast (Invasive)	00480
Cervical LNs, Occult Head & Neck	00060
CNS Other	09722
Conjunctiva	00650
Cutaneous Carcinoma Head and Neck	00150
Cystic Duct	00242
Digestive Other	00288
Endocrine Other	00778
Eye Other	00718
Fallopian Tube	00553
Gallbladder	00241
Genital Female Other	00559
Genital Male Other	00598
GIST (2018-2020)	00430
Heart, Mediastinum, and Pleura	00422
Ill-Defined Other	99999
Intracranial Gland	09723
Kaposi Sarcoma	00458
Kidney Parenchyma	00600
Kidney Renal Pelvis	00610
Lacrimal Gland	00690
Lacrimal Sac	00698
Liver	00220
Medulloblastoma	09724
Melanoma Choroid and Ciliary Body	00672
Melanoma Conjunctiva	00660
Melanoma Head and Neck	00140
Melanoma Iris	00671
Middle Ear	00119
Nasopharynx	09090
NET Adrenal Gland	00770
Net Jejunum and Ileum	09310
Orbital Sarcoma	00700
Ovary	00551
Parathyroid	00750
Pharynx Other	00118
Pleural Mesothelioma	09370
Primary Peritoneal Carcinoma	00552
Prostate	00580
Respiratory Other	00378
Retinoblastoma	00680
Retroperitoneum	00440
Sinus Other	00128

Skin Eyelid	00640
Skin Other	00478
Soft Tissue Abdomen and Thorax	00421
Soft Tissue Head and Neck	00400
Soft Tissue Other	00450
Soft Tissue Trunk and Extremities	00410
Trachea	00358
Urethra	00631
Urethra-Prostatic	00633
Urinary Other	00638

- e. Lymphovascular invasion must be coded 8 (not applicable) for all other Schema IDs:

Benign Brain/CNS	
GIST 2021+	00430
HemeRetic	00830
Lymphoma	00790
Lymphoma (CLL/SLL)	00795
Lymphoma Ocular Adnexa	00710
Mycosis Fungoides	00811
Plasma Cell Disorder	00822
Plasma Cell Myeloma	00821
Primary Cutaneous Lymphoma non-MF	00812

- f. Use code 9 when:

- i. there is no microscopic examination of a primary tissue specimen
- ii. the primary site specimen is cytology only or a fine needle aspiration
- iii. the biopsy is only a very small tissue sample
- iv. it is not possible to determine whether lymphovascular invasion is present
- v. the pathologist indicates the specimen is insufficient to determine lymphovascular invasion
- vi. lymphovascular invasion is not mentioned in the pathology report
- vii. primary site is unknown

- g. Clarification between codes 8 and 9:

- Code 8 should only be used in the following situations:
 1. Standard-setter does not require this item and you are not collecting it.
 2. Those schemas noted above described in code 8 for which LVI is always not applicable.
- For those cases where there is no information/documentation from the pathology report or other sources, use code 9.

Code	Label
0	Lymphovascular Invasion stated as Not Present
1	Lymphovascular Invasion Present/Identified (NOT used for thyroid and adrenal)
2	Lymphatic and small vessel invasion only (L) OR Lymphatic invasion only (thyroid and adrenal only)
3	Venous (large vessel) invasion only (V) OR Angioinvasion (thyroid and adrenal only)
4	BOTH lymphatic and small vessel AND venous (large vessel) invasion OR BOTH lymphatic AND angioinvasion (thyroid and adrenal only)
8	Not Applicable
9	Unknown/Indeterminate/not mentioned in path report

Macroscopic Evaluation of the Mesorectum

Item #	Length	Allowable Values	Required Status	Date Revised
3950	2	00, 10,20, 30, 40, 99 or Blank	2022+	01/22, 01/23

Description

This data item records whether a Total Mesorectal Excision (TME) was performed and the macroscopic evaluation of the completeness of the excision.

Rationale

Numerous studies have demonstrated that total mesorectal excision (TME) improves local recurrence rates and the corresponding survival by as much as 20%. Macroscopic pathologic assessment of the completeness of the mesorectum, scored as complete, partially complete, or incomplete, accurately predicts both local recurrence and distant metastasis.

Coding Instructions

- The American Society of Colon and Rectal Surgeons most recent Practice Parameters for the Management of Rectal Cancer states that total mesorectal excision is used for curative resection of tumors of the middle and lower thirds of the rectum, either as part of low anterior or abdomino- perineal resection. For tumors of the upper third of the rectum, a tumor-specific mesorectal excision should be used with the mesorectum divided ideally no less than 5 cm below the lower margin of the tumor. Pathologic evaluation of the resection specimen has been shown to be a sensitive means of assessing the quality of rectal surgery.
- Macroscopic pathologic assessment of the completeness of the mesorectum, is scored as complete, partially complete, or incomplete.
- Information for this data item comes from the pathology report only.
- Leave this field blank if primary site is other than C20.9.
- Neoadjuvant therapy does not alter coding of this data item.
- Code 00 if patient did not have a Total Mesorectal Excision.
- Codes 10, 20, and 30 must be based on pathology report.
- When TME is known to have been performed, registrars should not attempt to determine the level of completeness of TME when the pathology report does not indicate TME is incomplete, nearly complete or complete. Assign code 40.

Code	Label
00	Patient did not receive TME
10	Incomplete TME
20	Nearly Complete
30	Complete TME
40	TME performed not specified on pathology report as incomplete, nearly complete, or complete TME performed but pathology report not available Physician statement that TME performed, no mention of incomplete, nearly complete or complete status
99	UNKNOWN if TME performed
BLANK	Site not rectum (C20.9)

Sentinel and Regional Lymph Nodes

Date of Sentinel Lymph Node Biopsy

Item #	Length	Allowable Values	Required Status	Date Revised
832	8	CCYYMMDD, Blank	2018+	01/18, 01/23

Description

Records the date of the sentinel lymph node(s) biopsy procedure. This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of the sentinel lymph node biopsy procedure separate from the date of a subsequent regional node dissection procedure, if performed.

Coding Instructions

- Record the date of the sentinel lymph node biopsy procedure documented in the Sentinel Lymph Node Examined [834].
- This data item documents the date of sentinel node biopsy; do not record the date of lymph node aspiration, fine needle aspiration, fine needle aspiration biopsy, core needle biopsy, or core biopsy.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma.
- Use the AJCC N suffix to designate sentinel node procedures for **ALL** sites.
- If the sentinel lymph node biopsy is the first or only surgical procedure performed, record the date documented in this data item in the Date First Surgical Procedure [1200].
- If separate sentinel node biopsy procedure and subsequent regional node dissection procedure are performed, record the date of the sentinel lymph node biopsy in this data item, and record the date the subsequent regional node dissection was performed in the Date Regional Lymph Node Dissection [682].
- If a sentinel lymph node biopsy is performed in the same procedure as the regional node dissection, record the date of the procedure in both this data item and in the Date of Regional Lymph Node Dissection [682] (i.e., the dates should be equal).
- Blank is allowed.

Sentinel Lymph Nodes Examined

Item #	Length	Allowable Values	Required Status	Date Revised
834	2	00-90, 95, 98, 99, Blank	2018+	01/18, 01/22

Description

Records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of lymph nodes biopsied during the sentinel node biopsy procedure separate from the number of lymph nodes dissected during additional subsequent regional node procedures.

Coding Instructions

- If, during a sentinel node biopsy procedure, a few non-sentinel nodes happen to be sampled, document the **total number of nodes sampled during the sentinel node procedure** in this data item. I.e., record the total number of nodes from the sentinel node biopsy procedure regardless of sentinel node status.
- If a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the total number of nodes biopsied during the sentinel node procedure in this data item, and record the total number of regional lymph nodes biopsied/dissected (**which includes the number of nodes documented in this data item**) in Regional Lymph Nodes Examined [830].
- If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, record the total number of nodes biopsied during the sentinel node procedure in this data item, and record the total number of regional lymph nodes biopsied/dissected (**which includes the number of nodes documented in this data item**) in Regional Lymph Nodes Examined [830].
- If aspiration of sentinel lymph node(s) AND a sentinel node biopsy procedure were performed for same patient, record the results for the sentinel node biopsy.
- The number of sentinel lymph nodes examined will typically be found in the pathology report; radiology reports or documented by the physician. Determination of the exact number of sentinel lymph nodes examined may require assistance from the managing physician for consistent coding.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for **ALL** sites.
- The number of sentinel nodes should be equal to or less than the number of regional nodes examined recorded in the Regional Lymph Nodes Examined [830] data item.

Code	Label
00	No sentinel nodes were examined
01-90	Sentinel nodes were examined (code the exact number of sentinel lymph nodes examined)
95	No sentinel nodes were removed, but aspiration of sentinel node(s) was performed
98	Sentinel lymph nodes were biopsied, but the number is unknown
99	It is unknown whether sentinel nodes were examined; not applicable; not stated in medical record

Sentinel Lymph Nodes Positive

Item #	Length	Allowable Values	Required Status	Date Revised
835	2	00-90, 95, 97-99, Blank	2018+	01/18, 01/22

Description

Records the exact number of sentinel lymph nodes biopsied by the pathologist and found to contain metastases. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of positive sentinel lymph nodes biopsied separate from the number of positive lymph nodes identified during additional subsequent regional node dissection procedures, if performed.

Coding Instructions

- If, during a sentinel node biopsy procedure, a few non-sentinel nodes happen to be sampled and are positive, document the **total number of positive nodes identified during the sentinel node procedure** in this data item. I.e., record the total number of positive nodes from the sentinel node biopsy procedure regardless of whether the nodes contain dye or colloidal material (tracer or radiotracer).
- If both a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the total number of **positive sentinel nodes** identified during the sentinel node procedure in this data item, and record the total number of positive regional lymph nodes biopsied/dissected (**which includes the number of sentinel nodes documented in this data item**) in Regional Lymph Nodes Positive [820].
- If a positive aspiration of sentinel lymph node(s) AND a positive sentinel node biopsy procedure were performed for same patient, record the results for the positive sentinel node biopsy procedure.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for **ALL** sites
- **FOR BREAST ONLY:** If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, and the number of positive sentinel lymph nodes removed cannot be determined, use code 97 in this data item, and record the total number of positive regional lymph nodes biopsied/dissected (which includes the sentinel lymph nodes) in Regional Lymph Nodes Positive [820].
- If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection and the number of positive sentinel lymph nodes is recorded on the pathology report, record in this data item and then record the total number of positive regional lymph nodes (both sentinel and regional) in Regional Lymph Nodes Positive [820].
- **FOR MELANOMA ONLY:** If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, record the total number of **positive sentinel nodes** identified in this data item, and record the total number of positive regional lymph nodes identified (**which includes the number of positive sentinel nodes documented in this data item**) in Regional Lymph Nodes Positive [820].
- When the sentinel lymph node biopsy is performed during the same procedure as the regional node

dissection the CAP Protocol for Melanoma captures both the number of positive sentinel nodes as well as the number of positive regional nodes (i.e., the number of positive sentinel nodes is captured).

- The number of sentinel lymph nodes biopsied and found positive will typically be found in the pathology report; radiology reports or documented by the physician. Determination of the exact number of sentinel lymph nodes positive may require assistance from the managing physician for consistent coding.
- The number of sentinel nodes positive should be less than or equal to than the total number of Regional Nodes Positive [820].
- For carcinoma of the breast, if only positive Isolated Tumor Cells (ITC) are identified the sentinel lymph nodes are considered **negative**.
- For melanoma, if only positive Isolated Tumor Cells (ITC) are identified the sentinel lymph nodes are considered **positive**.
- mi (microscopic or micro mets) sentinel lymph nodes are considered positive.

Code	Label
00	All sentinel nodes examined are negative
01-90	Sentinel nodes are positive (code exact number of nodes positive)
95	Positive aspiration of sentinel lymph node(s) was performed
97	Positive sentinel nodes are documented, but the number is unspecified; For breast ONLY: SLN and RLND occurred during the same procedure
98	No sentinel nodes were biopsied
99	It is unknown whether sentinel nodes are positive; not applicable; not stated in medical record

Date Regional Lymph Node Dissection

Item #	Length	Allowable Values	Required Status	Date Revised
682	8	CCYYMMDD, Blank	2018+	01/18

Description

Records the date non-sentinel regional node dissection was performed. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of regional node dissection separate from the date of sentinel lymph node biopsy if performed.

Coding Instructions

- Record the date of regional lymph node dissection documented in the Regional Lymph Nodes Examined [830].
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma.
- For Breast and Melanoma cases**, if both a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the date of the regional lymph node dissection in this data item and record the date of the sentinel node biopsy procedure in the Date of Sentinel Lymph Node Biopsy [832].
- If a sentinel lymph node biopsy is **performed in the same procedure** as the regional node dissection, record the date of the procedure in both this data item and in the Date of Sentinel Lymph Node Biopsy [832] data item (i.e., the dates should be equal).
- For all other cases**, record the date of the regional lymph node dissection in this data item.

Regional Lymph Nodes Examined

Item #	Length	Allowable Values	Required Status	Date Revised
830	2	00–90, 95–99	All Years	09/06, 01/10, 2/21, 01/22, 1/23

Description

Records the total number of regional lymph nodes that were removed and examined by the pathologist. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016, use of CS was discontinued, however this data item continued to be required.

Rationale

This data item serves as a quality measure of the pathologic and surgical evaluation and treatment of the patient.

Coding Instructions

- **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Distant lymph node information should not be coded in this field.
- This field is **based on pathologic information only**. This field is to be recorded regardless of whether the patient received preoperative treatment.
- **Use of Code 00.** Code 00 may be used in several situations.
 - When the assessment of lymph nodes is clinical.
 - When no lymph nodes are removed and examined.
 - When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.
 - If Regional Nodes Examined is coded 00, Regional Nodes Positive is coded as 98.
- **Cumulative nodes removed and examined.** Record the total number of regional lymph nodes removed and examined by the pathologist.
 - The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment with the exception of aspiration or core biopsies coded to 95.
 - Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined.
 - If the aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Examined.
 - If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Examined.
 - When neither the type of lymph node removal procedure nor the number of lymph nodes examined is known, use code 98.
- **Priority of lymph node counts.** If there is a discrepancy regarding the number of lymph nodes examined, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.

- **Use of code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).
- **Lymph node biopsy.** If a lymph node biopsy was performed, code the number of nodes removed, if known. If the number of nodes removed by biopsy is not known, use code 96.
- **Definition of “sampling” (code 96).** A lymph node “sampling” is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection. Use code 96 when a limited number of nodes are removed but the number is unknown.
- **Definition of “dissection” (code 97).** A lymph node “dissection” is removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, lymph node stripping. Use code 97 when more than a limited number of lymph nodes are removed and the number is unknown.
- **Multiple lymph node procedures.** If both a lymph node sampling and a lymph node dissection are performed and the total number of lymph nodes examined is unknown, use code 97.
- **Use of Code 99.** If it is unknown whether nodes were removed or examined, code as 99.
- Use code 99 for
 - a. Any case coded to primary site: C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809
 - b. Lymphoma 00790
 - c. Lymphoma-CLL/SLL 00795
 - d. Plasma Cell Disorders (excluding 9734/3) 00822
 - e. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424)
 - f. III-Defined/Other 99999
 - g. Cases with no information about positive regional lymph nodes
- When definition of regional nodes differs between the *AJCC Cancer Staging System* and the SEER Program Coding and Staging Manual, use the AJCC definition.

Code	Label
00	No nodes were examined
01-89	1-89 nodes were examined (code the exact number of regional lymph nodes examined)
90	90 or more nodes were examined
95	No regional nodes were removed, but aspiration of regional nodes was performed
96	Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated
97	Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated
98	Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown
99	It is unknown whether nodes were examined; not applicable or negative; not stated in medical record

Regional Lymph Nodes Positive

Item #	Length	Allowable Values	Required Status	Date Revised
820	2	00–90, 95, 97-99	All Years	09/06, 01/10, 2/21, 01/22, 1/23

Description

Records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016, use of CS was discontinued, however this data item continued to be required.

Rationale

This data item is necessary for pathological staging, and it serves as a quality measure for pathology reports and the extent of the surgical evaluation and treatment of the patient.

Coding Instructions

- **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Distant lymph node information should not be coded in this field.
- This field is **based** on pathologic information only. This field is to be recorded regardless of whether the patient received preoperative treatment.
- **Cumulative nodes positive.** Record the total number of regional lymph nodes removed and found to be positive by pathologic examination.
 - The number of regional lymph nodes positive is cumulative from all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment.
 - Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Positive when there are positive nodes in the resection. In other words, if there are positive regional lymph nodes in a lymph node dissection, do not count the core needle biopsy or the fine needle aspiration if it is in the same chain. See also Use of Code 95 below.
 - If the aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Positive.
 - If the location of the lymph node that is core-biopsied or aspirated is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Positive.
- **Priority of lymph node counts.** If there is a discrepancy regarding the number of positive lymph nodes, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.
- **Positive Nodes in Multiple Primaries in Same Organ.** If there are multiple primary cancers with different histologic types in the same organ and the pathology report just states the number of nodes positive, the registrar should first try to determine the histology of the metastases in the nodes and code the nodes as positive for the primary with that histology. If no further information is available, code the nodes as positive for all primaries.
- **Isolated tumor cells (ITCs) in lymph nodes.** For all primary sites except cutaneous melanoma and Merkel cell carcinoma of skin, count only lymph nodes that contain micrometastases or larger

(metastases greater than 0.2 millimeters in size). Do not include in the count of lymph nodes positive any nodes that are identified as containing isolated tumor cells (ITCs). If the path report indicates that nodes are positive but the size of metastasis is not stated, assume the metastases are larger than 0.2 mm and count the lymph node(s) as positive.

- **For cutaneous melanoma and Merkel cell carcinoma**, count nodes with ITCs as positive lymph nodes.
- **Use of Code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue). Use code 95 when a positive lymph node is aspirated and there are no surgically resected lymph nodes. Use code 95 when a positive lymph node is aspirated and surgically resected lymph nodes are negative.
- **Definition of Code 97.** Use code 97 for any combination of positive aspirated, biopsied, sampled or dissected lymph nodes if the number of involved nodes cannot be determined on the basis of cytology or histology. Code 97 includes positive lymph nodes diagnosed by either cytology or histology. Note: If the aspirated node is the only one that is microscopically positive, use code 95.
- **Use of Code 98.** Code 98 may be used in several situations. When the assessment of lymph nodes is clinical only. When no lymph nodes are removed and examined. When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination. If Regional Nodes Positive is coded as 98, Regional Nodes Examined is usually coded 00.
- **Use of code 99.** Use code 99 if it is unknown whether regional lymph nodes are positive.
- Use code 99 for
 - a. Any case coded to primary site: C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809
 - b. Lymphoma 00790
 - c. Lymphoma-CLL/SLL 00795
 - d. Plasma Cell Disorders (excluding 9734/3) 00822
 - e. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424)
 - f. Ill-Defined/Other 99999
 - g. Cases with no information about positive regional lymph nodes
- When definition of regional nodes differs between the current *AJCC Cancer Staging System* and the SEER Program Coding and Staging Manual, **use the AJCC definition.**

Code	Label
00	All nodes examined are negative
01-89	1-89 nodes are positive (code exact number of nodes positive)
90	90 or more nodes are positive
95	Positive aspiration of lymph node(s) was performed
97	Positive nodes are documented, but the number is unspecified
98	No nodes were examined
99	It is unknown whether nodes are positive; not applicable; not stated in medical record

Tumor Size and Mets

Tumor Size Summary

Item #	Length	Allowable Values	Required Status	Date Revised
756	3	000-990, 998, 999	2016+	01/16, 2/21, 01/22

Description

This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen.

Rationale

Tumor size is one indication of the extent of disease. As such, it is used by both clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

Coding Instructions

Note: All measurements should be in millimeters (mm).

Record size in specified order:

- Size measured on the surgical resection specimen, when surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.
If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or pathology report checklist).
If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.
Example: Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).
Example: Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).
- If neoadjuvant therapy followed by surgery, do not record the size from the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size as 999.
Example: Patient has a 2.2 cm mass in the oropharynx; find needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).
- If no surgical resection, then largest measurement of the tumor from the imaging, physical exam, or other diagnostic procedures in this order of priority prior to any other form of treatment (See Coding Rules below).
- If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

Coding Rules

- Tumor size is the **diameter** of the tumor, **not the depth or thickness** of the tumor.
- Recording less than/greater than Tumor Size:
 - If tumor size is reported as less than x mm or less than x cm, the reported tumor size should be 1 mm less; for example if size is <10 mm, code size as 009. Often these are given in cm such

- as < 1 cm which is coded as 009, < 2 cm is coded as 019, < 3 cm is coded as 029, < 4 cm is coded as 039, < 5 cm is coded as 049. If stated as less than 1 mm, use code 001.
- b. If tumor size is reported as more than x mm or more than x cm, code size as 1 mm more; for example if size is >10 mm, size should be coded as 011. Often these are given in cm such as > 1 cm, which is coded as 011, > 2 cm is coded as 021, > 3 cm is coded as 031, > 4 cm is coded as 041, > 5 cm is coded as 051. If described as anything greater than 989 mm (98.9 cm) code as 989.
 - c. If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two ("between 2 and 3 cm" is coded as 025).
3. **Rounding:** Round the tumor size only if it is described in fractions of millimeters. If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm), record size as 001 (do not round down to 000). If tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to the nearest whole millimeter. Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters). For breast cancer, please follow the AJCC, Edition, Breast Chapter.
Examples:
 Breast cancer described as 6.5 millimeters in size. Round up *Tumor Size as 007*. Cancer in polyp described as 2.3 millimeters in size. Round down *Tumor Size as 002*.
 Focus of cancer described as 1.4 mm in size. *Round down as 001*.
 5.2 mm breast cancer. *Round down to 5 mm and code as 005*.
 4. **Priority of imaging/radiographic techniques:** Information on size from imaging/radiographic techniques can be used to code the tumor size when there is no more specific size information from pathology or operative report. It should be taken as a lower priority, but over a physical exam.
 5. **Tumor size discrepancies among imaging and radiographic reports:** If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.
 6. **Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.** However, if the tumor is described as a "cystic mass," and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.
 7. Record the size of the invasive component, if given.
 - a. If both an in situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.
Example: Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (14 mm)
 - b. If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.
Example: A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (23 mm).
Example: Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (19 mm).
 8. Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.
Example: Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).
 9. Record the size as stated for purely in situ lesions.

10. **Disregard microscopic residual or positive surgical margins when coding tumor size.** Microscopic residual tumor does not affect overall tumor size. The status of primary tumor margins may be recorded in a separate data item.
11. **Do not add the size of pieces or chips together to create a whole;** they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if the pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size), record that size. If the only measurement describes pieces or chips, record tumor size as 999.
12. **Multifocal/multicentric tumors:** If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all of the tumors are in situ, code the size of the largest in situ tumor.
13. **Tumor size code 999 is used when size is unknown or not applicable.** Sites/morphologies where tumor size is not applicable are listed here.
Primary sites: C420, C421, C423-C424, C770-C779 or C809
 - Hematopoietic, Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9993
 - *Excludes* cases collected in the following schemas: Lymphoma Ocular Adnexa, Primary Cutaneous Lymphomas, Mycosis Fungoides and lymphomas that are collected in the Brain, CNS Other and Intracranial Gland Schemas
 - Kaposi Sarcoma
 - Melanoma Choroid
 - Melanoma Ciliary Body
 - Melanoma Iris
14. Tumor size code 000 is used for the following schema:
 - i. Schema is Cervical Lymph Nodes and Unknown Primary 00060
 - ii. Occult Cervical Lymph Node (See STORE, Overview of Coding Principles, page 44).
15. Document the information to support coded tumor size in the appropriate text data item of the abstract.
16. Tumor size is also important for staging for the following sites/schemas and schema IDs:

Schema (Schema ID)

Adrenal Gland	00760
Anus	09210
Bile Duct Distal	00260
Bile Ducts Intrahepatic	00230
Bone Appendicular Skeleton	00381
Bone Pelvis	00383
Breast	00480
Buccal Mucosa	00076
Cervix	09520
Conjunctiva	00650
Corpus Sarcoma	00541
Cutaneous Carcinoma of Head and Neck	00150
Floor of Mouth	00074
GIST	00430
Gum	00073
Hypopharynx	00112
Kidney Parenchyma	00600
Lacrimal Gland	00690
Lip	00071

Liver	00220
Lung	09360
Major Salivary Glands	09081
Merkel Cell Skin	00460
Mouth Other	00077
NET Adrenal Gland	00770
NET Appendix	09320
NET Colon and Rectum	09330
NET Pancreas	09340
NET Stomach	09290
Orbital Sarcoma	00700
Oropharynx (p16-)	00111
Oropharynx HPV-Mediated (p16+)	09100
Palate Hard	00075
Pancreas	00280
Primary Cutaneous Lymphomas (excluding Mycosis Fungoides and Sezary Syndrome)	00812
Retroperitoneum	00440
Skin Eyelid	00640
Soft Tissues Head and Neck	00400
Soft Tissues Trunk and Extremities	00410
Thyroid	00730
Thyroid Medullary	00740
Tongue Anterior	00072
Vagina	00510
Vulva	09500

Code	Label
000	No mass/tumor found
001	1 mm or described as less than 1 mm
002-988	Exact size in millimeters (2 mm to 988 mm)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus is given
998	SITE-SPECIFIC CODES Alternate descriptions of tumor size for specific sites: Familial/multiple polyposis: Rectosigmoid and rectum (C19.9, C20.9) Colon (C18.0, C18.2-C18.9) If no size is documented: Circumferential: Esophagus (C15.0-C15.5, C15.8-C15.9) Diffuse; widespread: 3/4s or more; linitis plastica: Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9) Diffuse, entire lung or NOS: Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9) Diffuse: Breast (C50.0-C50.6, C50.8-C50.9)
999	Unknown; size not stated Not documented in medical record Size of tumor cannot be assessed Not applicable

Mets at Diagnosis – Bone

Item #	Length	Allowable Values	Required Status	Date Revised
1112	1	0, 1, 8, 9	2016+	01/16, 02/21, 01/22, 1/23

Description

This data item identifies whether bone is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

1. **Code information about bone metastases only** (discontinuous or distant metastases to bone) identified at the time of diagnosis. This data item should not be coded for bone marrow involvement.
 - a. Bone involvement may be single or multiple
 - b. Information about bone involvement may be clinical or pathological
 - c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has bone metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no bone metastases
 - iii. includes imaging reports that are negative for bone metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but bone is not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not bone
 - b. Use code 0 when:
 - i. Tumor is a borderline or benign brain or CNS tumor
 - ii. Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)
 - c. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and bone is mentioned as an involved site

- ii. indicates that bone is the primary site and there are metastases in a different bone or bones
- iii. do not assign code 1 for a bone primary with multifocal bone involvement of the same bone
- iv. indicates that the patient is diagnosed as an unknown primary (C80.9) and bone is mentioned as a distant metastatic site
- d. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant
 - i. Use code 8 when primary site is C420, C421, C423, C424 or histology is 9671, 9734, 9731 or 9761 for any primary site.
- e. Use code 9 when it cannot be determined from the medical record whether the patient specifically has bone metastases; for example, when there is documentation of carcinomatosis but bone is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include bone.

Code	Label
0	None; no bone metastases
1	Yes; distant bone metastases
8	Not applicable
9	Unknown whether bone is an involved metastatic site Not documented in patient record

Mets at Diagnosis – Brain

Item #	Length	Allowable Values	Required Status	Date Revised
1113	1	0, 1, 8, 9	2016+	01/16, 02/21, 01/22, 1/23

Description

This data item identifies whether brain is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

1. **Code information about brain metastases only** (discontinuous or distant metastases to brain) identified at the time of diagnosis. This data item should not be coded for involvement of spinal cord or other parts of the central nervous system.
 - a. Brain involvement may be single or multiple
 - b. Information about brain involvement may be clinical or pathological
 - c. Code this data item whether or not the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has brain metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no brain metastases
 - iii. includes imaging reports that are negative for brain metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but brain is not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not brain
 - b. Use code 0 when:
 - i. Tumor is a borderline or benign brain or CNS tumor
 - ii. Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)
 - c. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and brain is mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and brain is mentioned as a distant metastatic site

- d. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant
 - i. Use code 8 when primary site is C420, C421, C423, C424 or histology is 9671, 9734, 9731 or 9761 for any primary site.
- e. Use code 9 when it cannot be determined from the medical record whether the patient specifically has brain metastases; for example, when there is documentation of carcinomatosis but brain is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include brain.

Code	Label
0	None; no brain metastases
1	Yes; distant brain metastases
8	Not applicable
9	Unknown whether brain is involved metastatic site Not documented in patient record

Mets at Diagnosis – Distant Lymph Nodes

Item #	Length	Allowable Values	Required Status	Date Revised
1114	1	0, 1, 8, 9	2016+	01/16, 02/21, 1/23

Description

This data item identifies whether distant lymph node(s) are an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

- Code information about distant lymph node(s) metastases only** (metastases to distant lymph nodes) identified at the time of diagnosis.
 - Distant lymph node involvement may be single or multiple
 - Information about distant lymph node involvement may be clinical or pathological
 - Code this data item whether or not the patient had any preoperative systemic therapy
 - This data item should not be coded for regional lymph node involvement with the exception of lymph nodes for placenta which are in the M1 category
 - This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.
- Use of codes.** Assign the code that best describes whether the case has distant lymph node metastases at diagnosis.
 - Use code 0 when the medical record
 - indicates that there are no distant (discontinuous) metastases at all
 - includes a clinical or pathologic statement that there are no distant lymph node metastases
 - includes imaging reports that are negative for distant lymph node metastases
 - indicates that the patient has distant (discontinuous) metastases but distant lymph node(s) are not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not distant lymph node(s).
 - Use code 0 when:
 - Tumor is a borderline or benign brain or CNS tumor
 - Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)

- c. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and distant lymph node(s) are mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and distant lymph node(s) are mentioned as a metastatic site
- d. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.
 - i. Use code 8 when primary site is C420, C421, C423, C424, C770-C779 or histology is 9671, 9734, 9731 or 9761 for any primary site.
- e. Use code 9 when it cannot be determined from the medical record whether the patient specifically has distant lymph node metastases; for example, when there is documentation of carcinomatosis but distant lymph node(s) are not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include distant lymph node(s).

Code	Label
0	None; no distant lymph node metastases
1	Yes; distant lymph node metastases
8	Not applicable
9	Unknown whether distant lymph node(s) are involved metastatic site Not documented in patient record

Mets at Diagnosis – Liver

Item #	Length	Allowable Values	Required Status	Date Revised
1115	1	0, 1, 8, 9	2016+	01/16, 02/21, 01/22, 1/23

Description

This data item identifies whether liver is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

- Code information about liver metastases only** (discontinuous or distant metastases to liver) identified at the time of diagnosis.
 - Liver involvement may be single or multiple
 - Information about liver involvement may be clinical or pathological
 - Code this data item whether or not the patient had any preoperative systemic therapy
 - This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
- Use of codes.** Assign the code that best describes whether the case has liver metastases at diagnosis.
 - Use code 0 when the medical record
 - indicates that there are no distant (discontinuous) metastases at all
 - includes a clinical or pathologic statement that there are no liver metastases
 - includes imaging reports that are negative for liver metastases
 - indicates that the patient has distant (discontinuous) metastases but liver is not mentioned as an involved site

Example: use code 0 when the patient has lung and brain metastases but not liver
 - Use code 0 when:
 - Tumor is a borderline or benign brain or CNS tumor
 - Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)
 - Use code 1 when the medical record
 - indicates that the patient has distant (discontinuous) metastases and liver is mentioned as an involved site
 - indicates that the patient is diagnosed as an unknown primary (C80.9) and liver is mentioned as a distant metastatic site
 - Use code 8 (Not applicable) for the following site/histology/combinations for which a code for distant metastasis is not clinically relevant.
 - Use code 8 when primary site is C420, C421, C423, C424 or histology is 9671, 9734, 9731 or 9761 for any primary site.

- e. Use code 9 when it cannot be determined from the medical record whether the patient specifically has liver metastases; for example, when there is documentation of carcinomatosis but liver is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include liver.

Code	Label
0	None; no liver metastases
1	Yes; distant liver metastases
8	Not applicable
9	Unknown whether liver is involved metastatic site Not documented in patient record

Mets at Diagnosis – Lung

Item #	Length	Allowable Values	Required Status	Date Revised
1116	1	0, 1, 8, 9	2016+	01/16, 02/21, 01/22, 01/23

Description

This data item identifies whether lung is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

- Code information about lung metastases only** (discontinuous or distant metastases to lung) identified at the time of diagnosis. This data item should not be coded for pleural or pleural fluid involvement.
 - Lung involvement may be single or multiple
 - Information about lung involvement may be clinical or pathological
 - Code this data item whether or not the patient had any preoperative systemic therapy
 - This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
- Use of codes.** Assign the code that best describes whether the case has lung metastases at diagnosis.
- Use code 0 when the medical record
 - indicates that there are no distant (discontinuous) metastases at all
 - includes a clinical or pathologic statement that there are no lung metastases
 - includes imaging reports that are negative for lung metastases
 - indicates that the patient has distant (discontinuous) metastases but lung is not mentioned as an involved site

Example: use code 0 when the patient has liver and brain metastases but not lung
 - Use code 0 when:
 - Tumor is a borderline or benign brain or CNS tumor
 - Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)
 - Use code 1 when the medical record
 - indicates that the patient has distant (discontinuous) metastases and lung is mentioned as an involved site
 - indicates that lung is the primary site and there are metastases in the contralateral lung
 - do not assign code 1 for a lung primary with multifocal involvement of the same lung
 - indicates that the patient is diagnosed as an unknown primary (C80.9) and lung is mentioned as a distant metastatic site

- d. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant
 - i. Use code 8 when primary site is C420, C421, C423, C424 or histology is 9671, 9734, 9731 or 9761 for any primary site.
- e. Use code 9 when it cannot be determined from the medical record whether the patient specifically has lung metastases; for example, when there is documentation of carcinomatosis but lung is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include lung.

Code	Label
0	None; no lung metastases
1	Yes; distant lung metastases
8	Not applicable
9	Unknown whether lung is involved metastatic site Not documented in patient record

Mets at Diagnosis – Other

Item #	Length	Allowable Values	Required Status	Date Revised
1117	1	0, 1, 2, 8, 9	2016+	01/16, 01/18, 02/21, 01/22, 01/23

Description

The six Mets at Dx-Metastatic Sites fields provide information on metastases for data analysis. This data item identifies any type of distant involvement not captured in the **Mets at Diagnosis – Bone, Mets at Diagnosis – Brain, Mets at Diagnosis – Liver, Mets at Diagnosis – Lung, and Mets at Diagnosis – Distant Lymph Nodes** fields. It includes involvement of other specific sites and more generalized metastases such as carcinomatosis. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum, and skin.

Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

Coding Instructions

- Code information about other metastases only** (discontinuous or distant metastases) identified at the time of diagnosis. This data item should not be coded for bone, brain, liver, lung or distant lymph node metastases.
 - Other involvement may be single or multiple
 - Information about other involvement may be clinical or pathological.
 - Code this data item whether or not the patient had any preoperative (neoadjuvant) systemic therapy
 - This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.
- Use of codes.** Assign the code that best describes whether the case has other metastases at diagnosis.
 - Use code 0 when the medical record
 - indicates that there are no distant (discontinuous) metastases at all
 - includes a clinical or pathologic statement that there are no other metastases
 - includes imaging reports that are negative for other metastases
 - indicates that the patient has distant (discontinuous) metastases but other sites are not mentioned as involved

Example: use code 0 when the patient has lung and liver metastases only
 - Use code 1 when:
 - Tumor is a borderline or benign brain or CNS tumor
 - Any other reportable tumor with a behavior of benign (/0), borderline (/1), or in situ (/2)

- c. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases in any site(s) other than bone, brain, liver, lung or distant lymph node(s)
 - ii. Includes but not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum and skin.
- d. Use code 8 (Not applicable) for the following site/histology combination for which a code for distant metastasis is not clinically relevant.
 - i. Use code 8 when primary site is C420, C421, C423, C424 or histology is 9671, 9734, 9731 or 9761 for any primary site.
- e. Use code 9 when it cannot be determined from the medical record whether the patient has metastases other than bone, brain, liver, lung and distant lymph node(s). In other words, use code 9 when there are known distant metastases but it is not known specifically what they are.

Code	Label
0	None; no other metastases
1	Yes; distant metastases in known site(s) other than bone, brain, liver, lung or distant lymph nodes
2	Generalized metastases such as carcinomatosis
8	Not applicable
9	Unknown whether any other metastatic site Not documented in patient record

Summary Stage 2018

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
764	1	summaryStage2018	0-4, 7-9	2018+	

Description

This item stores the directly assigned Summary Stage 2018. Effective for cases diagnosed 1/1/2018+.

Rationale

The SEER program has collected staging information on cases since its inception in 1973. Summary Stage groups cases into broad categories of in situ, local, regional, and distant. Summary Stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.

From 2004 through 2015, NHSCR relied on the item *Derived SS2000* [3020] for the value of *SEER Summary Stage 2000* [759] as generated by the Collaborative Staging algorithm. For cases diagnosed in 2016 and 2017, the NHSCR required that directly-coded *SEER Summary Stage 2000* [759] be recorded. Effective with cases diagnosed January 1, 2018 the NHSCR requires that directly-coded *SEER Summary Stage 2018* [764] be recorded.

Note: This data item was included in Standards Volume II, Version 16; however, it was not implemented until 2018.

Coding Instructions

NH-45

- Refer to the site and histology-specific definitions of categories and coding instructions in the [SEER Summary Staging Manual 2018](#).
- Use Code 8 for benign and borderline brain/CNS cases.
- Note: For Summary Stage 2018, code 5 for “Regional, NOS” can no longer be coded. Coe (Regional, NOS) is still applicable.

Codes

Code	Label
0	In situ
1	Localized only
2	Regional by direct extension only
3	Regional lymph nodes only
4	Regional by BOTH direct extension AND lymph node involvement
7	Distant site(s)/node(s) involved
8	Benign/borderline*
9	Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case

*Applicable for the following SS2018 chapters: Brain, CNS Other, Intracranial Gland.

Source 1: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed](#). Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

AJCC TNM Stage, Current Edition

AJCC TNM Clin T

Item #	Length	Allowable Values	Required Status	Date Revised
1001	15	Alphanumeric, Blank	2018+	01/18

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known **prior** to the start of any therapy. Detailed site-specific values for the clinical T category as defined by the current AJCC edition.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The clinical T category staging data item must be recorded for Class of Case 10-22.
- It is strongly recommended that the clinical T category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigning of clinical T.
- Assign clinical T category as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical T, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current *AJCC* edition and for in situ tumors that are not staged according to the current *AJCC* edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current *AJCC* edition and for in situ tumors that are not staged according to the current *AJCC* edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for detailed staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Clin T Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1031	4	(m), (s), Blank	2018+	01/18

Description

Identifies the AJCC TNM clinical T category suffix for the tumor **prior** to the start of any therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the clinical T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the suffix when applicable, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the *AJCC Cancer Staging System*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

AJCC TNM Clin N

Item #	Length	Allowable Values	Required Status	Date Revised
1002	15	Alphanumeric, Blank	2018+	01/18

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known **prior** to the start of any therapy. Detailed site-specific values for the clinical N category as defined by the current AJCC edition.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The clinical N category staging data item must be assigned for Class of Case 10-22.
- It is strongly recommended that the clinical N category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigned of clinical N category.
- Record clinical N category as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical N, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Clin N Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1034	4	(sn), (f), Blank	2018+	01/18

Description

Identifies the AJCC TNM clinical N category suffix for the tumor **prior** to the start of any therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- To distinguish lymph nodes identified during diagnostic evaluation by sentinel node biopsy or FNA or core needle biopsy from those identified by physical examination and imaging, the following suffixes are used in assigning the clinical N (cN) category.
- If SLN biopsy is performed as part of the diagnostic workup, the cN category should have the sn suffix: for example, cN1(sn).
- If an FNA or a core biopsy is performed on lymph nodes as part of the diagnostic workup, the cN category should have the f suffix: for example, cN1(f).
- If you do not know which procedure was done, leave it blank.
- Record the clinical N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the current *AJCC Cancer Staging System*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(sn)	Sentinel node procedure with or without FNA or core needle biopsy
(f)	FNA or core needle biopsy only
(blank)	No suffix needed or appropriate; not recorded

AJCC TNM Clin M

Item #	Length	Allowable Values	Required Status	Date Revised
1003	15	Alphanumeric, Blank	2018+	01/18

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known **prior** to the start of any therapy. Detailed site-specific values for the clinical T category suffix as defined by the current AJCC edition.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The clinical M category staging data item must be assigned for Class of Case 10-22.
- It is strongly recommended that the clinical M category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigning of clinical M.
- Record clinical M category as documented by the first treating physician or managing physician in the medical record.
- If the managing physician has not recorded clinical M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Clin Stage Group

Item #	Length	Allowable Values	Required Status	Date Revised
1004	15	Alphanumeric	2018+	01/18, 1/2025

Description

Identifies the anatomic extent of disease based on the T, N, and M category data items known **prior** to the start of any therapy. Detailed site-specific values for the clinical stage group as defined by the current AJCC edition.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the clinical stage group as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the clinical stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical, pathological, post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Clin (yc) T

Item #	Length	Allowable Values	Required Status	Date Revised
1062	15	Alphanumeric, Blank	2021+	02/21

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries when the planned post- neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Registrars are only required to complete yc staging when the planned surgery following neoadjuvant therapy has been cancelled.
- The post therapy clin T category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy clin T category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Clin (yc) T Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1063	4	(m), (s), Blank	2021+	02/21

Description

Identifies the AJCC TNM post therapy clinical T category suffix for the tumor following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries when the planned post- neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the post therapy clin T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy clin T category suffix, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC system, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

AJCC TNM Post Therapy Clin (yc) N

Item #	Length	Allowable Values	Required Status	Date Revised
1064	15	Alphanumeric, Blank	2021+	02/21

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries when the planned post- neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Registrars are only required to complete yc staging when the planned surgery following neoadjuvant therapy has been cancelled.
- The post therapy clin N category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded post therapy clin N category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Clin (yc) N Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1065	4	(sn), (f), Blank	2021+	02/21

Description

Identifies the AJCC TNM post therapy clinical N suffix for the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries when the planned post- neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the ypN category should have the sn suffix: for example, ypN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the ypN category should have the f suffix: for example, ypN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the post therapy clinical N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the *AJCC Cancer Staging system*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(sn)	Sentinel node procedure with or without FNA or core needle biopsy
(f)	FNA or core needle biopsy only
(blank)	No suffix needed or appropriate; not recorded

AJCC TNM Post Therapy Clin (yc) M

Item #	Length	Allowable Values	Required Status	Date Revised
1066	15	Alphanumeric, Blank	2021+	02/21

Description

Identifies the presence or absence of distant metastasis (M) of the tumor as known in the clinical stage before initiation of neoadjuvant therapy and records this information following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries when the planned post- neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Registrars are only required to complete yc staging when the planned surgery following neoadjuvant therapy has been cancelled.
- The post therapy clin M category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy clin M category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

Grade Post Therapy Clin (yc)

Item #	Length	Allowable Values	Required Status	Date Revised
1068	1	1-5, 8, 9, A, B, C, D, E, L, H, M, S, Blank	2021+	02/21

Description

This data item records the grade of a solid primary tumor that has been microscopically sampled following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the current *AJCC Cancer Staging System*. Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

For cases diagnosed January 1, 2021 and later, this data item, along with *Grade Clinical* [3843], *Grade Pathological* [3844], and *Grade Post Therapy Path* [3845] replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Cancer Staging System. The AJCC Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

AJCC TNM Path T

Item #	Length	Allowable Values	Required Status	Date Revised
1011	15	Alphanumeric, Blank	2018+	01/18

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known **following** the completion of surgical therapy. Detailed site-specific values for the pathological tumor (T) as defined by the current AJCC edition.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The pathological T category staging data item must be assigned for Class of Case 10-22.
- Assign pathological T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathological T category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Path T Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1032	4	(m), (s), Blank	2018+	01/18

Description

Identifies the AJCC TMN pathological T category suffix for the tumor **following** the completion of surgical therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the pathological stage T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC system, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

AJCC TNM Path N

Item #	Length	Allowable Values	Required Status	Date Revised
1012	15	Alphanumeric, Blank	2018+	01/18

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known **following** the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The pathological N category staging data item must be assigned for Class of Case 10-22.
- Assign pathological N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded pathological N category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Path N Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1035	4	(sn), (f), Blank	2018+	01/18

Description

Identifies the AJCC TNM pathological N suffix for the tumor **following** the completion of surgical therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the pN category should have the sn suffix: for example, pN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the pN category should have the f suffix: for example, pN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the pathological N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the *AJCC Cancer Staging System*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
(blank)	No suffix needed or appropriate; not recorded

AJCC TNM Path M

Item #	Length	Allowable Values	Required Status	Date Revised
1013	15	Alphanumeric, Blank	2018+	01/18

Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *following* the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The pathological M category staging data item must be assigned for Class of Case 10-22.
- Assign pathological M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathological M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Path Stage Group

Item #	Length	Allowable Values	Required Status	Date Revised
1014	15	Alphanumeric	2018+	01/18, 01/2025

Description

Identifies the anatomic extent of disease based on the T, N, and M category data items known **following** the completion of surgical therapy.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the pathological stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the pathological stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical, pathological, post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Path (yp) T

Item #	Length	Allowable Values	Required Status	Date Revised
1021	15	Alphanumeric, Blank	2018+	01/18, 02/21

Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The post therapy path T category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy path T category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Path (yp) T Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1033	4	(m), (s), Blank	2018+	01/18, 02/21

Description

Identifies the AJCC TNM post therapy pathological T category suffix for the tumor following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the post therapy path T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy path T category suffix, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the current *AJCC Cancer Staging System*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

AJCC TNM Post Therapy Path (yp) N

Item #	Length	Allowable Values	Required Status	Date Revised
1022	15	Alphanumeric, Blank	2018+	01/18, 02/21

Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The post therapy path N category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded post therapy path N category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Path (yp) N Suffix

Item #	Length	Allowable Values	Required Status	Date Revised
1036	4	(sn), (f), Blank	2018+	01/18, 02/21

Description

Identifies the AJCC TNM post therapy pathological N suffix for the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the ypN category should have the sn suffix: for example, ypN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the ypN category should have the f suffix: for example, ypN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the post therapy pathological N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the *AJCC Cancer Staging System*, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
(blank)	No suffix needed or appropriate; not recorded

AJCC TNM Post Therapy Path (yp) M

Item #	Length	Allowable Values	Required Status	Date Revised
1023	15	Alphanumeric, Blank	2018+	01/18, 02/21

Description

Identifies the presence or absence of distant metastasis (M) of the tumor as known in the clinical stage before initiation of neoadjuvant therapy and records this information following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current *AJCC Cancer Staging System* in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- The post therapy path M category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy path M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

AJCC TNM Post Therapy Path (yp) Stage Group

Item #	Length	Allowable Values	Required Status	Date Revised
1024	15	Alphanumeric, Blank	2018+	01/18, 02/21

Description

Identifies the anatomic extent of disease based on the T, N, and M category data items of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

Coding Instructions

- Record the post therapy path stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy path stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical and pathological or post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. Refer to the most current list provided on the [AJCC](#) web site.

Grade Post Therapy Path (yp)

Item #	Length	Allowable Values	Required Status	Date Revised
3845	1	1-5, 8, 9, A, B, C, D, E, L, H, M, S, Blank	2018+	01/18

Description

This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the current *AJCC Cancer Staging System*.

Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Clinical* [3843], *Grade Pathological* [3844], and *Grade Post Therapy Clin* [1068] replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group. For those cases that are eligible AJCC staging, the recommended grading system is specified in the *AJCC Cancer Staging System*. The AJCC Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules:
<https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

Text--Staging

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2600	4000	textStaging	Neither carriage return nor line feed characters allowed	All Years	2021

Description

Additional text area for staging information not already entered in other Text fields.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values.

Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date(s) of procedure(s), including clinical procedures, that provided information for assigning stage
- Organs involved by direct extension
- Size of tumor
- Status of margins
- Number and sites of positive lymph nodes
- Site(s) of distant metastasis
- Physician's specialty and comments

Text--Staging, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
RxDate Dx/Stg Proc	1280
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Hosp--Surg Prim Site	670
RX Summ--Surg Prim Site	1290
RX Hosp--Scope Reg LN Sur	672
RX Summ--Scope Reg LN Sur	1292
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Oth Reg/Dis	1294
Mult Tum Rpt as One Prim	444
Laterality	410

Site-Specific Data Items NH-46

Site-Specific Data Items (SSDIs) are used for collection of site-specific information. The data items in the table below are required by CoC. Data items are listed by their respective NAACCR Data Item Number and Name.

Please see the SSDI Manual at the following URL for detailed descriptions, rationales, coding instructions and site-specific coding rules: <https://apps.naaccr.org/ssdi/list/>. Data items 3864, 3903, 3957-3959 were already being collected however were inadvertently not included in the table below. The data items 3905, 3906, 3908 and 3919 were removed. Three new SSDIs 1176, 1178, 1179 were added and a new primary site for 3890 was added.

Item #	Site-Specific Data Item
1172	Post Transplant Lymphoproliferative Disorder-PTLD
1174	PD-L1
1176	Lung Spread Through Air Spaces (STAS)
1178	Residual Cancer Burden (RBC)
1179	Residual Cancer Burden (RBC) Class
3801	Chromosome 1p: Loss of Heterozygosity (LOH)
3802	Chromosome 19q: Loss of Heterozygosity (LOH)
3803	Adenoid Cystic Basaloid Pattern
3804	Adenopathy
3805	AFP Post-Orchiectomy Lab Value
3806	AFP Post-Orchiectomy Range
3807	AFP Pre-Orchiectomy Lab Value
3808	AFP Pre-Orchiectomy Range
3809	AFP Pretreatment Interpretation
3810	AFP Pretreatment Lab Value
3811	Anemia
3812	B symptoms
3813	Bilirubin Pretreatment Total Lab Value
3814	Bilirubin Pretreatment Unit of Measure
3815	Bone Invasion
3817	Breslow Tumor Thickness
3818	CA-125 Pretreatment Interpretation
3819	CEA Pretreatment Interpretation
3820	CEA Pretreatment Lab Value
3821	Chromosome 3 Status
3822	Chromosome 8q Status
3823	Circumferential Resection Margin (CRM)
3824	Creatinine Pretreatment Lab Value
3825	Creatinine Pretreatment Unit of Measure

Item #	Site-Specific Data Item
3826	Estrogen Receptor Percent Positive or Range
3827	Estrogen Receptor Summary
3829	Esophagus and EGJ Tumor Epicenter
3830	Extranodal Extension Clin (non-Head and Neck)
3831	Extranodal Extension Head and Neck Clinical
3832	Extranodal Extension Head and Neck Pathological
3833	Extranodal Extension Path (non-Head and Neck)
3834	Extravascular Matrix Patterns
3835	Fibrosis Score
3836	FIGO Stage
3837	Gestational Trophoblastic Prognostic Scoring Index
3838	Gleason Patterns Clinical
3839	Gleason Patterns Pathological
3840	Gleason Score Clinical
3841	Gleason Score Pathological
3842	Gleason Tertiary Pattern
3843	Grade Clinical
3844	Grade Pathological
3845	Grade Post Therapy
3846	hCG Post-Orchiectomy Lab Value
3847	hCG Post-Orchiectomy Range
3848	hCG Pre-Orchiectomy Lab Value
3849	hCG Pre-Orchiectomy Range
3855	HER2 Overall Summary
3856	Heritable Trait
3857	High Risk Cytogenetics
3858	High Risk Histologic Features
3860	International Normalized Ratio Prothrombin Time

Item #	Site-Specific Data Item	Item #	Site-Specific Data Item
3861	Ipsilateral Adrenal Gland Involvement	3903	Oncotype DX Recurrence DCIS
3862	JAK2	3904	Oncotype Dx Recurrence Score- Invasive
3863	Ki-67	3907	Organomegaly
3864	Invasion Beyond Capsule	3909	Perineural Invasion
3865	KIT Gene Immunohistochemistry	3910	Peripheral Blood Involvement
3866	KRAS	3911	Peritoneal Cytology
3867	LDH Post-Orchiectomy Range	3913	Pleural Effusion
3868	LDH Pre-Orchiectomy Range	3914	Progesterone Receptor Percent Positive or Range
3869	LDH Level	3915	Progesterone Receptor Summary
3870	LDH Upper Limits of Normal	3917	Primary Sclerosing Cholangitis
3871	LN Assessment Method Femoral-Inguinal	3918	Profound Immune Suppression
3872	LN Assessment Method Para-Aortic	3920	PSA (Prostatic Specific Antigen) Lab Value
3873	LN Assessment Method Pelvic	3921	Residual Tumor Volume Post Cytoreduction
3874	LN Distant Assessment Method	3922	Response to Neoadjuvant Therapy
3875	LN Distant: Mediastinal, Scalene	3923	S Category Clinical
3876	LN Head and Neck Levels I-III	3924	S Category Pathological
3877	LN Head and Neck Levels IV-V	3925	Sarcomatoid Features
3878	LN Head and Neck Levels VI-VII	3926	Schema Discriminator 1
3879	LN Head and Neck Other	3927	Schema Discriminator 2
3880	LN Isolated Tumor Cells (ITC)	3928	Schema Discriminator 3
3881	LN Laterality	3929	Separate Tumor Nodules
3882	LN Positive Axillary Level I-II	3930	Serum Albumin Pretreatment Level
3883	LN Size	3931	Serum Beta-2 Microglobulin Pretreatment Level
3885	Lymphocytosis	3932	LDH Lab Value
3886	Major Vein Involvement	3933	Thrombocytopenia
3887	Measured Basal Diameter	3934	Tumor Deposits
3888	Measured Thickness	3935	Tumor Growth Pattern
3889	Methylation of O6-Methylguanine-Methyltransferase	3936	Ulceration
3890	Microsatellite Instability (MSI): Added Corpus Carcinoma & Carcinocarcinoma	3937	Visceral and Parietal Pleural Invasion
3891	Microvascular Density	3938	ALK (Anaplastic Lymphoma Kinase) Rearrangement
3892	Mitotic Count Uveal Melanoma	3939	EGFR (Epidermal Growth Factor Receptor) Mutational Analysis
3893	Mitotic Rate Melanoma	3940	BRAF Mutational Analysis
3894	Multigene Signature Method	3941	NRAS Mutational Analysis
3895	Multigene Signature Results	3942	CA 19-9 PreTx Lab Value
3896	NCCN International Prognostic Index (IPI)	3956	P 16
3897	Number of Cores Examined	3957	LN Status Pelvic
3898	Number of Cores Positive	3958	Lymph Node Status Para-Aortic
3899	Number of Examined Para-Aortic Nodes	3959	LN Status Femoral-Inguinal
3900	Number of Examined Pelvic Nodes	3960	Histologic Subtype
3901	Number of Positive Para-Aortic Nodes	3961	Clinical Margin Width
3902	Number of Positive Pelvic Nodes	3964	Brain Primary Tumor Location

Text--DX Proc--X-Ray/Scan

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2530	4000	textDxProcXRayScan	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation from all X-rays, scan, and/or other imaging examinations that provide information about staging.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date(s) and type(s) of X-ray/Scan(s)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Distant disease or metastasis

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Text--DX Proc--X-Ray/Scan, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Primary Site	400
Laterality	410
Histology (92-00) ICD-O-2	420
Histologic Type ICD-O-3	522
Collaborative Stage variables	2800-2930
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3901-3937

Text--DX Proc--Op

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2560	1000	textDxProcOp	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of all surgical procedures that provide information for staging.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Dates and descriptions of biopsies and all other surgical procedures from which staging information was derived
- Number of lymph nodes removed
- Size of tumor removed
- Documentation of residual tumor
- Evidence of invasion of surrounding areas
- Reason primary site surgery could not be completed

Text--DX Proc--Op, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Diagnostic Confirmation	490
Primary Site	400
RX Hosp--Dx/Stg Proc	740
RX Summ--Surg Prim Site	1290
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
Reason for No Surgery	1340
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Text--DX Proc--Scopes

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2540	4000	textDxProcScopes	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation from endoscopic examinations that provide information for staging and treatment.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date(s) of endoscopic exam(s)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Record site and type of endoscopic biopsy
- Record positive and negative clinical findings. Record positive results first

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Text--DX Proc--Scopes, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Diagnostic Confirmation	490
Primary Site	400
Laterality	410
Histology (92-00) ICD-O-2	420
Histologic Type ICD-O-3	522
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
RX Hosp--Surg Prim Site	670
RX Date Surgery	1200
Summary Stage 2018	764
Ajcc TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

First Course of Treatment

Date of First Course of Treatment

Item #	Length	Allowable Values	Required Status	Date Revised
1270	8	CCYYMMDD, Blank	2003+	01/10, 01/11, 01/23

Description

Records the date on which treatment (surgery, radiation, systemic, or other therapy) of the patient began at any facility.

Rationale

It is important to be able to measure the delay between diagnosis and the onset of treatment. A secondary use for this date is as a starting point for survival statistics (rather than using the diagnosis date). This date cannot be calculated from the respective first course treatment modality dates if no treatment was given. Therefore, providing the date on which active surveillance is chosen, a physician decides not to treat a patient, or a patient's family or guardian declines treatment is important.

[See Treatment Plan and Time Periods for First Course Treatment in Section One for further instructions.](#)

Coding Instructions

- Record the earliest of the following dates: Date of First Surgical Procedure [1200], Date Radiation Started [1210], Date Systemic Therapy Started [3230], or Date Other Treatment Started [1250].
- If active surveillance or watchful waiting is selected as the first course of treatment (RX Summ–Treatment Status [1285] = 2) record the date this decision is made.
- In cases of non-treatment (RX Summ–Treatment Status [1285] = 0), in which a physician decides not to treat a patient, a patient's family or guardian declines all treatment, or patient receives palliative care for pain management only, the date of first course of treatment is the date this decision was made.
- If the cancer was diagnosed at autopsy and not suspected prior to that, blank is allowed.

Examples

Code	Reason
20240214	A patient has a core biopsy on February 12, 2024, and subsequently undergoes an excisional biopsy on February 14, 2024.
20250421	A patient begins receiving preoperative radiation therapy elsewhere on April 21, 2025, and subsequent surgical therapy at this facility on June 2, 2025.
20240102	A patient was offered treatment, but the patient refused on 1/2/2024. Capture the date of the refusal in this data item.
20241005	A patient was offered either active surveillance or resection for first course treatment. The patient agreed to active surveillance on 10/5/2024. Capture date of the decision for active surveillance in this data item.
20240210	A patient had needle core biopsy on 2/5/2024, resection on 2/10/2024, was offered and refused hormone therapy on 2/20/2024. Capture the date of the resection as first course treatment.
20240215	A patient was offered chemotherapy as first course treatment but expired on 02/15/2024 before any treatment could start. Capture the date of death in this data item and assign the data item, Chemotherapy [1390] to code 85.

Rx Summ – Treatment Status

Item #	Length	Allowable Values	Required Status	Date Revised
1285	1	0-2, 9	2010+	01/11, 02/21

Description

This data item summarizes whether the patient received any treatment or the tumor was under active surveillance.

Rationale

This item documents active surveillance (watchful waiting) and eliminates searching each treatment modality to determine whether treatment was given. It is used in conjunction with *Date of First Course of Treatment* [1270] to document whether treatment was or was not given, it is unknown if treatment was given, or treatment was given on an unknown date.

Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Treatment given after a period of active surveillance is considered subsequent treatment, and it is not coded in this item.
- Use code 0 when treatment is refused or the physician decides not to treat for any reason such as the presence of comorbidities.
- Assign code 0 when the patient does not receive any treatment
 - Scope of Regional Lymph Node Surgery may be coded 0, 1-7, or 9
- Assign code 1 when the patient receives treatment collected in any of the following data items
 - Surgery of Primary Site
 - Surgical Procedure of Other Site
 - Radiation Treatment Modality, Phase I, II, III
 - Chemotherapy
 - Hormone Therapy
 - Immunotherapy
 - Hematologic Transplant and Endocrine Procedures
 - Other Therapy
- Assign code 2 when Active Surveillance is the only treatment administered.

Code	Label
0	No treatment given
1	Treatment given
2	Active surveillance (watchful waiting) ONLY
9	Unknown if treatment was given

Examples

Code	Reason
0	An elderly patient with pancreatic cancer requested no treatment.
0	Treatment was planned but patient expired before treatment started.
0	Patient taken to OR suite for hemicolectomy to treat colon primary. Upon entering abdominal cavity, surgeon noted peritoneal mets and the planned procedure was aborted. The patient went to hospice care.
1	First course treatment for renal cell carcinoma was a nephrectomy followed with active surveillance. As the patient had a first course resection, the active surveillance would not be captured as first course treatment.
2	Treatment plan for a lymphoma patient is active surveillance.

Surgery Data Items

[See Surgery in Section One for further instructions.](#)

Date of First Surgical Procedure

Item #	Length	Allowable Values	Required Status	Date Revised
1200	8	CCYYMMDD, Blank	<1996, 2002+	01/10, 01/11, 02/21, 01/23

Description

Records the earliest date on which any first course surgical procedure was performed. Formerly called “Date of Cancer-Directed Surgery.”

Rationale

This item can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

Coding Instructions

- Record the date of the first surgical procedure of the types coded as *Rx Summ – Surg 2023* [1291], Scope of Regional Lymph Node Surgery [1292] (excluding code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
- The date in this item may be the same as that in Date of Most Definitive Surgical Resection of the Primary Site [3170], if the patient received only one surgical procedure and it was a resection of the primary site.
- If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item Date of First Course Treatment [1270].
- Blank is allowed.

Examples

Code	Reason
20240323	A melanoma patient had an excisional biopsy on March 23, 2024, then a wide excision on March 28, 2024.
20241116	The patient had a small (0.5 cm) lump removed from her breast on November 16, 2024.
20240327	The patient’s primary tumor was treated with radiation beginning on April 16, 2024, after a distant metastasis was removed surgically on March 27, 2024.
20240214	A patient has a core biopsy on February 12, 2024, and subsequently undergoes an excisional biopsy on February 14, 2024 with no other treatment. Capture the date of the excisional biopsy in this data item.
20240210	A patient had needle core biopsy on 2/5/2024, resection on 2/10/2024. Capture the date of resection in this data item.

Date of Most Definitive Surgical Resection of the Primary Site

Item #	Length	Allowable Values	Required Status	Date Revised
3170	8	CCYYMMDD, Blank	2003+	09/08, 01/10, 01/11, 01/23

Description

Records the date of the most definitive (most invasive) surgical procedure of the primary site performed as part of the first course of treatment as described in Rx Summ-Surg 2023 [1291].

Rationale

This item is used to measure the lag time between diagnosis and the most definitive (most invasive) surgery of the primary site. It is also used in conjunction with *Date of Surgical Discharge* [3180] to calculate the duration of hospitalization following the most definitive (most invasive) primary site surgical procedure. This can then be used to evaluate treatment efficacy.

Coding Instructions

- Record the date on which the surgery described by *Rx Summ – Surg 2023* [1291] was performed at this or any facility.
- Blank is allowed.

Rx Hosp-- Surg 2023

Item #	Length	Allowable Values	Required Status	Date Revised
671	4	A000, B000, A200-A990, B200-B990, Alphanumeric	2023+	01/23, 01/25

Description

Records the surgical procedure(s) performed to the primary site at this facility with a diagnosis year of 2023 and forward.

Rationale

This data item can be used to compare the efficacy of treatment options.

Coding Instructions

- Site-specific surgical codes for this data item are found in [Appendix A](#).
 - All surgery codes begin with the letter A except for skin, colon, pancreas, lung, breast and thyroid.
 - Surgery codes begin with the letter B to indicate a significant change in coding.
- For diagnosis year 2023 and forward, this data item must be completed.
- For diagnosis years 2003 – 2022, this data item should be left blank.
 - Complete data item Surgical Procedure of Primary Site at this Facility [NAACCR #670] utilizing the STORE manual that is applicable for the date of diagnosis.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure for the primary site.
- For codes A000 or B000 through A790 or B790, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes A800 or B800 and A900 or B900 only if more precise information about the surgery is not available.
- Code A000 or B000 if tumor was diagnosed at autopsy.
- Code A980 for any case coded to primary site C420, C421, C423, C424, C760-C768, C809.
- Code A990 or B990 if diagnosis was by death certificate only.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive (invasive) surgery, and upon the excisional biopsy or more extensive (invasive) surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] and the excisional biopsy or more extensive (invasive) surgery in the *RX Summ-Surg 2023* [1291].
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.

- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].
- For cases diagnosed prior to January 1, 2023, this data item should be blank.
- *Clinical Margin Width* [3961] collected in the Site-Specific Data Item following SEER coding rules and instructions.
- For melanoma skin surgical codes ONLY:
 - The priority order for sources used to assign surgery codes:
 - Operative report, statement from a physician, description of the surgical procedure on a pathology report, results of the pathology report. Code based on the description of the procedure.
 - Do not code based on margin status documented in the pathology report.

Code	Label	Definition
A000 Or B000	None	No surgical procedure of primary site. Diagnosed at autopsy.
A100- A190 Or B100- B190	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to Appendix A for the correct site-specific code for the procedure.
A200- A800 Or B200- B800	Site-specific codes; resection	Refer to Appendix A for the correct site-specific code for the procedure.
A900 Or B900	Surgery, NOS	A surgical procedure to primary site was done, but no information on the type of surgical procedure is provided.
A980	Site-specific codes; special	Special code. Refer to Appendix A for the correct site-specific code for the procedure. Code A980 for the following sites/schema unless the case is death certificate only: Any case coded to primary site C420, C421, C423, C424, C760-C768, C809 When Surgery of Primary Site is coded A980 1. Code Surgical Margins of the Primary Site [1320] to 9 2. Code Reason for No Surgery of Primary Site [1340] to 1
A990 or B990	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed, and no information is available. Death certificate only.

Rx Summ—Surg 2023

Item #	Length	Allowable Values	Required Status	Date Revised
1291	4	A000, B000, A200-A990, B200-B990, Alphanumeric	2023+	01/23, 01/25

Description

Records the surgical procedure(s) performed to the primary site with a diagnosis year of 2023 and forward.

Rationale

This data item can be used to compare the efficacy of treatment options.

Coding Instructions

- Site-specific surgical codes for this data item are found in [Appendix A](#).
 - All surgery codes begin with the letter A except for skin, colon, pancreas, lung, breast, and thyroid.
 - Surgery codes begin with the letter B to indicate a significant change in coding.
- For diagnosis year 2023 and forward, this data item must be completed.
- For diagnosis years 2003 – 2022, this data item should be left blank.
 - Complete data item Surgical Procedure of Primary Site [NAACCR #1290] utilizing the STORE manual that is applicable for the date of diagnosis.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes A000 or B000 through A790 or B790, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes A800 or B800 and A900 or B900 only if more precise information about the surgery is not available.
- Code A000 or B000 if tumor was diagnosed at autopsy.
- Code A980 for any case coded to primary site C420, C421, C423, C424, C760-C768, C809.
- Code A990 or B990 if diagnosis was by death certificate only.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive (invasive) surgery, and upon the excisional biopsy or more extensive (invasive) surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] and the excisional biopsy or more extensive (invasive) surgery in the RX Summ-Surg 2023 [1291].
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in [Appendix A](#).
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.

- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- For cases diagnosed prior to January 1, 2023, this data item should be blank.
- *Clinical Margin Width* [3961] collected in the Site-Specific Data Item following SEER coding rules and instructions.
- For melanoma skin surgical codes ONLY:
 - The priority order for sources used to assign surgery codes:
 - Operative report, statement from a physician, description of the surgical procedure on a pathology report, results of the pathology report. Code based on the description of the procedure.
 - Do not code based on margin status documented in the pathology report.

Code	Label	Definition
A000 Or B000	None	No surgical procedure of primary site. Diagnosed at autopsy.
A100– A190 Or B100– B190	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to Appendix A for the correct site-specific code for the procedure.
A200– A800 Or B200– B800	Site-specific codes; resection	Refer to Appendix A for the correct site-specific code for the procedure.
A900 Or B900	Surgery, NOS	A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided.
A980	Site-specific codes; special	Special code. Refer to Appendix A for the correct site-specific code for the procedure. Code A980 for the following sites/schema unless the case is death certificate only: a. Any case coded to primary site C420, C421, C423, C424, C760-C768, C809 When Surgery of Primary Site is coded A980 1. Code Surgical Margins of the Primary Site (#1320) to 9 2. Code Reason for No Surgery of Primary Site (#1340) to 1
A990 or B990	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.

Rx Hosp—Recon Breast

Item #	Length	Allowable Values	Required Status	Date Revised
751	4	A000, A100-A640, A900-A980, A990, Alphanumeric, Blank	2024+	New

Description

Records the reconstruction procedure immediately following resection performed at this facility. This data item is required beginning with diagnosis year 2024 and breast cases only.

Rationale

Breast reconstruction was previously collected within the breast surgery codes. CoC will collect this data item to support the Synoptic Operative Reports and allow for more descriptive reconstruction codes.

Coding Instructions

- Code the breast reconstruction code for Breast primaries performed at this facility with diagnosis date $\geq$ 1/1/2024.
- Code only the ipsilateral breast reconstruction.
- Immediate reconstruction is defined as reconstruction performed during the same operative session as the operative procedure coded in Data item Rx Hosp – Surg 2023 [671].
- One surgeon can perform the surgical resection to primary site and another surgeon can perform the reconstruction during the same operative session. As long as reconstruction was done during the same operative session, an immediate reconstruction code should be assigned.
- Reconstruction performed on a different day than the breast primary definitive (most invasive) resection is not collected/coded.
- If the reconstruction was started but not completed assign code A000.
- Use code A300 when patient has reconstruction performed with parenchymal flap or adjacent tissue transfer.
- For Codes, A600-A900, information for this data item may be found in the Breast Plastic Reconstructive operative report.
- Oncoplastic surgery is typically coded by the surgeon but sometimes found in the plastics operative note.
- Oncoplastic surgery is defined as rebuilding the breast tissue after breast cancer resection and is a way to reconstruct and reshape the breast after a lumpectomy or mastectomy and involves rearrangement of breast tissue to correct a defect.
- Leave this data item blank for:
 - Breast cases diagnosed prior year 2024
 - All other primary sites

Code	Label
A000	No reconstruction No immediate reconstruction was performed at this facility
A100	Tissue expanded placement Tissue expanders were placed without implant or tissue placement
A200	Direct to implant placement Permanent implant is placed immediately following resection
A300	Oncoplastic tissue rearrangement (not a formal mastopexy/reduction) Reconstruction performed with parenchymal flap or adjacent tissue transfer
A400	Oncoplastic reduction and/or mastopexy Breast conserving resection and a breast reduction/lift is performed
A500	Oncoplastic reconstruction with regional tissue flaps Breast conserving resection and reconstruction is performed with skin flaps
A600	Mastectomy reconstruction with autologous tissue, source not specified Autologous tissue source is unknown or not specified
A610	Mastectomy reconstruction WITH abdominal tissue
A620	Mastectomy reconstruction WITH thigh tissue
A630	Mastectomy reconstruction WITH gluteal tissue
A640	Mastectomy reconstruction WITH back tissue
A900	Reconstruction performed, method unknown
A970	Implant based reconstruction, NOS
A980	Autologous tissue-based reconstruction, NOS
A990	Unknown if immediate reconstruction was performed

Rx Summ—Recon Breast

Item #	Length	Allowable Values	Required Status	Date Revised
1335	4	A000, A100-A640, A900-A980, A990, Alphanumeric, Blank	2024+	New

Description

Records the reconstruction procedure immediately following resection performed at any facility. This data item is required beginning with diagnosis year 2024 and breast cases only.

Rationale

Breast reconstruction was previously collected within the breast surgery codes. CoC will collect this data item to support the Synoptic Operative Reports and allow for more descriptive reconstruction codes.

Coding Instructions

- Code the breast reconstruction code for Breast primaries performed at any facility with diagnosis date $\geq$ 1/1/2024.
- Code only the ipsilateral breast reconstruction.
- Immediate reconstruction is defined as reconstruction performed during the same operative session as the operative procedure coded in Data item Rx Summ – Surg 2023 [1291] and/ or Rx Hosp—Surg 2023 [671] .
- One surgeon can perform the surgical resection to primary site and another surgeon can perform the reconstruction during the same operative session. As long as reconstruction was done during the same operative session, an immediate reconstruction code should be assigned.
- Reconstruction performed on a different day than the breast primary definitive (most invasive) resection is not collected/coded.
- If the reconstruction was started but not completed assign code A000.
- Use code A300 when patient has reconstruction performed with parenchymal flap or adjacent tissue transfer.
- For Codes, A600-A900, information for this data item may be found in the Breast Plastic Reconstructive operative report.
- Oncoplastic surgery is typically coded by the surgeon but sometimes found in the plastics operative note.
- Oncoplastic surgery is defined as rebuilding the breast tissue after breast cancer resection and is a way to reconstruct and reshape the breast after a lumpectomy or mastectomy and involves rearrangement of breast tissue to correct a defect.
- Leave this data item blank for:
 - Breast cases diagnosed prior year 2024
 - All other primary sites

Code	Label
A000	No reconstruction No immediate reconstruction was performed at any facility
A100	Tissue expanded placement Tissue expanders were placed without implant or tissue placement
A200	Direct to implant placement Permanent implant is placed immediately following resection
A300	Oncoplastic tissue rearrangement (not a formal mastopexy/reduction) Reconstruction performed with parenchymal flap or adjacent tissue transfer
A400	Oncoplastic reduction and/or mastopexy Breast conserving resection and a breast reduction/lift is performed
A500	Oncoplastic reconstruction with regional tissue flaps Breast conserving resection and reconstruction is performed with skin flaps
A600	Mastectomy reconstruction with autologous tissue, source not specified Autologous tissue source is unknown or not specified
A610	Mastectomy reconstruction WITH abdominal tissue
A620	Mastectomy reconstruction WITH thigh tissue
A630	Mastectomy reconstruction WITH gluteal tissue
A640	Mastectomy reconstruction WITH back tissue
A900	Reconstruction performed; method unknown
A970	Implant based reconstruction, NOS
A980	Autologous tissue-based reconstruction, NOS
A990	Unknown if immediate reconstruction was performed

Approach -Surgery of the Primary Site at this Facility(RxHospSurgApp2010)

Item #	Length	Allowable Values	Required Status	Date Revised
668	1	0-5, 9	2010+	05/10, 01/11, 01/13, 01/15, 02/21

Description

This item is used to describe the surgical method used to approach the primary site for patients undergoing surgery of the primary site at this facility.

Rationale

This item is used to monitor patterns and trends in the adoption and utilization of minimally-invasive surgical techniques.

Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- If the patient has multiple surgeries of the primary site, this item describes the approach used for the most invasive, definitive surgery (procedure recorded in the data item, Rx Summ-Surg 2023 [1291]).
- For ablation procedures, assign code 3.
- Assign code 2 or 4 if the surgery began as robotic assisted or endoscopic and was converted to open.
- If both robotic and minimally invasive (for example, endoscopic or laparoscopic) surgery are used, code to robotic (codes 1 or 2).
- Assign code 0 if tumor was diagnosed at autopsy.

Code	Label
0	No surgical procedure of primary site at this facility; Diagnosed at autopsy
1	Robotic assisted
2	Robotic converted to open
3	Minimally invasive (such as endoscopic or laparoscopic)
4	Minimally invasive (endoscopic or laparoscopic) converted to open
5	Open or approach unspecified
9	When Rx Summ – Surg 2023 [1291] and Rx Hosp –Surg 2023 [671] is coded to A980; Death Certificate Only Unknown whether surgery was performed at this facility

Examples

Code	Reason
0	Patient received radiation at this facility after having surgery elsewhere
3	Endoscopic surgery was performed
3	Patient treated with Radio Frequency Ablation (RFA) of kidney
4	Surgeon began a laparoscopic segmental colectomy for colon primary however due to significant adhesions had to change to open surgery.
5	The surgical report described conventional surgery, but did not use the term “open”
9	Patient with acute megakaryoblastic leukemia (C42.1) undergoes a bone marrow biopsy.

Surgical Margins of the Primary Site

Item #	Length	Allowable Values	Required Status	Date Revised
1320	1	0-3, 7-9	All Years	08/02, 01/10, 02/10, 01/13, 02/21

Description

Records the final status of the surgical margins after resection of the primary tumor.

Rationale

This data item serves as a quality measure for pathology reports and is used for staging and may be a prognostic factor in recurrence.

Coding Instructions

- Record the margin status as it appears in the pathology report.
- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- Code 7 if the pathology report indicates the margins could not be determined.
- Code 8 if no surgery of the primary site was performed or if tumor was diagnosed at autopsy.
- Code 9:
 - If the pathology report makes no mention of margins or no tissue was sent to pathology.
 - If the *Rx Summ – Surg 2023* (#1291) is coded to A980 (not applicable).
 - Any cases coded to primary sites C420, C421, C423, C424, C760-C768, C770-C779, C809
 - If diagnosis was by death certificate only.

Code	Label	Definition
0	No residual tumor	All margins are grossly and microscopically negative.
1	Residual tumor, NOS	Involvement is indicated, but not otherwise specified.
2	Microscopic residual tumor	Cannot be seen by the naked eye.
3	Macroscopic residual tumor	Gross tumor of the primary site which is visible to the naked eye.
7	Margins not evaluable	Cannot be assessed (indeterminate).
8	No primary site surgery	No surgical procedure of the primary site.
9	Unknown or not applicable	It is unknown whether a surgical procedure to the primary site was performed

Example

Code	Reason
2	A patient with breast primary had a left lumpectomy. Surgeon removed the complete nodule however the pathology report stated there was residual disease at deep margin.
3	(C18-Colon) The pathology report from a colon resection describes the proximal margin as grossly involved with tumor (code 3) and the distal margin as microscopically involved (code 2). Code macroscopic involvement (code 3).
7	A patient with ovarian cancer underwent a TAH/SPO and debulking. The pathology report states margins cannot be assessed.
9	A malignant appearing lesion was removed and pathology identified cutaneous mets from unknown primary (C80.9).

Scope of Regional Lymph Node Surgery

Item #	Length	Allowable Values	Required Status	Date Revised
1292	1	0-7, 9	All Years	01/04, 09/08, 02/10, 01/11, 01/12, 04/12, 01/13, 01/15, 02/21, 01/22, 1/23

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

Rationale

This data item can be used to compare and evaluate the extent of surgical treatment.

Coding Instructions

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose, stage or treat disease in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* [1270] and/or *Date of First Surgical Procedure* [1200] if applicable (excluding code 1).
- Record the date of this procedure in *Date of Sentinel Lymph Node Biopsy* [832] and/or *Date Regional Lymph Node Dissection* [682], if applicable.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.
- Code 9 for:
 - Any Schema ID with primary site: C420, C421, C423, C424, C589, C700-C709, C710-C729, C751- C753, C761-C768, C770-C779, C809
- Do not code *distant* lymph nodes remove during surgery to the primary site for this data item. Distant nodes are coded in the data field *Surgical Procedure/Other Site* [1294].
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the

past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. It is important to distinguish between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes.

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
		Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.	Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary lymph node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and an ALND.
0	No regional lymph node surgery	No regional lymph node surgery.	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
1	Biopsy or aspiration of regional lymph node(s)	Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed, and it did not include the use of dye or tracer for a SLNBx procedure (code 2). If additional procedures were performed on the lymph nodes, use the appropriate code 2-7.	Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7.
2	Sentinel Lymph Node Biopsy	The operative report states that a SLNBx was performed. Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination. When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes are palpably abnormal and selectively removed (or harvested) as part of the SLNBx procedure by the surgeon or may be discovered by the pathologist. Code this as a SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6.	If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items Regional Lymph Nodes Examined [830] and Regional Lymph Nodes Positive [820].

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
Codes 3 -5 are used for regional lymph node dissection/removal; these do NOT include sentinel lymph node biopsy (SLNBx).			
3	Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS	The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.	Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).
4	1-3 regional lymph nodes removed		
5	4 or more regional lymph nodes removed		

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed. Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6.	SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed. Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an ALND was performed.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	SLNBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events. Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.	Generally, SLNBx followed by ALND will yield a minimum of 7- 9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND was performed.
9	Unknown or not applicable	The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded A190-A900 in the data item <i>Rx Summ – Surg 2023</i> [1291]. Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code.	

Examples

Code	Reason
0	No effort was made to locate sentinel lymph nodes, and no nodes were found in pathologic analysis.
1	(C14.0-Pharynx) Aspiration of regional lymph node to confirm histology of widely metastatic disease.
2	(C50.1-Breast) There was an attempt at sentinel lymph node dissection, but no lymph nodes were found in the pathological specimen.
2	(C44.5-Skin of Back) Patient has melanoma of the back. A sentinel lymph node dissection was done with the removal of one lymph node. This node was negative for disease.
3	(C61.9-Prostate) Bilateral pelvic lymph node dissection for prostate cancer.
6	(C50.3-Breast) Sentinel lymph node biopsy (SLNBx) of right axilla, followed by right axillary lymph node dissection (ALND) during the same surgical event.
7	(50.4-Breast) Sentinel lymph node biopsy (SLNBx) of left axilla, followed in a second procedure 5 days later by a left axillary lymph node dissection (ALND).
9	(C34.9-Lung) Patient was admitted for radiation therapy following surgery for lung cancer. There is no documentation on the extent of lymph node surgery in patient record.

Scope of Regional Lymph Node Surgery at this Facility

Item #	Length	Allowable Values	Required Status	Date Revised
672	1	0-7, 9	All Years	01/04, 09/08, 02/10, 01/12, 02/21,1/23

Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at this facility.

Rationale

This item can be used to compare and evaluate the extent of surgical treatment.

Coding Instructions

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- If a surgical procedure which aspirates, biopsies, or removes regional lymph nodes to diagnose, stage or treat this cancer, record the scope of regional lymph nodes surgery in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* [1270] and/or *Date of First Surgical Procedure* [1200] as appropriate (excluding code1).
- Record the date of this procedure in *Date of Sentinel Lymph Node Biopsy* [832] and/or *Date Regional Lymph Node Dissection* [682], if applicable.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
 - If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.
- Code 9 for:
 - Any Schema ID with primary site: C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, C809
- Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. They are coded in the data field *Surgical Procedure/Other Site* [1294].
- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].

Note: One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items*.

Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. It is important to distinguish between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes.

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
		Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.	Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary lymph node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and an ALND.
0	No regional lymph node surgery	No regional lymph node surgery.	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
1	Biopsy or aspiration of regional lymph node(s)	Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed, and it did not include the use of dye or tracer for a SLNBx procedure (code 2). If additional procedures were performed on the lymph nodes, use the appropriate code 2-7.	Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7.
2	Sentinel Lymph Node Biopsy	The operative report states that a SLNBx was performed. Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination. When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes are palpably abnormal and selectively removed (or harvested) as part of the SLNBx procedure by the surgeon or may be discovered by the pathologist. Code this as a SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6.	If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items Regional Lymph Nodes Examined [830] and Regional Lymph Nodes Positive [820].

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
Codes 3 -5 are used for regional lymph node dissection/removal; these do NOT include sentinel lymph node biopsy (SLNBx).			
3	Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS	The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.	Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).
4	1-3 regional lymph nodes removed		
5	4 or more regional lymph nodes removed		

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed. Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6.	SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed. Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an ALND was performed.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	SLNBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events. Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.	Generally, SLNBx followed by ALND will yield a minimum of 7- 9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND was performed.
9	Unknown or not applicable	The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded A190-A900 in the data item <i>Rx Summ – Surg 2023</i> [1291]. Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code.	

Surgical Procedure/Other Site

Item #	Length	Allowable Values	Required Status	Date Revised
1294	1	0-5, 9	All Years	01/04, 09/08, 01/10, 02/10, 01/12, 01/13, 02/21, 1/23

Description

Records the surgical removal of *distant lymph nodes* or other tissue(s) or organ(s) removed beyond the primary site to evaluate for malignant involvement.

Rationale

The removal of non-primary tissue documents the extent of surgical treatment.

Coding Instructions

- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code when performed to evaluate for malignant involvement.
- If other tissue or organs are removed to evaluate for possible malignant involvement during primary site surgery that are not specifically defined by the site-specific Rx Hosp – Surg 2023 [1291] or Rx Summ-Surg 2023 [671] code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code. Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Assign code 0 if tumor was diagnosed at autopsy.
- Assign code 1 for:
 - Any case coded to primary site C420, C421, C423, C424, C760-C768, C770-C779, C809 Excluding cases coded to the Cervical Lymph Nodes and Unknown Primary 00060
- Assign code 9 if diagnosis was by death certificate only.
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].

Code	Label	Definition
0	None	No surgical procedure of non-primary site was performed.
1	Non-primary surgical procedure performed	Non-primary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
2	Non-primary surgical procedure to other regional sites	Resection of regional site.
3	Non-primary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> .
4	Non-primary surgical procedure to distant site	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a nonprimary site was performed.

Examples

Code	Reason
0	(C18.1–Colon) The incidental removal of the appendix during a surgical procedure to remove a primary malignancy in the right colon.
0	(C18.1–Colon) Surgical resection of primary malignancy in sigmoid colon. During sigmoidectomy, the surgeon removed the gallbladder due to the patient's abdominal pain. Since gallbladder was removed for reasons other than possible malignant involvement, the gallbladder resection would not be captured.
1	(C80.9–Unknown primary) Surgical removal of metastatic lesion from liver; primary site not identified.
2	(C18.3–Colon) Surgical ablation of solitary liver metastasis, hepatic flexure primary.
3	(C64.9 Kidney) Surgical removal of perihilar LN. Pathology identified Renal Cell Carcinoma.
4	(C34.9–Lung) Removal of solitary brain metastasis.
5	(C21.0–Anus) Excision of solitary liver metastasis and one large hilar lymph node.

Surgical Procedure/Other Site at this Facility

Item #	Length	Allowable Values	Required Status	Date Revised
674	1	0-5, 9	All Years	01/04, 01/10, 02/10, 01/12, 02/21, 1/23

Description

Records the surgical removal of *distant lymph nodes* or other tissue(s)/organ(s) beyond the primary site at this facility to evaluate for malignant involvement.

Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

Coding Instructions

- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code when performed to evaluate for malignant involvement.
- If other tissue or organs are removed during primary site surgery to evaluate for malignant involvement and are not specifically defined by the site-specific Rx Hosp – Surg 2023 [1291] or Rx Summ -Surg 2023 [671] code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Assign code 0 if tumor was diagnosed at autopsy.
- Assign code 1 for:
 - Any case coded to primary site C420, C421, C423, C424 C760-C768, C770-C779, C809 Excluding cases coded to the Cervical Lymph Nodes and Unknown Primary 00060
- Assign code 9 if diagnosis was by death certificate only.
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].

Code	Label	Definition
0	None	No non-primary surgical site resection was performed at this facility.
1	Non-primary surgical procedure performed	Non-primary surgical resection to other site(s) performed at this facility and it is unknown whether the site(s) is regional or distant.
2	Non-primary surgical procedure to other regional sites	Resection of regional site performed at this facility.
3	Non-primary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> performed at this facility.
4	Non-primary surgical procedure to distant site	Resection of distant site performed at this facility.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4 performed at this facility.
9	Unknown	It is unknown whether any surgical procedure of a non-primary site was performed at this facility.

Date of Surgical Discharge

Item #	Length	Allowable Values	Required Status	Date Revised
3180	8	CCYYMMDD, Blank	2003+	01/10, 01/11, 01/23

Description

Records the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in *Rx Summ – Surg 2023* [1291], and *Date of Most Definitive Surgical Resection* [3170].

Rationale

Length of stay is an important quality of care and financial measure among hospital administrations, those who fund public and private health care, and public health users. This date, in conjunction with the data item *Date of Most Definitive Surgical Resection* [3170], will allow for the calculation of a patient's length of hospitalization associated with primary site surgery.

Coding Instructions

- Record the date the patient was discharged from the hospital following the event recorded in *Rx Summ – Surg 2023* [1291].
- If the patient died following the event recorded in *Rx Summ – Surg 2023* [1291], but before being discharged from the treating facility, then the *Date of Surgical Discharge* is the same as the date recorded in the data item *Date of Last Contact or Death* [1750].
- If the patient received out-patient surgery, then the date of surgical discharge is the same as the date recorded in the data item *Date of Most Definitive Surgical Resection of the Primary Site* [3170].
- Blank is allowable.

Readmission to the Same Hospital within 30 Days of Surgical Discharge

Item #	Length	Allowable Values	Required Status	Date Revised
3190	1	0-3, 9	2003+	06/15, 01/10, 01/18

Description

Records an inpatient readmission to the same hospital, for the same illness, within 30 days of discharge following hospitalization for surgical resection of the primary site.

Rationale

This data item provides information related to the quality of care. A patient may have a readmission related to the primary diagnosis on discharge if the length of stay was too short, and then he/she needed to return due to problems or complications. A patient may also need to be readmitted if discharge planning and/or follow-up instructions were ineffective. It is important to distinguish a planned from an unplanned readmission, since a planned readmission is not an indicator of quality of care problems.

Coding Instructions

- Consult patient record or information from the billing department to determine if a readmission to the same hospital occurred within 30 days of the date recorded in the item *Date of Surgical Discharge* [3180].
- Only record a readmission related to the treatment of this cancer.
- Review the treatment plan to determine whether the readmission was planned.
- If there was an unplanned admission following surgical discharge, check for an ICD-10-CM “Y” codes and record it, space allowing, as an additional *Secondary Diagnosis 1-10* [3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Assign code 0 if tumor was diagnosed at autopsy.
- Assign code 9 if diagnosis was made by death certificate only.

Code	Label
0	No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge.
1	A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.
2	A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned.
3	A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital.
9	It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge.

Examples

Code	Reason
0	A patient does not return to the hospital following a local excision for Stage I breast cancer.
0	A patient was surgically treated and, upon discharge from acute hospital care, was admitted/transferred to an extended care ward of the hospital.
0	A patient was admitted three weeks post lumpectomy for breast cancer with the flu.
1	A patient is readmitted to the hospital three weeks following a colon resection due to unexpected perirectal bleeding.
2	Following surgical resection of primary site the patient had a planned inpatient readmission to the same hospital for a colostomy reversal.
3	A patient is readmitted to the hospital two weeks post op for chemotherapy port insertion followed by cycle 1 of chemotherapy. Two weeks later the patient was readmitted for treatment of port infection.

Reason for No Surgery of Primary Site

Item #	Length	Allowable Values	Required Status	Date Revised
1340	1	0-2, 5-9	2002+	01/04, 01/13, 02/21

Description

Records the reason that no surgery was performed on the primary site.

Rationale

This data item provides information related to the quality of care and describes why primary site surgery was not performed.

Coding Instructions

- If *Rx Summ – Surg 2023* [1291] is coded A000, then record the reason based on documentation in the patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include surgery of the primary site, if the option of “no treatment” was accepted by the patient, or if the tumor was diagnosed at autopsy.
- Code 1 if *Rx Summ – Surg 2023* [1291] is coded A980.
 - Any case coded to primary sites C420, C421, C423, C424, C760-C768, C809
- Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed.
- Cases coded 8 should be followed and updated to a more specific code as appropriate.
- Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any was provided or if diagnosis was by death certificate only.

Code	Label
0	Surgery of the primary site was performed.
1	Surgery of the primary site was not performed because it was not part of the planned first course treatment.
2	Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc.)
5	Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
6	Surgery of the primary site was not performed; it was recommended by the patient’s physician but was not performed as part of the first course of therapy. No reason was noted in patient record.
7	Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in patient record.

Code	Label
8	Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.
9	It is unknown whether surgery of the primary site was recommended or performed.

Examples

Code	Reason
1	A patient with acute megakaryoblastic leukemia (C42.1) had a bone marrow biopsy performed.
2	A patient was diagnosed with ovarian cancer in 2023. The patient was not a candidate for surgery due to poor functional status.
2	A patient with a primary tumor of the liver is not recommended for surgery due to advanced cirrhosis.
5	A patient expired during the primary site resection, the procedure was aborted.
8	A patient is referred to another facility for recommended surgical resection of a gastric carcinoma, but further information from the facility to which the patient was referred is not available.

RX Text--Surgery

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2610	4000	rxTextSurgery	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for information describing all surgical procedures performed as part of treatment.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date of each procedure.
- Type(s) of surgical procedure(s), including excisional biopsies and surgery to other and distant sites.
- Lymph nodes removed.
- Regional tissues removed.
- Metastatic sites.
- Facility where each procedure was performed.
- Record positive and negative findings. Record positive findings first.
- Other treatment information, e.g., planned procedure aborted; unknown if surgery performed.

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

RX Text--Surgery, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Date Surgery	1200
RX Summ--Surg Prim Site	1290
RX Hosp--Surg Prim Site	670
RX Summ--Scope Reg LN Sur	1292
RX Hosp--Scope Reg LN Sur	672
RX Summ--Surg Oth Reg/Dis	1294
RX Hosp--Surg Oth Reg/Dis	674
Reason for No Surgery	1340
RX Summ--Surgical Margins	1320
RX Hosp--Palliative Proc	3280
RX Summ--Palliative Proc	3270
Text--Place of Diagnosis	2690
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639

Radiation Data Items

[See *Radiation Therapy* in Section One for overview of coding principles.](#)

Date Radiation Started

Item #	Length	Allowable Values	Required Status	Date Revised
1210	8	CCYYMMDD, blank	All Years	06/05, 01/10, 01/11, 01/23

Description

Records the date on which the first radiation therapy for this diagnosis began at any facility that is part of the first course of treatment.

Rationale

It is important to be able to sequence the use of multiple treatment modalities and to evaluate the time intervals between the treatments. For some diseases, the sequence of radiation and surgical therapy is important when determining the analytic utility of pathological stage information.

Coding Instructions

- If radiation therapy is the first or only treatment administered to the patient, then the date radiation started should be the same as the date entered into the item Date of First Course of Treatment [1270].
- The date when treatment started will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Examples

Code	Reason
20241215	A patient started external beam radiation on December 15, 2024.
20241012	A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using Gamma Knife on October 12, 2024.
20240602	A patient enters the facility for interstitial radiation boost for prostate cancer that is performed on August 6, 2024. Just prior to this, the patient had external beam therapy to the lower pelvis that was started on June 2, 2024 at another facility.

Location of Radiation Treatment

Item #	Length	Allowable Values	Required Status	Date Revised
1550	1	0-4, 8, 9	2003+	01/04, 01/12, 01/18 02/21, 1/23, 01/24

Description

Identifies the location of the facility where radiation therapy was administered during the first course of treatment.

Rationale

This data item provides information useful to understanding the referral patterns for radiation therapy services and for assessing the quality and outcome of radiation therapy by delivery site.

Coding Instructions

- Location of radiation treatment will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the location of radiation treatment may require assistance from the radiation oncologist for consistent coding.
- Code the first course of treatment. Do not include subsequent treatments in the coding of this data item.
- If the radiation treatment was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the radiation administered in the items Palliative Care [3270] and/or Palliative Care at This Facility [3280], as appropriate.
- In this context, "regional" is used to distinguish from "boost" or "cone down"; it does not refer to "regional" as used to identify stage or disease spread. In general, regional treatment will correspond to the phase in which the treatment fields had their largest dimension and usually includes draining lymph nodes. In most, but not all, cases this will be phase I.
- For cases diagnosed January 1, 2018 and later, the first phase (regional treatment) may be commonly referred to as an initial plan and a subsequent phase may be referred to as a boost or cone down, and would be recorded as Phase II, Phase III, etc. accordingly.
- Code first course treatment only.
- Code 0 if tumor was diagnosed at autopsy.
- Code 9 if diagnosis was by death certificate only.

Code	Label	Definition
0	No radiation treatment	No radiation therapy was administered to the patient.
1	All radiation treatment at this facility	All radiation therapy was administered at the reporting facility.
2	Radiation started at reporting facility, continued elsewhere	Radiation was started at the reporting facility; one or more phases of radiation were administered elsewhere.
3	Radiation started elsewhere, continued at this facility.	Radiation was started elsewhere; one or more phases of radiation were administered at the reporting facility.

Code	Label	Definition
4	All radiation treatment elsewhere	All radiation therapy was administered elsewhere.
8	Other	Radiation therapy was administered, but the pattern does not fit the above categories.
9	Unknown	Radiation therapy was administered, but the location of the Treatment facility is unknown or not stated in patient record; or it is unknown whether radiation therapy was administered.

Examples

Code	Reason
2	A patient received radiation therapy to the entire head and neck region at the reporting facility and is then referred to another facility for a high-dose-rate (HDR) intracavitary boost.
3	A patient was diagnosed with breast cancer at another facility and received surgery and regional radiation therapy at that facility before being referred to the reporting facility for boost dose therapy.
8	Regional treatment was initiated at another facility and midway through treatment the patient was transferred to the reporting facility to complete the treatment regimen.
9	Patient is known to have received radiation therapy, but records do not define the facility or facilities where the treatment was administered.

Phase I-II-III Radiation Primary Treatment Volume

Item #	Phase	Length	Allowable Values	Required Status	Date Revised
1504	I	2	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-99	All Years	01/18, 02/21, 01/22, 01/23, 01/25
1514	II	2	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-99, Blank	All Years	01/18, 02/21, 01/22, 01/23
1524	III	2	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-96, 98-99, Blank	2018+	01/18, 02/21, 01/23

Description

Identifies the primary treatment volume or primary anatomic target treated during phase I-II-III of radiation therapy during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

This data item provides information describing the anatomical structure targeted by radiation therapy during the phases of radiation treatment and can be used to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility and on a regional or national basis.

Coding Instructions

- Phase I [1504] data item should be used to indicate the primary target volume, which is typically the primary tumor or tumor bed. If the primary tumor or primary tumor bed was not targeted, record the other regional or distant site that was targeted.
- Subsequent phase may be referred to as a boost or cone down, and would be recorded in fields with subsequent phases recorded as Phase II [1514], Phase III [1524], etc. accordingly.
- Draining lymph nodes may also be concurrently targeted most commonly during the first phase. Whether draining lymph nodes were targeted and which ones were targeted will be identified in a separate data item Phase I-II-III Radiation to Draining Lymph Nodes [1505, 1515, 1525].
- When the primary volume is a lymph node region, draining lymph nodes are not targeted. Record code 88 in the Phase I-II-III Radiation to Draining Lymph Nodes [1505, 1515, 1525] when primary volume is a lymph node region. Use codes 01 to 09 only when the lymph nodes are the primary target, for example, in lymphomas.
- Note that for many of the treatment volumes, the same code should be used when the anatomic structure is targeted or when the surgical bed of the resected anatomical structure is targeted. For example, when prostate cancer is treated with radiation alone, code 64 will be the Primary Treatment Volume. Similarly, when prostate cancer is treated with radiation after radical prostatectomy, code 64 will be the Primary Treatment Volume. There is an exception to the rule for breast cancer. In patients

with breast cancer, code 41 (Breast- partial) in patients who have had a lumpectomy and were treated with partial breast irradiation (sometimes called accelerated partial breast irradiation (APBI)), code 40 (Breast – whole) in patients who had a lumpectomy and whole breast radiation, and code 42 (chest wall) in patients who had a mastectomy and post-mastectomy radiation.

- A new paradigm of treatment called on-line adaptive (or on-table adaptive) radiation may be a source of confusion when coding the Primary Treatment Volume. New linear accelerators may now be attached to such high-quality imaging devices that they can function as both simulation scanners for planning and radiation delivery systems. If a new radiation plan is created while the patient is on the radiation delivery table to take into account that day's anatomy, this is referred to "on-line" or "on- table" adaptive radiation. If a new radiation plan is created while the patient is not on the delivery table, then it is referred to as "off-line" (or "off-table" adaptive therapy. Off-line adaptive therapy treatments are relatively common, but MR-guided and CT-guided on-line adaptive therapy treatments are just emerging. In adaptive therapy, new radiation plans are created to account for changes in the position or shape of a target volume, but this does NOT mean that there has been a change in "phase". When the adaptive therapy paradigm is being used, a new phase should be documented only when there has been a change in the conceptual anatomic target volume (for example, a change from whole prostate to partial prostate) or if there has been a change in the draining lymph node target, dose per fraction, modality or planning technique.
- Code 00 if patient received no radiation treatment and complete all phase I radiation treatment data items.
- Code 00 if the tumor was diagnosed at autopsy.
- Code 99 if diagnosis was by death certificate only.
- If the patient received just one phase of treatment, code the phase I Radiation Treatment Volume. Phase II and III data fields should be left blank.
- If the patient received just two phases of treatment, code the phase I and II Radiation Treatment Volume. Phase III data fields should be left blank.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient.
01	Neck lymph node regions	The primary treatment is directed at lymph node regions of the neck. Example situations include treatment of lymphoma or lymph node recurrence (in the absence of primary site failure) following definitive surgery of the primary tumor. If radiation to the neck lymph nodes includes the supraclavicular region use code 03.
02	Thoracic lymph node regions	Radiation therapy is directed to one or some combination of hilar, mediastinal, and supraclavicular lymph node regions without concurrent treatment of a visceral organ site. Example situations include treatment of lymphatic recurrence after complete surgical excision of a thoracic primary. Note that the supraclavicular region may be part of a head and neck lymph node region. Use code 03 for treatments directed at neck nodes and supraclavicular nodes with a head and neck primary. Use code 04 if supraclavicular lymph nodes are part of breast treatment.

Code	Label	Definition
03	Neck and thoracic lymph node regions	Treatment is directed to lymph nodes in the neck and thoracic region without concurrent treatment of a primary visceral tumor. This code might apply to treatments for lymphatic recurrences following definitive treatment for tumors of the head and neck or thoracic regions.
04	Breast/ Chest wall lymph node regions	Radiation is directed primarily to one or some combination of axillary, supraclavicular, and/or internal mammary lymph node regions WITHOUT concurrent treatment of the breast or chest wall. If the breast AND lymph nodes are being treated, then code the Primary Treatment Volume to Breast (codes 40 or 41) and Breast/chest wall lymph nodes (code 04) in Radiation to Draining Lymph Nodes.
05	Abdominal lymph nodes	Treatment is directed to one or some combination of the lymph nodes of the abdomen, including retro-crural, peri-gastric, peri-hepatic, portocaval and para-aortic node regions. Possible situations might include seminoma, lymphoma or lymph node recurrence following surgical resection of the prostate, bladder or uterus. If field or target is described as hockey stick, dog leg, and inverted Y then use code 07.
06	Pelvic lymph nodes	Treatment is directed to one or some combination of the lymph nodes of the pelvis, including the common, internal and external iliac, obturator, inguinal and peri-rectal lymph nodes. This might be done for lymphoma or lymph node recurrence following definitive surgery for a pelvic organ.
07	Abdominal and pelvic lymph nodes	Treatment is directed to a combination of lymph nodes in both the abdomen and pelvis. This code includes extended fields ("hockey stick", "dog-leg", "inverted Y", etc.) utilized to treat seminomas and lymphomas or recurrence of a solid tumor.
09	Lymph node region, NOS	This category should be used to code treatments directed at lymph node regions that are not adequately described by codes 01-07.
10	Eye/orbit/optic nerve	Treatment is directed at all or a portion of the eye, orbit and/or optic nerve.
11	Pituitary	Treatment is directed at the pituitary gland.
12	Brain	Treatment is directed at all the brain and its meninges ("Whole brain").
13	Brain (Limited)	Treatment is directed at one or more sub-sites of the brain but not the whole brain. Chart may describe "SRS", "Stereotactic Radiosurgery", "Gamma Knife®". Use code 13 when primary tumor volume is brain stem.
14	Spinal cord	Treatment is directed at all or a portion of the spinal cord or its meninges.
20	Nasopharynx	Treatment is directed at all or a portion of the nasopharynx.
21	Oral Cavity	Treatment is directed at all or a portion of the oral cavity, which may include the lips, gingiva, alveolus, buccal mucosa, retromolar trigone, hard palate, floor of mouth and/or oral tongue.
22	Oropharynx	Treatment is directed at all or a portion of the oropharynx, including the soft palate, tonsils, base of tongue and pharyngeal wall.

Code	Label	Definition
23	Larynx (glottis) or hypopharynx	Treatment is directed at all or a portion of the larynx and/or hypopharynx.
24	Sinuses/Nasal tract	Treatment is directed at all or a portion of the sinuses and nasal tract, including the frontal, ethmoid, sphenoid and maxillary sinuses.
25	Parotid or other salivary glands	Treatment is directed at the parotid or other salivary glands, including the submandibular, sublingual and minor salivary glands.
26	Thyroid	Treatment is directed at all or a portion of the thyroid. Code 98 when the thyroid is treated with I-131 radioisotope.
29	Head and neck (NOS)	The treatment volume is directed at a primary tumor of the head and neck, but the primary sub-site is not a head and neck organ identified by codes 20-26 or it is an "unknown primary". Use code 29 when the Primary Tumor Volume is Paraganglioma of the jugular foramen in the middle ear.
30	Lung or bronchus	Treatment is directed at all or a portion of the lung or bronchus.
31	Mesothelium	Treatment is directed to all or a portion of the mesothelium. This code should be used for mesothelioma primaries, even if a portion of the lung is included in the radiation field.
32	Thymus	Treatment is directed to all or a portion of the thymus.
39	Chest/lung (NOS)	The treatment is directed at a primary tumor of the chest, but the primary sub-site is unknown or not identified in codes 30-32. For example, this code should be used for sarcomas arising from the mediastinum.
40	Breast - whole	Treatment is directed at all the intact breast. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy.
41	Breast - partial	Treatment is directed at a portion of the intact breast but not the whole breast. The chart may have terms such as "Mammosite", "interstitial (seed) implant)", or "(accelerated) partial breast irradiation". Consider the possibility of partial breast irradiation when "IMRT" is documented in the record.
42	Chest wall	Treatment encompasses the chest wall (following mastectomy).
50	Esophagus	Treatment is directed at all or a portion of the esophagus. Include tumors of the gastro-esophageal junction.
51	Stomach	Treatment is directed at all or a portion of the stomach.
52	Small bowel	Treatment is directed at all or a portion of the small bowel.
53	Colon	Treatment is directed at all or a portion of the colon.
54	Rectum	Treatment is directed at all or a portion of the rectum.
55	Anus	Treatment is directed at all or a portion of the anus.
56	Liver	Treatment is directed at all or a portion of the liver.
57	Biliary tree or gallbladder	Treatment is directed at all or a portion of the biliary tree or gallbladder.
58	Pancreas or hepatopancreatic ampulla	Treatment is directed at all or a portion of the pancreas or the hepatopancreatic ampulla. Hepatopancreatic ampulla tumors are sometimes referred to as periampullary tumors.

Code	Label	Definition
59	Abdomen (NOS)	The treatment volume is directed at a primary tumor of the abdomen, but the primary sub-site is not an abdominal organ defined by codes 50-58 or it is considered to be an "unknown primary". For example, this code should be used for sarcomas arising from the abdominal retroperitoneum.
60	Bladder - whole	Treatment is directed at all the bladder.
61	Bladder - partial	Treatment is directed at a portion of the bladder but not the whole bladder.
62	Kidney	Treatment is directed at all or a portion of the kidney.
63	Ureter	Treatment is directed at all or a portion of the ureter.
64	Prostate - whole	Treatment is directed at all of the prostate with/without all or part of the seminal vesicles. Use this code even if seminal vesicles are not explicitly targeted.
65	Prostate - partial	Treatment is directed at a portion of the prostate but not the whole prostate.
66	Urethra	Treatment is directed at all or a portion of the urethra.
67	Penis	Treatment is directed at all or a portion of the penis. Treatments of urethral primaries should be coded as 'urethra' (code 66).
68	Testicle or scrotum	Treatment is directed at all or a portion of the testicle and/or scrotum.
70	Ovaries or fallopian tubes	Treatment is directed at all or a portion of the ovaries or fallopian tubes.
71	Uterus or Cervix	Treatment is directed at all or a portion of the uterus, endometrium, cervix or parametrium.
72	Vagina	Treatment is directed at all or a portion of the vagina. Treatments of urethral primaries should be coded as 'urethra' (code 66).
73	Vulva	Treatment is directed at all or a portion of the vulva. Treatments of urethral primaries should be coded as 'urethra' (code 66).
80	Skull	Treatment is directed at all or a portion of the bones of the skull. Any brain irradiation is a secondary consequence.
81	Spine/vertebral bodies	Treatment is directed at all or a portion of the bones of the spine/vertebral bodies, including the sacrum. Spinal cord malignancies should be coded using 'spinal cord' (code 14).
82	Shoulder	Treatment is directed to all or a portion of the proximal humerus, scapula, clavicle, or other components of the shoulder complex.
83	Ribs	Treatment is directed at all or a portion of one or more ribs.
84	Hip	Treatment is directed at all or a portion of proximal femur or acetabulum.
85	Pelvic bones	Treatment is directed at all or a portion of the bones of the pelvis other than the hip or sacrum.
86	Pelvis (NOS, non-visceral)	The treatment volume is directed at a primary tumor of the pelvis, but the primary sub-site is not a pelvic organ or is not known or indicated. For example, this code should be used for sarcomas arising from non-visceral soft tissues of the pelvis.
88	Extremity bone, NOS	Treatment is directed at all or a portion of the bones of the arms or legs. This excludes the proximal femur (Hip, code 84). This excludes the proximal humerus (Shoulder, code 82).

Code	Label	Definition
90	Skin	Treatment is directed at all or a portion of the skin. The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastases are usually subcutaneous and should be coded as a soft tissue site.
91	Soft tissue	This category should be used to code primary or metastatic soft tissue malignancies when localizing to a region of the body (e.g. pelvis) is not possible or when the case does not fit other categories.
92	Hemibody	A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer.
93	Whole body	Treatment is directed to the entire body included in a single treatment, for example as with total body irradiation (TBI).
94	Mantle, mini-mantle (obsolete after 2017)	For conversion of historical data only
95	Lower extended field (obsolete after 2017)	For conversion of historical data only
96	Inverted Y (obsolete after 2017)	For conversion of historical data only
97	Invalid historical FORDS value	Conversion to new STORE data item could not take place due to an invalid FORDS Volume code
98	Other	Radiation therapy administered; treatment volume other than those previously categorized by codes 01-93. For example, code 98 when the radioisotope I-131 is used in the treatment of thyroid cancer.
99	Unknown	This category should be used to code treatments for which there is no information available about the treatment volume, or it is unknown if radiation treatment was administered.

Examples

Code	Reason
00	An elderly man with mild fatigue is found to have an elevated lymphocyte count on CBC. Bone marrow biopsy in your facility confirms a diagnosis of chronic lymphocytic leukemia. Physician and patient agree that no treatment is indicated at this time. Record Phase I Radiation Primary Treatment Volume as 00 (No radiation treatment).
98	A man with a history of prostate cancer and prior radical prostatectomy is treated with SBRT to 3500cGy in five fractions to a recurrent tumor in a remnant right seminal vesicle. Record Phase I Radiation Primary Treatment Volume as 98 because there is no specific code for seminal vesicles.
93	A woman with advanced multiple myeloma is referred for total body irradiation and is treated twice daily for three consecutive days in a total body stand at extended distance with open rectangular photon fields, 200cGy to mid-body per treatment. Record Phase I Radiation Primary Treatment Volume as 93 (Whole body).

Phase I-II-III Radiation to Draining Lymph Nodes

Item #	Length	Allowable Values	Required Status	Date Revised
1505	2	00-08, 88, 99	All Years	01/18, 02/21, 01/22, 01/25
1515	2	00-08, 88, 99, Blank	All Years	01/18, 02/21
1525	2	00-08, 88, 99, Blank	2018+	01/18, 02/21

Description

Identifies the draining lymph nodes treated (if any) during the phase I-II-III of radiation therapy delivered to the patient during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

The first phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the first phase of radiation to the primary site.

The second and third phase of radiation treatment commonly targets just the primary tumor (or tumor bed) but in some cases also target both the primary and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the second and third phase of radiation to the primary site.

Coding Instructions

- When the primary volume is lymph nodes, draining lymph nodes are not targeted. Record code 88 in the Phase I-II-III Radiation to Draining Lymph Nodes [1505,1515,1525]. Use codes 01 to 09 only when the lymph nodes are the primary target, for example, in lymphomas.
- Code 00 if the tumor was diagnosed at autopsy.
- Code 99 if diagnosis was by death certificate only.
- Phase II and III radiation treatment includes primary tumor or tumor bed in addition to the draining lymph node regions that are associated with the primary tumor or tumor bed. The primary tumor or tumor bed is recorded in the Phase II-III Radiation Primary Treatment Volume [1514, 1524].
- Note: When the Phase II Primary Treatment Volume is lymph nodes, draining lymph nodes are not targeted. Record code 88 in this data item.
- Blanks allowed only for Phase II or III if no radiation treatment administered.

Code	Label
00	No radiation treatment to draining lymph nodes.
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/Chest wall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
08	Lymph node region, NOS
88	Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes
99	Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered

Examples

Code	Reason
04	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions. Axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Radiation to Draining Lymph Nodes as 04 (Breast/Chest wall lymph node regions).
88	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. Record the Phase I Radiation to Draining Lymph Nodes as 88 because Phase I Radiation Primary Treatment Volume is lymph nodes.
06	Prostate cancer patient declines surgery for management of his prostate cancer, and opts for EBRT. The treatment summary states that pelvis/prostate were targeted on phase 1 with 180 cGy X 25 fx= 45 Gy. Record Phase I Radiation to Draining Lymph Nodes as 06 because when the pelvis is specifically mentioned in the treatment summary, we can assume that regional lymph nodes were targeted.

Phase I-II-III Radiation Treatment Modality

Item #	Length	Allowable Values	Required Status	Date Revised
1506	2	00-16, 98-99	All Years	01/18, 02/21, 01/23, 01/25
1516	2	00-16, 98-99, Blank	All Years	01/18, 02/21, 01/23
1526	2	00-16, 98-99, Blank	2018+	01/18, 02/21, 01/23

Description

Identifies the radiation modality administered during phase I-II-III of radiation treatment delivered during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. These data items should be used to indicate the radiation modality administered during phase I-II-III of radiation.

Historically, the previously-named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of radiation modality and external beam radiation treatment planning techniques is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end of treatment summaries.

Coding Instructions

- Radiation treatment modality will typically be found in the radiation oncologist's treatment summary. Segregation of treatment components into Phases and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- For purposes of this data item, photons, x-rays and gamma-rays are equivalent.
- Use code 13 - Radioisotopes, NOS for radioembolization procedures, e.g. intravascular Yttrium-90 for cases diagnosed January 1, 2018 or later. For cases diagnosed prior January 1, 2018, use code 07-Brachytherapy, NOS.
- This data item intentionally does not include reference to various MV energies because this is not a clinically important aspect of technique. A change in MV energy (e.g., 6MV to 12MV) is not clinically relevant and does not represent a change in treatment technique. It is rare for change in MV energy to occur during any phase of radiation therapy.
- If this data item is coded to any of the External beam codes (01-06 or 12), the planning technique must be recorded in the data item Phase I-II-III External Beam Radiation Planning Technique [1502, 1512, 1522].
- If Radiation Treatment Modality is coded to any of the Brachytherapy or Radioisotopes codes (07-11 and 13-16) the code of 88 must be recorded in the data item Phase I-II-III External Beam Radiation Planning Technique [1502, 1512, 1522].

- Code 00 when tumor is diagnosed at autopsy .
- Code 98 was added to the data item Phase I Radiation Treatment Modality for cases where it is known radiation was given, but modality is unknown.
- Code 99 is only used when it is unknown if radiation was given or if diagnosis was by death certificate only.
- Note: Do not confuse a radioiodine scan with treatment. Only treatment is recorded in this item.
- Phase I must be coded however blanks allowed for Phase II-III if no treatment administered.

Code	Label
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-223
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
98	Radiation treatment administered; modality unknown
99	Unknown if radiation treatment administered

Examples

Code	Reason
13	A patient with follicular carcinoma of the thyroid is treated with post-operative injection of radioiodine (I-131) for a total dose of 150 millicuries. Record Phase I Radiation Treatment Modality as 13 (Radioisotopes, NOS).
02	A woman with multiple myeloma is treated using locally opposed conformal 15Mv photons to a total dose of 2000cGy in 5 fractions. Record Phase I Radiation Treatment Modality as 02 (External beam, photons).

Phase I-II-III External Beam Radiation Planning Technique

Item #	Length	Allowable Values	Required Status	Date Revised
1502	2	00-10, 88, 98, 99	All Years	01/18, 02/21, 01/22, 01/23, 01/25
1512	2	00-10, 88, 98, 99, Blank	All Years	01/18, 02/21, 01/23
1522	2	00-10, 88, 98, 99, Blank	2018+	01/18, 02/21, 01/23

Description

Identifies the external beam radiation planning technique used to administer the first, second or third phase of radiation treatment during the first course of treatment. This data item is required for CoC accredited facilities as of 01/01/2018.

Rationale

External beam radiation is the most commonly used radiation modality in North America. In this data item we specified the planning technique for external beam treatment. Identifying the radiation technique is of interest for patterns of care and comparative effectiveness studies.

Historically, the previously named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of *Phase I-II-III Radiation Treatment Modality* [1506,1516,1526], and *Phase I-II-III External Beam Radiation Planning Technique* [1502,1512, 1522] is to clarify this information and implement mutually exclusive categories. Note that Planning Technique details are not being captured for non-External Beam modalities. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Coding Instructions

- A new paradigm of treatment called on-line adaptive (or on-table) adaptive radiation may be the source of confusion when coding External Beam Radiation Planning Technique. New linear accelerators are attached to such high-quality imaging devices that they can function as both simulation scanners for planning and radiation delivery systems. If a new radiation plan is created while the patient is on the radiation delivery table to take into account that day's anatomy, this is referred to "on-line" (or "on-table") adaptive radiation. If a new radiation plan is created while the patient is not on the delivery table, then it is referred to as "off-line" (or "off-table") adaptive therapy. Off-line adaptive therapy treatments are relatively common, but MR-guided and CT-guided online adaptive therapy treatments are just emerging. If treatment is described as both MR-guided (or CT-Guided) on-line adaptive as well as another external beam planning technique (e.g. IMRT, SBRT, etc) code as MR-guided (or CT-Guided) online adaptive therapy. On-line adaptive techniques are the most complex and usually include IMRT and/or SBRT techniques within them, so the on-line adaptive component is most important to capture.
- If a treatment is described as off-line adaptive then the on-line adaptive codes should NOT be used to describe the phase planning technique.
- Code 00, no radiation treatment or when diagnosed at autopsy.

- Code 04 for Conformal or 3-D Conformal Therapy whenever either is explicitly mentioned.
- Code 05 for Intensity Modulated Therapy (IMT) or Intensity Modulated Radiation Therapy (IMRT).
- Code 99 if diagnosis was by death certificate only.
- Phase I must be coded however blanks are allowed for Phase II-III.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient.
01	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific planning technique.
02	Low energy x-ray/photon therapy	External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Energies are typically expressed in units of kilovolts (kV). These types of treatments are sometimes referred to as electronic brachytherapy or orthovoltage or superficial therapy. Clinical notes may refer to the brand names of low energy x-ray delivery devices, e.g. Axxent®, INTRABEAM®, or Esteya®.
03	2-D therapy	An external beam planning technique using 2-D imaging, such as plain film x-rays or fluoroscopic images, to define the location and size of the treatment beams. Should be clearly described as 2-D therapy. This planning modality is typically used only for palliative treatments.
04	Conformal or 3-D conformal therapy	An external beam planning technique using multiple, fixed beams shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.
05	Intensity modulated therapy	An external beam planning technique where the shape or energy of beams is optimized using software algorithms. Any external beam modality can be modulated but these generally refer to photon or proton beams. Intensity modulated therapy can be described as intensity modulated radiation therapy (IMRT), intensity modulated x-ray or proton therapy (IMXT/IMPT), volumetric arc therapy (VMAT) and other ways. If a treatment is described as IMRT with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning.
06	Stereotactic radiotherapy or radiosurgery, NOS	Treatment planning using stereotactic radiotherapy/radiosurgery techniques, but the treatment is not described as Cyberknife® or Gamma Knife®. These approaches are sometimes described as SBRT (stereotactic body radiation), SABR (stereotactic ablative radiation), SRS (stereotactic radiosurgery), or SRT (stereotactic radiotherapy). If the treatment is described as robotic radiotherapy (e.g. Cyberknife®) or Gamma Knife®, use stereotactic radiotherapy subcodes below. If a treatment is described as stereotactic radiotherapy or radiosurgery with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning.

Code	Label	Definition
07	Stereotactic radiotherapy or radiosurgery, robotic.	Treatment planning using stereotactic radiotherapy/radiosurgery techniques which is specifically described as robotic (e.g. Cyberknife®).
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife®	Treatment planning using stereotactic radiotherapy/radiosurgery techniques which uses a Cobalt-60 gamma ray source and is specifically described as Gamma Knife®. This is most commonly used for treatments in the brain.
09	CT-guided online adaptive therapy	An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient's tumor or normal anatomy radiation using a CT or cone beam CT (CBCT) scan obtained at the treatment machine (online). These approaches are sometimes described as CT-guided online re- optimization or online re-planning. If a treatment technique is described as both CT-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as CT-guided online adaptive therapy. If a treatment is described as "adaptive" but does not include the descriptor "online", this code should not be used. Clinic notes may refer to the brand name of a linear accelerator called Ethos.
10	MR-guided online adaptive therapy	An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient's tumor or normal anatomy radiation using an MRI scan obtained at the treatment machine (online). These approaches are sometimes described as MR-guided online re-optimization or online re-planning. If a treatment technique is described as both MR-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as MR-guided online adaptive therapy. If a treatment is described as "adaptive" but does not include the descriptor "online", this code should not be used. Clinic notes may refer to an MR-Linac or the brand name of an MR-Linac called MRlidian or Unity.
88	Not Applicable	Treatment not by external beam.
98	Other, NOS	Other radiation, NOS; Radiation therapy administered, but the treatment planning technique is not specified or is unknown.
99	Unknown	It is unknown whether radiation therapy was administered.

Examples

Code	Reason
04	A man with prostate cancer is initially treated with whole pelvis RT using a four-field approach, all fields shaped conformally to pelvic anatomy. He then was treated with an IMRT boost. Record the Phase I External Beam Radiation Planning Technique as 04 (Conformal or 3-D conformal therapy)
03	A woman with advanced multiple myeloma is referred for total body irradiation and is treated twice daily for three consecutive days in a total body stand at extended distance with open rectangular photon fields, 200cGy to mid-body per treatment. Record the Phase I External Beam Radiation Planning Technique as 03 (2-D therapy)
88	Record 88 as the Phase I External Beam Radiation Planning Technique for any phase uses radioisotopes or brachytherapy (e.g. I-131 radioiodine for thyroid cancer, brachytherapy for prostate cancer).

Phase I-II-III Dose per Fraction

Item #	Length	Allowable Values	Required Status	Date Revised
1501	5	00000-99999	All Years	01/18, 02/21, 01/22, 01/23, 01/25
1511	5	00000-99999, Blank	All Years	01/18, 02/21, 01/23
1521	5	00000-99999, Blank	2018+	01/18, 02/21, 01/23

Description

Records the dose per fraction (treatment session) delivered to the patient in the first phase, second or third phase of radiation during the first course of treatment. The unit of measure is centi-Gray (cGy). This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation therapy is delivered in one or more phases with identified dose per fraction. It is necessary to capture information describing the dose per fraction to evaluate patterns of radiation oncology care.

Coding Instructions

- In general, (Phase Dose per Fraction x Phase Number of Fractions = Phase Total Dose). But, there may be inconsistencies in rounding of dose or the way the dose is automatically measured in a treatment which will result in slight inconsistencies in the math. That is, in some radiation treatment summaries, Phase Dose per Fraction x Phase Number of Fractions $\approx$ Phase Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGe units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGE = 1 Gy = 100 cGy. For a Phase Total Dose, you would need to multiply dose in CGE by 100 to get dose in cGy.
- Note that dose is still occasionally specified in “rads”. One (1) rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy.
- Code 99998 when radioisotopes were administered to the patient (codes 13-16) for Phase I-II-III Radiation Treatment Modality [1506, 1516, 1526].
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I-II-III Treatment Modality [1506, 1516, 1526]). If the dose is not available/provided in cGy for a brachytherapy procedure, code 99999.
- Record the actual dose delivered (NOT the initially prescribed dose) as documented in the treatment summary.
- Code 00000 when diagnosed at autopsy.
- Code 99999 if diagnosis was by death certificate only.

Code	Label
00000	No radiation treatment
00001-99997	Record the actual Phase I dose delivered in cGy
99998	Not applicable, radioisotopes administered to the patient
99999	Regional radiation therapy was administered but dose is unknown; Unknown whether radiation therapy was administered

Examples

Code	Reason
00200	A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy over 25 fractions followed by a Phase II (boost) prostate irradiation to 7,000 cGy. Record the Phase I dose per fraction as 00200 (5000/25).
00150	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region over 40 fractions. The dose is calculated at the prescribed depth of 3cm. A secondary calculation shows a Dmax dose of 6,450 cGy. Record the Phase I dose per fraction as 00150 (6000/40). Note that deposited radiation dose in the body is 3 dimensional and will vary slightly at any point in the body. Unfortunately, we can't capture this complexity, so we attempt to capture the nominal prescription dose as indicative of the 3 dimensional dose.
00180	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record phase I dose per fraction as 00180 (4500/25). See a detailed discussion of this example in the "CTR Guide to Coding Radiation Therapy Treatment in the STORE"

Phase I-II-III Number of Fractions

Item #	Length	Allowable Values	Required Status	Date Revised
1503	3	000-999	All Years	01/18, 02/21, 01/22, 01/23, 01/25
1513	3	000-999, Blank	All Years	01/18, 02/21, 01/23
1523	3	000-999, Blank	2018+	01/18, 02/21, 01/23

Description

Records the total number of fractions (treatment sessions) delivered to the patient in the first, second, and third phase of radiation during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation therapy is delivered in one or more phases with each phase spread out over a number of fractions (treatment sessions). It is necessary to capture information describing the number of fraction(s) to evaluate patterns of radiation oncology care.

Coding instructions

- A fraction is a session during which radiation was delivered. The number of beams is independent from the number of fractions. If several beam positions were delivered in a session, it is still only considered one fraction (session).
- Multiple fractions may be delivered in a single day. This may be documented as BID treatment or twice daily treatment. Usually, multiple fractions in a single day are separated by at least 4 hours.
- Count each separate administration of brachytherapy, implant or radioisotope as a single fraction or treatment.
- Record the actual number of fractions delivered (NOT initially prescribed), as documented in the treatment summary.
- Code 000 when tumor is diagnosed at autopsy.
- Code 999 for Death Certificate Only (DCO) cases.
- Phase I must be coded however blanks allowed for Phase II-III if no radiation treatment administered.

Code	Label
000	No radiation treatment
001-998	Number of fractions administered to the patient during the first phase of radiation therapy
999	Phase I Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered

Examples

Code	Reason
050	A patient with advanced head and neck cancer was treated using “hyper-fractionation.” Three fields were delivered in each session; two sessions were given each day, six hours apart, with each session delivering a total dose of 150 cGy. Treatment was given for a total of 25 days. The total course dose was 7500cGy. Record 50 fractions as 050.
010	The patient was given Mammosite® brachytherapy, repeated in 10 separate sessions. Record 10 fractions as 010.
001	Prostate cancer patient treated with a single administration of seeds. Record 1 fraction as 001.

Phase I-II-III Total Dose

Item #	Length	Allowable Values	Required Status	Date Revised
1507	6	000000-999999	All Years	01/18, 02/21, 1/22, 01/23, 01/25
1517	6	000000-999999, Blank	All years	01/18, 02/21, 01/23
1527	6	000000-999999, Blank	2018+	01/18, 02/21, 01/23

Description

Identifies the total radiation dose delivered to the patient during phase I-II-III of radiation treatment during the first course of treatment. Each phase is meant to reflect the delivered radiation prescription. The unit of dose is centi-Gray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018.

Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the maximum delivered dose of Phase I-II-III radiation to the patient during the first course of treatment.

Coding instructions

- Record the actual total dose delivered (NOT initially prescribed), as documented in the radiation treatment summary. The value recorded for this data item should NOT be auto-calculated within the registry abstraction software. In general, (Phase Dose per Fraction x Phase Number of Fractions = Phase Total Dose). But, there may be inconsistencies in rounding of dose or the way the dose is automatically measured in a treatment which will result in slight inconsistencies in the math. That is, in some radiation treatment summaries, Phase Dose per Fraction x Phase Number of Fractions $\approx$ Phase Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGe units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGe = 1 Gy = 100 cGy. For a Phase Total Dose, you would need to multiply dose in CGe by 100 to get dose in cGy.
- Note that dose is still occasionally specified in “rads”. One (1) rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy. A dose of Code 99998 when radioisotopes were administered to the patient (codes 13-16 for Phase I-II-III Treatment Modality [1506, 1516, 1526]).
- Code 000000, radiation therapy not administered, when diagnosed at autopsy.
- Code 999998 when radioisotopes are administered to the patient (codes 13-16 recorded in the Phase I-II-III Treatment Modality [1506, 1516, 1526]).
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I-II-III Treatment Modality [1506, 1516, 1526]). If only one fraction of brachytherapy was delivered, then then the Phase I Dose per Fraction and the Phase I Total Dose will be the same.
- Code 000000 when tumor is diagnosed at autopsy .
- Code 999999 for Death Certificate Only (DCO) cases.
- Phase I must be coded however blanks are allowed for Phase II-III if no radiation treatment was administered.

Code	Label
000000	No radiation treatment.
000001-999997	Record the actual total dose delivered in cGy
999998	Not applicable, radioisotopes administered to the patient
999999	Radiation therapy was administered, but the total dose is unknown; it is unknown whether radiation therapy was administered

Examples

Code	Reason
005000	A patient with Stage III prostate carcinoma received pelvic irradiation of 5,000 cGy in 25 fractions during Phase I Radiation Treatment. Record the Phase I Total Dose of 5,000 cGy as 005000.
006000	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. Record the Phase I Total Dose of 6,000 cGy as 006000.
004500	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Total Dose of 4500 cGy as 004500. See a detailed discussion of this example in the “CTR Guide to Coding Radiation Therapy Treatment in the STORE”.

Number of Phases of Radiation Treatment

Item #	Length	Allowable Values	Required Status	Date Revised
1532	2	00-98, 99	2018+	01/18

Description

A course of radiation is made up of one or more phases and each phase reflects a distinct delivered prescription. STORE has fields for up to 3 phases of a radiation course to be documented. This field identifies the actual number of distinct radiation phases in a course so that it is clear when only a portion of the course is being captured in the phase summary sections.

Rationale

The number of phases of radiation treatment is used to flag cases where only a subset of phase data is being captured.

Coding Instructions

Code 00 when case is diagnosed at autopsy.

Code 99 when case is a death certificate only case.

Code	Label
00	No radiation treatment
01-98	Record the actual number of phases in the radiation course
99	Unknown number of phases; Unknown if radiation therapy administered.

Examples

Code	Reason
00	Radiation therapy was not administered.
01	A patient with advanced head and neck cancer was treated using “hyper-fractionation.” Three fields were delivered in each session; two sessions were given each day, six hours apart, with each session delivering a total fractional dose of 150 cGy. Treatment was given for a total of 25 days. The total course dose was 7500cGy. Record the Number of Phases of Radiation Treatment as 01.
03	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record 03 as the Number of Phases of Radiation Treatment. See a detailed discussion of this example in the “CTR Guide to Coding Radiation Therapy Treatment in the STORE”

Radiation Treatment Discontinued Early

Item #	Length	Allowable Values	Required Status	Date Revised
1531	2	00-07, 99	2018+	01/18

Description

This field is used to identify patients/tumors whose radiation treatment course was discontinued earlier than initially planned. That is, the patients/tumors received fewer treatment fractions (sessions) than originally intended by the treating physician. This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later.

Rationale

Currently, the total dose of radiation reflects what was actually delivered rather than what was intended. When a patient does not complete a radiation course as initially intended this is typically commented on within the radiation treatment summary. By flagging these patients within the cancer registry database, these patients can be excluded from analyses attempting to describe adherence to radiation treatment guidelines or patterns of care analyses.

Coding Instructions

- Use code 00 when tumor is diagnosed at autopsy.
- Use code 01 when there is no indication in the record that radiation therapy was discontinued or completed early.
- Use code 02-07 when there is an indication in the record that the radiation therapy discontinued or was completed early.
- Use code 99 when radiation therapy was administered, but it is not clear if the treatment course was discontinued early, or if it is unknown whether radiation therapy was administered, or it is a death certificate only case.

Code	Label
00	No radiation treatment.
01	Radiation treatment completed as prescribed
02	Radiation treatment discontinued early - toxicity
03	Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)
04	Radiation treatment discontinued early - patient decision
05	Radiation discontinued early - family decision
06	Radiation discontinued early - patient expired
07	Radiation discontinued early - reason not documented
99	Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered.

Examples

Code	Reason
01	A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy over 25 fractions followed by a Phase II (boost) prostate irradiation to 7,000 cGy. Record Radiation Treatment Discontinued Early field as 01.
03	A patient with a metastasis from a gastric carcinoma at the L1 vertebral body was planned to receive 3000 cGy over 10 fractions. However, after 5 fractions, the patient developed cord compression symptoms and imaging evidence of compression and was taken for urgent surgical resection of the mass at L1. He did not resume radiotherapy. Record Radiation Treatment Discontinued Early field as 03 because there was clear evidence of progression.
02	A patient with muscle-invasive bladder cancer was being treated with radiation to the whole bladder. The initial plan was to treat the whole bladder to 6480cGy in 36 fractions but after 23 fractions he developed severe radiation enteritis and unrelenting diarrhea requiring a prolonged hospital admission. He discontinued treatment early after a total dose of 4140cGy. Record Radiation Treatment Discontinued Early field as 02 because treatment was stopped early due to treatment toxicity.

Radiation Course Total Dose

Item #	Length	Allowable Values	Required Status	Date Revised
1533	6	000000-999999	2018+	01/18, 01/23

Description

Identifies the total cumulative radiation dose administered to the patient across all phases during the first course of treatment to the same body site. The unit of measure is centi-Gray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later.

Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the total delivered prescribed total dose of radiation during the first course of treatment. Outcomes are strongly related to the dose delivered.

Coding Instructions

- If the total dose for the course is not documented, then add the dose from each of the sequential phases (I, II, III, or IV or more) that target the same body site and document the total cumulative dose. Note when calculating the Radiation Course Total Dose, all of the phases should be used, not just the first three.
- Doses should **ONLY** be summed across phases to create a Total Dose when all of the phases were delivered *sequentially* to the *same body site*. If phases were delivered to multiple body sites (e.g. simultaneous treatment to multiple metastatic sites), then code the Radiation Course Total Dose as the dose to the body site that received the highest dose. Examples are provided in the “CTR Guide to Coding Radiation Therapy Treatment in the STORE”.
- Doses should **ONLY** be summed across phases to create a Total Dose when all of the phases were delivered *using the same major modality type* (*External Beam, Brachytherapy, or Radioisotopes*). If phases were delivered using two or more major different modalities (e.g. external beam and brachytherapy to the same body site), then code 999998, Not applicable.
- Doses *can* be summed across phases even if the fraction size of phases is different. That is, if phase I to the whole prostate and seminal vesicles is 180 cGy x 28 = 5040 cGy, Phase II to a partial prostate volume is 200 cGy x 15 = 3000cGy, and these phases are delivered sequentially, then record 8040 cGy as the Radiation Course Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGe units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGE = 1 Gy = 100 cGy. For a Radiation Course Total Dose, you would need to multiply dose in CGE by 100 to get dose in cGy.
- Note that dose is still occasionally specified in “rads”. One (1) rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy. A dose of Code 999998 when radioisotopes were administered to the patient (codes 13-16 for *Phase I Treatment Modality* [1506]).
- Code 000000 when tumor was diagnosed at autopsy.
- Code 999998 when radioisotopes are administered to the patient (codes 13-16 recorded in the Phase I, Phase II, or Phase III Treatment Modality [1506, 1516, 1526] data items).
- Code 999999 when it is a death certificate only case.
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I Treatment Modality [1506]).

Code	Label
000000	No radiation treatment.
000001-999997	Record the actual total dose delivered in cGy
999998	Not applicable, radioisotopes administered to the patient, or the patient was treated with a mixed modalities (e.g. external beam and brachytherapy).
999999	Radiation therapy was administered, but the total dose is unknown; it is unknown whether radiation therapy was administered

Examples

Code	Reason
006040	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions. Axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Total Dose as 004500. Record the Phase II Total Dose as 000540. Record the Phase III Total Dose as 001000. Record the Radiation Course Total Dose as 006040.
008040	A patient with Stage III prostate carcinoma received 5,040 cGy to his pelvic nodes, prostate and seminal vesicles over 28 fractions using IMRT followed by a Phase II (boost) of 3000 cGy in 30 fractions using proton therapy. Record the Phase I Total Dose as 005040. Record the Phase II Total Dose as 003000. Record the Radiation Course Total Dose as 008040.
999998	A patient with Stage III prostate carcinoma received 4600cGy to his pelvic nodes, prostate and seminal vesicles over 23 fractions using IMRT followed by a Phase II (boost) of 11500 cGy using a low dose rate (LDR) brachytherapy implant. Record the Phase I Total Dose as 004600. Record the Phase II Total Dose as 011500. Record the Radiation Course Total Dose as 999998 because it is a mixed modality course.

Radiation/Surgery Sequence

Item #	Length	Allowable Values	Required Status	Date Revised
1380	1	0, 2-7, 9	2003+	01/04, 01/10, 01/11, 01/12, 02/21, 01/23

Description

Records the sequencing of radiation and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of radiation and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Coding Instructions

- For the purpose of coding the data item Radiation Sequence with Surgery, 'Surgery' is defined as a Rx Summ-Surg 2023 [1291] (codes A/B100-A/B900) or Scope of Regional Lymph Node Surgery (codes 2- 7) or Surgical Procedure of Other Site (codes 1-5).
- Surgical procedures include *Rx Summ – Surg 2023* [1291]; *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1); *Surgical Procedure/Other Site* [1294]. If all these procedures are coded 0, or it is not known whether the patient received both surgery and radiation, this item should be coded 0.
- Code the administration of radiation therapy in sequence with the first surgery performed, described in the item Date of First Surgical Procedure [1200].
- If the patient received both radiation therapy and any one or a combination of the following surgical procedures: *Rx Summ – Surg 2023*, *Regional Lymph Node Surgery* (excluding code 1), or *Surgical Procedure/Other Site*, then code this item 2–9, as appropriate. Assign codes 2-9 when first course of therapy includes both cancer-directed surgery and radiation therapy.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies.

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given.
2	Radiation therapy before surgery	Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).

Code	Label	Definition
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Radiation therapy both before and after surgery	At least one phase of radiation therapy was given before and at least one more phase after a surgical procedure of primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
5	Intraoperative radiation therapy	Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative radiation therapy with other therapy administered before or after surgery	Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
7	Surgery both before and after radiation	Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record.

Examples

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	A large lung lesion received radiation therapy prior to resection.
3	A patient received a wedge resection of a right breast mass with axillary lymph node dissection followed by radiation to right breast.
4	Preoperative radiation therapy was given to a large, bulky vulvar lesion and was followed by a lymph node dissection. This was then followed by radiation therapy to treat positive lymph nodes.
5	In the same procedure, a cone biopsy of the cervix was followed by intracavitary implant for IIIB cervical carcinoma.
6	Stage IV vaginal carcinoma was treated with 5,000 cGy to the pelvis followed by a lymph node dissection and 2,500 cGy of intracavitary brachytherapy.
9	An unknown primary of the head and neck was treated with surgery and radiation prior to admission, but the sequence is unknown. The patient enters for chemotherapy.

Date Radiation Ended

Item #	Length	Allowable Values	Required Status	Date Revised
3220	8	CCYYMMDD, Blank	2003+	06/05, 01/10, 01/11, 01/12

Description

The date on which the patient completes or receives the last radiation treatment at any facility.

Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful to evaluate the quality of care and the success of patient support programs designed to maintain continuity of treatment.

Coding Instructions

- Date radiation ended will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the date radiation ended may require assistance from the radiation oncologist for consistent coding.
- For brachytherapy if the treatment is applied only once, this date will be the same as Date Radiation Started [1210].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Examples

Code	Reason
20250104	A patient starts IMRT radiation treatment on December 15, 2024 and treatment continues until January 4, 2025.
20241002	A patient receives one radiation treatment on October 2, 2024, then refuses further treatments.
20240404	A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on April 4, 2024.

Reason for No Radiation

Item #	Length	Allowable Values	Required Status	Date Revised
1430	1	0-2, 5-9	2003+	09/04, 01/13

Description

Records the reason that no regional radiation therapy was administered to the patient.

Rationale

When evaluating the quality of care, it is useful to know the reason that various methods of therapy were not used, and whether the failure to provide a given type of therapy was due to the physician's failure to recommend that treatment, or due to the refusal of the patient, a family member, or the patient's guardian.

Coding Instructions

- If *Number of Phases of Radiation Treatment to this Volume* [1532] is coded 00, *Phase I Radiation Primary Treatment Volume* [1504] is coded 00, *Radiation Treatment Discontinued Early* [1531] is coded 00, and *Total Dose* [1533] is coded 000000, then record the reason based on documentation in patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include radiation therapy or when diagnosed at autopsy.
- Code 7 if the patient refused recommended radiation therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended radiation treatment, but no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a radiation oncologist was made and the registry should follow to determine whether radiation was administered. If follow-up to the specialist or facility determines the patient was never there and no other documentation can be found, code 1.
- Cases coded 8 should be followed and updated to a more specific code as appropriate.
- Code 9 if the treatment plan offered radiation or multiple alternative treatment options including radiation, but it is unknown which treatment, if any, was provided. Death Certificate only.

Code	Label
0	Radiation therapy was administered.
1	Radiation therapy was not administered because it was not part of the planned first course treatment.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).
5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.
6	Radiation therapy was not administered; it was recommended by the patient's physician but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.

Code	Label
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered.

Examples

Code	Reason
1	A patient with Stage I prostate cancer is offered either surgery or brachytherapy to treat his disease. The patient elects to be surgically treated.

RX Text--Radiation (Beam)

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2620	4000	rxTextRadiation	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding treatment of the tumor being reported with beam radiation.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date radiation treatment began
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of beam radiation, e.g., Orthovoltage, Cobalt 60, MV X-rays, Electrons, Mixed modalities
- Other treatment information, e.g., patient discontinued after 5 treatments; unknown if radiation was given

RX Text--Radiation (Beam), cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Summ--Radiation	1360
RX Summ--Surg/Rad Seq	1380
Reason For No Radiation	1430
RX Date Radiation	1210
Rad Regional RX Modality	1570
RX Hosp--Radiation	690
RX Date Rad Ended	3220
RX Summ--Rad to CNS	1370
Rad--No of Treatment Vol	1520
Rad--Regional Dose cGy	1510
Rad Treatment Volume	1540
Rad Location of RX	1550
Rad Boost RX Modality	3200
Rad Boost Dose cGy	3210
Phase I dose per Fraction	1501
Phase II dose per Fraction	1511
Phase III dose per Fraction	1521
Phase I Number of Fractions	1503
Phase II Number of Fractions	1513
Phase III Number of Fractions	1523
Phase I Radiation Treatment Modality	1506
Phase II Radiation Treatment Modality	1516
Phase III Radiation Treatment Modality	1526

RX Text--Radiation Other

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2630	1000	rxTextRadiationOther	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding treatment of the tumor being reported with radiation other than beam radiation. This includes brachytherapy and systemic radiation therapy.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of nonbeam radiation, e.g., High Dose rate brachytherapy, seed implant, Radioisotopes (I-131)
- Other treatment information, e.g., unknown if radiation was given

RX Text--Radiation Other, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Summ--Radiation	1360
RX Summ--Surg/Rad Seq	1380
Reason For No Radiation	1430
RX Date Radiation	1210
Rad Regional RX Modality	1570
RX Hosp--Radiation	690
RX Date Rad Ended	3220
RX Summ--Rad to CNS	1370
Rad--No of Treatment Vol	1520
Rad--Regional Dose cGy	1510
Rad Treatment Volume	1540
Rad Location of RX	1550
Rad Boost RX Modality	3200
Rad Boost Dose cGy	3210
Phase I dose per Fraction	1501
Phase II dose per Fraction	1511
Phase III dose per Fraction	1521
Phase I Number of Fractions	1503
Phase II Number of Fractions	1513
Phase III Number of Fractions	1523
Phase I Radiation Treatment Modality	1506
Phase II Radiation Treatment Modality	1516
Phase III Radiation Treatment Modality	1526

Systemic Therapy Data Items

[See *Systemic Therapy* in Section One for overview of coding principles.](#)

Date Systemic Therapy Started

Item #	Length	Allowable Values	Required Status	Date Revised
3230	8	CCYYMMDD, Blank	2003+	01/10, 01/11

Description

Records the date of initiation for systemic therapy that is part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormonal agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Coding Instructions

- Record the first or earliest date on which systemic therapy was administered. Systemic therapy includes *Chemotherapy* [1390], *Hormone Therapy* [1400], *Immunotherapy* [1410], and *Hematologic Transplant and Endocrine Procedures* [3250].

Examples

Code	Reason
20241215	A patient with breast cancer begins her regimen of chemotherapy on December 15, 2024, and is subsequently given Tamoxifen on January 20, 2025.
20240602	A patient with Stage IV prostate cancer has an orchiectomy on June 2, 2024. He is then started on a regime of hormonal agents on June 9, 2024.

Chemotherapy

Date Chemotherapy Started

Item #	Length	Allowable Values	Required Status	Date Revised
1220	8	CCYYMMDD, Blank	1996- 2002, 2010+	01/11, 01/23

Description

Records the date of initiation of chemotherapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Coding Instructions

- Record the first or earliest date on which chemotherapy was administered by any facility. This date corresponds to administration of the agents coded in *Chemotherapy* [1390].

Chemotherapy

Item #	Length	Allowable Values	Required Status	Date Revised
1390	2	00-03, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/15

Description

Records the type of chemotherapy administered as first course treatment at this and all other facilities. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Coding Instructions

- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer or tumor is diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Code 88 to indicate referral was made to a medical oncologist and the registry must follow to determine whether it was given. If follow-up with the specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.
- Code chemoembolization as Chemotherapy when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term chemoembolization is used with no reference to the agent. Use SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents.
- Code as Chemotherapy when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as Other Therapy.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.

- The managing physician may change a chemotherapy agent or one of the agents in a combination regimen, to an agent belonging to a different subcategory (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous). First course treatment would not necessarily end due to these changes and does **not** automatically represent subsequent therapy. Changes in an agent or agents may occur due to reasons other than disease progression.
- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as a chemotherapeutic agent should be coded as chemotherapy regardless of primary sites listed in SEER*RX for that agent. This would not be coded under the data item, Other Treatment [1420].
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care [3270].

Code	Label
00	None, chemotherapy was not part of the planned first course of therapy.
01	Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy.
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age progression of tumor prior to administration, etc.).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record.

Examples

Code	Reason
01	A patient with primary liver cancer is known to have received chemotherapy; however, the name(s) of agent(s) administered is not stated in patient record.
02	A patient with Stage III colon cancer is treated with a combination of fluorouracil and levamisole. Code the administration of fluorouracil as single agent chemotherapy, and levamisole as an immunotherapeutic agent.
02	A patient with non-Hodgkin's lymphoma is treated with fludarabine.
03	A patient with breast cancer receives chemotherapy. The patient chart indicates that a regimen with taxotere, avastin and cytoxan was initiated.
86	After surgical resection of an ovarian mass the following physician recommends chemotherapy. The patient record states that chemotherapy was not subsequently administered to the patient, but the reason why chemotherapy was not administered is not given.
88	A patient was referred to an outside oncology office where chemotherapy was recommended however it cannot be confirmed the chemotherapy was administered.

Chemotherapy at this Facility

Item #	Length	Allowable Values	Required Status	Date Revised
700	2	00-03, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/12, 01/13, 01/15

Description

Records the type of chemotherapy administered as first course treatment at this facility. If chemotherapy was not administered, then this item records the reason it was not administered to the patient.

Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

Coding Instructions

- Record only chemotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer or tumor was diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy, but no further documentation is available yet to confirm its administration
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.
- Code chemoembolization as Chemotherapy when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term chemoembolization is used with no reference to the agent. Use SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents.
- Code as Chemotherapy when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as Other Therapy.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.

- The managing physician may change a chemotherapy agent or one of the agents in a combination regimen, to an agent belonging to a different subcategory (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous). First course treatment would not necessarily end due to these changes and does **not** automatically represent subsequent therapy. Changes in an agent or agents may occur due to reasons other than disease progression.
- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as a chemotherapeutic agent should be coded as chemotherapy regardless of primary sites listed in SEER*RX for that agent. This would not be coded under the data item, Other Treatment [1420].
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care at This Facility [3280].

Code	Label
00	None, chemotherapy was not part of the planned first course of therapy.
01	Chemotherapy administered as first course therapy; but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to planned administration).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record.

RX Text--Chemo

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2640	4000	rxTextChemo	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding chemotherapy treatment of the reported tumor.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date chemotherapy began
- Where treatment was given, e.g., at this facility, at another facility
- Type of chemotherapy, e.g., name of agent(s) or protocol
- Other treatment information, e.g., treatment cycle incomplete, unknown if chemotherapy was given

RX Text—Chemo, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 st Crs RX CoC	1270
RX Hosp--Chemo	700
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--Chemo	1390
RX Date Chemo	1220
RX Summ--Systemic/Sur Seq	1639

Hormone Therapy

Date Hormone Therapy Started

Item #	Length	Allowable Values	Required Status	Date Revised
1230	8	CCYYMMDD, Blank	1996-2002, 2010+	01/11, 01/12, 1/23

Description

Records the date of initiation of hormone therapy that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Coding Instructions

- Record the first or earliest date on which hormone therapy was administered by any facility. This date corresponds to administration of the agents coded in *Hormone Therapy* [1400].

Hormone Therapy (Hormone/Steroid Therapy)

Item #	Length	Allowable Values	Required Status	Date Revised
1400	2	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13

Description

- Records the type of hormone therapy administered as first course treatment at this and all other facilities. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

- Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Coding Instructions

- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer or tumor was diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of "no treatment" was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate the patient was referred to a medical oncologist and the registry should follow the case for hormone therapy. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.

- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as hormonal agents. A drug administered to a patient for treatment, listed in SEER*Rx as a hormonal agent should be coded as Hormone Therapy regardless of primary sites listed in SEER*RX for that agent. This would **not** be coded under the data item, Other Treatment [1420].
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* [3270].

Code	Label
00	None, hormone therapy was not part of the planned first course of therapy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record.

Examples

Code	Reason
00	A patient has advanced lung cancer with multiple metastases to the brain. The physician orders Decadron to reduce the edema in the brain and relieve the neurological symptoms. Decadron is not coded as hormonal therapy.
00	A patient with advanced disease is given prednisone to stimulate the appetite and improve nutritional status. Prednisone is not coded as hormone therapy.
01	A patient with cancer was administered MOPP (mechlorethamine, vincristine, procarbazine, prednisone). Capture prednisone as hormonal therapy when part of a drug regime.
01	A patient with breast cancer is treated with aminoglutethimide (Cytadren, Elipten), which suppresses the production of glucocorticoids and mineralocorticoids.
01	A patient with metastatic prostate cancer is administered flutamide (an antiestrogen).
87	A patient with metastatic prostate cancer declines the administration of Megace (a progestational agent) and the refusal is noted in the patient record.
88	A patient was referred to an outside oncology office where hormone therapy was recommended however it cannot be confirmed the hormone was administered.

Hormone Therapy at this Facility (Hormone/Steroid Therapy)

Item #	Length	Allowable Values	Required Status	Date Revised
710	2	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13

Description

Records the type of hormone therapy administered as first course treatment at this facility. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

Coding Instructions

- Record only hormone therapy received at this facility. Do not record procedures done at other facilities.
- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer or tumor diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of "no treatment" was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why not.
- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.

- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as hormonal agents. A drug administered to a patient for treatment, listed in SEER*Rx as a hormonal agent should be coded as Hormone Therapy regardless of primary sites listed in SEER*RX for that agent. This would **not** be coded under the data item, Other Treatment [1420].
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* [3270].

Code	Label
00	None, hormone therapy was not part of the planned first course of therapy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record.

RX Text--Hormone

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2650	4000	rxTextHormone	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for information about hormonal treatment.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of hormone or antihormone, e.g., Tamoxifen
- Type of endocrine surgery or radiation, e.g., orchiectomy
- Other treatment information, e.g., treatment cycle incomplete; unknown if hormones were given

RX Text--Hormone, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 st Crs RX CoC	1270
RX Hosp--Hormone	710
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--Hormone	1400
RX Date Hormone	1230
RX Summ--Systemic/Sur Seq	1639

Immunotherapy

Date Immunotherapy Started

Item #	Length	Allowable Values	Required Status	Date Revised
1240	8	CCYYMMDD, Blank	1996-2002, 2010+	01/11, 01/23

Description

Records the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment.

Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Coding Instructions

- Record the first or earliest date on which immunotherapy or a biologic response modifier was administered by any facility. This date corresponds to administration of the agents coded in *Immunotherapy* [1410].

Immunotherapy

Item #	Length	Allowable Values	Required Status	Date Revised
1410	2	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13, 01/15

Description

Records the type of immunotherapy administered as first course treatment at this and all other facilities. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

Coding Instructions

- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of "no treatment" was accepted by the patient or tumor was diagnosed at autopsy.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed and the code updated as appropriate.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.
- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as immunotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as an immunotherapeutic agent should be coded as Immunotherapy regardless of primary sites listed in SEER*RX for that agent. This would **not** be coded under the data item, Other Treatment [1420].
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item Palliative Care [3270].

Code	Label
00	None, immunotherapy was not part of the planned first course of therapy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record.

Examples

Code	Reason
01	A patient with malignant melanoma is treated with interferon.
85	Before recommended immunotherapy could be administered, the patient died from cancer.
88	A patient was referred to an outside oncology office where immunotherapy was recommended however it cannot be confirmed the immunotherapy was administered.

Immunotherapy at this Facility

Item #	Length	Allowable Values	Required Status	Date Revised
720	2	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13, 01/15

Description

Records the type of immunotherapy administered as first course treatment at this facility. If immunotherapy was not administered, then this item records the reason it was not administered to the patient.

Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason immunotherapy was not administered.

Coding Instructions

- Record only immunotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of "no treatment" was accepted by the patient or tumor was diagnosed at autopsy.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received immunotherapy or why not.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.
- Refer to the SEER*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as immunotherapeutic agents. A drug administered to a patient for treatment, listed in SEER*Rx as an immunotherapeutic agent should be coded as Immunotherapy regardless of primary sites listed in SEER*RX for that agent. This would **not** be coded under the data item, Other Treatment [1420].

- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item *Palliative Care at This Facility* [3280].

Code	Label
00	None, immunotherapy was not part of the planned first course of therapy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record.

RX Text--BRM

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2660	4000	rxTextBrm	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding the treatment of the tumor being reported with biological response modifiers or immunotherapy.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date treatment began
- Where treatment was given, e.g., at this facility, at another facility
- Type of BRM agent, e.g., Interferon, BCG
- BRM procedures, e.g., bone marrow transplant, stem cell transplant
- Other treatment information, e.g., treatment cycle incomplete; unknown if BRM was given

RX Text--BRM, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 st Crs RX CoC	1270
RX Hosp--BRM	720
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--BRM	1410
RX Date BRM	1240
RX Summ--Systemic/Sur Seq	1639

Hematologic Transplant and Endocrine Procedures

Item #	Length	Allowable Values	Required Status	Date Revised
3250	2	00, 10-12, 20, 30, 40, 82, 85-88, 99	All Years	06/05, 01/10, 01/12, 01/13

Description

Identifies systemic therapeutic *procedures* administered as part of the first course of treatment at this and all other facilities. If none of these *procedures* were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

Rationale

This data item allows the evaluation of patterns of treatment which involve the alteration of the immune system or change the patient's response to tumor cells but does not involve the administration of antineoplastic agents. In addition, when evaluating the quality of care, it is useful to know the reason if these *procedures* were not performed.

Coding Instructions

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.
- Code 00 if a transplant or endocrine procedure was not administered to the patient, and it is known that these procedures are not usually administered for this type and stage of cancer or tumor was diagnosed at autopsy
- Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include a transplant or endocrine procedure or if the option of "no treatment" was accepted by the patient.
- As first course therapy, hematologic procedures will rarely be administered in conjunction with endocrine radiation or surgery. The use of code 40 in response to this data item should be reviewed and confirmed with the managing physician(s)
- If it is known that a transplant or endocrine procedure is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused a recommended transplant or endocrine procedure, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended a hematologic transplant or endocrine procedure, but no further documentation is available yet to confirm its administration.

- Code 88 to indicate referral to a specialist for hematologic transplant or endocrine procedures and the registry should follow the case. If follow-up to the specified specialist or facility determines the patient was never there, code 00.
- Use code 88 if a bone marrow or stem cell harvest was undertaken, but was not followed by a rescue or re-infusion as part of first course treatment.
- Cases coded 88 should be followed to determine whether they were given a hematologic transplant or endocrine procedure or why not.
- Code 99 if it is not known whether a transplant or endocrine procedure is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered or it is a death certificate only case.
- If the hematologic transplant or endocrine procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hematologic transplant or endocrine procedure provided in the items *Palliative Care* [3270] and/or *Palliative Care at This Facility* [3280], as appropriate.

Code	Label
00	No transplant procedure or endocrine therapy was administered as part of first course therapy.
10	A bone marrow transplant procedure was administered, but the type was not specified.
11	Bone marrow transplant—autologous.
12	Bone marrow transplant—allogeneic.
20	Stem cell harvest and infusion. Umbilical cord stem cell transplant, with blood from one or multiple umbilical cords
30	Endocrine surgery and/or endocrine radiation therapy.
40	Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.)
82	Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of disease prior to administration, etc.).
85	Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.
86	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.
99	It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record.

Systemic/Surgery Sequence

Item #	Length	Allowable Values	Required Status	Date Revised
1639	1	0, 2-7, 9	2006+	01/10, 01/11, 01/12, 02/21

Description

Records the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment.

Rationale

The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

Coding Instructions

- For the purpose of coding the data item Systemic Sequence with Surgery, 'Surgery' is defined as (Rx Summ – Surg 2023 [1291] codes A/B100-A/B900) or Scope of Regional Lymph Node Surgery (codes 2-7) or Surgical Procedure of Other Site (codes 1-5).
- Surgical procedures include Rx Summ – Surg 2023 [1291]; Scope of Regional Lymph Node Surgery [1292] (excluding code 1); Surgical Procedure/Other Site [1294]. If all these procedures are coded 0, or it is not known whether the patient received both surgery and systemic therapy, this item should be coded 0.
- Code the administration of systemic therapy in sequence with the first surgery performed, described in the item *Date of First Surgical Procedure* [1200].
- If the patient received both systemic therapy and any one or a combination of the following surgical procedures: Rx Summ – Surg 2023 [1291], Scope of Regional Lymph Node Surgery [1292] (excluding code 1), or Surgical Procedure/Other Site [1294], then code this item 2-9, as appropriate. Assign codes 2-9 when first course of therapy includes both cancer-directed surgery and systemic therapy.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies. For example: the sequence, chemo then surgery then hormone therapy then surgery is coded 4 for "chemo then surgery then hormone".

Code	Label	Definition
0	No systemic therapy and/or surgical procedures	No systemic therapy was given; and/or no surgical procedure of primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s); or no reconstructive surgery was performed. It is unknown whether both surgery and systemic treatment were provided.
2	Systemic therapy before surgery	Systemic therapy was given before surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
3	Systemic therapy after surgery	Systemic therapy was given after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.

Code	Label	Definition
4	Systemic therapy both before and after surgery	At least one course of systemic therapy was given before and at least one more after a surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
5	Intraoperative systemic therapy	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative systemic therapy with other systemic therapy administered before or after surgery	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
7	Surgery both before and after systemic therapy	Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Both surgery and systemic therapy were provided, but the sequence is unknown.

Examples

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	Patient with prostate cancer received hormone therapy prior to a radical prostatectomy.
3	Patient underwent a colon resection followed by a 5-FU based chemotherapy regimen.
4	Patient with breast cancer receives pre-operative chemotherapy followed by post-operative Tamoxifen.
5	Patient with an intracranial primary undergoes surgery at which time a glial wafer is implanted into the resected cavity.
6	Patient with metastatic colon cancer receives intraoperative chemotherapy to the liver.
9	An unknown primary of the head and neck was treated with surgery and chemotherapy prior to admission, but the sequence is unknown. The patient enters for radiation therapy.

Other Treatment

[See *Other Treatment* in Section One for overview of coding principles.](#)

Date Other Treatment Started

Item #	Length	Allowable Values	Required Status	Date Revised
1250	8	CCYYMMDD, Blank	All Years	01/10, 01/11

Description

Records the date on which other treatment began at any facility.

Rationale

Collecting dates for each treatment modality allows for the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

Coding Instructions

- Record the date on which the care coded as *Other Treatment* [1420] was initiated.
- If other treatment is the first or only treatment administered to the patient, then the date other treatment started should be the same as the *Date of First Course of Treatment* [1270].

Examples

Code	Reason
20240316	A patient with metastatic disease was started on an experimental therapy on March 16, 2024.
20240801	Alcohol was used as an embolizing agent for a patient on August 1, 2024.
20240917	A polycythemia vera patient was given several phlebotomies, the first being on September 17, 2024.

Other Treatment

Item #	Length	Allowable Values	Required Status	Date Revised
1420	1	0-3, 6-9	All Years	06/05, 09/08, 01/10, 01/11, 01/12, 01/15

Description

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Coding Instructions

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item.
- Code 0 when the tumor was diagnosed at autopsy.
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care* [3270].
- Code 8 if it is known that a physician recommended treatment coded as Other Treatment, and no further documentation is available yet to confirm its administration
- Code 8 to indicate referral to a specialist for Other Treatment and the registry should follow. If follow-up with the specialist or facility determines the patient was never there, code 0.
- Code 9 for Death Certificate Only (DCO) cases.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy).
2	Other—Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other—Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other—Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient's physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment.

Other Treatment at this Facility

Item #	Length	Allowable Values	Required Status	Date Revised
730	1	0-3, 6-9	All Years	01/04, 09/08, 01/10, 01/12, 01/15

Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Coding Instructions

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item.
- Code 0 when tumor was diagnosed at autopsy.
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care at This Facility* [3280].
- Code 8 if it is known that a physician recommended the patient receive treatment coded as Other Treatment, but no further documentation is available yet to confirm its administration.
- Code 9 for Death Certificate Only (DCO) cases.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy). Use this code for treatment unique to hematopoietic diseases.
2	Other–Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other–Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other–Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient's physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment.

RX Text--Other

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2670	4000	rxTextOther	Neither carriage return nor line feed characters allowed	All Years	

Description

Text area for manual documentation of information regarding the treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments (when the mechanism of action for a drug is unknown), and blinded clinical trials. If the mechanism of action for the experimental drug is known, code to the appropriate treatment field.

Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

Note: For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of other treatment, e.g., blinded clinical trial, hyperthermia
- Other treatment information, e.g., treatment cycle incomplete; unknown if other treatment was given

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

RX Text--Other, cont.

Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 st Crs RX CoC	1270
RX Summ--Other	1420
RX Date Other	1250
RX Hosp--Other	730

Neoadjuvant Therapy

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1632	1	neoadjuvantTherapy	0-3, 9	2021+	

Description

This data item records whether the patient had neoadjuvant therapy prior to planned definitive surgical resection of the primary site.

Rationale

This data item provides information related to the quality of care and describes whether a patient had neoadjuvant therapy.

For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine / hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy before intended or performed surgical resection to improve local therapy and long term outcomes.

Codes

Code	Label
0	No neoadjuvant therapy, no treatment before surgery, surgical resection not part of first course of treatment plan; Autopsy only
1	Neoadjuvant therapy completed according to treatment plan and guidelines
2	Neoadjuvant therapy started, but not completed OR unknown if completed
3	Limited systemic exposure when the intent was not neoadjuvant; treatment did not meet the definition of neoadjuvant therapy
9	Unknown if neoadjuvant therapy performed; Death Certificate only (DCO)

Neoadjuvant Therapy--Clinical Response

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1633	1	neoadjuvTherapyClinicalResponse	0-9	2021+	

Description

This data item records the clinical outcomes of neoadjuvant therapy prior to planned surgical resection.

Rationale

This data item provides information related to the quality of care and describes the clinical outcomes after neoadjuvant therapy. This data item provides prognostically relevant information by quantifying the extent of therapy-induced tumor regression. Therefore, this item can provide a better risk stratification for patients who received neoadjuvant therapy. In addition, this data item can contribute to assessments of cancer care quality.

This data item records the clinical outcomes of neoadjuvant therapy as determined by the managing physician (oncologic surgeon, radiation oncologist or medical oncologist).

For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine / hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy given to shrink a tumor before surgical resection.

Codes

Code	Label
0	Neoadjuvant therapy not given
1	Complete clinical response (CR)(per managing/treating physician statement)
2	Partial clinical response (PR) (per managing/treating physician statement)
3	Progressive disease (PD)(per managing/treating physician statement)
4	Stable disease (SD)(per managing/treating physician statement)
5	No response (NR) (per managing/treating physician statement; Not stated as progressive disease (PD) or stable disease (SD)
6	Neoadjuvant therapy done, managing/treating physician interpretation not available, treatment response inferred from imaging, biomarkers, or yc stage
7	Complete clinical response based on pathology report (per pathologist assessment)
8	Neoadjuvant therapy done, response not documented or unknown
9	Unknown if neoadjuvant therapy performed; Death Certificate only (DCO)

Neoadjuvant Therapy--Treatment Effect

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1634	1	neoadjuvTherapyTreatmentEffect	0-4, 6, 7, 9	2021+	

Description

This data item records the pathologist's statement of neoadjuvant treatment effect on the primary tumor from the surgical pathology report. Whenever treatment effect definitions are recommended by or available in CAP Cancer Protocols, this data item follows the CAP definitions indicating absent or present effect. When specific CAP definitions are not available, registrars should use treatment effect general use categories.

Rationale

This data item provides information related to the quality of care and describes the pathological outcomes after neoadjuvant therapy. This data item provides prognostically relevant information by quantifying the extent of therapy-induced tumor regression. Therefore, this item can provide a better risk stratification for patients who received neoadjuvant therapy. In addition, this data item can contribute to assessments of cancer care quality.

Codes

Code	Label
0	Neoadjuvant therapy not given/no known presurgical therapy
1-4	Site-specific code; type of response
6	Neoadjuvant therapy completed and surgical resection performed, response not documented or unknown; Cannot be determined
7	Neoadjuvant therapy completed and planned surgical resection not performed
9	Unknown if neoadjuvant therapy performed Unknown if planned surgical procedure performed after completion of neoadjuvant therapy Death Certificate only (DCO)

Palliative Care (Palliative Procedure)

Item #	Length	Allowable Values	Required Status	Date Revised
3270	1	0-7, 9	All Years	01/04, 01/10

Description

Identifies any care provided in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Coding Instructions

- Record the type of palliative care provided.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded palliative care and as first course therapy if that procedure removes or modifies either primary or metastatic malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.
- If hospice was recommended and received, capture the type of care provided to palliate or relieve the patient's symptoms.
- If hospice was recommended and received but it is unknown what type of care patient received, assign code 7.

Code	Label
0	No palliative care provided.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Examples

Code	Reason
0	No palliative care was given.
1	A patient undergoes palliative surgical removal of brain metastasis. [Surgery recorded in <i>Surgical Procedure/Other Site</i> [1294]]
1	A patient with unresectable pancreatic carcinoma (no surgical procedure of the primary site is performed) receives bypass surgery to alleviate jaundice and pain.
2	A patient is diagnosed with Stage IV prostate cancer. His only symptoms are painful bony metastases in his right hip and lower spine. XRT is given to those areas. (Record all radiotherapy items also).
2	A patient with lung cancer with a primary tumor extending into the spine is treated with XRT to shrink tumor away from spine/nerves to provide pain relief. (Record all radiotherapy items also).
3	A patient is given palliative chemotherapy for Stage IIIB lung cancer. (Record all chemotherapy items also).
4	A 93-year old patient is diagnosed with multiple myeloma and enters a pain management clinic to treat symptoms. No other therapy is planned due to other medical problems.
5	A patient is diagnosed with widely disseminated small cell lung cancer. A palliative resection of a solitary brain metastasis is performed followed by XRT to the lower spine for painful bony metastasis. There is no known pain management. (Record all surgery and radiotherapy items also).
6	A patient diagnosed with colon cancer receives bypass surgery to alleviate symptoms and XRT to the liver for metastasis, and then enters a pain management clinic for treatment for unremitting abdominal pain. (Record all radiotherapy items also).
7	A patient enters the facility with a clinical diagnosis of unresectable carcinoma of the pancreas. A stent was inserted into the bile duct to relieve obstruction and improve the bile duct flow.

Palliative Care at this Facility (Palliative Procedure at this Facility)

Item #	Length	Allowable Values	Required Status	Date Revised
3280	1	0-7, 9	All Years	01/04, 01/10

Description

Identifies care provided at this facility in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Coding Instructions

- Record only the type of palliative care at this facility.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable at this facility should be coded as palliative care and as first course therapy if that procedure removes or modifies either primary or secondary malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.
- If hospice was recommended and received, capture the type of care provided to palliate or relieve the patient's symptoms.
- If hospice was recommended and received but it is unknown what type of care patient received, assign code 7.

Code	Label
0	No palliative care provided.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Outcomes

NH-47

[See *Outcomes* in Section One for further coding instructions.](#)

Date of First Recurrence

Item #	Length	Allowable Values	Required Status	Date Revised
1860	8	CCYYMMDD, Blank	All Years	06/05, 01/10, 01/11, 01/12, 01/23

Description

Records the date of the first recurrence.

Rationale

This data item is used to measure the efficacy of the first course of treatment.

Coding Instructions

- Record the date the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period.
- Blank is allowable.

Type of First Recurrence

Item #	Length	Allowable Values	Required Status	Date Revised
1880	2	00, 04, 06, 10, 13-17, 20-22, 25-27, 30, 36, 40, 46, 51-59, 60, 62, 70, 88, 99	All Years	06/05, 01/10, 01/11, 01/13, 01/15, 01/18

Description

Identifies the type of first recurrence after a period of documented disease-free intermission or remission.

Rationale

This item is used to evaluate treatment efficacy and as a long-term prognostic factor.

Coding Instructions

- Code the type of first recurrence. First recurrence may occur well after completion of the first course of treatment or after subsequent treatment.
- Check the SEER *Multiple Primary and Histology Coding Rules Manual* or the current Solid Tumor Rules to determine which subsequent tumors should be coded as recurrences.
- If the patient has never been disease-free (code 70), continue to track for disease-free status which may occur after subsequent treatment has been completed.
- If the patient is disease-free (code 00), continue to track until a recurrence occurs. First recurrence may occur well after completion of the first course of treatment.
- Once a recurrence has been recorded (code 04-62 or 88), subsequent recurrences are NOT to be recorded.
- Codes 00 through 70 are hierarchical; record the highest-numbered applicable response, with the following limits. The first time a patient converts from disease status (70) to disease-free, change the code to 00. Then the first time a patient converts from 00 to a recurrence, then record the proper code for the recurrence. No further changes (other than corrections) should be made.
- If the tumor was originally diagnosed as in situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only. Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51–59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or “seeding”) within the distant location.
- Code lymphomas or leukemias that are in remission 00. If the patient relapses, then code recurrence as 59. If one of these is controlled by drugs (for example, Gleevec for CML), the patient is in remission.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor. If the recurrent primary is identified later, revise the codes appropriately.

Code	Label
00	Patient became disease-free after treatment and has not had a recurrence.
04	In situ recurrence of an invasive tumor.
06	In situ recurrence of an in situ tumor.
10	Local recurrence, and there is insufficient information available to code to 13–17. Local recurrence includes recurrence confined to the remnant of the organ of origin, to the organ of origin, to the anastomosis, or to scar tissue where the organ previously existed.
13	Local recurrence of an invasive tumor.
14	Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery.
15	Both local and trocar recurrence of an invasive tumor (both 13 and 14).
16	Local recurrence of an in situ tumor, NOS
17	Both local and trocar recurrence of an in situ tumor.
20	Regional recurrence, and there is insufficient information available to code to 21–27.
21	Recurrence of an invasive tumor in adjacent tissue or organ(s) only.
22	Recurrence of an invasive tumor in regional lymph nodes only.
25	Recurrence of an invasive tumor in adjacent tissue or organ(s) and in regional lymph nodes (both 21 and 22) at the same time.
26	Regional recurrence of an in situ tumor, NOS.
27	Recurrence of an in situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time.
30	Both regional recurrence of an invasive tumor in adjacent tissue or organs(s) and/or regional lymph nodes (20–25) and local and/or trocar recurrence (10, 13, 14, or 15).
36	Both regional recurrence of an in situ tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17).
40	Distant recurrence, to a site not listed in 46–62 or there is insufficient information available to code to 46–62.
46	Distant recurrence of an in situ tumor.
51	Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid.
52	Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura.
53	Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid.
54	Distant recurrence of an invasive tumor in the liver only.
55	Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site.
56	Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye.
57	Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site.

Code	Label
58	Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site.
59	Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease.
60	Distant recurrence of an invasive tumor in a single distant site (51–58) and local, trocar and/or regional recurrence (10–15, 20–25, or 30).
62	Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51–59).
70	Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated.
88	Disease has recurred, but the type of recurrence is unknown.
99	It is unknown whether the disease has recurred or if the patient was ever disease-free.

Examples

Code	Reason
00	A patient had nephrectomy for Renal Cell Carcinoma with clear margins. Physician noted NED. No recurrence noted in chart.
14	A patient has an abdominal wall recurrence at the trocar site for previous lap segmental resection for colon cancer.
22	A patient with lung cancer underwent lobectomy with clean margins. Work-up scans were negative. Adjuvant chemotherapy recommended, patient refused. During post-op visit physician stated patient is currently NED. Physician plan is to scan in six months. Sixth month follow up with scan identified malignant appearing hilar LNs. A few weeks later patient complained of headaches. MRI of brain performed and identified frontal lobe mets. Capture the first recurrence only.
52	Distant recurrence in the lung.
59	Relapse of AML after a period of remission.
62	Recurrence in liver, lung, and bone
70	Initially diagnosed with Stage IV lung cancer and never disease free.

Date of Last Cancer (tumor) Status

Item #	Length	Allowable Values	Required Status	Date Revised
1772	8	CCYYMMDD, Blank	2018+	01/18, 01/23

Description

This data item documents the date of last cancer (tumor status) of the patient's malignant or non-malignant tumor. Record in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

Rationale

This information is used for patient follow-up and outcomes studies.

Coding Instructions

- Record the last date on which the patient's cancer status (Cancer Status [1770]) was known to be updated.
- Cancer Status is based on information from the patient's physician or other official source such as a death certificate.
- The patient's Cancer Status should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other non-physician, then Cancer Status is not updated.
- Cancer Status changes if the patient has a recurrence or relapse.
- Blank is allowed.
- This data item differs from the Date of Last Contact or Death [1750] as it is a tumor-level data item. If a patient has multiple primaries, each primary could have a different Date of Last Cancer (tumor) Status [1772].

Examples

Code	Reason
20240205	The patient was initially diagnosed on 10/31/2023 with NHL and Cancer Status [1770], was initially assigned to code 2 (Evidence of this tumor). Follow up performed on 2/5/2024 stated the patient is in remission. Cancer Status [1770] is updated to code 1 (No evidence of this tumor) and Date of Cancer (tumor) Status [1772] is updated to 20240205.
20240415	The patient was diagnosed with prostate cancer and noted to be NED post-operatively on November 11, 2022. Imaging identified bone mets on April 15, 2024. Cancer Status [1770] is updated from code 1 (No evidence of this tumor) to code 2 (Evidence of this tumor) and Date of Cancer Status [1772] is updated to 20240415.

Cancer Status

Item #	Length	Allowable Values	Required Status	Date Revised
1770	1	1, 2, 9	All Years	01/04, 01/18

Description

Records the presence or absence of clinical evidence of the patient's malignant or non-malignant tumor as of the *Date of Last Cancer (tumor) Status* [1772].

Rationale

This information is used for patient follow-up and outcomes studies.

Coding Instructions

- *Cancer Status* is based on information from the patient's physician or other official source such as death certificate.
- The patient's *Cancer Status* should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other non-physician, then cancer status is not updated.
- *Cancer Status* changes if the patient has a recurrence or relapse.
- If a patient has multiple primaries, each primary could have a different cancer status.

Code	Label
1	No evidence of this tumor
2	Evidence of this tumor
9	Unknown, indeterminate whether this tumor is present; not stated in patient record

Examples

Code	Reason
1	Patient with hematopoietic disease who is in remission.
1	A patient is seen by the physician on February 2, 2023 with no evidence of this tumor. The patient did not return to the physician. The patient was then called by the registry on August 29, 2024. The <i>Date of Last Contact or Death</i> [1750] is updated, but the <i>Cancer Status</i> [1770] is not.
1	The patient was NED at first post op clinic visit on 2/21/2023. <i>Cancer Status</i> [1770] was assigned to code 1 (No evidence of this tumor). The patient returns for one year follow up still NED. Since there was no updating of the <i>Cancer Status</i> [1770], there is no change to <i>Date of Cancer (tumor) Status</i> [1772],
1	The patient was initially diagnosed on 10/31/2023 with NHL and <i>Cancer Status</i> [1770], was initially assigned to code 2 (Evidence of this tumor). Follow up performed on 2/5/2024 stated the patient is in remission. <i>Cancer Status</i> [1770] is updated to code 1 (No evidence of this tumor) and <i>Date of Cancer (tumor) Status</i> [1772] is updated to 20240205.

Code	Reason
1	The patient was diagnosed with prostate cancer and noted to be NED post-operatively on November 11, 2022. Imaging identified bone mets on April 15, 2024. Cancer Status [1770] is updated from code 1 (No evidence of this tumor) to code 2 (Evidence of this tumor) and Date of Cancer Status [1772] would be updated to 20240415.
2	A patient with prostate cancer is diagnosed with bone metastasis in April 2023. The registrar finds an obituary documenting the patient's death in a nursing home in June 2023.
2	The patient is initially diagnosed at Stage IV and has entered hospice care. Cancer Status [1770] should be assigned code 2 (Evidence of this tumor).

Date of Last Contact or Death

Item #	Length	Allowable Values	Required Status	Date Revised
1750	8	CCYYMMDD	All Years	06/05, 01/10, 01/11, 01/15, 01/23

Description

Records the date of last contact with the patient or the date of death.

Rationale

This information is used for patient follow-up and outcomes studies.

Coding Instructions

- Record the last date on which the patient was known to be alive or the date of death.
- Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same date of last contact.
- As of January 1, 2006, the CoC does not require *Class of Case* 00 cases to be followed.
- Blanks are not allowed.

Vital Status

Item #	Length	Allowable Values	Required Status	Date Revised
1760	1	0, 1	All Years	01/15

Description

Records the vital status of the patient as of the date entered in *Date of Last Contact or Death* [1750].

Rationale

This information is used for patient follow-up and outcomes studies.

Coding Instructions

- This item is collected during the follow-up process with *Date of Last Contact or Death* [1750].
- Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same vital status.

Code	Label
0	Dead
1	Alive

Examples

Code	Reason
0	Death clearance information obtained from a state central registry confirms the death of the patient within the past year.
1	In response to a follow-up letter to a patient's following physician, it is learned the patient is alive.

Cause of Death

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1910	4	causeOfDeath	Valid ICD-7, ICD-8, ICD-9, and ICD-10 codes; also 0000, 7777, 7797	All Years	

Description

Official cause of death as coded from the death certificate in valid ICD-7, ICD-8, ICD-9, and ICD-10 codes.

Rationale

Cause of death is used for calculation of adjusted survival rates by the life table method. The adjustment corrects for deaths other than from the diagnosed cancer.

Note: This data item is no longer supported by CoC (as of January 1, 2003).

Special codes in addition to ICD-7, ICD-8, ICD-9, and ICD-10

(Refer to [SEER Program Code Manual](#) for additional instructions.)

Code	Label
0000	Patient alive at last contact
7777	State death certificate not available
7797	State death certificate available but underlying cause of death is not coded

Place of Death--State

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1942	2	placeOfDeathState	USPS or CanadaPost 2-character codes; CD, US, XX, YY, ZZ, Blank	2013+	

Description

State or Province where the patient died and where certificate of death is filed. This data item became part of the NAACCR transmission record effective with Volume II, Version 13 in order to include country and state for each geographic item and to use interoperable codes. It supplements the item *Place of Death--Country* [1944]. It replaces the use of *Place of Death* [1940].

Rationale

This field also helps carry out death clearance. When a reporting facility reports a place of death, the information can help in death certificate matching. It can also signal an out-of-state death for which the death certificate is to be requested.

Codes

Code	Label
Blank	Not applicable, patient alive

See [Appendix D](#) for numeric and alphabetic lists of places and codes (also see Appendix B of the *SEER Program Code Manual* at seer.cancer.gov/tools/codingmanuals/index.html).

Place of Death--Country

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1944	3	placeOfDeathCountry	USPS or CanadaPost 2-character codes; CD, US, XX, YY, ZZ, Blank	2013+	

Description

Code for the country in which the patient died and where certificate of death is filed. If the patient has multiple tumors, all records should contain the same code. This data item became part of the NAACCR transmission record effective with Volume II, Version 13 in order to include country and state for each geographic item and to use interoperable codes. It supplements the item *Place of Death--State* [1942]. It replaces the use of *Place of Death* [1940].

Rationale

Place of death is helpful for carrying out death clearance. When a reporting facility reports a place of death that is outside of the registry's country, the information can signal a death for which the death certificate will not be available from another state or through the NDI linkage.

Codes

Use the International Standards Organization (ISO) 3166-1 Country Three Character Codes, whenever possible, augmented by custom codes. See [Appendix D](#) for complete list of country names and corresponding three character alpha codes.

Code	Label
ZZN	Not applicable, patient alive
ZZC	Central America NOS
ZZS	South America NOS
ZZP	Pacific NOS
ZZE	Europe NOS
ZZF	Africa NOS
ZZA	Asia NOS
ZZX	Non-US NOS
ZZU	Unknown

Place of Death--Country, cont.

Code	Label
Custom codes for historic use only	
XNI	North American Islands
ZCB	Other Caribbean Islands
XEN	England, Channel Islands, Isle of Man
XSC	Scandinavia
XGR	Germanic Countries
XSL	Slavic Countries
CSK	Czechoslovakia (former)
YUG	Yugoslavia (former)
XUM	Ukraine and Moldova
XNF	North Africa
XSD	Sudanese Countries
XWF	West Africa
XSF	South Africa
XEF	East Africa
XIF	African Islands
XET	Ethiopia and Eritrea
XAP	Arabian Peninsula
XIS	Israel and Palestine
XCR	Caucasian Republics of former USSR
XOR	Other Asian Republics of former USSR
XSE	Southeast Asia
XMS	Malaysia, Singapore, Brunei
XCH	China, NOS
XML	Melanesian Islands
XMC	Micronesian Islands
XPL	Polynesian Islands
Blank	Not applicable, patient alive

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Follow-Up Source

Item #	Length	Allowable Values	Required Status	Date Revised
1790	1	0-5, 7-9	All Years	

Description

Records the source from which the latest follow-up information was obtained.

Rationale

This data item is used by registries to identify the most recent follow-up source.

Coding Instructions

Code	Label	Definition
0	Reported hospitalization	Hospitalization at another institution/hospital or first admission to the reporting facility.
1	Readmission	Hospitalization or outpatient visit at the reporting facility.
2	Physician	Information from a physician.
3	Patient	Direct contact with the patient.
4	Department of Motor Vehicles	The Department of Motor Vehicles confirmed the patient has a current license.
5	Medicare/Medicaid file	The Medicare or Medicaid office confirmed the patient is alive.
7	Death certificate	Information from the death certificate only.
8	Other	Friends, relatives, employers, other registries, or any sources not covered by other codes.
9	Unknown; not stated in patient record	The follow-up source is unknown or not stated in patient record.

Next Follow-Up Source (Next Follow-Up Method)

Item #	Length	Allowable Values	Required Status	Date Revised
1800	1	0-5, 8, 9	All Years	01/10

Description

Identifies the method planned for the next follow-up.

Rationale

This data item is used by registries to identify the method planned for the next follow-up.

Coding Instructions

- Registries in CoC-accredited cancer programs are not required to follow foreign residents.
- As of January 1, 2006, the CoC does not require Class of Case 00 cases to be followed.

Code	Label
0	Chart requisition
1	Physician letter
2	Contact letter
3	Phone call
4	Other hospital contact
5	Other, NOS
8	Foreign residents (not followed)
9	Not followed. Other cases for which follow-up is not required.

Case Administration

[See *Case Administration* in Section One for overview of coding principles.](#)

Abstracted By

Item #	Length	Allowable Values	Required Status	Date Revised
570	3	Alphanumeric	1996+	

Description

Records the initials or assigned code of the individual abstracting the case.

Rationale

This item can be used for quality control and management in multi-staffed registries.

Coding Instructions

NH-48

- Code the initials of the abstractor.

Code	Label
(fill spaces)	Initials or code of abstractor.

Facility Identification Number (FIN)

Item #	Length	Allowable Values	Required Status	Date Revised
540	10	10 digits	All Years	09/08, 01/12

Description

Identifies the facility reporting the case.

Rationale

Each facility's identification number (FIN) is unique. The number is essential to the National Cancer Database (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

Coding Instructions

- Facility Identification Number is automatically coded by the software provider.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific FIN in their data for submission to the National Cancer Database.
- Facilities that merge are legally a single hospital. Consult NCDB for instructions for recording the FIN for newly-merged programs.

Examples

Code	Reason
0006439999	6439999, General Hospital, Anytown, Illinois
0010000099	10000099, Anytown Medical Center, Anytown, Illinois

NPI–Reporting Facility

Item #	Length	Allowable Values	Required Status	Date Revised
545	10	10 digits, Blank	2008+	04/07, 09/08, 01/10, 01/12

Description

Identifies the facility whose data are in the record.

Rationale

Each facility's NPI is unique. The number is essential to the National Cancer Database (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

NPI–Reporting Facility is the NPI equivalent of *Facility Identification Number* [540]. Both are required during a period of transition.

Coding Instructions

- NPI–Reporting Facility is automatically coded by the software provider.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- The facility's NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/#/>.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number in their data for submission to the National Cancer Database.
- Facilities that merge are legally a single hospital. Use the NPI number for the merged hospital.
- NPI may be blank for cases diagnosed on or before December 31, 2007.

Examples

Code	Reason
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

Archive FIN

Item #	Length	Allowable Values	Required Status	Date Revised
3100	10	10 digits	2003+	01/10, 01/12

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

Coding Instructions

- Archive FIN is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the Archive FIN and FIN [540] will be the same.
- If facilities merged after January 1, 2003, a new FIN was assigned to represent the merged facility. This new FIN was assigned to all cases in the merged registry, but the Archive FIN for cases from each registry prior to the merger does not change.
- If a merged program continues to operate multiple campuses, the Archive FIN is the historic FIN for the respective facilities that are now separate campuses of the same hospital.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific FIN for the Archive FIN in their data for submission to the National Cancer Database.
- Programs that are not part of a merged facility or an INCP will use their hospital's FIN as the Archive FIN.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number. The Archive FIN must be recorded similarly.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number. The Archive FIN must be recorded similarly.

Examples

Code	Reason
0006439999	General Hospital, Anytown, Illinois (FIN: 6439999). Original diagnosis was made at this facility; both the FIN and the Archive FIN are the same.
0006439999 or 0006430000	General Hospital (FIN: 6439999) and Anytown Medical Center (FIN: 6430000) in Anytown IL merged; the two cancer registries were combined and now report as Anytown Medical Center. The new FIN for this reporting facility is 10000099. All cases from the merged General Hospital and Anytown Medical Center registry have the new FIN (0010000099) assigned to them. In addition, either the General Hospital Archive FIN (0006439999) or the Anytown Medical Center Archive FIN (0006430000) is retained in each record depending on which registry originally accessioned the case.

NPI–Archive FIN

Item #	Length	Allowable Values	Required Status	Date Revised
3105	10	10 digits, Blank	2008+	01/10, 01/12

Description

Identifies the facility that originally abstracted the case.

Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

NPI–Archive FIN is the NPI equivalent of *Archive FIN* [3100]. Both are required during a period of transition.

Coding Instructions

- NPI–Archive FIN is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- The facility’s NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/#/>.
- For facilities that have not merged, the NPI–Archive FIN and the NPI–Reporting Facility [545] will be the same. Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number for the NPI–Archive FIN in their data for submission to the National Cancer Database.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2007.

Examples

Code	Reason
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

Date Case Completed – CoC

Item #	Length	Allowable Values	Required Status	Date Revised
2092	8	CCYYMMDD	≥2010	01/12

Description

This data item identifies the date that specified items are completed, based on the *Class of Case*, and those items pass the relevant edits. Follow-up information, including delayed treatment received elsewhere, may be coded after the *Date Case Completed–CoC*. This item should be autocoded by the registry software. The CoC specifications will not necessarily be the same as those used for *Date Case Completed* [NAACCR Item #2090], which CoC does not require.

NH-49

Rationale

This item was created to measure abstracting timeliness of information that should be available when the facility's main involvement in the patient's first course care is completed, based on *Class of Case*. This may also be used as part of CoC Standard 6.1 Cancer Registry Quality Control for timeliness determined by the program.

Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Follow-up information, information about delayed treatment received elsewhere, and information about multiple tumors diagnosed later may be coded after the *Date Case Completed – CoC*.
- Corrections and updates may be made after the *Date Case Completed – CoC*.
- Information can be found on the [NCDB Data Submission](#) webpage under Layouts, NAACCR current version Record Layout and Items to Be Submitted.
- After all required items identified below for the patient's *Class of Case* have been abstracted, the registrar should run the current NAACCR edit set "Hosp: CoC Required - All" using the registry software. The registry software will record the *Date Case Completed – CoC* when those items are abstracted and the case passes all edits in that set.

Class of Case	Description	Items that Must Be Completed by Date Case Completed - CoC
00-22	All analytic cases	Identification, demographic, diagnostic
10-22	Patient received part or all first course treatment from facility	Staging, hospital-specific treatment
10, 12, 14, 20, 22	Patient received all first course treatment from facility, or unspecified whether all or part	Summary treatment (treatment at any facility)
00	Patient diagnosed at facility, received all treatment elsewhere	NPI number for the facility the patient was referred to or a treating physician
20-22	Patient diagnosed elsewhere, received part or all of treatment from facility	NPI number for the facility the patient was referred to or from OR the physician who diagnosed or treated the patient

Override Site/TNM-Stage Group

Item #	Length	Allowable Values	Required Status	Date Revised
1989	1	1, Blank	All Years	09/04, 09/08, 01/10, 01/12

Description

Used with the EDITS software to override the edits of the type *Primary Site, AJCC Stage Group*, for AJCC staging editions 6 and later.

Rationale

This override flag allows identification of pediatric cancers that were staged according to a system other than the **AJCC Cancer Staging System** (which is predominantly directed toward adult staging) if they are not also **AJCC**-staged. In that situation an otherwise-stageable case may be coded 88 (not applicable) for all **AJCC** items.

EDITS Use

Edits of the type, *Primary Site, AJCC Stage Group*, check that the pathological and clinical AJCC stage group codes are valid for the site and histology group according to the applicable *AJCC Cancer Staging System*, using the codes described for the items *Clinical Stage Group* [970] and *Pathological Stage Group* [910]. Combinations of site and histology not represented in any AJCC schema must be coded 88. Unknown codes must be coded 99. Blanks are not permitted.

Since pediatric cancers whose sites and histologies have an AJCC scheme may be coded according to a pediatric scheme instead, use *Override Site/TNM-Stage Group* to indicate the case was coded according to a pediatric staging system if it was not also coded according to the AJCC Cancer Staging System. Pediatric stage groups should *not* be recorded in the *Clinical Stage Group* or *Pathological Stage Group* items. When neither clinical nor pathological AJCC staging is used for pediatric cases, code all AJCC items 88. When any AJCC component is used to stage a pediatric case, follow the instructions for coding AJCC items and leave *Override Site/TNM- Stage Group* blank.

Coding Instructions

- Leave blank if the EDITS program does not generate an error message for the edits of the type, Primary Site, AJCC Stage Group.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if the case is confirmed to be a pediatric case that was coded using a pediatric coding system.

Code	Label
(Leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

Over-ride Age/Site/Morph

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1990	1	overRideAgeSiteMorph	1-3 or blank		2007, 2008, 2010, 2021

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Age, Primary Site, Morphology ICDO2 (SEER IF15)
- Age, Primary Site, Morphology ICDO3 (SEER IF15)
- Age, Primary Site, Morph ICDO3--Adult (SEER)
- Age, Primary Site, Morph ICDO3--Pediatric (NPCR)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Some cancers occur almost exclusively in certain age groups.

Edits of the type Age, Primary Site, Morphology require review if a site/morphology combination occurs in an age group for which it is extremely rare. The edit Age, Primary Site, Morph ICDO3--Adult (SEER) edits cases with an Age at Diagnosis of 15 and older. The edit Age, Primary Site, Morph ICDO3--Pediatric (NPCR) edits cases with an Age at Diagnosis of less than 15. The edits Age, Primary Site, Morphology ICDO2 (SEER IF15) and Age, Primary Site, Morphology ICDO3 (SEER IF15) contain logic for all ages.

Coding Instructions

- Leave blank if the program does not generate an error message (and if the case was not diagnosed in utero) for the edits of the type Age, Primary Site, Morphology.
- Correct any errors for the case if an item is discovered to be incorrect.
- Code 1 or 3 as indicated if review of items in the error or warning message confirms that all are correct.

Codes

Code	Label
1	Reviewed and confirmed that age/site/histology combination is correct as reported
2	Reviewed and confirmed that case was diagnosed in utero
3	Reviewed and confirmed that conditions 1 and 2 both apply
Blank	Not reviewed or reviewed and corrected.

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Over-ride Surg/DXConf

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2020	1	overRideSurgDxconf	1 or blank		2006, 2008

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- RX Summ--Surg Prim Site, Diag Conf (SEER IF76)
- RX Summ--Surg Site 98-02, Diag Conf (SEER IF106)
- RX Summ--Surgery Type, Diag Conf (SEER IF46)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Edits of the type RX Summ--Surg Prim Site, Diag Conf check that cases with a primary site surgical procedure coded 20-90 are histologically confirmed. If the patient had a surgical procedure, most likely there was a microscopic examination of the cancer. Verify the surgery and diagnostic confirmation codes, and correct any errors. Sometimes there are valid reasons why no microscopic confirmation is achieved with the surgery; for example, the tissue removed may be inadequate for evaluation.

Coding Instructions

- Leave blank if the program does not generate an error message for edits of the type, RX Summ--Surg Prim Site, Diag Conf.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review confirms that they are correct. The patient had surgery, but the tissue removed was not sufficient for microscopic confirmation.

Codes

Code	Label
Blank	Not reviewed or reviewed and corrected.
1	Reviewed and confirmed as reported

Override Site/Type

Item #	Length	Allowable Values	Required Status	Date Revised
2030	1	1, Blank	All Years	09/06, 09/08, 01/10

Description

Used with the EDITS software to override edits of the type *Primary Site, Morphology-Type and Primary Site, Morphology-Type, Behavior ICDO3*.

Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept *Override CoC-Site/Type* or *Override Site/Type* as equivalent.

The Site/Histology Validation List (available on the SEER website) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations not listed.

Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if Primary Site [400] is in the range C440-C449 (skin), and the ICD-O-3 histology is in the range 8000- 8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

Coding Instructions

- Leave blank if the EDITS program does not generate an error message for edits of the type Primary Site, Morphology-Type.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Label
(Leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

Over-ride Histology

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2040	1	overrideHistology	1-3 or blank		2007, 2008

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Diagnostic Confirmation, Behavior ICDO2 (SEER IF31)
- Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)
- Morph (1973-91) ICD-O-1 (SEER MORPH)
- Morphology--Type/Behavior ICDO2 (SEER MORPH)
- Morphology--Type/Behavior ICDO3 (SEER MORPH)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Edits of the type Diagnostic Confirmation, Behavior differ in the use of ICD-O-2 or ICD-O-3 and check that, for *in situ* cases (Behavior = 2), Diagnostic Confirmation specifies microscopic confirmation (1, 2, or 4).

The distinction between *in situ* and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissues, i.e., *in situ*, is made microscopically, cases coded *in situ* in behavior should have a microscopic confirmation code. However, very rarely, a physician will designate a case noninvasive or *in situ* without microscopic evidence.

If an edit of the type, Diagnostic Confirmation, Behavior, gives an error message or warning, check that Behavior and Diagnostic Confirmation have been coded correctly. Check carefully for any cytologic or histologic evidence that may have been missed in coding.

Edits of the type, Morphology--Type/Behavior, perform the following check:

- Codes listed in ICD-O-2 or ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since the behavior matrix of ICD-O-2 and ICD-O-3 allows for the elevation of the behavior of such histologies when the tumor is *in situ* or malignant. This edit forces review of these rare cases to verify that they are indeed *in situ* or malignant.
- The following histologies are generally not accepted as *in situ*: ICD-O-2 histologies 8000-8004, 8020, 8021, 8331, 8332, 8800-9054, 9062, 9082, 9083, 9110-9491, 9501-9989, ICD-O-3 histologies 8000-8005, 8020, 8021, 8331, 8332, 8800-9055, 9062, 9082, 9083, 9110-9493, 9501-9989. This edit forces review of these cases.

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

3. If a Morphology-Type/Behavior edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-2 or ICD-O-3 only with behavior codes of 0 or 1, or the case is one in which the 4-digit morphology code is not generally accepted with a behavior code of 2, verify the coding of morphology and that the behavior should be coded malignant or *in situ*. The registrar may need to consult a pathologist or medical advisor in problem cases.

Exceptions:

If year of Date of Diagnosis > 2000, then a behavior code of 1 is valid for the following ICD-O-2 histologies and no over-ride flag is needed: 8931, 9393, 9538, 9950, 9960-9962, 9980-9984, and 9989. Similarly, the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473. If year of Date of Diagnosis > 2003, the following ICD-O-3 benign histologies will pass without review: 8146, 8271, 8861, 8897, 9121, 9122, 9131, 9161, 9350, 9351, 9352, 9360, 9361, 9383, 9384, 9394, 9412, 9413, 9444, 9492, 9493, 9506, 9531, 9532, 9533, 9534, 9537, 9541, 9550, 9562, and 9570.

4. Grade 5-8 with histologies not in the range of 9590-9948 is impossible.
5. Some terms in ICD-O-2 and ICD-O-3 carry an implied statement of grade. These histologies must be reported with the correct grade as stated below. An error of this type cannot be over-ridden.

ICD-O-2

8020/34 Carcinoma, undifferentiated
 8021/34 Carcinoma, anaplastic
 8331/31 Follicular adenocarcinoma, well differentiated
 8851/31 Liposarcoma, well differentiated
 9062/34 Seminoma, anaplastic
 9082/34 Malignant teratoma, undifferentiated
 9083/32 Malignant teratoma, intermediate type
 9401/34 Astrocytoma, anaplastic
 9451/34 Oligodendroglioma, anaplastic
 9511/31 Retinoblastoma, differentiated
 9512/34 Retinoblastoma, undifferentiated

ICD-O-3

8020/34 Carcinoma, undifferentiated
 8021/34 Carcinoma, anaplastic
 8331/31 Follicular adenocarcinoma, well differentiated
 9082/34 Malignant teratoma, undifferentiated
 9083/32 Malignant teratoma, intermediate type
 9401/34 Astrocytoma, anaplastic
 9451/34 Oligodendroglioma, anaplastic
 9511/31 Retinoblastoma, differentiated
 9512/34 Retinoblastoma, undifferentiated

Coding Instructions

- Leave blank if the program does not generate an error message for edits of the types, Diagnostic Confirmation, Behav Code or Morphology--Type/Behavior.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1, 2, or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

Codes

Code	Label
1	Reviewed and confirmed that the pathologist states the primary to be " <i>in situ</i> " or "malignant" although the behavior code of the histology is designated as "benign" or "uncertain" in ICD-O-2 or ICD-O-3
2	Reviewed and confirmed that the behavior code is " <i>in situ</i> ," but the case is not microscopically confirmed
3	Reviewed and confirmed that conditions 1 and 2 both apply
Blank	Not reviewed or reviewed and corrected

Over-ride Leuk, Lymphoma

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2070	1	overRideLeukLymphoma	1 or blank		2006, 2008, 2010, 2021

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Diagnostic Confirmation, Histology ICDO2 (SEER IF48)

Diagnostic Confirmation, Histology ICDO3 (SEER IF48)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Edits of the type Diagnostic Confirmation, Histology differ in use of ICD-O-2 or ICD-O-3 and check the following:

1. Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma that have diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.
2. If histology = 9590-9717 for ICD-O-2 or 9590-9729 for ICD-O-3 (lymphoma) then Diagnostic Confirmation cannot be 6 (direct visualization) or 8 (clinical).
3. If histology = 9720-9941 for ICD-O-2 or 9731-9948 for ICD-O-3 (leukemia and other) then Diagnostic Confirmation cannot be 6 (direct visualization).

Coding Instructions

- Leave blank if the program does not generate an error message for edits of the type Diagnostic Confirmation, Histology.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- If the edit produces an error or warning message, verify that the ICD-O-2 or ICD-O-3 histology and diagnostic confirmation are correctly coded. Remember that positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in Diagnostic Confirmation) for leukemia. Code 1 indicates that a review has taken place and histologic type and diagnostic confirmation are correctly coded.

Codes

Code	Label
Blank	Not reviewed or reviewed and corrected.
1	Reviewed and confirmed as reported

Over-ride Site/Behavior

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2071	1	overRideSiteBehavior	1 or blank	1997+	2006, 2008

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Primary Site, Behavior Code ICDO2 (SEER IF39)

Primary Site, Behavior Code ICDO3 (SEER IF39)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Edits of the type, Primary Site, Behavior Code, require review of the following primary sites with a behavior of *in situ* (ICD-O-2 or ICD-O-3 behavior = 2):

C269	Gastrointestinal tract, NOS
C399	Ill-defined sites within respiratory system
C559	Uterus, NOS
C579	Female genital tract, NOS
C639	Male genital organs, NOS
C689	Urinary system, NOS
C729	Nervous system, NOS
C759	Endocrine gland, NOS
C760-C768	Ill-defined sites
C809	Unknown primary site

Since the designation of *in situ* is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being *in situ* is reliable.

If an *in situ* diagnosis is stated, try to obtain a more specific primary site. A primary site within an organ system can sometimes be identified based on the diagnostic procedure or treatment given or on the histologic type. If no more specific site can be determined, it is usually preferable to code a behavior code of 3. In the exceedingly rare situation in which it is certain that the behavior is *in situ* and no more specific site code is applicable, set Over-ride Site/Behavior to 1.

Source: Thornton ML, (ed). [Data Standards and Data Dictionary, Version 26, 27th ed.](#) Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025).

Over-ride Site/Behavior, cont.

Coding Instructions

- Leave blank if the program does not generate an error message for the edit Primary Site, Behavior Code ICDO2 (SEER IF39) and/or the edit Primary Site, Behavior Code ICDO3 (SEER IF39).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of site and behavior verifies that the patient has an *in situ* cancer of a nonspecific site and no further information about the primary site is available.

Codes

Code	Label
Blank	Not reviewed or reviewed and corrected
1	Reviewed and confirmed as reported

Note: The IF 39 edit does not allow *in situ* cases of nonspecific sites, such as gastrointestinal tract, NOS; uterus, NOS; female genital tract, NOS; male genital organs, NOS; and others. The over-ride indicates that the conflict has been reviewed.

Over-ride Site/Lat/Morph

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2074	1	overrideSiteLatMorph	1 or blank		2006, 2008, 2021

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Laterality, Primary Site, Morph ICDO2 (SEER IF42)

Laterality, Primary Site, Morph ICDO3 (SEER IF42)

Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

Over-ride Flag as Used in the EDITS Software Package

Edits of the type Laterality, Primary Site, Morph differ in use of ICD-O-2 or ICD-O-3 morphology and do the following:

1. If the Primary Site is a paired organ and ICD-O-2 or ICD-O-3 behavior is *in situ* (2), then laterality must be 1, 2, or 3.
2. If diagnosis year less than 1988 and ICD-O-2 or ICD-O-3 histology = 9590, no further editing is performed.
3. If diagnosis year greater than 1987 and ICD-O-2 or ICD-O-3 histology = 9140, 9700, 9701, 9590-9980, no further editing is performed.

The intent of this edit is to force review of *in situ* cases for which laterality is coded 4 (bilateral) or 9 (unknown laterality) as to origin. In rare instances when the tumor is truly midline (9) or the rare combination is otherwise confirmed correct, enter a code 1 for Override Site/Lat/Morph.

Coding Instructions

- Leave blank if the program does not generate an error message for the edit Laterality, Primary site, Morph ICDO2 (SEER IF 42) and/or the edit Laterality, Primary site, Morph ICDO3 (SEER IF42).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of site, laterality and morphology verifies that the case had behavior code of “*in situ*” and laterality is not stated as “right: origin of primary;” “left: origin of primary;” or “only one side involved, right or left origin not specified”.

Codes

Code	Label
Blank	Not reviewed or reviewed and corrected
1	Reviewed and confirmed as reported

TNM Edition Number

Item #	Length	Allowable Values	Required Status	Date Revised
1060	1	00–09, 88, 99	1996+	01/04, 01/10, 01/18

Description

Identifies the edition of the *AJCC Cancer Staging System* used to stage the case.

Rationale

AJCC stage and component T, N, and M codes and rules have changed over time. This item enables the analysis of cases grouped by edition number.

Coding Instructions

- This item is auto-coded by the software provider.

Code	Label
00	Not staged (cases that have an AJCC staging scheme and staging was not done).
01	First Edition
02	Second Edition
03	Third Edition
04	Fourth Edition
05	Fifth Edition
06	Sixth Edition
07	Seventh Edition
08	Eighth Edition
09	Ninth Edition
88	Not applicable (cases that do not have an AJCC staging scheme)
99	Staged, but the edition is unknown

APPENDIX A: Current Site-Specific Surgery Codes for 2024+

Coding of Data Items Rx Hosp – Surg 2023 [671] and Rx Summ- Surg 2023 [1291]

Surgical Codes

The code ranges and corresponding descriptions for site-specific Surgical Procedure of Primary Site code are grouped according to the general nature of the procedure:

- Codes A/B100 through A/B190 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.
- Codes A/B200 through A/B800 are site-specific descriptions of resection procedures.
- Code A980 applies only to specific tumors that cannot be clearly defined in terms of primary/nonprimary site. Surgical Procedure of Primary Site should be coded A980 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for Unknown and Ill-Defined Primary Sites and Hematopoietic/Reticuloendothelial/Immunoproliferating/ Myeloproliferative Disease. (The item Surgical Procedure/Other Site is used to indicate whether surgery was performed for these tumors.)
- Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.
- These codes are for first course treatment only. CoC does not collect subsequent treatment.

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more invasive forms of resection. The numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

- For codes A/B000 through A/B790, the descriptions of the surgical procedures are hierarchical.
- Last-listed responses take precedence over earlier-listed responses (regardless of the code or numeric value).

Example: A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed after polypectomy alone, is coded A220.

- A200 Local tumor excision, NOS
- A260 Polypectomy
- A270 Excisional biopsy
- Combination of A200 or A260–A270 WITH
 - A220 Electrocautery

*Please refer to the data items, Rx Hosp - Surg 2023 [671] and Rx Summ- Surg 2023 [1291], for complete guidance.

Most site-specific surgery codes begin with a letter A. The primary sites listed below, start with a letter B indicating a significant change in coding and provides the diagnosis year the change was implemented.

- C44.0-C44.9 Skin (2023)
- C18.0-C18.9 Colon (2024)
- C25.0-C25.9 Pancreas (2024)
- C34.0-C34.9 Lung (2024)
- C50.0-C50.9 Breast (2024)
- C73.9 Thyroid (2024)

Oral Cavity

**Lip C00.0–C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0–C02.9,
Gum C03.0–C03.9, Floor of Mouth C04.0–C04.9, Palate C05.0–C05.9,
Other Parts of Mouth C06.0–C06.9**

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

No specimen sent to pathology from surgical events A100–A140.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Wide excision, NOS

Code A300 includes:

Hemiglossectomy

Partial glossectomy

A400 Radical excision of tumor, NOS

A410 Radical excision of tumor ONLY

A420 Combination of A410 WITH resection in continuity with mandible (marginal, segmental, hemi-, or total resection)

A430 Combination of A410 WITH resection in continuity with maxilla (partial, subtotal, or total resection)

Codes A400–A430 includes:

Total glossectomy

Radical glossectomy

Specimen sent to pathology from surgical events A200–A430.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 12/4/02, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Parotid and Other Unspecified Glands

Parotid Gland C07.9, Major Salivary Glands C08.0–C08.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

No specimen sent to pathology from surgical events A100–A140.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Less than total parotidectomy, NOS; less than total removal of major salivary gland, NOS

A310 Facial nerve spared

A320 Facial nerve sacrificed

A330 Superficial lobe ONLY

A340 Facial nerve spared

A350 Facial nerve sacrificed

A360 Deep lobe (Total)

A370 Facial nerve spared

A380 Facial nerve sacrificed

A400 Total parotidectomy, NOS; total removal of major salivary gland, NOS

A410 Facial nerve spared

A420 Facial nerve sacrificed

A500 Radical parotidectomy, NOS; radical removal of major salivary gland, NOS

A510 WITHOUT removal of temporal bone

A520 WITH removal of temporal bone

A530 WITH removal of overlying skin (requires graft or flap coverage)

A800 Parotidectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Pharynx

**Tonsil C09.0–C09.9, Oropharynx C10.0–C10.9, Nasopharynx C11.0–C11.9
Pyriiform Sinus C12.9, Hypopharynx C13.0–C13.9, Pharynx C14.0**

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Stripping

No specimen sent to pathology from surgical events A100–A150.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A280 Stripping

A300 Pharyngectomy, NOS

A310 Limited/partial pharyngectomy; tonsillectomy, bilateral tonsillectomy

A320 Total pharyngectomy

A400 Pharyngectomy WITH laryngectomy OR removal of contiguous bone tissue, NOS (does NOT include total mandibular resection)

A410 WITH Laryngectomy (laryngopharyngectomy)

A420 WITH bone

A430 WITH both A410 and A420

A500 Radical pharyngectomy (includes total mandibular resection), NOS

A510 WITHOUT laryngectomy

A520 WITH laryngectomy

Specimen sent to pathology from surgical events A200–A520.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Esophagus

C15.0–C15.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

No specimen sent to pathology from surgical events A100–A140.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Partial esophagectomy

A400 Total esophagectomy, NOS

A500 Esophagectomy, NOS WITH laryngectomy and/or gastrectomy, NOS

A510 WITH laryngectomy

A520 WITH gastrectomy, NOS

A530 Partial gastrectomy

A540 Total gastrectomy

A550 Combination of A510 WITH any of A520–A540

A800 Esophagectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Stomach

C16.0–C16.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

No specimen sent to pathology from surgical events A100–A140.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Gastrectomy, NOS (partial, subtotal, hemi-)

A310 Antrectomy, lower (distal-less than 40% of stomach)***

A320 Lower (distal) gastrectomy (partial, subtotal, hemi-)

A330 Upper (proximal) gastrectomy (partial, subtotal, hemi-)

Code A300 includes:

Partial gastrectomy, including a sleeve resection of the stomach

Billroth I: anastomosis to duodenum (duodenostomy)

Billroth II: anastomosis to jejunum (jejunostomy)

A400 Near-total or total gastrectomy, NOS

A410 Near-total gastrectomy

A420 Total gastrectomy

A total gastrectomy may follow a previous partial resection of the stomach.

A500 Gastrectomy, NOS WITH removal of a portion of esophagus

A510 Partial or subtotal gastrectomy

A520 Near total or total gastrectomy

Codes A500–A520 are used for gastrectomy resection when only portions of esophagus are included in procedure.

A600 Gastrectomy with a resection in continuity with the resection of other organs, NOS***

A610 Partial or subtotal gastrectomy, in continuity with the resection of other organs***

A620 Near total or total gastrectomy, in continuity with the resection of other organs***

A630 Radical gastrectomy, in continuity with the resection of other organs***

Codes A600–A630 are used for gastrectomy resections with organs other than esophagus.

Portions of esophagus may or may not be included in the resection.

A800 Gastrectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

*** Incidental splenectomy NOT included

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Colon

C18.0–C18.9

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

B000 None; no surgery of primary site

B100 Local tumor destruction, NOS, any form of local tumor destruction, includes electrocautery, and/or fulguration

Note: B100 includes electrocautery; fulguration (includes use of hot forceps for tumor destruction).

No specimen sent to pathology from surgical event B100

B200 Local tumor excision, NOS

B260 Polypectomy, NOS

B270 Excisional biopsy

B280 Polypectomy-endoscopic

Note: Code B280 includes a polypectomy during an initial colonoscopy for screening or symptoms without knowledge of whether the polyp is benign or malignant.

B281 Polypectomy-endoscopic mucosal resection or dissection

Note: Code B281 includes a more complicated polypectomy performed during a colonoscopy. Usually, the polyp is known to be a superficial malignancy.

B290 Polypectomy-open approach surgical excision, or laparoscopic

Any combination of B200 or B260-B290 **WITH**

B220 Electrocautery

Note: Code B220 should be used when electrocautery is used to destroy the tumor but there is still tumor sent to pathology.

B291 Wide Local Excision with Tumor

Note: Code B291 includes procedures focused on just removing the primary tumor and not removing a portion of colon or rectum. In these local procedures the adjacent colon, rectum and lymph nodes are not removed, just the tumor with a bit of margin. Procedures are typically reserved for removal of early tumors that are superficial and not known to be associated with lymph node involvement. Alternate names for B291 includes: Wide local excision, Wide excision, Local tumor resection, or Transanal resection

B300 Partial colectomy, removal of one or more segments with colon resection but less than half of colon is removed.

Note: Code B300 includes removal of one or more colon segments, but **less than** half of the colon.

- Segments include cecum, ascending, hepatic flexure, transverse colon, splenic flexure, sigmoid colon and/or the descending colon
 - Transverse colectomy includes transverse colon
 - Splenic flexure colectomy includes transverse colon and the splenic flexure
 - Sigmoidectomy includes removal of sigmoid colon and descending colon

B320 Plus resection of contiguous organ; example: small bowel, bladder

B330 Appendectomy for appendiceal primaries only, includes incidental findings

Note: When an appendix primary is found incidentally during resection for a colon primary, code the extent of the surgical resection for the colon primary. Assign B330 for the appendix primary site.

B400 Hemicolectomy (total right or left colon and a portion of the transverse colon)

B401 Subtotal colectomy (total right or left colon and entire/all of transverse colon)

Note: Code B400 includes removal of the total right or left colon with a portion of the transverse colon

- A total left hemicolectomy includes removal of the splenic flexure, descending colon, and the sigmoid colon
- A total right hemicolectomy includes removal of the cecum (with appendix, if present), ascending colon and the hepatic flexure

B410 Plus resection of contiguous organ; example: small bowel, bladder

Note: Assign code B400 for extended left/right hemicolectomy

B500 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)

Note: Code B500 includes removal of all segments of colon, NOT including the entire rectum

B510 Plus resection of contiguous organ; example: small bowel, bladder

B600 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)

Note: Code B600 includes removal of the entire colon, including the entire rectum

B610 Plus resection of contiguous organ; example: small bowel, bladder

B700 Colectomy or proctocolectomy with resection of contiguous organ(s), NOS,

Note: Use code B700 when there is not enough information to assign code B320, B410, B510, or B610. Code B700 includes any colectomy (partial, hemicolectomy, or total) WITH a resection of any other organs in continuity with the primary site (enbloc resection). Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.

B800 Colectomy, NOS

Specimen sent to pathology from surgical events B200–B800.

B900 Surgery, NOS

B990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23, 01/24)

Rectosigmoid

C19.9

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

No specimen sent to pathology from surgical events A100–A120.

A200 Local tumor excision, NOS

A260 Polypectomy, NOS

A270 Excisional biopsy

Any combination of A200 or A260-A270 WITH
A220 Electrocautery

A300 Segmental resection; partial proctosigmoidectomy, NOS

A310 Plus resection of contiguous organs; example: small bowel, bladder

Procedures coded A300 include, but are not limited to:

Anterior resection

Hartmann's operation

Low anterior resection (LAR)

Partial colectomy, NOS

Rectosigmoidectomy, NOS

Sigmoidectomy

A400 Pull through WITH sphincter preservation (colo-anal anastomosis)

A500 Total proctectomy

A510 Total colectomy

A550 Total colectomy WITH ileostomy, NOS

A560 Ileorectal reconstruction

A570 Total colectomy WITH other pouch; example: Koch pouch

A600 Total proctocolectomy, NOS

A650 Total proctocolectomy WITH ileostomy, NOS

A660 Total proctocolectomy WITH ileostomy and pouch

Removal of the colon from cecum to the rectosigmoid or a portion of the rectum.

A700 Colectomy or proctocolectomy resection in continuity with other organs; pelvic exenteration

A800 Colectomy, NOS; Proctectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Rectum

C20.9

Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

No specimen sent to pathology from surgical events A100-A120

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A220 Electrocautery

A280 Curette and fulguration

A300 Segmental resection; partial proctectomy, NOS

Procedures coded A300 include, but are not limited to:

Anterior resection

Hartmann's operation

Low anterior resection (LAR)

Transsacral rectosigmoidectomy

A400 Pull through WITH sphincter preservation (coloanal anastomosis)

A500 Total proctectomy

Procedure coded A500 includes, but is not limited to:

Abdominoperineal resection

A600 Total proctocolectomy, NOS

A700 Proctectomy or proctocolectomy with resection in continuity with other organs; pelvic exenteration

A800 Proctectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 05/10, 01/16, 02/21, 01/22, 01/23)

Anus

C21.0–C21.8

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A150 Thermal Ablation

No specimen sent to pathology from surgical events A100, A120 and A150.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A220 Electrocautery

A600 Abdominal perineal resection, NOS (APR)

A610 APR and sentinel node excision

A620 APR and unilateral inguinal lymph node dissection

A630 APR and bilateral inguinal lymph node dissection

The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).

Specimen sent to pathology from surgical events A200–A630.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Liver and Intrahepatic Bile Ducts

C22.0–C22.1

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Alcohol (Percutaneous Ethanol Injection-PEI)

A160 Heat-Radio-frequency ablation (RFA)

A170 Other (ultrasound, acetic acid)

No specimen sent to pathology from surgical events A100–A170.

A200 Wedge or segmental resection, NOS

A210 Wedge resection

A220 Segmental resection, NOS

A230 One

A240 Two

A250 Three

A260 Segmental resection AND local tumor destruction

A300 Lobectomy, NOS

A360 Right lobectomy

A370 Left lobectomy

A380 Lobectomy AND local tumor destruction

A500 Extended lobectomy, NOS (extended: resection of a single lobe plus a segment of another lobe)

A510 Right lobectomy

A520 Left lobectomy

A590 Extended lobectomy AND local tumor destruction

A600 Hepatectomy, NOS

A610 Total hepatectomy and transplant

A650 Excision of a bile duct (for an intra-hepatic bile duct primary only)

A660 Excision of an intrahepatic bile duct PLUS partial hepatectomy

A750 Extrahepatic bile duct and hepatectomy WITH transplant

Specimen sent to pathology from surgical events A200–A750.

A900 Surgery, NOS

A990 Unknown if surgery performed

Revised 01/10, 02/10, 01/11, 01/16, 02/21, 01/22, 01/23)

Pancreas

C25.0–C25.9

Codes

B000 None; no surgery of primary site

B250 Local excision of tumor, NOS, Example Enucleation

Note: Laser tumor destruction, thermal therapy, or ablation

B300 Partial pancreatectomy, NOS; example: Distal pancreatectomy or subtotal pancreatectomy

B350 Local or partial pancreatectomy and duodenectomy, NOS, Example: Pancreaticoduodenectomy (Whipple Procedure)

B351 WITHOUT distal/partial gastrectomy, pylorus preserving Whipple

B352 WITH partial gastrectomy, Classic Whipple

Note: Use code B350 when it is not specified where the stomach was cut

B400 Total pancreatectomy

B600 Total pancreatectomy and subtotal gastrectomy and/or duodenectomy, extended pancreatoduodenectomy

Note: B600 includes extended pancreatoduodenectomy.

B800 Pancreatectomy, NOS

B900 Surgery, NOS

B990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23, 01/24)

Larynx

C32.0–C32.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Stripping

No specimen sent to pathology from surgical events A100–A150.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A280 Stripping

A300 Partial excision of the primary site, NOS; subtotal/partial laryngectomy NOS; hemilaryngectomy NOS

A310 Vertical laryngectomy

A320 Anterior commissure laryngectomy

A330 Supraglottic laryngectomy

A400 Total or radical laryngectomy, NOS

A410 Total laryngectomy ONLY

A420 Radical laryngectomy ONLY

A500 Pharyngolaryngectomy

A800 Laryngectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Lung

C34.0–C34.9

Codes

B000 None; no surgery of primary site

B150 Local tumor destruction, NOS

B120 Laser ablation or cryosurgery

B130 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

No specimen sent to pathology from surgical events B120–B130 and B150.

B190 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded B190

B200 Excision or resection of less than one lobe, NOS

B210 Wedge resection

B220 Segmental resection, for example a lingulectomy

B230 Excision, NOS

B240 Laser excision

B250 Bronchial sleeve resection ONLY

B300 Resection of lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)

B320 Bronchial sleeve lobectomy/bilobectomy

B330 Lobectomy WITH mediastinal lymph node dissection

Note: A sleeve lobectomy/bilobectomy includes resection of the entire lobe(s) in addition to part of the bronchus. A sleeve lobectomy is distinct from a typical lobectomy or bilobectomy, in which the bronchus is not resected.

The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).

B450 Lobe or bilobectomy extended, NOS

B460 WITH chest wall

B470 WITH pericardium

B480 WITH diaphragm

B550 Pneumonectomy, NOS

B560 WITH mediastinal lymph node dissection (radical pneumonectomy)

The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).

B650 Extended pneumonectomy, NOS

B660 Extended pneumonectomy plus pleura or diaphragm.

Note: An extended pneumonectomy is the resection of the entire lung in addition to one or more of the following structures: superior vena cava, carina, left atrium, aorta, or chest wall.

B800 Resection of lung, NOS

Specimen sent to pathology from surgical events B200–B800.

B900 Surgery, NOS

B990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23, 01/24)

Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease

C42.0, C42.1, C42.3, C42.4 (with any histology)

Code

A980 All hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment.

Surgical procedures for hematopoietic/reticuloendothelial/immunoproliferative/ myeloproliferative primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

(Revised 01/04, 01/10, 02/10, 01/16, 01/22, 01/23)

Bones, Joints, and Articular Cartilage

C40.0–C41.9

Peripheral Nerves and Autonomic Nervous System

C47.0–C47.9

Connective, Subcutaneous, and Other Soft Tissues

C49.0–C49.9

Codes

A000 None; no surgery of primary site

A190 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded A190 (principally for cases diagnosed prior to January 1, 2003).

A150 Local tumor destruction

No specimen sent to pathology from surgical event A150.

A250 Local excision

A260 Partial resection

A300 Radical excision or resection of lesion WITH limb salvage

A400 Amputation of limb

A410 Partial amputation of limb

A420 Total amputation of limb

A500 Major amputation, NOS

A510 Forequarter, including scapula

A520 Hindquarter, including ilium/hip bone

A530 Hemipelvectomy, NOS

A540 Internal hemipelvectomy

Specimen sent to pathology from surgical events A250–A540.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 8/17/02, 01/10, 02/10, 01/16, 02/21, 01/22,01/23)

Spleen

C42.2

Codes

A000 None; no surgery of primary site

A190 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded A190 (principally for cases diagnosed prior to January 1, 2003).

A210 Partial splenectomy

A220 Total splenectomy

A800 Splenectomy, NOS

Specimen sent to pathology for surgical events A210-A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22,01/23)

Skin

C44.0–C44.9

The priority order for sources used to assign surgery codes is:

Operative report, statement from a physician, description of the surgical procedure on a pathology report, results of the pathology report. Code based on the description of the procedure.

Do not code based on margin status documented in the pathology report.

Codes

B000 None; no surgery of primary site

B100 Local tumor destruction, NOS

B110 Photodynamic therapy (PDT)

B120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

B130 Cryosurgery

B140 Laser

B200 Local tumor excision, NOS; Excisional biopsy, NOS

B220-Shave Biopsy, NOS

B230-Punch Biopsy, NOS

B240-Elliptical Biopsy (aka fusiform)

Note: Elliptical/fusiform excisions are eye shape excisions around the circle outlining the amount of normal skin to take during the excision and are performed to allow for a better-looking scar.

B300 Mohs Surgery NOS

B310 Mohs surgery performed on the same day (all Mohs procedures performed during the same day).

B320 Mohs surgery performed on different days (slow Mohs)(each Mohs procedure performed on different day)

B500 Biopsy (NOS) of primary tumor followed wide excision of the lesion; Wide Excision NOS, Re-excision

B510-Incisional Biopsy followed by wide excision

B520-Shave Biopsy followed by wide excision

B530-Punch Biopsy followed by wide excision

B540-Elliptical Biopsy (aka fusiform) followed by wide excision

Note: An incisional biopsy would be a needle or core biopsy of the primary tumor. An incisional biopsy would be coded as a Diagnostic Staging Procedure (NAACCR Item 1350).

B600 Major Amputation

B900 Surgery, NOS

B990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/15, 01/16, 02/21, 01/22, 01/23)

Breast

C50.0–C50.9

Coding Instructions

- Code the surgical resection code for breast primaries performed with diagnosis date $\geq$ 1/1/2024.
- Do not record reconstruction in this data items. See Rx Hosp-Recon Breast [item #751] and/or Rx Summ-Recon breast [item #1335].
- If the contralateral breast reveals a second primary, each breast is abstracted separately.

Codes

B000 None; no surgery of primary site

B200 Partial mastectomy; less than total mastectomy; lumpectomy, segmental mastectomy, quadrantectomy, tylectomy, with or without nipple resection.

Note: Use code B200 when there is a previous positive biopsy (either core or FNA).

B210 Excisional breast biopsy - Diagnostic excision, no pre-operative biopsy proven diagnosis of cancer
Note: Use code B210 when a surgeon removes the (positive) mass and there was no biopsy (either core or FNA) done prior to the mass being removed. An excisional biopsy can occur when the nodule was previously not expected to be cancer.

B215 Excisional breast biopsy, for atypia
Note: Use code B215 when patient has biopsy that shows atypical ductal hyperplasia, an excision is then performed, and pathology shows in situ or invasive cancer. The excisional breast biopsy for ADH diagnosed the cancer, not the core biopsy.
An excisional breast biopsy removes the entire tumor and/or leaves only microscopic margins. This surgical code was added for situations when atypia tissue is excised and found to be reportable. Approx. 10-15% of excised atypia are cancer and reportable.

B240 Re-excision of margins from primary tumor site for gross or microscopic residual disease when less than total mastectomy performed

B290 Central lumpectomy, only performed for a prior diagnosis of cancer, which includes removal of the nipple areolar complex
Note: Use code B290 when the nipple areolar complex needs to be removed for patients with Paget disease or cancer directly involving the nipple areolar complex.
A central lumpectomy removes the nipple areolar complex, whereas a lumpectomy does not. Central lumpectomy and central portion lumpectomy, central portion excision, central partial mastectomy are interchangeable terms.

B300 Skin-sparing mastectomy

B310 WITHOUT removal of uninvolved contralateral breast

B320 WITH removal of uninvolved contralateral breast

Note: A skin-sparing mastectomy removes all breast tissue and the nipple areolar complex and preserves native breast skin. It is performed with and without sentinel node biopsy or ALND.

B400 Nipple-sparing mastectomy

B410 WITHOUT removal of uninvolved contralateral breast

B420 WITH removal of uninvolved contralateral breast

Note: A nipple-sparing mastectomy removal all breast tissue but preserves the nipple areolar complex and breast skin. It is performed with and without sentinel node biopsy or ALND.

B500 Areolar-Sparing Mastectomy**B510** WITHOUT removal of uninvolved contralateral breast**B520** WITH removal of uninvolved contralateral breast**Note:** An areolar-sparing mastectomy removes all breast tissue and the nipple but preserves the areola and breast skin. It is performed with and without sentinel node biopsy or ALND.**B600 Total (simple mastectomy)****B610** WITHOUT removal of uninvolved contralateral breast**B620** WITH removal of uninvolved contralateral breast**Note:** A total (simple) mastectomy removes all breast tissue, the nipple areolar complex and breast skin. It is performed with and without sentinel node biopsy or ALND.

Use code B600, B610, B620 if patient had a modified radical mastectomy.

B700 Radical mastectomy, NOS**B710** WITHOUT removal of uninvolved contralateral breast**B720** WITH removal of uninvolved contralateral breast**B760** Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma**Note:** A radical mastectomy removes all breast tissue, the nipple areolar complex, breast skin, and pectoralis muscle. It is performed with level I-III ALND.**B800 Mastectomy, NOS (including extended radical mastectomy)****B900 Surgery, NOS****B990 Unknown if surgery was performed**

(Revised 01/04, 01/10, 02/10, 05/10, 01/11, 01/13, 01/16, 02/21, 01/22, 01/23, 1/24, 1/25)

Cervix Uteri

C53.0–C53.9

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Loop Electrocautery Excision Procedure (LEEP)

A160 Laser ablation

A170 Thermal ablation

No specimen sent to pathology from surgical events A100–A170.

A200 Local tumor excision, NOS

A260 Excisional biopsy, NOS

A270 Cone biopsy

A240 Cone biopsy WITH gross excision of lesion

A290 Trachelectomy; removal of cervical stump; cervicectomy

Any combination of A200, A240, A260, A270 or A290 WITH

A210 Electrocautery

A220 Cryosurgery

A230 Laser ablation or excision

A250 Dilatation and curettage; endocervical curettage (for in situ only)

A280 Loop electrocautery excision procedure (LEEP)

A300 Total hysterectomy (simple, pan-) WITHOUT removal of tubes and ovaries

Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.

A400 Total hysterectomy (simple, pan-) WITH removal of tubes and/or ovary

Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.

A500 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

A510 Modified radical hysterectomy

A520 Extended hysterectomy

A530 Radical hysterectomy; Wertheim procedure

A540 Extended radical hysterectomy

A600 Hysterectomy, NOS, WITH or WITHOUT removal of tubes and ovaries

A610 WITHOUT removal of tubes and ovaries

A620 WITH removal of tubes and ovaries

A700 Pelvic exenteration

A710 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

A720 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

A730 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

A740 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events A200–A740.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Corpus Uteri

C54.0–C55.9

For invasive cancers, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

Codes

A000 None; no surgery of primary site

A190 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded A190 (principally for cases diagnosed prior to January 1, 2003).

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Loop Electrocautery Excision Procedure (LEEP)

A160 Thermal ablation

No specimen sent to pathology from surgical events A100–A160.

A200 Local tumor excision, NOS; simple excision, NOS

A240 Excisional biopsy

A250 Polypectomy

A260 Myomectomy

Any combination of A200 or A240–A260 WITH

A210 Electrocautery

A220 Cryosurgery

A230 Laser ablation or excision

A300 Subtotal hysterectomy/supracervical hysterectomy/fundectomy WITH or WITHOUT removal of tube(s) and ovary(ies).

A310 WITHOUT tube(s) and ovary(ies)

A320 WITH tube(s) and ovary(ies)

A400 Total hysterectomy (simple, pan-) WITHOUT removal of tube(s) and ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

A500 Total hysterectomy (simple, pan-) WITH removal of tube(s) and/or ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

A600 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

A610 Modified radical hysterectomy

A620 Extended hysterectomy

A630 Radical hysterectomy; Wertheim procedure

A640 Extended radical hysterectomy

A650 Hysterectomy, NOS, WITH or WITHOUT removal of tube(s) and ovary(ies)

A660 WITHOUT removal of tube(s) and ovary(ies)

A670 WITH removal of tube(s) and ovary(ies)

A750 Pelvic exenteration

A760 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

A770 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

A780 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

A790 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events A200–A790.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Ovary

C56.9

Codes

A000 None; no surgery of primary site

A170 Local tumor destruction, NOS

No specimen sent to pathology from surgical event A170.

A250 Total removal of tumor or (single) ovary, NOS

A260 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done

A270 WITHOUT hysterectomy

A280 WITH hysterectomy

A350 Unilateral (salpingo-)oophorectomy; unknown if hysterectomy done

A360 WITHOUT hysterectomy

A370 WITH hysterectomy

A500 Bilateral (salpingo-)oophorectomy; unknown if hysterectomy done

A510 WITHOUT hysterectomy

A520 WITH hysterectomy

A550 Unilateral or bilateral (salpingo-)oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done

A560 WITHOUT hysterectomy

A570 WITH hysterectomy

A600 Debulking; cytoreductive surgery, NOS

A610 WITH colon (including appendix) and/or small intestine resection (not incidental)

A620 WITH partial resection of urinary tract (not incidental)

A630 Combination of A610 and A620

Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.

A700 Pelvic exenteration, NOS

A710 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

A720 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

A730 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

A740 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

A800 (Salpingo-)oophorectomy, NOS

Specimen sent to pathology from surgical events A250–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Prostate

C61.9

Do not code an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).

Codes

A000 None; no surgery of primary site

A180 Local tumor destruction or excision, NOS

A190 Transurethral resection (TURP), NOS, and no specimen sent to pathology or unknown if sent

Unknown whether a specimen was sent to pathology for surgical events coded A180 or A190 (principally for cases diagnosed prior to January 1, 2003).

A100 Local tumor destruction, NOS

A140 Cryoprostectomy

A150 Laser ablation

A160 Hyperthermia

A170 Other method of local tumor destruction

No specimen sent to pathology from surgical events A100–A170.

A200 Local tumor excision, NOS

A210 Transurethral resection (TURP), NOS, with specimen sent to pathology

A220 TURP–cancer is incidental finding during surgery for benign disease

Assign code A220 for a tumor destruction procedure or other minimally invasive procedure when cancer is an incidental finding during surgery/procedure for benign disease (such as ablation [aqua, cold, heat, laser] HoLEP, TURP)

A230 TURP–patient has suspected/known cancer

Any combination of A200, A210 and A230 WITH (excludes incidental findings)

A240 Cryosurgery

A250 Laser

A260 Hyperthermia

A300 Subtotal, segmental, or simple prostatectomy, which may leave all or part of the capsule intact

A500 Radical prostatectomy, NOS; total prostatectomy, NOS

Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.

A700 Prostatectomy WITH resection in continuity with other organs; pelvic exenteration

Surgeries coded A700 are any prostatectomy WITH resection in continuity with any other organs. The other organs may be partially or totally removed. Procedures may include, but are not limited to, cystoprostatectomy, radical cystectomy, and prostatectomy.

A800 Prostatectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 12/4/02, 01/10, 02/10, 1/11, 01/16, 02/21, 01/22, 01/23, 1/25)

Testis

C62.0–C62.9

Codes

A000 None; no surgery of primary site

A120 Local tumor destruction, NOS

No specimen sent to pathology from surgical event A120.

A200 Local or partial excision of testicle

A300 Excision of testicle WITHOUT cord

A400 Excision of testicle WITH cord or cord not mentioned (radical orchiectomy)

A800 Orchiectomy, NOS (unspecified whether partial or total testicle removed)

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Kidney, Renal Pelvis, and Ureter

Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Thermal ablation

No specimen sent to pathology from this surgical event A100–A150.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial ureterectomy (ureter)

Procedures coded A300 include, but are not limited to:

Segmental resection

Wedge resection

A400 Complete/total/simple nephrectomy—for kidney parenchyma

Nephroureterectomy

Includes bladder cuff for renal pelvis or ureter.

A500 Radical nephrectomy

May include removal of a portion of vena cava, adrenal gland(s), Gerota's fascia, perinephric fat, or partial/total ureter.

A700 Any nephrectomy (simple, subtotal, complete, partial, simple, total, radical) in continuity with the resection of other organ(s) (colon, bladder)

The other organs, such as colon or bladder, may be partially or totally removed.

A800 Nephrectomy, NOS

Ureterectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Bladder

C67.0–C67.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

A150 Intravesical therapy

A160 Bacillus Calmette-Guerin (BCG) or other immunotherapy

Also code the introduction of immunotherapy in the immunotherapy items. If immunotherapy is followed by surgery of the type coded A200-A800 code that surgery instead and code the immunotherapy only as immunotherapy.

No specimen sent to pathology from surgical events A100–A160.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Combination of A200 or A260-A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Partial cystectomy

A500 Simple/total/complete cystectomy

A600 Complete cystectomy with reconstruction

A610 Radical cystectomy PLUS ileal conduit

A620 Radical cystectomy PLUS continent reservoir or pouch, NOS

A630 Radical cystectomy PLUS abdominal pouch (cutaneous)

A640 Radical cystectomy PLUS in situ pouch (orthotopic)

When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code A600-A640).

A700 Pelvic exenteration, NOS

A710 Radical cystectomy including anterior exenteration

For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code A600-A640).

A720 Posterior exenteration

For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.

A730 Total exenteration

Includes all tissue and organs removed for an anterior and posterior exenteration.

A740 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

A800 Cystectomy, NOS

Specimen sent to pathology from surgical events A200–A800.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/12, 01/16, 02/21, 01/22, 01/23)

Brain

**Meninges C70.0–C70.9, Brain C71.0–C71.9,
Spinal Cord, Cranial Nerves and Other Parts of Central Nervous System C72.0–C72.9**

Do not code laminectomies for spinal cord primaries.

Codes

A000 None; no surgery of primary site

A100 Tumor destruction, NOS

No specimen sent to pathology from surgical event A100.

Do not record stereotactic radiosurgery (SRS), Gamma knife, Cyber knife, or Linac radiosurgery as surgical tumor destruction. All of these modalities are recorded in the radiation treatment fields.

A200 Local excision of tumor, lesion or mass; excisional biopsy

A210 Subtotal resection of tumor, lesion or mass in brain

A220 Resection of tumor of spinal cord or nerve

A300 Radical, total, gross resection of tumor, lesion or mass in brain

A400 Partial resection of lobe of brain, when the surgery cannot be coded as A200-A300.

A550 Gross total resection of lobe of brain (lobectomy)

Codes A300-A550 are not applicable for spinal cord or spinal nerve primary sites.

Specimen sent to pathology from surgical events A200–A550.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Thyroid Gland

C73.9

Please note the order of the Codes B200-B253 have changed from STORE 2023

Codes

B000 None; no surgery of primary site

B130 Local tumor destruction, NOS

No specimen sent to pathology from surgical event B130

B200 Removal of less than a lobe, NOS

B210 Local surgical excision

B220 Removal of a partial lobe ONLY

B250 Lobectomy and/or isthmectomy, NOS

B251 Lobectomy ONLY (right or left)

B252 Isthmectomy ONLY

B253 Lobectomy WITH isthmus

B300 Removal of a lobe and partial removal of the contralateral lobe

B400 Subtotal or near total thyroidectomy

B500 Total thyroidectomy

B800 Thyroidectomy, NOS

Specimen sent to pathology from surgical events B200–B800.

B900 Surgery, NOS

B990 Unknown if surgery performed

(Revised 01/10, 02/10, 01/15, 01/16, 02/21, 01/22, 01/23, 01/24)

Lymph Nodes

C77.0–C77.9

Codes

A000 None; no surgery of primary site

A190 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded to A190 (principally for cases diagnosed prior to January 1, 2003).

A150 Local tumor destruction, NOS

No specimen sent to pathology from surgical event A150.

A250 Local tumor excision, NOS

Less than a full chain, includes an excisional biopsy of a single lymph node.

A300 Lymph node dissection, NOS

A310 One chain

A320 Two or more chains

A400 Lymph node dissection, NOS PLUS splenectomy

A410 One chain

A420 Two or more chains

A500 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)

A510 One chain

A520 Two or more chains

A600 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) PLUS splenectomy
(Includes staging laparotomy for lymphoma.)

A610 One chain

A620 Two or more chains

Specimen sent to pathology for surgical events A250-A620.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 09/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

All Other Sites

C14.2–C14.8, C17.0–C17.9, C23.9, C24.0–C24.9, C26.0–C26.9, C30.0–C 30.1, C31.0–C31.9, C33.9, C37.9, C38.0–C38.8, C39.0–C39.9, C48.0–C48.8, C51.0–C51.9, C52.9, C57.0–C57.9, C58.9, C60.0–C60.9, C63.0–C63.9, C68.0–C68.9, C69.0–C69.9, C74.0–C74.9, C75.0–C75.9

Codes

A000 None; no surgery of primary site

A100 Local tumor destruction, NOS

A110 Photodynamic therapy (PDT)

A120 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

A130 Cryosurgery

A140 Laser

No specimen sent to pathology from surgical events A100–A140.

A200 Local tumor excision, NOS

A260 Polypectomy

A270 Excisional biopsy

Any combination of A200 or A260–A270 WITH

A210 Photodynamic therapy (PDT)

A220 Electrocautery

A230 Cryosurgery

A240 Laser ablation

A250 Laser excision

A300 Simple/partial surgical removal of primary site

A400 Total surgical removal of primary site; enucleation

A410 Total enucleation (for eye surgery only)

A500 Surgery stated to be “debulking”

A600 Radical surgery

Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.

Specimen sent to pathology from surgical events A200–A600.

A900 Surgery, NOS

A990 Unknown if surgery performed

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

Unknown and Ill-Defined Primary Sites

C76.0–C76.8, C80.9

Code

A980 All unknown and ill-defined disease sites, WITH or WITHOUT surgical treatment.

Surgical procedures for unknown and ill-defined primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22, 01/23)

APPENDIX B: ICD-O-3 Eligibility Reporting Table for diagnosis year 2026+

The table below represents the additional ICD-O-3 terms that CoC is required to collect for diagnosis year 2026+.

2026 ICD-O-3.2 Update (Alpha)

- Codes/terms listed alphabetically
- Only new terminology to existing ICD-O-3.2 codes are included in the 2026 ICD-O Implementation guidelines and documentation. Terms are those listed in WHO Blue Books
- Update based on 5th Ed Classification of Head and Neck Tumors and 5th Ed Hematolymphoid Tumors

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9896/3	Acute myeloid leukemia, FLT3-TKD	Y	Y	Y	Y	New related term
9871/3	Acute myeloid leukemia, inv(16)(p13;q22)	Y	Y	Y	Y	New related term
9805/3	Acute leukemia of ambiguous lineage with BCL11B rearrangement	Y	Y	Y	Y	New related term
9805/3	Acute leukemia of ambiguous lineage with other defined genetic abnormalities	Y	Y	Y	Y	New related term
9920/3	Acute myeloid leukemia post cytotoxic therapy	Y	Y	Y	Y	New related term
9895/3	Acute myeloid leukemia post myelodysplastic-myeloproliferative neoplasm	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with CBFA2T3::GLIS2 fusion	Y	Y	Y	Y	New related term
9871/3	Acute myeloid leukemia with CBFB rearrangement	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with DEK::NUP214 fusion	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with FUS::ERG fusion	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with KAT6A::CREBBP fusion	Y	Y	Y	Y	New related term
9897/3	Acute myeloid leukemia with KMT2A rearrangement	Y	Y	Y	Y	New related term
9897/3	Acute myeloid leukemia with t(9;11)(p22;q23) with KMT2A-MLL3 or other exact fusion	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with MNX1::ETV6 fusion	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with NPM1::MLF1 fusion	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with NUP98 rearrangement	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9861/3	Acute myeloid leukemia with other defined genetic alterations	Y	Y	Y	Y	New related term
9861/3	Acute myeloid leukemia with RUNX1T3 (CBFA2T3):: GLIS2	Y	Y	Y	Y	New related term
9897/3	Acute myeloid leukemia with t(9;11)(p21.3;q23.3 or other exact balanced translocation	Y	Y	Y	Y	New related term
9912/3	Acute myeloid leukemia with t(9;22)(q34;q11.2)	Y	Y	Y	Y	New related term
9680/3	AIDS-related diffuse large B-cell lymphoma	Y	Y	Y	Y	New related term
9330/3	Ameloblastic fibrodentinosa sarcoma	Y	Y	Y	Y	New related term
9330/3	Ameloblastic fibro-odontosarcoma	Y	Y	Y	Y	New related term
9714/3	ALK-positive anaplastic large cell lymphoma, common	Y	Y	Y	Y	New related term
9714/3	ALK positive anaplastic large cell lymphoma, Composite	Y	Y	Y	Y	New related term
9714/3	ALK positive anaplastic large cell lymphoma, Hodgkin like	Y	Y	Y	Y	New related term
9714/3	ALK positive anaplastic large cell lymphoma, lymphohistiocytic	Y	Y	Y	Y	New related term
9714/3	ALK positive anaplastic large cell lymphoma, small cell	Y	Y	Y	Y	New related term
9750/3	ALK-positive histiocytosis	Y	Y	Y	Y	New related term
9750/3	ALK-rearranged histiocytosis	Y	Y	Y	Y	New related term
9750/3	ALK-related histiocytosis	Y	Y	Y	Y	New related term
9330/3	Ameloblastic fibrodentinosa sarcoma	Y	Y	Y	Y	New related term
9330/3	Ameloblastic fibro-odontosarcoma	Y	Y	Y	Y	New related term
8500/2	Apocrine intraductal carcinoma	Y	Y	Y	Y	New related term for salivary gland
8500/3	Basal-like salivary duct carcinoma	Y	Y	Y	Y	New related term
9690/3	BCL2-R-negative CD23-positive follicle centre lymphoma	Y	Y	Y	Y	New related term
9812/3	B-(acute) lymphoblastic leukemia/lymphoma (B-ALL) with BCR::ABL1 fusion	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with DUX4 rearrangement	Y	Y	Y	Y	New related term
9814/3	B-lymphoblastic leukemia/lymphoma with ETV6:RUNX1 fusion	Y	Y	Y	Y	New related term
9817/3	B-lymphoblastic leukemia/lymphoma with IGH::IL3 fusion	Y	Y	Y	Y	New related term
9813/3	B-lymphoblastic leukemia/lymphoma with KMT2A rearrangement	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with MEF2D rearrangement	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with MYC rearrangement	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9811/3	B-lymphoblastic leukemia/lymphoma NUTM1 rearrangement	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with other defined genetic alterations	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with PAX5 alt	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with PAX5p.P80R	Y	Y	Y	Y	New related term
9818/3	B-lymphoblastic leukemia/lymphoma with TCF3::PBX1	Y	Y	Y	Y	New related term
9811/3	B-lymphoblastic leukemia/lymphoma with ZNF384 rearrangement	Y	Y	Y	Y	New related term
9816/3	B-ALL with high hypodiploidy	Y	Y	Y	Y	New related term
9816/3	B-ALL with low hypodiploidy	Y	Y	Y	Y	New related term
9816/3	B-ALL with near-haploidy	Y	Y	Y	Y	New related term
9687/3	Burkitt lymphoma, EBV-associated	Y	Y	Y	Y	New related term
9687/3	Burkitt lymphoma, EBV-negative	Y	Y	Y	Y	New related term
8051/3	Carcinoma cuniculatum	Y	Y	Y	Y	New related term
8420/3	Ceruminous adenoid cystic carcinoma	Y	Y	Y	Y	New related term
9983/3	Childhood myelodysplastic neoplasm with excess blasts	Y	Y	Y	Y	New related term
9966/3	Chronic myelomonocytic leukemia with eosinophilia associated with t(5;12)	Y	Y	Y	Y	New related term
9690/3	Classic Follicular Lymphoma (cFL)	Y	Y	Y	Y	New related term
9712/3	Classic intravascular (large) B-cell lymphoma (Classic IVLBCL)	Y	Y	Y	Y	New related term
9860/0	Clonal hematopoiesis (CH)	N	N	N	N	Non-reportable
9860/0	Clonal hematopoiesis, age related (ARCH)	N	N	N	N	Non-reportable
9860/0	Clonal hematopoiesis of indeterminate potential (CHIP)	N	N	N	N	Non-reportable
9760/1	Cold agglutin disease	N	N	N	N	Non-reportable
9827/3	Cutaneous adult T-cell leukemia/lymphoma	Y	Y	Y	Y	New related term
9673/3	Cyclin D1-negative MCL	Y	Y	Y	Y	New related term
9673/3	Cyclin D1-positive MCL	Y	Y	Y	Y	New related term
9680/3	DLBCL/HGBL-MYC/BCL2 with BCL6 rearrangement	Y	Y	Y	Y	New related term
	DLBCL/HGBL-MYC/BCL2 (with or without BCL6 rearrangement) with TdT expression					New related term
	DLBCL/HGBL-MYC/BCL2 without BCL6 rearrangement					New related term
8072/3	DRK::AFF2 squamous cell carcinoma	Y	Y	Y	Y	New related term for nasal cavity and paranasal sinuses
9719/3	EBV-positive extranodal NK/T-cell lymphoma	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9766/3	EBV-positive diffuse large B-cell lymphoma	Y	Y	Y	Y	New related term
9719/3	EBV-positive extranodal NK/T-cell lymphoma	Y	Y	Y	Y	New related term
9758/3	EBV-positive inflammatory follicular dendritic cell sarcoma	Y	Y	Y	Y	New related term
9702/3	EBV-positive nodal T- and NK-cell lymphoma	Y	Y	Y	Y	New related term
9717/3	Enteropathy-associated T-cell lymphoma, type 1	Y	Y	Y	Y	New related term
9717/3	Enteropathy-associated T-cell lymphoma, type 2	Y	Y	Y	Y	New related term
9759/3	Fibroblastic reticular cell sarcoma	Y	Y	Y	Y	New related term
9678/3	Fluid overload-associated large B-cell lymphoma	Y	Y	Y	Y	New related ter
9678/3	Fluid-overload effusion lymphoma KSHV/HHV8-negative effusion-based lymphoma	Y	Y	Y	Y	New related term
9698/3	Follicular large B-cell lymphoma	Y	Y	Y	Y	New related term
9705/3	Follicular helper T-cell lymphoma, angioimmunoblastic type	Y	Y	Y	Y	New related term
9690/3	Follicular lymphoma with uncommon features	Y	Y	Y	Y	New related term
9690/3	Follicular lymphoma with unusual cytological features (uFL)	Y	Y	Y	Y	New related term
9690/3	Follicular lymphoma with a predominantly diffuse growth pattern (dFL)	Y	Y	Y	Y	New related term
9769/1	Heavy chain AL amyloidosis	N	N	N	N	Non-reportable
9680/3	High grade B-cell lymphoma with MYC and BCL6 rearrangement	Y	Y	Y	Y	New related term
8085/0	HPV-associated oral epithelial dysplasia, low grade	N	N	N	N	Non-reportable
8085/2	HPV-associated oral epithelial dysplasia, high grade	Y	Y	Y	Y	Valid for the following sites only: C020-C023, C028, C029, C030, C031, C039, C040, C041, C048, C049, C050- C052, C058, C059, C060-C062, C068, C069
8085/3	HPV-associated squamous cell carcinoma	Y	Y	Y	Y	Code and term now valid for nasal cavity and paranasal sinuses
8086/3	HPV- independent squamous cell carcinoma	Y	Y	Y	Y	Code and term now valid for nasal cavity and paranasal sinuses
8483/3	HPV-related multiphenotypic sinonasal carcinoma	Y	Y	Y	Y	New related term for nasal cavity and paranasal cavity

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
8070/3	Hybrid verrucous carcinoma	Y	Y	Y	Y	New related term for hypopharyngeal, laryngeal, tracheal, parapharyngeal sites
9725/1	Hydroa vacciniforme lymphoproliferative disorder, classic	N	N	N	N	Non-reportable
9725/1	Hydroa vacciniforme lymphoproliferative disorder, systemic	N	N	N	N	Non-reportable
9700/3	Hypopigmented mycosis fungoides	Y	Y	Y	Y	New related term
9756/1	IgA MGUS	N	N	N	N	Non-reportable
9756/1	IgD MGUS	N	N	N	N	Non-reportable
9756/1	IgE MGUS	N	N	N	N	Non-reportable
9756/1	IgG MGUS	N	N	N	N	Non-reportable
9761/3	IgM LPL/Waldenstrom Macroglobulinemia type	Y	Y	Y	Y	New related term
9761/3	IgM-type lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia	Y	Y	Y	Y	New related term
9760/1	IgG4-related disease	N	N	N	N	Non-reportable
9680/3	Immunodeficiency-associated lymphoproliferative disorders	Y	Y	Y	Y	New related term
9769/1	Immunoglobulin-related amyloidosis (AL amyloidosis), NOS	N	N	N	N	Non-reportable
9757/3	Indeterminate dendritic cell histiocytosis	Y	Y	Y	Y	New related term
9702/1	Indolent clonal T-cell lymphoproliferative disorder of the gastrointestinal tract	N	N	N	N	Non-reportable
9702/1	Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract	N	N	N	N	Non-reportable
8500/2	Intercalated duct intraductal carcinoma	Y	Y	Y	Y	New related term for salivary gland
9712/3	Intravascular large B-cell lymphoma, classic	Y	Y	Y	Y	New related term
9712/3	Intravascular large B-cell lymphoma, cutaneous	Y	Y	Y	Y	New related term
9712/3	Intravascular large B-cell lymphoma, hemophagocytic	Y	Y	Y	Y	New related term
9673/1	In situ mantle cell neoplasm	N	N	N	N	Non-reportable
9946/3	JMML in children with CBL syndrome	Y	Y	Y	Y	New related term
9946/3	JMML in neurofibromatosis type 1 (NF1)	Y	Y	Y	Y	New related term
9946/3	JMML-like disorders in children with Noonan syndrome (NS)	Y	Y	Y	Y	New related term
9946/3	KRAS-mutated JMML	Y	Y	Y	Y	New related term
9738/3	KSHV/HHV8-positive diffuse large B-cell lymphoma	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9738/1	KSHV/HHV8-positive germinotropic lymphoproliferative disorder (GLPD)	N	N	N	N	Non-reportable
9756/3	Langerhans cell sarcoma, Primary	Y	Y	Y	Y	New related term
9756/3	Langerhans cell sarcoma, Secondary	Y	Y	Y	Y	New related term
9673/3	Leukemic non-nodal mantle cell lymphoma	Y	Y	Y	Y	New related term
9765/1	Light chain MGUS	N	N	N	N	Non-reportable
9769/1	Localized AL amyloidosis	N	N	N	N	Non-reportable
8070/0	Low-grade squamous intraepithelial lesion	N	N	N	N	Non-reportable. Replaces grade 2/II neoplasms
9702/1	Lymphomatoid gastropathy	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis type A	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis type B	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis type C	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis type D	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis type E	N	N	N	N	Non-reportable
9718/1	Lymphomatoid papulosis with DUSP22 locus rearrangement	N	N	N	N	Non-reportable
9756/3	Malignant histiocytosis of Langerhans phenotype	Y	Y	Y	Y	New related term
9727/1	Mature plasmacytoid dendritic cell proliferation	N	N	N	N	Non-reportable
9727/1	Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm	N	N	N	N	Non-reportable
9823/1	MBL, low count or clonal B-cell expansion (CLL/SLL) type	N	N	N	N	Non-reportable
8265/3	Micropapillary salivary duct carcinoma	Y	Y	Y	Y	New related term
8240/3	Middle ear neuroendocrine tumor	Y	Y	Y	Y	New related term
8500/2	Mixed intraductal carcinoma	Y	Y	Y	Y	New related term for salivary gland
9805/3	Mixed-phenotype acute leukemia B/T	Y	Y	Y	Y	New related term
9805/3	Mixed-phenotype acute leukemia B/T/Myeloid	Y	Y	Y	Y	New related term
9805/3	Mixed-phenotype acute leukemia, T/megakaryocytic	Y	Y	Y	Y	New related term
9806/3	Mixed-phenotype acute leukemia with <i>BCR::ABL1</i>	Y	Y	Y	Y	New related term
9807/3	Mixed-phenotype acute leukemia with <i>KMT2A</i> rearrangement	Y	Y	Y	Y	New related term
9805/3	Mixed-phenotype acute leukemia (MPAL) with <i>ZNF384</i> rearrangement	Y	Y	Y	Y	New related term
9765/1	Monoclonal gammopathy of renal significance	N	N	N	N	Non-reportable
8481/3	Mucin-rich salivary duct carcinoma	Y	Y	Y	Y	New related term
9982/3	MDS with low blasts and ring sideroblasts	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm, hypoplastic	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9945/3	Myelodysplastic chronic myelomonocytic leukemia	Y	Y	Y	Y	New related term
9945/3	Myeloproliferative chronic myelomonocytic leukemia	Y	Y	Y	Y	New related term
9983/3	Myelodysplastic neoplasm with increased blasts and fibrosis	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm with low blasts and multilineage dysplasia	Y	Y	Y	Y	New related term
9982/3	Myelodysplastic neoplasm with low blast count and SF3B1	Y	Y	Y	Y	New related term
9982/3	Myelodysplastic neoplasm with low blasts and SF3B1 mutation	Y	Y	Y	Y	New related term
9986/3	Myelodysplastic syndrome with low blasts and 5q deletion	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm with low blasts, NOS	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm with multi-hit TP53 inactivation	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm with multi-hit TP53 inactivation	Y	Y	Y	Y	New related term
9966/3	Myeloid neoplasms associated with PDGFRB rearrangement	Y	Y	Y	Y	New related term
9985/3	Myelodysplastic neoplasm with multi-hit TP53 inactivation	Y	Y	Y	Y	New related term
9920/3	Myeloid neoplasm post cytotoxic therapy	Y	Y	Y	Y	New related term
9920/3	Myelodysplastic/myeloproliferative neoplasm post cytotoxic therapy	Y	Y	Y	Y	New related term
9876/3	Myelodysplastic/myeloproliferative neoplasm with neutrophilia	Y	Y	Y	Y	New related term
9982/3	Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis	Y	Y	Y	Y	New related term
9968/3	Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion	Y	Y	Y	Y	New related term
9968/3	Myeloid/lymphoid neoplasm with FLT3 rearrangement	Y	Y	Y	Y	New related term
9968/3	Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion	Y	Y	Y	Y	New related term
9968/3	Myeloid/lymphoid neoplasm with other tyrosine kinase fusion genes	Y	Y	Y	Y	New related term
9966/3	Myeloid neoplasms associated with PDGFRB rearrangement	Y	Y	Y	Y	New related term
8070/3	Nasopharyngeal carcinoma	Y	Y	Y	Y	New related term for nasopharyngeal sites
9702/1	NK-cell enteropathy	N	N	N	N	Non-reportable
9719/3	NK-lymphoblastic Leukemia/lymphoma	Y	Y	Y	Y	New related term
9702/3	Nodal EBV+ cytotoxic T-cell lymphoma	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9702/3	Nodal peripheral T-cell lymphoma, EBV+ positive	Y	Y	Y	Y	New related term
9705/3	Nodal T follicular helper cell lymphoma, angioimmunoblastic type (nTFHL-AL)	Y	Y	Y	Y	New related term
9702/3	Nodal T follicular helper cell lymphoma, follicular type (nTFHL-F)	Y	Y	Y	Y	New related term
9702/3	Nodal T follicular helper cell lymphoma, NOS (nTFHL)	Y	Y	Y	Y	New related term
9719/3	Non-nasal (extranasal) lymphoma Nasal ENKTL	Y	Y	Y	Y	New related term
9761/3	Non-IgM-type lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia	Y	Y	Y	Y	New related term
9761/3	Non-IgM LPL/Waldenstrom Macroglobulinemia type	Y	Y	Y	Y	New related term
9946/3	NRAS-mutated JMML	Y	Y	Y	Y	New related term
9718/3	Ocular adnexal T-cell lymphoma	Y	Y	Y	Y	New related term
8500/2	Oncocytic intraductal carcinoma	Y	Y	Y	Y	New related term for salivary gland
8290/3	Oncocytic salivary duct carcinoma	Y	Y	Y	Y	New related term
9690/3	Pediatric follicular lymphoma					
9819/3	Philadelphia-like (Ph-like) B-ALL <i>BCR::ABL1</i> -like B-ALL/LBL	Y	Y	Y	Y	New related term
8525/3	Polymorphous adenocarcinoma, cribriform subtype/cribriform adenocarcinoma of salivary glands	Y	Y	Y	Y	New related term
8525/3	Polymorphous adenocarcinoma, conventional subtype	Y	Y	Y	Y	New related term
9709/3	Primary cutaneous peripheral T-cell lymphoma, unspecified	Y	Y	Y	Y	New related term
9699/3	Primary cutaneous marginal zone lymphoma (PCMZL)	Y	Y	Y	Y	New related term
9699/3	Primary cutaneous marginal zone lymphoma, heavy chain class-switched form (IgG+, IgA+, or IgE+)	Y	Y	Y	Y	New related term
9699/3	Primary cutaneous marginal zone lymphoma, non-class-switched form (IgM+)	Y	Y	Y	Y	New related term
9699/3	Primary cutaneous marginal zone lymphoproliferative disorder	Y	Y	Y	Y	New related term
9680/3	Primary large B-cell lymphoma of immune privileged sites	Y	Y	Y	Y	New related term
9680/3	Primary large B-cell lymphoma of the testis	Y	Y	Y	Y	New related term
9718/3	Primary mucosal CD30 positive large T-cell lymphoma	Y	Y	Y	Y	New related term

ICD-O Code	Term	Req SEER	Req NPCR	Req CoC	Req CCCR	Remarks
9718/1	Primary mucosal CD30+ T-cell lymphoproliferative disorder	N	N	N	N	Non-reportable
9702/3	Primary nodal EBV-positive T/NK-cell lymphoma	Y	Y	Y	Y	New related term
9184/3	Radiation-induced osteosarcoma	Y	Y	Y	Y	New related term
9946/3	PTPN11-mutated JMML	Y	Y	Y	Y	New related term
8140/3	Renal cell-like sinonasal adenocarcinoma	Y	Y	Y	Y	New related term for nasal cavity and paranasal cavity
8900/3	Rhabdosarcoma with TFCP2 rearrangement	Y	Y	Y	Y	New related term
8033/3	Sarcomatoid salivary duct carcinoma	Y	Y	Y	Y	New related term
8407/3	Sclerosing microcystic adenocarcinoma	Y	Y	Y	Y	New related term
9270/3	Sclerosing odontogenic carcinoma	Y	Y	Y	Y	New related term
9715/3	Seroma-associated anaplastic large cell lymphoma	Y	Y	Y	Y	New related term
8082/3	Sinonasal lymphoepithelial carcinoma	Y	Y	Y	Y	New related term
8044/3	SMARCB1-deficient sinonasal adenocarcinoma					New related term for nasal cavity and paranasal cavity
8044/3	SMARCB1-deficient sinonasal carcinoma	Y	Y	Y	Y	New related term for nasal cavity and paranasal cavity
8044/3	SMARCA4-deficient sinonasal carcinoma	Y	Y	Y	Y	New related term for nasal cavity and paranasal cavity
9591/3	Splenic B-cell lymphoma/leukemia with prominent nuclei	Y	Y	Y	Y	New related term
9860/0	VEXAS syndrome	N	N	N	N	Non-reportable

APPENDIX C: Country and State Codes

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
United States (state and armed forces codes)		
Alabama	USA	AL
Alaska	USA	AK
Arizona	USA	AZ
Arkansas	USA	AR
Armed Forces Americas	USA	AA
Armed Forces Canada, Europe, Middle East, Africa	USA	AE
Armed Forces Pacific	USA	AP
California	USA	CA
Colorado	USA	CO
Connecticut	USA	CT
Delaware	USA	DE
District of Columbia	USA	DC
Florida	USA	FL
Georgia	USA	GA
Hawaii	USA	HI
Idaho	USA	ID
Illinois	USA	IL
Indiana	USA	IN
Iowa	USA	IA
Kansas	USA	KS
Kentucky	USA	KY
Louisiana	USA	LA
Maine	USA	ME
Maryland	USA	MD
Massachusetts	USA	MA
Michigan	USA	MI
Minnesota	USA	MN
Mississippi	USA	MS
Missouri	USA	MO
Montana	USA	MT
Nebraska	USA	NE
Nevada	USA	NV
New Hampshire	USA	NH

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
New Jersey	USA	NJ
New Mexico	USA	NM
New York	USA	NY
North Carolina	USA	NC
North Dakota	USA	ND
Ohio	USA	OH
Oklahoma	USA	OK
Oregon	USA	OR
Pennsylvania	USA	PA
Rhode Island	USA	RI
South Carolina	USA	SC
South Dakota	USA	SD
Tennessee	USA	TN
Texas	USA	TX
Utah	USA	UT
Vermont	USA	VT
Virginia	USA	VA
Washington	USA	WA
West Virginia	USA	WV
Wisconsin	USA	WI
Wyoming	USA	WY
Canada (province and territory codes)		
Alberta	CAN	AB
British Columbia	CAN	BC
Manitoba	CAN	MB
New Brunswick	CAN	NB
Newfoundland and Labrador	CAN	NL
Northwest Territories	CAN	NT
Nova Scotia	CAN	NS
Nunavut	CAN	NU
Ontario	CAN	ON
Prince Edward Island	CAN	PE
Quebec	CAN	QC
Saskatchewan	CAN	SK
Yukon Territory	CAN	YT

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Afghanistan	AFG	XX
Africa, NOS	ZZF	YY
Alabama	USA	AL
Aland Islands	ALA	XX
Alaska	USA	AK
Albania	ALB	XX
Alberta	CAN	AB
Algeria	DZA	XX
American Samoa	ASM	AS
Andorra	AND	XX
Angola	AGO	XX
Anguilla	AIA	XX
Antarctica	ATA	XX
Antigua and Barbuda	ATG	XX
Argentina	ARG	XX
Arizona	USA	AZ
Arkansas	USA	AR
Armed Forces Americas	USA	AA
Armed Forces Canada, Europe, Middle East, Africa	USA	AE
Armed Forces Pacific	USA	AP
Armenia	ARM	XX
Aruba	ABW	XX
Asia, NOS	ZZA	YY
Australia	AUS	XX
Austria	AUT	XX
Azerbaijan	AZE	XX
Bahamas	BHS	XX
Bahrain	BHR	XX
Bangladesh	BGD	XX
Barbados	BRB	XX
Belarus	BLR	XX
Belgium	BEL	XX
Belize	BLZ	XX
Benin	BEN	XX
Bermuda	BMU	XX
Bhutan	BTN	XX
Bolivia	BOL	XX
Bonaire, Saint Eustatius and Saba	BES	XX
Bosnia and Herzegovina	BIH	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Botswana	BWA	XX
Bouvet Island	BVT	XX
Brazil	BRA	XX
British Columbia	CAN	BC
British Indian Ocean Territory	IOT	XX
British Virgin Islands	VGB	XX
Brunei	BRN	XX
Bulgaria	BGR	XX
Burkina Faso	BFA	XX
Burundi	BDI	XX
California	USA	CA
Cambodia	KHM	XX
Cameroon	CMR	XX
Canada	CAN	CD
Cape Verde	CPV	XX
Cayman Islands	CYM	XX
Central African Republic	CAF	XX
Central America, NOS	ZZC	YY
Chad	TCD	XX
Chile	CHL	XX
China	CHN	XX
Christmas Island	CXR	XX
Cocos (Keeling) Islands	CCK	XX
Colombia	COL	CO
Colorado	USA	XX
Comoros	COM	XX
Congo	COG	XX
Congo, Democratic Republic of	COD	XX
Connecticut	USA	CT
Cook Islands	COK	XX
Costa Rica	CRI	XX
Cote d'Ivoire	CIV	XX
Croatia	HRV	XX
Cuba	CUB	XX
Curacao	CUW	XX
Cyprus	CYP	XX
Czech Republic	CZE	XX
Czechoslovakia	CSK	YY

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Delaware	USA	DE
Denmark	DNK	XX
District of Columbia	USA	DC
Djibouti	DJI	XX
Dominica	DMA	XX
Dominican Republic	DOM	XX
Ecuador	ECU	XX
Egypt	EGY	XX
El Salvador	SLV	XX
England	ENG	XX
Equatorial Guinea	GNQ	XX
Eritrea	ERI	XX
Estonia	EST	XX
Ethiopia	ETH	XX
Europe, NOS	ZZE	YY
Falkland Islands	FLK	XX
Faroe Islands	FRO	XX
Fiji	FJI	XX
Finland	FIN	XX
Florida	USA	FL
France	FRA	XX
French Guiana	GUF	XX
French Polynesia	PYF	XX
French Southern Territories	ATF	XX
Gabon	GAB	XX
Gambia	GMB	XX
Georgia	USA	GA
Georgia	GEO	XX
Germany	DEU	XX
Ghana	GHA	XX
Gibraltar	GIB	XX
Greece	GRC	XX
Greenland	GRL	XX
Grenada	GRD	XX
Guadeloupe	GLP	XX
Guam	GUM	GU
Guatemala	GTM	XX
Guernsey	GGY	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Guinea	GIN	XX
Guinea Bissau	GNB	XX
Guyana	GUY	XX
Haiti	HTI	XX
Hawaii	USA	HI
Heard Island and McDonald Islands	HMD	XX
Honduras	HND	XX
Hong Kong	HKG	XX
Hungary	HUN	XX
Iceland	ISL	XX
Idaho	USA	ID
Illinois	USA	IL
India	IND	XX
Indiana	USA	IN
Indonesia	IDN	XX
Iowa	USA	IA
Iran	IRN	XX
Iraq	IRQ	XX
Ireland	IRL	XX
Isle of Man	IMN	XX
Israel	ISR	XX
Italy	ITA	XX
Jamaica	JAM	XX
Japan	JPN	XX
Jersey	JEY	XX
Jordan	JOR	XX
Kazakhstan	KAZ	XX
Kentucky	USA	KY
Kenya	KEN	XX
Kiribati	KIR	XX
Korea	KOR	XX
Kuwait	KWT	XX
Kyrgyzstan	KGZ	XX
Laos	LAO	XX
Latvia	LVA	XX
Lebanon	LBN	XX
Lesotho	LSO	XX
Liberia	LBR	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Libya	LBY	XX
Liechtenstein	LIE	XX
Lithuania	LTU	XX
Louisiana	US	LA
Luxembourg	LUX	XX
Macao	MAC	XX
Macedonia	MKD	XX
Madagascar	MDG	XX
Maine	USA	ME
Malawi	MWI	XX
Malaysia	MYS	XX
Maldives	MDV	XX
Mali	MLI	XX
Malta	MLT	XX
Manitoba	CAN	MB
Marshall Islands	MHL	MH
Martinique	MTQ	XX
Maryland	USA	MD
Massachusetts	USA	MA
Mauritania	MRT	XX
Mauritius	MUS	XX
Mayotte	MYT	XX
Mexico	MEX	XX
Michigan	USA	MI
Micronesia	FSM	FM
Minnesota	USA	MN
Mississippi	USA	MS
Missouri	USA	MO
Moldova	MDA	XX
Monaco	MCO	XX
Mongolia	MNG	XX
Montana	USA	MT
Montenegro	MNE	XX
Montserrat	MSR	XX
Morocco	MAR	XX
Mozambique	MOZ	XX
Myanmar	MMR	XX
Namibia	NAM	XX
Nauru	NRU	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Nepal	NPL	XX
Netherlands	NLD	XX
Nevada	USA	NV
New Brunswick	CAN	NB
New Caledonia	NCL	XX
New Hampshire	USA	NH
New Jersey	USA	NJ
New Mexico	USA	NM
New York	USA	NY
New Zealand	NZL	XX
Newfoundland and Labrador	CAN	NL
Nicaragua	NIC	XX
Niger	NER	XX
Nigeria	NGA	XX
Niue	NIU	XX
Non-US/Canada NOS	ZZX	YY
Norfolk Island	NFK	XX
North America, NOS	ZZN	YY
North Carolina	USA	NC
North Dakota	USA	ND
North Korea	PRK	XX
Northern Ireland	NIR	XX
Northern Mariana Islands	MNP	MP
Northwest Territories	CAN	NT
Norway	NOR	XX
Nova Scotia	CAN	NS
Nunavut	CAN	NU
Ohio	USA	OH
Oklahoma	USA	OK
Oman	OMN	XX
Ontario	CAN	ON
Oregon	USA	OR
Pacific, NOS	ZZP	YY
Pakistan	PAK	XX
Palau	PLW	PW
Palestine	PSE	XX
Panama	PAN	XX
Papua New Guinea	PNG	XX
Paraguay	PRY	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Pennsylvania	USA	PA
Peru	PER	XX
Philippines	PHL	XX
Pitcairn Islands	PCN	XX
Poland	POL	XX
Portugal	PRT	XX
Prince Edward Island	CAN	PE
Puerto Rico	PRI	PR
Qatar	QAT	XX
Quebec	CAN	QC
Republic of South Africa	ZAF	XX
Réunion	REU	XX
Rhode Island	USA	RI
Romania	ROU	XX
Russia	RUS	XX
Rwanda	RWA	XX
Saint-Martin (French part)	MAF	XX
Samoa	ASM	XX
San Marino	SMR	XX
Sao Tome & Principe	STP	XX
Saskatchewan	CAN	SK
Saudi Arabia	SAU	XX
Scotland	SCT	XX
Senegal	SEN	XX
Serbia	SRB	XX
Seychelles	SYC	XX
Sierra Leone	SLE	XX
Singapore	SGP	XX
Sint-Maarten	SXM	XX
Slovakia	SVK	XX
Slovenia	SVN	XX
Solomon Islands	SLB	XX
Somalia	SOM	XX
South America, NOS	ZZS	YY
South Carolina	USA	SC
South Dakota	USA	SD
South Georgia and the South Sandwich Islands	SGS	XX
South Korea	KOR	XX
South Sudan	SSD	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Spain	ESP	XX
Sri Lanka	LKA	XX
St Pierre and Miquelon	SPM	XX
St. Barthelemy	BLM	XX
St. Helena	SHN	XX
St. Kitts and Nevis	KNA	XX
St. Lucia	LCA	XX
St. Vincent and the Grenadines	VCT	XX
Sudan	SDN	XX
Suriname	SUR	XX
Svalbard and Jan Mayen	SJM	XX
Swaziland	SWZ	XX
Sweden	SWE	XX
Switzerland	CHE	XX
Syria	SYR	XX
Taiwan	TWN	XX
Tajikistan	TJK	XX
Tanzania	TZA	XX
Tennessee	USA	TN
Texas	USA	TX
Thailand	THA	XX
Timor-Leste	TLS	XX
Togo	TGO	XX
Tokelau Islands	TKL	XX
Tonga	TON	XX
Trinidad and Tobago	TTO	XX
Tunisia	TUN	XX
Turkey	TUR	XX
Turkmenistan	TKM	XX
Turks and Caicos	TCA	XX
Tuvalu	TUV	XX
U.S Minor Outlying Islands	UMI	UM
U.S. Virgin Islands	VIR	VI
Uganda	UGA	XX
Ukraine	UKR	XX
United Arab Emirates	ARE	XX
United Kingdom	GBR	XX
United States	USA	US
Unknown	ZZU	ZZ

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Uruguay	URY	XX
Utah	USA	UT
Uzbekistan	UZB	XX
Vanuatu	VUT	XX
Vatican City	VAT	XX
Venezuela	VEN	XX
Vermont	USA	VT
Vietnam	VNM	XX
Virginia	USA	VA
Wales	WLS	XX
Wallis and Fotuna	WLF	XX
Washington	USA	WA
West Virginia	USA	WV
Western Sahara	ESH	XX
Wisconsin	USA	WI
Wyoming	USA	WY
Yemen	YEM	XX
Yugoslavia	YUG	YY
Yukon Territory	CAN	YT
Zambia	ZMB	XX
Zimbabwe	ZWE	XX

General

Geographic Area	Country Code	State or Province Code
General: Codes to Use In the Absence of More Specific Information		
United States, NOS	USA	US
Canada, NOS	CAN	CD
Africa, NOS (Central, Equatorial)	ZZF	YY
Asia, NOS	ZZA	YY
Asian and Arab Countries	ZZA	YY
Atlantic/Caribbean Area	ZZN	YY
Baltic Republic(s), NOS (Baltic States, NOS)	ZZE	YY
Central America	ZZC	YY
Czechoslovakia	CSK	YY
East Asia	ZZA	YY
Europe, NOS (Central, Eastern, Northern, Southern, Western)	ZZE	YY
Latin America, NOS	ZZU	YY
Near East	ZZA	YY
North America, NOS	ZZN	YY
Other Atlantic/Caribbean Area (not on detailed list)	ZZN	YY
Other Mainland Europe (not on detailed list)	ZZE	YY
Other Mediterranean Isles (not on detailed list)	ZZE	YY
Other Pacific Area (not on first list)	ZZP	YY
Pacific Area, NOS	ZZP	YY
Pacific Islands, NOS	ZZP	YY
Romance-Language Countries	ZZE	YY
South America, NOS	ZZS	YY
South American Islands	ZZS	YY
United Kingdom, NOS	GBR	XX
Yugoslavia	YUG	YY
Not U.S., but no other information	ZZX	YY
Unknown, no mention in patient record	ZZU	ZZ

APPENDIX D: NEW HAMPSHIRE TOWN/COUNTY & ZIP CODES

The city, town, and village zip codes with county were taken from the website of the New Hampshire Hospital Association (<http://www.nhha.org/>) and reformatted by NHSCR to reflect the required county names and codes to be used by reporting registries.

[Coding instructions for *City/Town at Diagnosis*](#)

[Coding instructions for *Postal Code at Diagnosis*](#)

[Coding instructions for *County at Diagnosis*](#)

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Abbottville	03301	Merrimack	013
Acworth	03601	Sullivan	019
Albany	03812	Carroll	003
Albany	03818	Carroll	003
Albany	03860	Carroll	003
Albany	03897	Carroll	003
Alder Brook	03574	Grafton	009
Alexandria	03222	Grafton	009
Allen Mills	03237	Belknap	001
Allenstown	03234	Merrimack	013
Allenstown	03275	Merrimack	013
Alstead	03602	Cheshire	005
Alstead Center	03602	Cheshire	005
Alton	03809	Belknap	001
Alton Bay	03810	Belknap	001
Ames	03249	Belknap	001
Amherst	03031	Hillsborough	011
Ammonoosuc	03589	Coos	007
Amoskeag	03101	Hillsborough	011
Andover	03216	Merrimack	013
Antrim	03440	Hillsborough	011
Antrim Center	03440	Hillsborough	011
Apthorp	03561	Grafton	009
Arlington	03431	Cheshire	005
Ashland	03217	Grafton	009
Ashuelot	03441	Cheshire	005
Atkinson	03811	Rockingham	015
Atkinson And Gilmanton Academy	03579	Coos	007
Atkinson Depot	03865	Rockingham	015
Atlantic	03874	Rockingham	015
Atlantic Heights	03801	Rockingham	015
Auburn	03032	Rockingham	015
Austins Corner	03833	Rockingham	015
Baboosic Lake	03031	Hillsborough	011
Back River	03820	Strafford	017
Bagley	03278	Merrimack	013
Baileys Corner	03046	Merrimack	013
Bakersville	03101	Hillsborough	011
Bald Hill District	03101	Hillsborough	011
Balloch	03745	Sullivan	019
Ballou	03452	Cheshire	005
Bangor	03581	Coos	007
Banks Village	03071	Hillsborough	011
Barnstead	03218	Belknap	001
Barrett	03585	Grafton	009

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Barrington	03825	Strafford	017
Bartlett	03812	Carroll	003
Bass Beach	03862	Rockingham	015
Bass Beach	03870	Rockingham	015
Batchelders Corner	03844	Rockingham	015
Bath	03740	Grafton	009
Battle Street	03303	Merrimack	013
Bayside	03840	Rockingham	015
Bean Island	03034	Rockingham	015
Beans Grant	03581	Coos	007
Beans Purchase	03581	Coos	007
Bear Island	03253	Belknap	001
Beatties	03590	Coos	007
Bedford	03110	Hillsborough	011
Bedford Center	03110	Hillsborough	011
Beebe River	03219	Grafton	009
Beechwood Corners	03447	Cheshire	005
Belknap Point	03249	Belknap	001
Bellamy	03820	Strafford	017
Belmont	03220	Belknap	001
Belmont Junction	03276	Belknap	001
Bennett Corners	03886	Carroll	003
Bennington	03442	Hillsborough	011
Benton	03279	Grafton	009
Benton	03780	Grafton	009
Benton	03785	Grafton	009
Berlin	03570	Coos	007
Berlin Mills	03570	Coos	007
Berrys Corner	03884	Strafford	017
Bethlehem	03574	Grafton	009
Birch Hill	03855	Strafford	017
Birchdale	03301	Merrimack	013
Black Hill	03301	Merrimack	013
Blackmount Station	03765	Grafton	009
Blackwater	03820	Strafford	017
Blackwater District	03878	Strafford	017
Blair	03223	Grafton	009
Blodgett	03234	Merrimack	013
Blodgett Landing	03255	Merrimack	013
Blood	03060	Hillsborough	011
Bloody Corner	03878	Strafford	017
Bonds Corner	03444	Cheshire	005
Boscawen	03224	Merrimack	013
Boscawen	03303	Merrimack	013
Bow	03304	Merrimack	013

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Bow Center	03304	Merrimack	013
Bow Junction	03304	Merrimack	013
Bow Lake Village	03884	Strafford	017
Bow Mills	03304	Merrimack	013
Bow Street	03235	Merrimack	013
Bowkerville	03447	Cheshire	005
Bowman	03593	Coos	007
Boyce	03224	Merrimack	013
Boynton Park	03801	Rockingham	015
Bradford	03221	Merrimack	013
Bradford Center	03221	Merrimack	013
Break Of Day	03301	Merrimack	013
Breakfast Hill	03870	Rockingham	015
Breezy Point	03279	Grafton	009
Brentwood	03833	Rockingham	015
Brentwood Corners	03833	Rockingham	015
Bretton Woods	03575	Coos	007
Brick Yard	03878	Strafford	017
Bridgewater	03222	Grafton	009
Bridgewater	03264	Grafton	009
Brightwood	03255	Merrimack	013
Brimstone Hill	03801	Rockingham	015
Bristol	03222	Grafton	009
Broad Cove	03301	Merrimack	013
Brookdale	03809	Belknap	001
Brookfield	03872	Carroll	003
Brookfield Station	03872	Carroll	003
Brookhurst	03809	Belknap	001
Brookline	03033	Hillsborough	011
Bucks Corner	03266	Grafton	009
Burkehaven	03782	Sullivan	019
Burleyville Station	03872	Carroll	003
Cable Road	03870	Rockingham	015
Calef Hill Road	03235	Merrimack	013
Cambridge	03579	Coos	007
Cambridge	03588	Coos	007
Camp Crossing	03042	Rockingham	015
Campton	03223	Grafton	009
Campton Bog	03223	Grafton	009
Campton Hollow	03223	Grafton	009
Campton Lower Village	03223	Grafton	009
Campton Station	03223	Grafton	009
Campton Upper Village	03223	Grafton	009
Canaan	03741	Grafton	009
Canaan Center	03741	Grafton	009

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Candia	03034	Rockingham	015
Canobie Lake	03079	Rockingham	015
Canterbury	03224	Merrimack	013
Canterbury Center	03224	Merrimack	013
Cardigan Station	03240	Grafton	009
Carroll	03574	Coos	007
Carroll	03575	Coos	007
Carroll	03583	Coos	007
Carroll	03595	Coos	007
Carroll	03598	Coos	007
Cascade	03570	Coos	007
Cascade	03581	Coos	007
Cavender	03449	Hillsborough	011
Cemetery Hill	03235	Merrimack	013
Center Barnstead	03218	Belknap	001
Center Barnstead	03225	Belknap	001
Center Conway	03813	Carroll	003
Center Effingham	03882	Carroll	003
Center Harbor	03226	Belknap	001
Center Haverhill	03765	Grafton	009
Center Langdon	03602	Sullivan	019
Center Ossipee	03814	Carroll	003
Center Sandwich	03227	Carroll	003
Center Strafford	03815	Strafford	017
Center Tuftonboro	03816	Carroll	003
Central Park	03878	Strafford	017
Chandler Station	03773	Sullivan	019
Chandlers Purchase	03589	Coos	007
Charlestown	03603	Sullivan	019
Chase Village	03281	Hillsborough	011
Chases Corner	03301	Merrimack	013
Chateau Guay	03301	Merrimack	013
Chateau Guay	03304	Merrimack	013
Chatham	03813	Carroll	003
Chatham	03845	Carroll	003
Cheever	03266	Grafton	009
Cherry Mountain	03583	Coos	007
Chesham	03450	Cheshire	005
Cheshire	03446	Cheshire	005
Chester	03036	Rockingham	015
Chesterfield	03443	Cheshire	005
Chichester	03258	Merrimack	013

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Chichester	03263	Merrimack	013
Chichester Station	03234	Merrimack	013
Chickenboro	03223	Grafton	009
Chicks Corner	03223	Carroll	003
Chocorua	03817	Carroll	003
Chocorua Inn	03886	Carroll	003
Christian Hollow	03608	Cheshire	005
Christian Shore	03801	Rockingham	015
Churchill	03801	Rockingham	015
Cilleyville	03216	Merrimack	013
Clam Shell Road	03878	Strafford	017
Claremont	03743	Sullivan	019
Claremont Center	03743	Sullivan	019
Claremont Junction	03743	Sullivan	019
Clarksville	03592	Coos	007
Clinton Grove	03281	Hillsborough	011
Clinton Village	03440	Hillsborough	011
Cocheco	03820	Strafford	017
Colby	03242	Merrimack	013
Cold River	03608	Cheshire	005
Cold River District	03602	Sullivan	019
Colebrook	03576	Coos	007
Columbia	03576	Coos	007
Columbia	03590	Coos	007
Columbia Bridge	03576	Coos	007
Concord	03301	Merrimack	013
Concord	03302	Merrimack	013
Concord	03303	Merrimack	013
Concord	03304	Merrimack	013
Concord	03305	Merrimack	013
Concord	03306	Merrimack	013
Concord Point	03870	Rockingham	015
Condon Corner	03602	Sullivan	019
Contoocook	03229	Merrimack	013
Converse Station	03230	Merrimack	013
Converseville	03461	Cheshire	005
Conway	03818	Carroll	003
Coos Junction	03584	Coos	007
Copperville	03588	Coos	007
Cornish	03745	Sullivan	019
Cornish Flat	03746	Sullivan	019
Cotton Valley Station	03894	Carroll	003

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Courser Hill	03303	Merrimack	013
Cowbell Corners	03079	Rockingham	015
Crawford House	03598	Coos	007
Crawford Notch	99999	Coos	007
Crawfords Purchase	99999	Coos	007
Crawleys Falls	03833	Rockingham	015
Crockett Corner	03257	Merrimack	013
Crocketts Crossing	03820	Strafford	017
Crown Hill	03060	Hillsborough	011
Croydon	03773	Sullivan	019
Crystal	03582	Coos	007
Curtisville	03301	Merrimack	013
Cushings	03820	Strafford	017
Cushman	03598	Coos	007
Cutts Grant	03846	Coos	007
Dalton	03598	Coos	007
Danbury	03230	Merrimack	013
Danville	03819	Rockingham	015
Davisville	03278	Merrimack	013
Deerfield	03037	Rockingham	015
Deerfield Center	03037	Rockingham	015
Deering	03244	Hillsborough	011
Deering Center	03244	Hillsborough	011
Derry	03038	Rockingham	015
Derry Village	03038	Rockingham	015
Dimond	03278	Merrimack	013
Dixs Grant	99999	Coos	007
Dixville	03576	Coos	007
Dorchester	03266	Grafton	009
Dover	03820	Strafford	017
Dover	03821	Strafford	017
Dover	03822	Strafford	017
Dover	03869	Strafford	017
Dover Neck	03820	Strafford	017
Dover Point	03820	Strafford	017
Drewsville	03604	Cheshire	005
Dublin	03444	Cheshire	005
Dummer	03588	Coos	007
Dunbarton	03046	Merrimack	013
Dunbarton Center	03046	Merrimack	013
Dundee	03846	Carroll	003
Durham	03824	Strafford	017

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
East Acworth	03601	Sullivan	019
East Alstead	03602	Cheshire	005
East Alton	03809	Belknap	001
East Andover	03231	Merrimack	013
East Barrington	03825	Strafford	017
East Bear Island	03253	Belknap	001
East Candia	03040	Rockingham	015
East Canterbury	03224	Merrimack	013
East Concord	03301	Merrimack	013
East Conway	03813	Carroll	003
East Conway	03818	Carroll	003
East Deering	03244	Hillsborough	011
East Derry	03041	Rockingham	015
East Freedom	03836	Carroll	003
East Grafton	03240	Grafton	009
East Hampstead	03826	Rockingham	015
East Harrisville	03450	Cheshire	005
East Haverhill	03780	Grafton	009
East Hebron	03232	Grafton	009
East Hebron	03241	Grafton	009
East Holderness	03245	Grafton	009
East Jaffrey	03452	Cheshire	005
East Kensington	03827	Rockingham	015
East Kingston	03827	Rockingham	015
East Lempster	03605	Sullivan	019
East Madison	03849	Carroll	003
East Manchester	03104	Hillsborough	011
East Milford	03055	Hillsborough	011
East Orford	03777	Grafton	009
East Rindge	03461	Cheshire	005
East Rochester	03868	Strafford	017
East Springfield	03284	Sullivan	019
East Sullivan	03445	Cheshire	005
East Sutton	03278	Merrimack	013
East Swanzey	03446	Cheshire	005
East Tilton	03276	Belknap	001
East Unity	03643	Sullivan	019
East Unity	03773	Sullivan	019
East Wakefield	03830	Carroll	003
East Washington	03280	Sullivan	019
East Weare	03281	Hillsborough	011
East Westmoreland	03467	Cheshire	005

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
East Wolfeboro	03894	Carroll	003
Easton	03580	Grafton	009
Eaton	03832	Carroll	003
Eaton Center	03832	Carroll	003
Edgemont	03255	Merrimack	013
Effingham	03882	Carroll	003
Effingham Falls	03882	Carroll	003
Elkins	03233	Merrimack	013
Ellsworth	03223	Grafton	009
Ellsworth	03266	Grafton	009
Enfield	03748	Grafton	009
Enfield Center	03748	Grafton	009
Enfield Center	03749	Grafton	009
Epping	03042	Rockingham	015
Epsom	03234	Merrimack	013
Errol	03579	Coos	007
Erving's Grant	99999	Coos	007
Etna	03750	Grafton	009
Exeter	03833	Rockingham	015
Fabyan	03595	Coos	007
Farmington	03835	Strafford	017
Fernald	03894	Carroll	003
Ferncroft	03818	Carroll	003
Fitzwilliam	03447	Cheshire	005
Fitzwilliam Depot	03447	Cheshire	005
Fords Crossing	03230	Merrimack	013
Francestown	03043	Hillsborough	011
Francestown Village	03043	Hillsborough	011
Franconia	03580	Grafton	009
Franklin	03235	Merrimack	013
Freedom	03836	Carroll	003
Fremont	03044	Rockingham	015
Gardners Grove	03220	Belknap	001
Garrison Hill	03820	Strafford	017
Georges Mills	03751	Sullivan	019
Gilford	03249	Belknap	001
Gilmanton	03237	Belknap	001
Gilmanton Iron Works	03237	Belknap	001
Gilmanton Iron Works	03837	Belknap	001
Gilsum	03448	Cheshire	005
Glen	03838	Carroll	003
Glenclyff	03238	Grafton	009

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Glendale	03249	Belknap	001
Goffstown	03045	Hillsborough	011
Gonic	03839	Strafford	017
Goodrich Falls	03812	Carroll	003
Goodrich Falls	03838	Carroll	003
Gorham	03581	Coos	007
Goshen	03752	Sullivan	019
Grafton	03240	Grafton	009
Grafton Center	03240	Grafton	009
Granite	03864	Carroll	003
Grantham	03753	Sullivan	019
Grasmere	03045	Hillsborough	011
Greenfield	03047	Hillsborough	011
Greenland	03840	Rockingham	015
Greens Grant	99999	Coos	007
Greenville	03048	Hillsborough	011
Groton	03241	Grafton	009
Groveton	03582	Coos	007
Guild	03754	Sullivan	019
Hadleys Purchase	99999	Coos	007
Hales Location	03860	Carroll	003
Hampstead	03841	Rockingham	015
Hampton	03842	Rockingham	015
Hampton	03843	Rockingham	015
Hampton	03844	Rockingham	015
Hampton	03862	Rockingham	015
Hampton	03874	Rockingham	015
Hampton Beach	03842	Rockingham	015
Hampton Beach	03843	Rockingham	015
Hampton Falls	03844	Rockingham	015
Hancock	03449	Hillsborough	011
Hanover	03748	Grafton	009
Hanover	03750	Grafton	009
Hanover	03755	Grafton	009
Hanover	03756	Grafton	009
Hanover Center	03755	Grafton	009
Harrisville	03450	Cheshire	005
Harts Location	03812	Carroll	003
Hastings	03257	Merrimack	013
Haverhill	03765	Grafton	009
Hebron	03241	Grafton	009
Hedding	03042	Rockingham	015

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Hell Gate	03579	Coos	007
Hemlock Center	03743	Sullivan	019
Henniker	03242	Merrimack	013
Hill	03243	Merrimack	013
Hillsborough	03244	Hillsborough	011
Hillsborough Center	03244	Hillsborough	011
Hillsborough Lower Village	03244	Hillsborough	011
Hillsborough Upper Village	03244	Hillsborough	011
Hinsdale	03451	Cheshire	005
Holderness	03245	Grafton	009
Hollis	03049	Hillsborough	011
Hooksett	03106	Merrimack	013
Hopkinton	03229	Merrimack	013
Hopkinton	03242	Merrimack	013
Hudson	03051	Hillsborough	011
Hudson Center	03051	Hillsborough	011
Intervale	03812	Carroll	003
Intervale	03845	Carroll	003
Intervale-Bartlett	03812	Carroll	003
Jackson	03846	Carroll	003
Jaffrey	03452	Cheshire	005
Jefferson	03583	Coos	007
Kearsarge	03812	Carroll	003
Kearsarge	03847	Carroll	003
Keene	03431	Cheshire	005
Keene State College	03435	Cheshire	005
Kensington	03833	Rockingham	015
Kensington Center	03833	Rockingham	015
Kidderville	03576	Coos	007
Kilkenny	03848	Coos	007
Kingston	03827	Rockingham	015
Kingston	03848	Rockingham	015
Laconia	03246	Belknap	001
Laconia	03247	Belknap	001
Lakeport	03246	Belknap	001
Lancaster	03584	Coos	007
Landaff	03585	Grafton	009
Landaff	03785	Grafton	009
Langdon	03602	Sullivan	019
Langdon	03603	Sullivan	019
Langdon	03608	Sullivan	019
Lebanon	03766	Grafton	009

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Lee	03824	Strafford	017
Lee	03861	Strafford	017
Lee Center	03861	Strafford	017
Lee Mills	03254	Carroll	003
Lempster	03605	Sullivan	019
Lincoln	03251	Grafton	009
Lisbon	03585	Grafton	009
Litchfield	03052	Hillsborough	011
Littleton	03561	Grafton	009
Livermore	03251	Grafton	009
Lochmere	03252	Belknap	001
Lochmere	03276	Belknap	001
Locke Haven	03748	Grafton	009
Londonderry	03053	Rockingham	015
Long Island	03254	Carroll	003
Loudon	03307	Merrimack	013
Loudon Center	03307	Merrimack	013
Loudon Village	03307	Merrimack	013
Low And Burbanks Grant	99999	Coos	007
Lower Gilmanston	03237	Belknap	001
Lower Shaker Village	03748	Grafton	009
Lyman	03585	Grafton	009
Lyme	03768	Grafton	009
Lyme Center	03769	Grafton	009
Lyndeborough	03082	Hillsborough	011
Lyndeborough Center	03082	Hillsborough	011
Lynn	03601	Sullivan	019
Madbury	03823	Strafford	017
Madbury	03825	Strafford	017
Madison	03849	Carroll	003
Manchester	03101	Hillsborough	011
Manchester	03102	Hillsborough	011
Manchester	03103	Hillsborough	011
Manchester	03104	Hillsborough	011
Manchester	03105	Hillsborough	011
Manchester	03108	Hillsborough	011
Manchester	03109	Hillsborough	011
Manchester	03111	Hillsborough	011
Manchester	03431	Hillsborough	011
Mapleton	03590	Coos	007
Marlborough	03455	Cheshire	005
Marlow	03456	Cheshire	005

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Marlow Junction	03456	Cheshire	005
Martins Location	99999	Coos	007
Mascoma	03766	Grafton	009
Mason	03048	Hillsborough	011
Meadows	03587	Coos	007
Melvin Mills	03278	Merrimack	013
Melvin Village	03816	Carroll	003
Melvin Village	03850	Carroll	003
Meredith	03253	Belknap	001
Meredith Center	03253	Belknap	001
Meriden	03770	Sullivan	019
Merrimack	03054	Hillsborough	011
Middleton	03887	Strafford	017
Milan	03588	Coos	007
Milford	03055	Hillsborough	011
Millsfield	03579	Coos	007
Millsfield	03582	Coos	007
Millsfield	03588	Coos	007
Milton	03851	Strafford	017
Milton Mills	03852	Strafford	017
Mirror Lake	03853	Carroll	003
Monroe	03771	Grafton	009
Mont Vernon	03057	Hillsborough	011
Moultonborough	03254	Carroll	003
Moultonborough Falls	03254	Carroll	003
Moultonville	03864	Carroll	003
Mount Sunapee	03255	Merrimack	013
Mount Washington	03589	Coos	007
Mount Washington Summit	03589	Coos	007
Munsonville	03457	Cheshire	005
Nashua	03060	Hillsborough	011
Nashua	03061	Hillsborough	011
Nashua	03062	Hillsborough	011
Nashua	03063	Hillsborough	011
Nashua	03064	Hillsborough	011
Nelson	03457	Cheshire	005
New Boston	03070	Hillsborough	011
New Castle	03801	Rockingham	015
New Castle	03854	Rockingham	015
New Durham	03855	Strafford	017
New Durham Corner	03855	Strafford	017
New Hampton	03256	Belknap	001

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
New Hampton Village	03256	Belknap	001
New Ipswich	03071	Hillsborough	011
New London	03257	Merrimack	013
Newbury	03255	Merrimack	013
Newfields	03856	Rockingham	015
Newington	03801	Rockingham	015
Newmarket	03857	Rockingham	015
Newport	03773	Sullivan	019
Newton	03858	Rockingham	015
Newton Junction	03859	Rockingham	015
Noone	03468	Hillsborough	011
North Barnstead	03218	Belknap	001
North Barnstead	03225	Belknap	001
North Benton	03780	Grafton	009
North Benton	03785	Grafton	009
North Branch	03440	Hillsborough	011
North Brookline	03033	Hillsborough	011
North Charlestown	03603	Sullivan	019
North Chatham	03813	Carroll	003
North Chester	03036	Rockingham	015
North Chichester	03258	Merrimack	013
North Conway	03818	Carroll	003
North Conway	03860	Carroll	003
North Danville	03819	Rockingham	015
North Dorchester	03266	Grafton	009
North Epping	03042	Rockingham	015
North Grantham	03753	Sullivan	019
North Groton	03241	Grafton	009
North Hampton	03862	Rockingham	015
North Haverhil	03774	Grafton	009
North Hinsdale	03451	Cheshire	005
North Lee	03861	Strafford	017
North Londonderry	03053	Rockingham	015
North Newport	03773	Sullivan	019
North Nottingham	03291	Rockingham	015
North Pelham	03076	Hillsborough	011
North Pembroke	03275	Merrimack	013
North Rochester	03867	Strafford	017
North Salem	03073	Rockingham	015
North Sanbornton	03269	Belknap	001
North Sandwich	03259	Carroll	003
North Stratford	03590	Coos	007

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
North Stratford	03884	Strafford	017
North Sutton	03260	Merrimack	013
North Swanzey	03431	Cheshire	005
North Swanzey	03446	Cheshire	005
North Village	03458	Hillsborough	011
North Wakefield	03872	Carroll	003
North Walpole	03609	Cheshire	005
North Weare	03281	Hillsborough	011
North Wilmot	03287	Merrimack	013
North Wolfeboro	03894	Carroll	003
North Woodstock	03262	Grafton	009
Northfield	03276	Merrimack	013
Northumberland	03582	Coos	007
Northwood	03261	Rockingham	015
Northwood Center	03261	Rockingham	015
Northwood Narrows	03261	Rockingham	015
Northwood Ridge	03261	Rockingham	015
Nottingham	03290	Rockingham	015
Nottingham Square	03290	Rockingham	015
Nuttings Beach	03222	Grafton	009
Odell	03582	Coos	007
Odell	03590	Coos	007
Orange	03741	Grafton	009
Orford	03777	Grafton	009
Orfordville	03777	Grafton	009
Ossipee	03864	Carroll	003
Otterville	03257	Merrimack	013
Pages Corner	03046	Merrimack	013
Paris	03582	Coos	007
Paris	03588	Coos	007
Passaconaway	03818	Carroll	003
Pelham	03076	Hillsborough	011
Pelham Center	03076	Hillsborough	011
Pembroke	03275	Merrimack	013
Penacook	03224	Merrimack	013
Penacook	03303	Merrimack	013
Percy	03582	Coos	007
Peterborough	03458	Hillsborough	011
Peterborough	03468	Hillsborough	011
Pierce Bridge	03574	Grafton	009
Piermont	03779	Grafton	009
Piermont Village	03779	Grafton	009

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Pike	03780	Grafton	009
Pinardville	03045	Hillsborough	011
Pinardville	03102	Hillsborough	011
Pine River	03882	Carroll	003
Pinkhams Grant	03846	Coos	007
Pittsburg	03592	Coos	007
Pittsfield	03263	Merrimack	013
Plainfield	03781	Sullivan	019
Plaistow	03865	Rockingham	015
Plymouth	03264	Grafton	009
Ponemah	03031	Hillsborough	011
Portsmouth	03801	Rockingham	015
Portsmouth	03802	Rockingham	015
Portsmouth	03803	Rockingham	015
Portsmouth	03804	Rockingham	015
Puckershire	03743	Sullivan	019
Quaker City	03603	Sullivan	019
Quebec Junction	03598	Coos	007
Quincy	03266	Grafton	009
Randolph	03593	Coos	007
Raymond	03077	Rockingham	015
Redstone	03818	Carroll	003
Reeds Ferry	03054	Hillsborough	011
Richmond	03470	Cheshire	005
Rindge	03461	Cheshire	005
Riverhill	03303	Merrimack	013
Riverton	03583	Coos	007
Rochester	03866	Strafford	017
Rochester	03867	Strafford	017
Rochester	03839	Strafford	017
Rochester	03868	Strafford	017
Rollinsford	03820	Strafford	017
Rollinsford	03869	Strafford	017
Rollinsford	03878	Strafford	017
Rollinsford Junction	03869	Strafford	017
Roxbury	03431	Cheshire	005
Rumney	03266	Grafton	009
Rye	03870	Rockingham	015
Rye Beach	03871	Rockingham	015
Rye North Beach	03871	Rockingham	015
Salem	03079	Rockingham	015
Salisbury	03268	Merrimack	013

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Salmon Falls	03869	Strafford	017
Sanbornton	03269	Belknap	001
Sanbornville	03872	Carroll	003
Sandown	03873	Rockingham	015
Sandwich	03223	Carroll	003
Sandwich	03227	Carroll	003
Sandwich	03259	Carroll	003
Sandwich	03883	Carroll	003
Sandwich	03886	Carroll	003
Sandwich	03897	Carroll	003
Sargents Purchase	03589	Coos	007
Scotland	03470	Cheshire	005
Seabrook	03874	Rockingham	015
Second College Grant	03579	Coos	007
Severance	03032	Rockingham	015
Shaker Village	03224	Merrimack	013
Sharon	03458	Hillsborough	011
Shelburne	03581	Coos	007
Shoreyville	03867	Strafford	017
Short Falls	03234	Merrimack	013
Silver Lake	03875	Carroll	003
Smithtown	03874	Rockingham	015
Snowville	03849	Carroll	003
Somersworth	03878	Strafford	017
South Acworth	03607	Sullivan	019
South Albany	03818	Carroll	003
South Alexandria	03222	Grafton	009
South Barnstead	03218	Belknap	001
South Barnstead	03225	Belknap	001
South Barrington	03825	Strafford	017
South Bennington	03442	Hillsborough	011
South Charlestown	03603	Sullivan	019
South Chatham	03813	Carroll	003
South Conway	03813	Carroll	003
South Conway	03818	Carroll	003
South Cornish	03745	Sullivan	019
South Danbury	03230	Merrimack	013
South Danville	03881	Rockingham	015
South Deerfield	03037	Rockingham	015
South Effingham	03882	Carroll	003
South Hampton	03827	Rockingham	015
South Hampton	03827	Rockingham	015

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
South Hemlock	03603	Sullivan	019
South Hooksett	03106	Merrimack	013
South Keene	03431	Cheshire	005
South Kingston	03827	Rockingham	015
South Lancaster	03584	Coos	007
South Lee	03861	Strafford	017
South Lyndeborough	03082	Hillsborough	011
South Merrimack	03054	Hillsborough	011
South Milford	03055	Hillsborough	011
South Newbury	03272	Merrimack	013
South Pittsfield	03263	Merrimack	013
South Seabrook	03874	Rockingham	015
South Stoddard	03464	Cheshire	005
South Sutton	03273	Merrimack	013
South Tamworth	03883	Carroll	003
South Weare	03281	Hillsborough	011
South Wolfeboro	03894	Carroll	003
Spofford	03462	Cheshire	005
Spragueville	03446	Cheshire	005
Springfield	03284	Sullivan	019
Stark	03582	Coos	007
Stewartstown	03576	Coos	007
Stewartstown	03597	Coos	007
Stinson Lake	03274	Grafton	009
Stoddard	03464	Cheshire	005
Strafford	03884	Strafford	017
Stratford	03590	Coos	007
Stratham	03885	Rockingham	015
Success	03570	Coos	007
Success	03581	Coos	007
Success	03588	Coos	007
Sugar Hill	03301	Merrimack	013
Sugar Hill	03586	Grafton	009
Sullivan	03445	Cheshire	005
Sunapee	03782	Sullivan	019
Suncook	03275	Merrimack	013
Surry	03431	Cheshire	005
Surry Village	03431	Cheshire	005
Sutton	03221	Merrimack	013
Sutton	03255	Merrimack	013
Sutton	03257	Merrimack	013
Sutton	03260	Merrimack	013

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Sutton	03273	Merrimack	013
Sutton	03278	Merrimack	013
Sutton	03287	Merrimack	013
Swanzey	03446	Cheshire	005
Swanzey Center	03446	Cheshire	005
Tamworth	03886	Carroll	003
Tappan Corners	03827	Rockingham	015
Temple	03084	Hillsborough	011
Thompson And Meserves Purch	03589	Coos	007
Thornton	03223	Grafton	009
Thornton	03285	Grafton	009
Tilton	03276	Belknap	001
Trapshire	03603	Sullivan	019
Troy	03465	Cheshire	005
Tuftonboro	03816	Carroll	003
Turtle town	03301	Merrimack	013
Twin Mountain	03595	Coos	007
Union	03887	Carroll	003
Unity	03603	Sullivan	019
Unity	03743	Sullivan	019
Unity	03773	Sullivan	019
Upper Kitterville	03576	Coos	007
Upper Shaker Village	03748	Grafton	009
Wakefield	03830	Carroll	003
Wakefield	03872	Carroll	003
Wakefield	03887	Carroll	003
Walpole	03608	Cheshire	005
Warner	03278	Merrimack	013
Warren	03279	Grafton	009
Washington	03280	Sullivan	019
Water Village	03864	Carroll	003
Waterville Valley	03215	Grafton	009
Weare	03281	Hillsborough	011
Webster	03303	Merrimack	013
Weirs Beach	03246	Belknap	001
Wendell	03782	Sullivan	019
Wentworth	03282	Grafton	009
Wentworth Village	03282	Grafton	009
Wentworths Location	03579	Coos	007
West Alton	03810	Belknap	001
West Andover	03216	Merrimack	013
West Barrington	03825	Strafford	017

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
West Brentwood	03833	Rockingham	015
West Campton	03223	Grafton	009
West Canaan	03741	Grafton	009
West Chesterfield	03466	Cheshire	005
West Claremont	03743	Sullivan	019
West Concord	03301	Merrimack	013
West Concord	03303	Merrimack	013
West Deering	03244	Hillsborough	011
West Epping	03042	Rockingham	015
West Hampstead	03841	Rockingham	015
West Henniker	03242	Merrimack	013
West Hollis	03049	Hillsborough	011
West Hopkinton	03229	Merrimack	013
West Keene	03431	Cheshire	005
West Kingston	03848	Rockingham	015
West Lebanon	03784	Grafton	009
West Manchester	03102	Hillsborough	011
West Milan	03588	Coos	007
West Nottingham	03291	Rockingham	015
West Ossipee	03890	Carroll	003
West Peterborough	03468	Hillsborough	011
West Rindge	03461	Cheshire	005
West Rumney	03266	Grafton	009
West Rye	03870	Rockingham	015
West Salisbury	03268	Merrimack	013
West Stewartstown	03597	Coos	007
West Sutton	03221	Merrimack	013
West Sutton	03260	Merrimack	013
West Sutton	03273	Merrimack	013
West Swanzey	03469	Cheshire	005
West Thornton	03285	Grafton	009
West Wilton	03086	Hillsborough	011
West Windham	03087	Rockingham	015
Westmoreland	03467	Cheshire	005
Westport	03446	Cheshire	005
Westville	03865	Rockingham	015
Whitefield	03598	Coos	007
Whitefield Junction	03598	Coos	007
Whittier	03886	Carroll	003
Wilder	03071	Hillsborough	011
Wildwood	03585	Grafton	009
Wilmot	03287	Merrimack	013

CITY	POSTAL CODE	COUNTY NAME	COUNTY CODE
Wilmot Flat	03287	Merrimack	013
Wilton	03086	Hillsborough	011
Wilton Center	03086	Hillsborough	011
Winchester	03470	Cheshire	005
Windham	03087	Rockingham	015
Windsor	03244	Hillsborough	011
Winnisquam	03289	Belknap	001
Wolfeboro	03894	Carroll	003
Wolfeboro Center	03894	Carroll	003
Wolfeboro Falls	03894	Carroll	003
Wolfeboro Falls	03896	Carroll	003
Wonalancet	03897	Carroll	003
Woodlands	03810	Belknap	001
Woodmere	03461	Cheshire	005
Woodstock	03293	Grafton	009
Woodsville	03765	Grafton	009
Woodsville	03785	Grafton	009
York Pond	03570	Coos	007
Youngsville	03104	Hillsborough	011
Youngsville	03109	Hillsborough	011
Zealand	03598	Coos	007

APPENDIX E: NHSCR Supplement to STORE 2026

NEW HAMPSHIRE STATE CANCER REGISTRY ***DATA COLLECTION MANUAL***

Supplement to

STandards for **O**ncology **R**egistry **E**ntry
STORE 2026

Effective for cases diagnosed January 1, 2026



NEW HAMPSHIRE STATE CANCER REGISTRY
P.O. BOX 186, Hanover, NH 03755
(603)653-6265

Section One: Case Eligibility

Case Eligibility (STORE 2026, p11)

1. NHSCR requires registries in accredited programs to accession and abstract required tumors diagnosed and/or treated at the abstracting facility. NHSCR does not conduct follow-up activities for reportable cancers after the diagnosis and complete first-course treatment has been reported. NHSCR collects analytic cases (Class of Case 00-22) as well as most non-analytic cases (Class of Case 30-43). ([See NH-19](#))

Required Tumors (STORE 2026, p11)

2. Examples of reportable and non-reportable cancers are provided on pages [E-4 – E-9](#) of this supplement.
3. A brain or a CNS neoplasm identified only by diagnostic imaging is reportable.¹
 - **Neoplasm** and **tumor** are **reportable** terms for brain and CNS because they are listed in ICD-O-3 with behavior codes of /0 and /1.
 - **Mass** and **lesion** are not reportable terms for brain and CNS because they are not listed in ICD-O-3 with behavior codes of /0 or /1.
4. Cases diagnosed clinically are reportable. In the absence of a histologic or cytologic confirmation of a reportable neoplasm, accession a case based on the **clinical diagnosis** (when a recognized medical practitioner says the patient has a cancer, carcinoma, malignant neoplasm, or reportable neoplasm). A clinical diagnosis may be recorded in the discharge diagnosis on the face sheet or other parts of the medical record.²

Note: A pathology report normally takes precedence over a clinical diagnosis. If the patient has a negative biopsy, the case would **not** be reported.

Exceptions

1. Patient receives **treatment** for cancer. Accession the case.
Note: Standard treatments for cancer may be given for non-malignant conditions. Follow back with the physician to clarify if needed.
2. It has been **six months or longer** since the negative biopsy, and the physician continues to call this a reportable disease. Accession the case.
5. Intraepithelial neoplasia, grade III, for all sites are reportable, EXCEPT carcinoma in situ of cervix (CIS, CIN III) and of the prostate (PIN III).
6. 8210/3 Adenomatous polyp, high grade dysplasia is reportable for stomach and small intestines (C160-C166, C168-C169, C170-C1763, C178-C179) ONLY beginning 01/01/2022 and forward.

Required Tumors (STORE 2026, p12)

7. Low grade appendiceal mucinous neoplasms (LAMN) (8480) are reportable effective January 1, 2022.
8. Lobular carcinoma in situ (LCIS) of breast is reportable.
9. Examples of which PI-RADS, BI-RADS, and LI-RADS are reportable versus non-reportable are provided on pages [E-4 – E-9](#). If reportable, use the date of the imaging procedure as the date of diagnosis when this is the earliest date and there is no information to dispute the imaging findings.

Reportable-by-Agreement Cases (STORE 2026, p12)

10. Reportable-by-agreement cases that fall outside the NHSCR's reportable list should not be transferred to the NHSCR.
11. NHSCR requires the reporting of most non-analytic cases. ([See NH-20](#))

Ambiguous Terms at Diagnosis (STORE 2026, p12-13)

12. The use of ambiguous terminology is further defined on pages [E-10 – E-11](#) of this supplement.
 - a. Report cases that use the words on the list or an equivalent word such as “favored” rather than “favor(s).” Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable. Do not substitute “likely” for “most likely.”
 - b. There may be ambiguous terms preceded by a modifier, such as “mildly” suspicious. In general, ignore modifiers or other adjectives and accept the reportable ambiguous term.²
13. This includes any cytology report diagnosis that uses ambiguous terms that are listed as reportable in this manual.
14. Cases with a final diagnosis using any of the non-diagnostic terms are reportable if cancer-directed treatment is given or if the physician states the final diagnosis is a malignancy. ([See NH-12](#))

Class of Case (STORE 2026, p14)

15. NHSCR requires the staging (SEER Summary Stage) of all cases, including Class of Case 00 and 30-43.
16. NHSCR requires the collection of most non-analytic cases (Class of Case 30-43). ([See NH-20](#))

Date of First Contact (STORE 2026, p15)

17. NHSCR requires the reporting of pathology-only cases.
18. Facilities that have agreements with staff physicians to collect cases seen off site are to abstract as physician-only cases.
19. NHSCR requires NH reporting facilities to accession and abstract all cases seen with evidence of a reportable cancer or for cancer-directed treatment, on or after the NHSCR reference date (June 1986) only IF the case has not been reported by the diagnosing or treating facility. Refer to [Appendix G: NHSCR Non-Analytic Tracking Form](#) for procedure to determine which non-analytic cases do not need to be collected.
20. Non-analytic cases include patients receiving transient care, patients with active cancer admitted for medical conditions other than cancer, patients with a history of cancer that are now undergoing cancer-directed treatment, as well as pathology-only, physician-only, and consult-only cases (i.e. class case 30-99). NHSCR does not require the reporting of historical cases when they do not have active disease. Place of diagnosis, residence, and class of case are not determining factors for reportability.

Appendix E.1 - 2026 SEER Program Coding and Staging Manual*

Reportable Examples

As referenced in the Reportability instructions of the 2026 SEER Program Coding and Staging Manual

Reportable Malignant Examples

#	Diagnosis/Condition	Notes
1	Atypical fibroxanthoma (superficial malignant fibrous histiocytoma)	The information in parentheses provides more detail and confirms a reportable malignancy.
2	Positive histology from needle biopsy followed by negative resection	This case is reportable based on positive needle biopsy.
3	Biopsy-proven squamous cell carcinoma of the nipple with a subsequent areolar resection showing foreign body granulomatous reaction to suture material and no evidence of residual malignancy in the nipple	This case is reportable. The fact that no residual malignancy was found in the later specimen does not disprove the malignancy diagnosed by the biopsy.
4	Ulcerated histologically malignant spindle cell neoplasm, consistent with atypical fibroxanthoma; an exhaustive immunohistochemical work-up shows no melanocytic, epithelial or vascular differentiation	Atypical fibroxanthoma is a superficial form of a malignant fibrous histiocytoma. This case is reportable. The pathologist has the final say on behavior for a particular case. In this case, the pathologist states that this tumor is malignant.
5	Aggressive adult granulosa cell tumor with one of two lymph nodes positive for malignant metastatic granulosa cell tumor	This case is reportable because malignant granulosa cell tumor is reportable. The lymph node metastases prove malignancy.
6	Carcinoid of the appendix found on appendectomy	Carcinoid tumor, NOS is reportable (8240/3).
7	Microcarcinoid tumors of the stomach	Microcarcinoid and carcinoid tumors are reportable. The ICD-O-3.2 histology code is 8240/3. Microcarcinoid is a designation for neuroendocrine tumors of the stomach when they are less than 0.5 cm. in size. Neuroendocrine tumors of the stomach are designated carcinoid when they are 0.5 cm or larger. The term microcarcinoid tumor is not equivalent to carcinoid tumorlet.
8	Ovarian mucinous borderline tumor with foci of intraepithelial carcinoma	This case is reportable because there are foci of intraepithelial carcinoma (carcinoma in situ).
9	Squamous cell carcinoma of the anus, NOS	Squamous cell carcinoma of the anus (C210) is reportable. Note: Squamous cell carcinoma of the perianal skin (C445) is not reportable.
10	Mature teratoma of the testis when diagnosed after puberty (malignant)	For testis: Mature teratoma in adults is malignant (9080/3). Note: Do not report when diagnosed in a child (benign). Do not report mature teratoma of the testis when it is not known whether the patient is prepubescent or postpubescent. Pubescence can take place over a number of years; review physical history and do not rely only on age.
11	Well-differentiated neuroendocrine tumor (NET) of the stomach	The WHO classification of digestive system tumors uses the term NET G1 (grade 1) as a synonym for carcinoid and well-differentiated NET, 8240/3.
12	Cystic pancreatic endocrine neoplasm (CPEN)	Assign 8150/3 unless specified as a neuroendocrine tumor, Grade 1 (8240/3) or neuroendocrine tumor, Grade 2 (8249/3).

*Sanchez P, Groves C, Adamo M. (September 2025). SEER Program Coding and Staging Manual 2026. (Appendix E1: Reportable Examples) National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

#	Diagnosis/Condition	Notes
13	Solid pseudopapillary neoplasm of the pancreas	Assign 8452/3.
14	Liver cases with an LI-RADS category LR-4, LR-5, or LR-M	Report based on the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) definitions . Use the date of the LR-4 (Probably HCC) or LR-5 (Definitely HCC) scan as the date of diagnosis when it is the earliest confirmation of the malignancy. If there is no statement of the LI-RADS score but there is reference that a lesion is in the Organ Procurement and Transplantation Network (OPTN) 5 category, report based on the OPTN class of 5. OPTN class 5 indicates that a nodule meets radiologic criteria for hepatocellular carcinoma.
15	Mammary analogue secretory carcinoma (MASC)	MASC is a tumor that predominantly arises in the parotid gland. If the primary site is submandibular gland, assign C080. Assign 8502/3. Override any edits triggered by the combination of C080 and 8502/3.
16	Malignant perivascular epithelioid cell tumor (PEComa)	Assign 8714/3 to malignant PEComa. Some PEComas such as angiomyolipoma and lymphangiomyomatosis have specific ICD-O codes and their malignant counterparts may be coded to 8860/3 and 9174/3, respectively. There are no separate ICD-O codes for other specific PEComas, e.g., clear cell sugar tumor of lung, clear cell myomelanocytic tumor of the falciform ligament, and some unusual clear cell tumors occurring in other organs or for PEComa, NOS. These PEComas may therefore be coded to 8005 as clear cell tumors NOS; in other words, clear cell tumors are not clear cell variants of carcinomas, sarcomas, or other specific tumor type. Note : PEComa is non-specific as to behavior. Unless the pathologist states that it is malignant, the default code is 8005/1 (non-reportable).
17	Noninvasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia	For neoplasms of the pancreas, MCN with high grade dysplasia is the preferred term and mucinous cystadenocarcinoma, noninvasive is a related term (8470/2).
18	Noninvasive low grade (micropapillary) serous carcinoma (MPSC) of the ovary	Assign code 8460/2, applying the ICD-O-3 matrix concept to this noninvasive carcinoma. Noninvasive can be used as a synonym for in situ, ICD-O-3 behavior code /2. See page 66 in ICD-O-3.
19	Prostate cancer cases with an PI-RADS category 4 or 5	Report based on the American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS) definitions . PI-RADS categories 4 (high-clinically significant cancer is likely to be present) and 5 (very high-clinically significant cancer is highly likely to be present) are reportable, unless there is other information to the contrary.
20	Early or evolving melanoma, in situ or invasive	As of 1/1/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
21	Low-grade appendiceal mucinous neoplasm (LAMN)	Report LAMN beginning with January 1, 2022 diagnoses. LAMN is assigned a behavior of /2 or /3 making it reportable. LAMNs are slow-growing neoplasms that have the potential for peritoneal spread and can result in patient death. LAMNs demonstrate an interesting biology in that they do not have hematogenous dissemination risk, but risk for appendiceal perforation, which can result in peritoneal dissemination, repeated recurrences after surgery and even death.
22	Clear cell papillary renal cell carcinoma	Clear cell papillary renal cell carcinoma (8323/3) is reportable.

#	Diagnosis/Condition	Notes
23	Intraepithelial neoplasia examples (not an exhaustive list) • Squamous intraepithelial neoplasia, high grade, or grade II, or grade III (with exceptions) • High grade squamous intraepithelial lesion (HGSIL or HSIL) (with exception) • Intraepithelial neoplasia grade II/III; II-III • Squamous dysplasia, high grade (for stomach, small intestine, and esophagus only) • Anal intraepithelial neoplasia (AIN), grade II • Anal intraepithelial neoplasia (AIN), grade III • Biliary intraepithelial neoplasia, high grade • Conjunctival intraepithelial neoplasia grade III • Penile intraepithelial neoplasia (PeIN), undifferentiated • Vaginal intraepithelial neoplasia (VaIN), grade III • Vulvar intraepithelial neoplasia (VIN), grade III	Exceptions (not reportable) Squamous intraepithelial neoplasia (SIN) of cervix (C53_) and skin sites coded to C44_ Carcinoma in situ (CIS) arising in cervix (C53_) and perianal skin (C445) Cervical intraepithelial neoplasia (CIN III) of cervix (C53_) High grade squamous intraepithelial lesion (HGSIL or HSIL) arising in perianal skin (C445) AIN II and AIN III (8077) arising in perianal skin (C445) High grade prostatic intraepithelial neoplasia (PIN) Squamous intraepithelial neoplasia, high grade of colon and rectum See also the SEER manual, Reportability section, for additional reportable terms.
24	8380/2 (C54_) • Endometrioid intraepithelial neoplasia (EIN) • Intraepithelial neoplasm of endometrium • Atypical hyperplasia of endometrium	
25	Pancreatic intraepithelial neoplasia (PanIN III) 8148/2	
26	Differentiated penile intraepithelial neoplasia 8071/2	
27	Intracholecystic papillary neoplasm (ICPN) with high-grade dysplasia 8503/2	
28	Bosniak IV cystic renal mass	Bosniak Classification of cystic renal masses, version 2019, IV designation is reportable unless there is information to disprove the Bosniak designation
29	Conjunctival melanocytic intraepithelial lesions (C-MIL); low-grade conjunctival melanocytic intraepithelial lesion (LG-CMIL) with focal high-grade features of the conjunctiva (C690) (8720/2)	C-MIL represent a spectrum of morphological changes ranging from melanocytic hyperplasia through degrees of melanocytic atypia to melanoma in situ. Acceptable terms include conjunctival melanocytic intraepithelial neoplasia (C-MIN); Primary acquired melanosis (PAM); Melanoma in situ.

Reportable Non-Malignant Examples

#	Diagnosis/Condition	Notes
30	Hemangioma, NOS (9120/0) and cavernous hemangioma (9121/0)	Report the CNS site in which the hemangioma originates. Cavernous angioma is a related term for cavernous hemangioma. Note: For cavernous sinus hemangioma, report the site as cerebral meninges C700.
31	Dermoid cyst of the brain	This condition is reportable for cases diagnosed 2004 and later. Assign 9084/0.
32	Tectal plate lipoma	This is a reportable brain tumor. It is a benign neoplasm (lipoma) of the mid brain (brain stem) as noted by the location "tectal plate."
33	Lhermitte-Duclos disease	The WHO classification for CNS tumors lists this entity as dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) signifying that the terms are used synonymously. Assign C716, 9493/0.
34	Rathke pouch tumor (C751, 9350/1)	Rathke pouch tumor is a reportable neoplasm for cases diagnosed 2004 and later. Rathke cleft cyst and Rathke pouch tumor are different conditions. Note: Rathke cleft cyst is not reportable.

Appendix E.2 - 2026 SEER Program Coding and Staging Manual

Non-Reportable Examples

As referenced in the Reportability instructions of the 2026 SEER Program Coding and Staging Manual

#	Diagnosis/Condition	Notes
1	Sclerosing pneumocytoma of the lung with multiple regional lymph nodes involved with sclerosing pneumocytoma	Lymph node involvement with sclerosing pneumocytoma, formerly sclerosing hemangioma (an obsolete term), is non-malignant. According to the WHO Classification of Thoracic Tumors, 5th edition, "most sclerosing pneumocytomas behave in a benign fashion. However, although cases with lymph node metastases and distant organ metastases have occasionally been reported, these findings do not appear to adversely affect prognosis."
2	High grade squamous intraepithelial lesion (HGSIL or HSIL), carcinoma in situ (CIS), and AIN III (8077) arising in perianal skin (C445)	HGSIL or HSIL, CIS, and AIN III arising in perianal skin are not reportable. Refer to the Reportability Section of the main manual.
3	Squamous cell carcinoma of the perianal skin (C445)	Squamous cell carcinoma of sites in C44 is not reportable. Squamous cell carcinoma of the anus (C210) is reportable.
4	Squamous cell carcinoma of the canthus (C441)	Squamous cell carcinoma in sites coded to C44 is not reportable.
5	Breast cases designated BIRADS 4, 4A, 4B, 4C or BIRADS 5 without any additional information	The American College of Radiology defines Category 4 as "Suspicious." The descriptions in categories 4, 4a, 4b, and 4c are not diagnostic of malignancy. They all represent a percentage of likelihood, the highest being 4c which is greater than 50% but less than 95% likelihood of malignancy. The ACR states "This category is reserved for findings that do not have the classic appearance of malignancy but are sufficiently suspicious to justify a recommendation for biopsy." Category 5 is "Highly Suggestive of Malignancy." "Suggestive" is not reportable ambiguous terminology. ACR states that Category 5 has a "very high probability" of malignancy, but again, it is not diagnostic.
6	Lung cases designated "Lung-RADS 4A," 4B, or 4X	Lung: Do not use the ACR Lung Imaging Reporting and Data System (Lung-RADS™) to determine reportability. Look for reportable terminology from the managing physician or other sources.
7	Liver cases based only on an LI-RADS category of LR-3	Do not report liver cases based only on an LI-RADS category of LR-3.
8	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)	DIPNECH is a generalized proliferation of scattered single cells, small nodules (neuroendocrine bodies) or linear proliferation of pulmonary neuroendocrine cells (PNCs) according to the WHO classification of lung tumors.
9	Basal cell carcinoma (BCC) with neuroendocrine differentiation of the skin	BCC in sites coded to C44 is not reportable to SEER.
10	Lentiginous melanocytic lesion	Not reportable.
11	Intraductal papillary mucinous neoplasms with low or moderate grade dysplasia (also called IPMN adenomas)	Not reportable.
12	Noninvasive mucinous cystic neoplasm (MCN) of the pancreas with low or intermediate grade dysplasia	Not reportable.
13	Subdural hygroma	Subdural hygroma is not a neoplasm; it is a collection of cerebrospinal fluid in the subdural space. It may be related to a head injury.
14	Brain lesions associated with multiple sclerosis	These brain lesions are not neoplastic; they are part of the disease process of multiple sclerosis.
15	Mature teratoma of the testis when diagnosed before puberty (benign, 9084/0).	Pubescence can take place over a number of years; review history and physical information and do not rely only on age. Do not report mature teratoma when it is not known whether the patient is pre- or post-pubescent.
16	Mature teratoma of the ovary (9080/0)	Not reportable.
17	Venous angiomas (9122/0)	The primary site for venous (hem)angioma arising in the brain is blood vessel (C490). The combination of 9122/0 and C490 is not reportable. This is a venous abnormality. Previously called venous angiomas, these are currently referred to as developmental venous anomalies (DVA).

#	Diagnosis/Condition	Notes
18	Multilocular cystic renal neoplasm of low malignant potential	Previously called multilocular cystic renal cell carcinoma, this diagnosis became non-reportable beginning with the new designation in 2016. Refer to the Solid Tumor Tumor Coding Rules, Kidney Equivalent Terms and Definitions, for histology/morphology information.
19	Lymphangioma of the brain or CNS	Lymphangioma is a malformation of the lymphatic system. Even though it has an ICD-O code, do not report it.
20	Carcinoid heart disease based on clinical information	Carcinoid heart disease is not reportable but this diagnosis indicates that the patient likely has a carcinoid tumor which may be reportable. Obtain further information.
21	Carcinoid tumorlet of the lung	Not reportable.
22	Pulmonary benign metastasizing leiomyoma (BML) (8898/1)	According to WHO, this resembles a typical leiomyoma but it is found in the lungs of women with a history of typical uterine leiomyomas. A recent article states that because of the hormone-sensitive characteristics of BML, treatments are based on hormonal manipulation along with either surgical or medical oophorectomy. Tamoxifen treatment is in keeping with the BML diagnosis.
23	Colloid cyst at the foramen of Monro	Colloid cysts are endodermal congenital malformations and do not have an ICD-O-3 code. See the glossary for registrars at: Colloid cyst
24	Mammary fibromatosis	Mammary fibromatosis is not reportable. The WHO classification for breast tumors assigns mammary fibromatosis a behavior code of /1. According to WHO, mammary fibromatosis is a locally infiltrative lesion without metastatic potential.
25	Thalamic amyloidoma	Amyloidoma (tumoral amyloidosis, amyloid tumor) is a tumor-like deposit of amyloid. It is not neoplastic. Amyloid is a protein derived substance deposited in various clinical settings.
26	Pseudotumor cerebri	Pseudotumor cerebri is not a neoplasm. The pressure inside the skull is increased and the brain is affected in a way that appears to be a tumor, but it is not a tumor.
27	Conjunctival primary acquired melanosis (PAM) with atypia	According to our expert pathologist consultant, there has been a lot of debate in the literature about the diagnostic criteria, terminology, and natural history of PAM. The main issue is whether PAM with atypia should be regarded as melanoma in situ. In most studies it appears that PAM with no atypia or mild atypia does not progress to melanoma, and only a small percentage of those with severe atypia do so. PAM, even with atypia, is not melanoma in situ, and should not be reported. For further information, see this article for a review of a large number of patients: Shields, Jerry A, Shields, Carol L, et al. Primary Acquired Melanosis of the Conjunctiva: Experience with 311 Eyes. Trans. Am Ophthalmol Soc 105:61-72, Dec 2007.
28	Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2)	Genetic disease that produces non-malignant tumors in skin, brain, CNS, and other sites. The brain and CNS tumors spawned by NF1 or NF2 are reportable, the genetic disease is not.
29	Ovarian mucinous borderline tumor with microinvasion	For an ovarian mucinous borderline tumor, the term "microinvasion" is not an indication of malignancy. Low malignant potential/borderline ovarian tumors are defined by the pathology of the primary tumor and are not affected by microinvasion or invasion in implants. Though a case may be staged, this does not mean it is reportable.
30	Rathke cleft cyst	Rathke cleft cyst, also called pars intermedia cyst of the parotid gland, is not reportable; whereas, Rathke pouch tumor is reportable.
31	Colon atypical hyperplasia	Not reportable.
32	High grade dysplasia (8148/2) in gastrointestinal sites other than stomach, small intestine, and esophageal primary sites. The non-reportable gastrointestinal sites include colorectal primaries (C180-C189, C199, and C209).	Not reportable.
33	Ecchordosis physaliphora	Ecchordosis physaliphora, a lesion within the prepontine cistern, is not reportable.

#	Diagnosis/Condition	Notes
34	Low to intermediate grade neuroendocrine neoplasm or middle ear adenomatoid tumor (MEANT)	Not reportable.
35	Moderate squamous dysplasia and severe squamous dysplasia of lung	Not reportable.
36	High grade prostatic intraepithelial neoplasia	PIN III is not reportable.
37	Atypical lentiginous melanocytic proliferation	Not reportable.
38	Malignant tumorlet, NOS in the lung	Not reportable.
39	Conjunctival intraepithelial neoplasia, NOS	Not reportable.
40	Ductal intraepithelial neoplasia type 1a	Not reportable.
41	Endometrial hyperplasia with focal atypia	Not reportable.
42	Pancreatic intraepithelial neoplasia (PanIN) low grade (formerly PanIN-I, PanIN-2, PanIN grade II), PanIN, NOS	Not reportable.
43	Pancreatic neuroendocrine microadenoma	Not reportable.
44	Vaginal intraepithelial neoplasia (VaIN or VAIN), NOS	Not reportable.
45	Vulvar intraepithelial neoplasia (VIN), NOS	Not reportable.
46	Cavernous malformation	Not reportable.

How to Use Ambiguous Terminology for Case Ascertainment²

[See *Ambiguous Terminology* in Section One for overview of coding principles](#)

1. **In Situ and Invasive** (Behavior codes /2 and /3)

- a. If any of the reportable **ambiguous terms precede** a word that is **synonymous** with an in situ or invasive tumor (e.g., cancer, carcinoma, malignant neoplasm, etc.), accession the case.

Example: The pathology report says: Prostate biopsy with markedly abnormal cells that are typical of adenocarcinoma. Accession the case.

Negative Example: The final diagnosis on the outpatient report reads: Rule out pancreatic cancer. Do not accession the case.

b. Discrepancies

- i. Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record

1. Do **not** accession a case when the original source document used a **non-reportable** ambiguous term and subsequent documents refer to history of cancer

Example: Report from the dermatologist is “possible melanoma.” Patient admitted later for unrelated procedure and physician listed history of melanoma. Give priority to the information from the dermatologist and do not report this case. “Possible” is **not** a reportable ambiguous term. The later information is less reliable in this case.

- ii. Accept the reportable term and accession the case when there is a single report in which both reportable and non-reportable terms are used

Example: Abdominal CT reveals a 1 cm liver lesion. “The lesion is consistent with hepatocellular carcinoma” appears in the discussion section of the report. The final diagnosis is “1 cm liver lesion, possibly hepatocellular carcinoma.” Accession the case. “Consistent with” is a reportable ambiguous term. Accept “consistent with” over the non-reportable term “possibly.”

c. Do **not** accession a case based ONLY on **suspicious** cytology

Note: “Suspicious cytology” means any cytology report diagnosis that uses an ambiguous term, including ambiguous terms that are listed as reportable on the preceding page.

Follow back on cytology diagnoses using ambiguous terminology is strongly recommended.

Cytology refers to the microscopic examination of cells in body fluids obtained from aspirations, washings, scrapings, and smears; usually a function of the pathology department.

Important: Accession cases with cytology diagnoses that are **positive** for malignant cells.

- d. Use the reportable ambiguous terms when **screening** diagnoses on pathology reports, operative reports, scans, mammograms, and other diagnostic testing with the exception of tumor markers

- i. Do not accession a case when resection, excision, biopsy, cytology, or physician’s statement proves the ambiguous diagnosis is not reportable

Example 1: Mammogram shows calcifications suspicious for intraductal carcinoma. The biopsy of the area surrounding the calcifications is negative for malignancy. Do not accession the case.

Example 2: CT report states “mass in the right kidney, highly suspicious for renal cell carcinoma.” CT-guided needle biopsy with final diagnosis “Neoplasm suggestive of oncocytoma. A malignant neoplasm cannot be excluded.” Discharged back to the nursing home and no other information is available. Do not accession the case. The suspicious CT finding was biopsied and not proven to be malignant. “Suggestive of” is not a reportable ambiguous term.

Example 3: Stereotactic biopsy of the left breast is “focally suspicious for DCIS” and is followed by a negative needle localization excisional biopsy. Do not accession the case. The needle localization excisional biopsy was performed to further evaluate the suspicious stereotactic biopsy finding. The suspicious diagnosis was proven to be false.

Example 4: Esophageal biopsy with diagnosis of “focal areas suspicious for adenocarcinoma in situ.” Diagnosis on partial esophagectomy specimen “with foci of high grade dysplasia; no invasive carcinoma identified.” Do not accession the case. The esophagectomy proved that the suspicious biopsy result was false.

2. **Benign and borderline primary intracranial and CNS tumors**

- a. Use the “Ambiguous terms that are reportable” list above to identify benign and borderline primary intracranial and CNS tumors that are reportable
- b. **Neoplasm** and **tumor** are **reportable** terms for brain and CNS because they are listed in ICD-O-3 with behavior codes of /0 and /1
- c. Accession the case when any of the reportable **ambiguous terms precede** either the word “**tumor**” or the word “**neoplasm**”
Example: The mass on the CT scan is consistent with pituitary tumor. Accession the case.
- d. **Mass and lesion are not reportable terms for brain and CNS because they are not listed in ICD-O-3 with behavior codes of /0 or /1**
- e. **Discrepancies**
 - i. Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record
 1. Do not accession a case when subsequent documents refer to history of tumor and the original source document used a **non-reportable** ambiguous term
 - ii. Accept the reportable term and accession the case when there is a single report and one section of a report uses a reportable term such as “apparently” and another section of the same report uses a term that is not on the reportable list
Exception: Do not accession a case based ONLY on ambiguous **cytology** (the reportable term is preceded by an ambiguous term such as apparently, appears, compatible with, etc.).
- f. Use these terms when **screening** diagnoses on pathology reports, scans, ultrasounds, and other diagnostic testing other than tumor markers
 - i. Do not accession the case when resection, excision, biopsy, cytology or physician’s statement proves the ambiguous diagnosis is not reportable

Determining Multiple Primaries²

Solid Tumors

Apply the general instructions and site-specific instructions for determining multiple primaries in the current [Solid Tumor Rules](#).

Apply the site-specific multiple primary rules in the current [Solid Tumor Rules](#).

Site-specific multiple primary rules cover the following

Primary Site	Topography Code
Head & Neck	C000-C148, C300-C329, C410, C411, C442
Colon	C180-C189, C199, C209
Lung	C340-C349
Cutaneous Melanoma	C440-C449 with Histology 8720 – 8780
Breast	C500-C506, C508-C509
Kidney	C649
Urinary Sites	C659, C669, C670-C679, C680-C681, C688-C689
Non-malignant CNS	C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
Malignant CNS and Peripheral Nerves	C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
Other Sites	Excludes Head and Neck, Colon, Rectosigmoid, Rectum, Lung, Cutaneous Melanoma, Breast, Kidney, Urinary Sites, Peripheral Nerves, CNS

The General rules do not apply to hematopoietic primaries (lymphoma and leukemia) of any site. The head and neck, colon, rectosigmoid and rectum, breast, kidney, urinary sites, and malignant CNS and peripheral nerves rules exclude lymphoma and leukemia (M9590-M9993) and Kaposi sarcoma (M9140). All other sites rules exclude lymphoma and leukemia (M9590-M9993).

Hematopoietic and Lymphoid Neoplasms

No updates were made to the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database for 2026 cases. Apply the Multiple Primary Rules in the [Hematopoietic and Lymphoid Neoplasm Coding Manual and Database](#).

Transplants

Transplanted organs or tissue may originate from

- Organs or tissue from the patient's own body (called autograft) or
- Another human donor (homograft or allograft)

Accession a new primary in the transplanted organ as you would any new primary, applying the current Solid Tumor Rules. Code the primary site to the location of the transplanted organ, i.e., code the malignancy where it resides/lies.

Example: Diagnosis of malignancy in transplanted section of colon serving as esophagus. Code the primary site as esophagus. Document the situation in a text field.

Section One: Overview of Coding Principles (STORE 2026, p16)

Unique Patient Identifier Codes (STORE 2026, p16)

21. When assigning sequence numbers, only count cases that are reportable to NHSCR. If your facility collects non-reportable cancers (e.g. CIS, PIN, etc.), assign the sequence pertinent to your facility after the case has been transmitted. See [Determining Multiple Primaries](#) for additional instructions.

National Provider Identifier (STORE 2026, p16)

22. NHSCR requires the collection and transmission of the National Provider Identifier—Reporting Facility and National Provider Identifier—Managing Physician when available.

Cancer Identification, Primary Site (STORE 2026, p17)

23. The current Solid Tumor Rules contain additional coding instructions for some primary sites, including Head and Neck, Lung, and Urinary.²

Note: Continue to use ICD-O-3 for assigning topography codes. ICD-O-3.2 did not change any of the topography codes.

Revising the Original Diagnosis (STORE 2026, p19)

24. If a completed definitive case is revised as a result of additional information becoming available, submit a revised abstract to the NHSCR with a notation referencing the revision. Additional instructions are provided on [page E-13](#) of this supplement.

Patient Name, Address and Residency Rules (STORE 2026, p19)

25. *Current Address* is not required by NHSCR.
26. Use residency information from a death certificate only when the residency from other sources is coded as unknown. Review each case carefully and apply the U.S. Census Bureau/SEER rules for determining residence.
- Example:** The death certificate may give the person's previous home address rather than the nursing home address as the place of residence. If the person was a resident of a nursing home at diagnosis, use the nursing home address as the place of residence.
27. For *Address at Diagnosis*, collect the street address of usual residence as stated by the patient. When PO Box is the only address available, record UNKNOWN for address at diagnosis, and record the PO Box address in the *Address at Diagnosis-Supplemental* data field.

In utero Diagnosis and Treatment (STORE 2026, p20, p54, and p79)

28. NHSCR follows NPCR and SEER² guidelines for in utero diagnosis and treatment:

Diagnosis Prior to Birth. SEER reportability requirements apply to diagnoses made in utero. Diagnoses made in utero are reportable only when the pregnancy results in a live birth. In the absence of documentation of stillbirth, abortion or fetal death, assume there was a live birth and report the case.

Disease Regression. When a reportable diagnosis is confirmed prior to birth and disease is not evident at birth due to regression, accession the case based on the pre-birth diagnosis.

Cases Diagnosed Before Birth. Record the actual date of diagnosis for diagnoses made in utero even though this date will precede the date of birth.

Example: Fetal intrahepatic mass consistent with hepatoblastoma diagnosed via ultrasound at 39 weeks gestation (01/30/2026). Live birth by C-section 02/04/2026. Code the date of diagnosis as 01/30/2026. **Note:** Prenatal diagnoses are reportable when there is a live birth.

Comorbidities and Complications/Secondary Diagnoses (STORE 2026, p21)

29. The recording of *Comorbidities and Complications* is required for cases diagnosed January 1, 2010 – September 30, 2015; *Secondary Diagnosis* is required effective for cases diagnosed October 1, 2015 forward, when ICD-10-CM was implemented.

Stage of Disease at Initial Diagnosis (STORE 2026, p21)

30. The following staging systems apply to all reportable cancers by diagnosis year: ([See NH-45](#))

DX Year	Staging System(s)
≤ 2003	AJCC and SEER Summary Stage
2004 - 2015	Collaborative Stage
2015 - 2017	AJCC and SEER Summary Stage
2018+	AJCC and Summary Stage 2018
2011 Breast and Colorectal only	AJCC and SEER Summary Stage

First Course Treatment, Leukemias (STORE 2026, p23)

31. For information regarding first course of therapy for hematopoietic and lymphoid neoplasms, refer to the NCI SEER [Hematopoietic and Lymphoid Neoplasm Coding Manual](#).

Surgery (STORE 2026, p23)

32. NHSCR collects ALL surgical procedures of a primary site. Registries with software allowing for multiple treatments to be coded are to code all surgical procedures performed at their facility and elsewhere.

Outcomes (STORE 2026, p32)

33. NHSCR does not conduct follow-up activities for reportable cancers after the diagnosis and complete first-course treatment has been reported. ([See NH-1](#))

Administrative Tracking (STORE 2026, p34)

34. In registries with more than one abstractor, *Abstracted By* should reflect the abstractor who completed the case.

EDITS Overrides (STORE 2026, p34)

35. NHSCR highly recommends that data be put through edits before submission. The use of overrides depends on whether the standard NAACCR edits or the EDITS software have been integrated into registry software.

Changing Information on the Abstract²

The information originally collected on the abstract should be changed or modified under the following circumstances

1. To **correct** coding or abstracting **errors** (for example, errors found during quality control activities)
2. **When clarifications or rule changes** retroactively affect data item code
Example: SEER adds codes to a data item and asks the registries to review a set of cases and update using the new codes.
3. **When better information** is available later
Example 1: Consults from specialty labs, pathology report addenda or comments or other information have been added to the chart. Reports done during the diagnostic workup and placed on the chart after the registrar abstracted the information may contain valuable information. Whenever these later reports give better information about the histology, grade of tumor, primary site, etc., change the codes to reflect the better information.
Example 2: The primary site was recorded as unknown at the time of diagnosis. At a later date, the physician determines that the cancer is primary to the testis. Change the primary site from unknown to testis.
Example 3: The original diagnosis was in situ. Metastases are diagnosed at a later date. Change the behavior code for the original diagnosis from in situ to invasive when **no new primary has been diagnosed** in the interim.
Example 4: Patient seen in Hospital A. The pathologic diagnosis was negative for malignancy. Patient goes to Hospital B and the slides from Hospital A are re-read. The diagnosis at Hospital B is reportable. Hospital B sends their slide report back to Hospital A. Hospital A reports the case based on the info from Hospital B. Enter supporting documentation in a text field.
4. **When the date of diagnosis is confirmed in retrospect to be earlier than the original date abstracted**
Example: Patient has surgery for a benign argentaffin carcinoid (8240/1) of the sigmoid colon in May 2022. In January 2023, the patient is admitted with widespread metastasis consistent with malignant argentaffin carcinoid. The registrar accessions the malignant argentaffin carcinoid as a 2023 diagnosis. Two months later, the pathologist reviews the slides from the May 2022 surgery and concludes that the carcinoid diagnosed in 2022 was malignant. Change the date of diagnosis to May 2022 and histology to 8241 and the behavior code to malignant (/3).

Section Two: Instructions for Coding

36. At a minimum, reporting facilities must collect the NHSCR required data items.

(See [Appendix I: Table of Required Data Items](#))

Patient Identification

Age at Diagnosis (STORE 2026, p55)

37. Registry software automatically calculates the *Age at Diagnosis*. When the diagnosis date is unknown, confirm that *Age at Diagnosis* is recorded as 999.

Primary Payer at Diagnosis (STORE 2026, p60)

38. Additional coding instructions for *Primary Payer at Diagnosis*²

1. Code the type of insurance reported on the patient's admission record
2. Code the **first** insurance mentioned when multiple insurance carriers are listed on one admission record
3. Code the type of insurance reported **closest to the date of diagnosis** when there are multiple insurance carriers reported for multiple admissions and/or multiple physician encounters
4. Code the patient's insurance at the time of **initial diagnosis and/or treatment**. Do not change the insurance information based on subsequent information
 - a. Code the first insurance mentioned when there is more than one type of insurance specified during the initial diagnosis and/or treatment
5. Use code **02** when the only information available is "self-pay"
6. Use code **10** for prisoners when no further information is available
7. Assign code **99** for death certificate only (DCO) cases when the primary payer at diagnosis is unknown

39. Tobacco Use Smoking Status [344] is required effective with diagnosis year 2022.

Cancer Identification

Class of Case (STORE 2026, p71-73)

40. Certain nonanalytic cases are required by the NHSCR. ([See NH-20](#))

41. CIS, CIN III, and PIN III are not reportable to NHSCR. ([See NH-5](#))

42. Non-analytic cases are required by NHSCR to be abstracted and reported by New Hampshire reporting facilities only IF the case has not been reported by the diagnosing or treating facility. ([See Appendix G: NHSCR Non-Analytic Tracking Form](#)) ([See NH-20](#))

43. DCO cases are accessioned only by NHSCR.

Cancer Identification, cont.

Grade Clinical and Grade Pathological, (STORE 2026, p90 and p91)

44. Grade Post Therapy Clin (yc) [1068] and Grade Post Path (yp) [3845] can be found in the AJCC TNM Stage section, [page 149](#) and [page 162](#).

Stage of Disease at Diagnosis

SEER Summary Stage (STORE 2026, p96 and p136a)

45. NHSCR requires SEER Summary Stage on all cases. ([See NH-30](#))

- Direct staging for cases diagnosed prior to year 2004 and 2015+.
- Collaborative Staging is used for cases diagnosed 2004-2015.
- NHSCR also requires AJCC staging for breast and colorectal cancer diagnosed in year 2011.
- SEER Summary Staging is required for ALL cases, including non-analytic cases. ([See NH-15](#) and [NH-16](#)) If there is insufficient information to assign stage, code to unknown.

Site-Specific Data Items (STORE 2026, p163)

46. Refer to [Appendix I: NHSCR Table of Required Data Items](#) for full list of required SSDIs.

Outcomes

Follow-up (STORE 2026, p272)

47. NHSCR is a population-based incidence registry responsible for collecting *all* cancer cases seen and/or treated in NH since June 1986. However, it is not required to conduct annual follow-up of cases reported to NHSCR once initial diagnosis and complete first-course treatment information has been reported.

Refer to [page E-13](#) of this supplement when cases are updated after they have been transmitted to NHSCR.

Case Administration

Abstracted By (STORE 2026, p285)

48. In a registry with more than one abstractor, *Abstracted By* should reflect the abstractor who completes the definitive case report.

Date Case Completed - CoC (STORE 2026, p290)

49. NHSCR uses *Date Case Complete – CoC* [2092] to distinguish between a *rapid* (suspense) case and a *definitive* (completed) case. Cases without a *Date Case Complete – CoC* are flagged as rapid reports and not included in the NHSCR main database.

References

¹Thornton ML, (ed). *Data Standards and Data Dictionary*, Version 26, 27th ed. Springfield, Ill.: North American Association of Central Cancer Registries, June 2025. (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025). Available at: <https://apps.naaccr.org/data-dictionary/data-dictionary/version=26/chapter-view/>. (Accessed February 18, 2026.)

²Sanchez P, Groves C, Adamo M. (September 2025). SEER Program Coding and Staging Manual 2026. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Available at: <https://seer.cancer.gov/tools/codingmanuals/>. (Accessed February 18, 2026.)

APPENDIX F: NEW HAMPSHIRE RULES AND REGULATIONS

PART He-P 304 CANCER REGISTRY RULES

He-P 304.01 Definitions.

(a) “Clinic” means a health care facility licensed by the state of New Hampshire, where a physician, nurse practitioner, or other health care professional provides cancer diagnosis and treatment or both, and that is not an operational entity of and not affiliated with a hospital. Such facilities include urology clinics, dermatology clinics, out-patient surgical centers, ambulatory oncology treatment centers, ambulatory radiation treatment centers, and physician group practices devoted to oncology.

(b) “Commissioner” means the commissioner of the department of health and human services.

(c) “Confidence interval” means an estimated range of values, which is likely to include an unknown population parameter, the estimated range being calculated from a given set of sample data.

(d) “Courier service” means a mail delivery service that provides guaranteed delivery of documents or packages by using a reliable tracking system.

(e) “Definitive report” means information or data in the format of an electronic or paper document, or report, describing a reportable cancer, including the information described in He-P 304.02(e), that is submitted to the state cancer registry (SCR) as follows:

(1) No sooner than 90 days and no later than 180 days of an initial diagnosis or treatment; or

(2) In cases where the patient has died, or is transferred to hospice care, within 90 days of death and transfer.

(f) “Department” means the New Hampshire department of health and human services.

(g) “Facility” means “facility” as defined in RSA 141-B:3, VI, namely, “a governmental or private agency, department, institution, clinic, laboratory, hospital, health maintenance organization, association, physician, or other similar unit diagnosing or providing treatment for cancer.”

(h) “Medical laboratory” means a facility performing tests or analyses of human samples from patients suspected to have cancer.

(i) “Mutual agreement” means an understanding, arrangement, or stipulation which establishes the responsible reporter to the SCR as made between 2 facilities, clinics, or physicians, which can be confirmed in writing, but for which written documentation is not required.

(j) “Pathology report” means electronic or paper report(s) prepared by a pathologist providing a description of laboratory test results, and an evaluation of cells, tissues, and organs based on evidence from a sample of body tissue, which is used to diagnose and characterize disease.

(k) “Protected health information” means protected health information as defined in 45 CFR 160.103.

(l) “Rapid report” means information or data in an electronic or paper document or report, describing a reportable cancer, including the information described in He-P 304.02(d), that is submitted to the SCR within 45 days of diagnosis.

(m) “Reportable cancer” means any syndrome, condition, or disease listed in “Table 2 “NAACCR Layout Version 15: Comparison of Reportable Cancers” (Thornton ML, (ed.)) “Standards and Registry Operations/Volume II/Data Standards and Data Dictionary,” Version 15, 19th ed. (Posted October 2014, Revised February 27, 2015)/Chapter III, “Standards for Tumor Inclusion and Reportability” “Table 2 NPCR Requirements”, Springfield, Ill., North American Association of Central Cancer Registries. As listed in Appendix A and available as a free electronic document at <http://www.naaccr.org>.

(n) “State cancer registry (SCR)” means the department or, if the department meets its statutory obligations by contract, an organization, system, or individual contracted by the department to collect, manage and store information on cases of reportable cancer pursuant to RSA 141-B:5 and RSA 141-B:10.

Source. #4055, eff 5-27-86; amd by #4869, eff 7-24-90; ss by #5601, eff 3-24-93; amd by #6075, eff 8-5-95; ss by #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.02 Reporting Requirements.

(a) In accordance with RSA 141-B:7, all facilities shall report diagnosis or treatment of a reportable cancer to the SCR in accordance with the rules specified below, and using the means described in He-P 304.02(f), (g) and (h). SCR may be contacted through <http://geiselmed.dartmouth.edu/nhscr/contact>.

(b) Pursuant to (a) above, all facilities shall include information and data in each report describing cancer diagnosis or treatment according to one of the following standards, as applicable:

(1) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries, Volume II/Data Standards and Data Dictionary, 19th Edition, Record Layout Version 15,” (January 1, 2015) Edited by Monica Thornton, Revised (February, 27, 2015.), as listed in Appendix A and available as a free document at www.naaccr.org;

(2) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries/Volume V: “Pathology Laboratory Electronic Reporting, Version 4.0.” Klein Wt., Havener L (eds.), Springfield (IL); North American Association of Central Cancer Registries, Inc., April, 2011, as listed in Appendix A and available as a free electronic document at www.naaccr.org; or

(3) The National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, “Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries HL7 Clinical Document Architecture (CDA) Release 1.1” (March, 2014), as listed in Appendix A and available as a free electronic document in PDF format at <http://cdc.gov/cancer/npcr/ehrmeaningfuluse/cancer.htm>.

(c) Each report shall contain information or data required by the appropriate standard in (b) above, as listed in elements (1)-(10) below, and include any supporting information, as follows:

- (1) Item numbers defining demographics;
- (2) Item numbers defining cancer identification;
- (3) Item numbers defining hospital-specific information;
- (4) Item numbers defining stage prognostic factors;
- (5) Item numbers defining the first course of treatment;
- (6) Item numbers defining follow-up, recurrence, and death;
- (7) Item numbers defining confidential patient information;
- (8) Item numbers defining confidential hospital information;
- (9) Item numbers defining other confidential information; and
- (10) Item numbers defining diagnosis.

(d) Of the item numbers specified in (b) and (c) above, the following shall require rapid reporting as defined in He-P 304.01(l) and described in He-P 304.03(b) and (c):

- (1) Item numbers defining demographics;
- (2) Item numbers defining cancer identification;
- (3) Item numbers defining hospital-specific information;
- (4) Item numbers defining confidential patient information; and
- (5) Item numbers defining other confidential information.

(e) The items listed in (c) above shall require definitive reporting as defined in He-P 304.01(e), and described in He-P 304.03(a), He-P 304.03(d), He-P 304.04(a), and He-P 304.06(a) and (b).

(f) All facilities making an electronic report to the SCR in accordance with (a) above, shall submit through a secure internet-based encrypted mechanism, such as a direct file transfer, or a web-based reporting form supported by the SCR.

(g) All facilities reporting electronically shall format reports as specified by one of the following standards, as applicable:

- (1) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries, Volume II/Data Standards and Data Dictionary, 19th Edition, Record Layout Version 15.” (January 1, 2015) Edited by Monica Thornton, Revised (February, 27, 2015), as listed in Appendix A and available as a free document at <http://www.naaccr.org>;
- (2) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries/Volume V: Pathology Laboratory Electronic Reporting, Version 4.0.” Klein Wt., Havener L. (eds.) Springfield (IL); North American Association of Central Cancer Registries, Inc., (April, 2011), as listed in Appendix a and available as a free electronic document at <http://www.naaccr.org>; or
- (3) The National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, “Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries HL7 Clinical Document Architecture (CDA) Release 1.1” (March, 2014), as listed in Appendix A and available as a free electronic document in PDF format at <http://cdc.gov/cancer/npcr/ehrmeaningfuluse/cancer.htm>.

(h) Where electronic reporting is not feasible, facilities shall complete and file the New Hampshire State Cancer Registry (NHSCR) “Cancer Report Form” (July, 2015) provided by the SCR and faxed or mailed by the facilities to the SCR, via regular mail or a courier service.

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93; amd by #6075, eff 8-5-95; ss by #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.03 Reporting of Information by Hospitals Licensed by the State of New Hampshire.

- (a) Hospitals licensed by the state of New Hampshire that diagnose or treat at least 105 new reportable cancer cases per year shall employ a cancer registrar to abstract the definitive report.
- (b) Hospitals licensed by the state of New Hampshire that diagnose or treat at least 105 new reportable cancer cases per year shall provide a rapid report to SCR in accordance with He-P 304.01(l) and a definitive report in accordance with He-P 304.01(e).
- (c) Hospitals licensed by the state of New Hampshire that diagnose or treat fewer than 105 reportable cancer cases per year shall provide a rapid report to SCR in accordance with He-P 304.01(l), and a paper or electronic report to SCR in accordance with He-P 304.02.
- (d) Hospitals licensed by the state of New Hampshire that diagnose or treat fewer than 105 reportable cancer cases per year shall make available to SCR the medical records of all patients with a reportable cancer for the creation of the definitive report in accordance with He-P 304.01(e).
- (e) Facilities owned by a hospital licensed by the state of New Hampshire shall have met the reporting requirements of this rule if reports are submitted to SCR on their behalf by the hospital.

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.04 Reporting of Information by a Physician Licensed by the State of New Hampshire.

- (a) A physician, surgeon, or other licensed health care practitioner who diagnoses or treats cancer patients shall complete and provide a definitive report in accordance with He-P 304.01(d) for each newly diagnosed cancer case when that patient will not be immediately referred to a hospital or other treatment center for additional diagnosis or treatment.
- (b) A physician, surgeon, or other licensed health care practitioner shall provide additional information to SCR regarding a patient as is considered necessary for abstraction of required cancer incidence data in accordance with He-P 304.07(a).
- (c) A physician, surgeon, or other licensed health care practitioner may fulfill his or her responsibility for cancer reporting for a cancer patient through a mutual agreement allowing cases to be reported by a hospice or other facility that provided medical or nursing care to that cancer patient.
- (d) A physician, surgeon or other licensed health care practitioner shall make available to the SCR the medical records of all patients with a reportable cancer for creation of the definitive report in accordance with He-P 304.01(e).

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.05 Reporting of Information by a Medical Laboratory Licensed by the State of New Hampshire.

(a) A medical laboratory licensed by the state of New Hampshire that obtains a specimen of human tissue which, upon examination, shows evidence of cancer, shall:

- (1) Within 180 days after that pathology report is complete, provide information concerning its findings to the SCR; and
- (2) Fax, mail, or electronically transmit a copy of the pathology report using procedures described in this section.

(b) A medical laboratory may fulfill its responsibility for cancer reporting through a mutual agreement allowing cases to be submitted by the cancer registrar at an affiliated hospital or other facility.

(c) The SCR shall be granted access to pathology reports used to confirm or rule out a diagnosis of cancer by medical laboratories for the purpose of case finding and quality assurance.

(d) The SCR shall be authorized to identify cancer cases from the pathology reports and request information about missing cancer reports from the reporting facility.

Source. #4055, eff 5-27-86; amd by #4869, eff 7-24-90; ss by #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.06 Reporting of Information by Clinics that Diagnose or Treat Patients With Cancer.

(a) A clinic shall provide a definitive report for each case in accordance with He-P 304.01(e).

(b) A clinic licensed by the state of New Hampshire shall:

- (1) Be responsible for the submission of all definitive reports to the SCR; or
- (2) Develop a mutual agreement with a cancer registrar at a hospital or other affiliated facility for the submission of a definitive report to the SCR.

(c) A clinic shall provide additional information to SCR regarding a cancer patient as necessary for abstraction of required cancer incidence data in accordance with He-P 304.07(a).

Source. #4055, eff 5-27-86; ss by #4377, eff 3-1-88; ss by #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.07 Quality Assurance, Verification, and Confidentiality.

(a) All facilities shall respond to SCR requests for case information pursuant to He-P 304.02(b) and (c) within 14 working days of receipt of such requests.

(b) All facilities shall respond to SCR requests to perform a site visit.

- (c) SCR shall perform a site visit at each facility in order to:
- (1) Audit pathology reports and other information to ensure that no cancer cases are overlooked in reporting; and
 - (2) Monitor the completeness and accuracy of the cancer reports.
- (d) Each facility shall make available for reviewing and copying all paper or electronically stored information including the following:
- (1) Laboratory analyses including tissue, cytology, and pathology reports;
 - (2) Records regarding radiological examinations, in relation to cancer diagnoses or treatment;
 - (3) Reports of diagnoses of malignant disease, and notations of the reasons for such diagnoses, including both primary clinicians' reports and consultants' reports;
 - (4) Pharmacy records;
 - (5) Reports regarding any operations or an autopsy;
 - (6) Discharge plans and abstracts regarding cancer diagnoses; and
 - (7) A list of the applicable discharge diagnoses or treatment as identified in the "Casefinding Lists, Current Lists/Code List," (October 1, 2015-September 30, 2016), as listed in Appendix A and available as a free electronic document at <http://seer.cancer.gov/tools/casefinding/case2016-icd10cm.html>.
- (e) Pursuant to 42 USC 280e(c)(2)(D)(viii), individuals complying with the law shall not be held liable in any civil action with respect to a report of cancer provided to the SCR, or with respect to access to data or information provided to the SCR.

Source. #4377, eff 3-1-88; ss by #5601, eff 3-24-93,
EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss
by #11054, eff 3-15-16

He-P 304.08 Procedures for Disclosure of Protected Health Information.

- (a) The SCR shall use and disclose protected health information in accordance with RSA 141-B:9 and the provisions of 45 CFR 164 generally, and specifically, 45 CFR 164.502, 164.506 and 164.512.
- (b) The department shall maintain the confidentiality of reports submitted to the SCR pursuant to RSA 141-B:9 except in accordance with (c) below.
- (c) A report submitted to the SCR concerning an individual, and any other information maintained by the SCR, which, because of a personal identifier, can be readily associated with an individual, shall only be released:

- (1) To the individual upon:
 - a. Receipt of a written request which shall be signed by the individual; and
 - b. Presentation of identification, such as a driver's license, by the individual;

- (2) If the individual is a minor, to a parent of the individual upon:
 - a. Receipt of a written request, which shall be signed by the parent;
 - b. Receipt of a certified copy of the birth certificate of the individual; and
 - c. Receipt of a copy of the parent's identification, such as a driver's license of the parent;
- (3) If the individual has a court-appointed guardian or if the individual is deceased, to the court-appointed guardian or to the executor or administrator of the individual's estate upon:
 - a. Receipt of a written request, which shall be signed by the court-appointed guardian, executor, or administrator of the estate;
 - b. Receipt of a certified copy of the order or decree which appoints the guardian, executor, or administrator; and
 - c. Receipt of a copy of identification, such as a driver's license, by the guardian, executor, or administrator;
- (4) To an attorney or other person designated by the individual upon receipt of a written medical release request which shall be signed by the individual;
- (5) To persons conducting health related research, upon receipt and approval pursuant to He-P 304.09 of a written application to the department, which shall be signed by the applicant and includes:
 - a. The following information about the principal investigator:
 - 1. Name, address, and phone number;
 - 2. Organizational affiliation;
 - 3. Professional qualification; and
 - 4. Name and phone number of principal investigator's contact person, if any;
 - b. The following information about the data or record copies being requested:
 - 1. Type of event or record copies;
 - 2. Time period of the data or record copies;
 - 3. Specific data items required, if applicable;
 - 4. Medium in which the data or record copies are to be supplied by the bureau; and
 - 5. Any special format or layout of data required by the principal investigator;
 - c. A research protocol which shall contain:
 - 1. A summary of background and origin of the research;
 - 2. A statement of the health-related problem or issue to be addressed by the research;
 - 3. The primary research hypothesis to be tested;

4. The research design, which shall include:
 - (i) Case definition;
 - (ii) Method of case selection; and
 - (iii) Method of data analysis;
 5. The research methodology, which shall include:
 - (i) The way in which the requested data will be used; and
 - (ii) The procedures for follow-back to any persons or facilities named in records, if applicable;
 6. Procedures to obtain informed consent from the research participants, if applicable;
 7. The procedures that shall be followed to maintain the confidentiality of any data or copies of records provided to the requester; and
 8. The intended completion date;
- d. A statement signed by the principal investigator agreeing to the following:
1. The investigator shall acknowledge the department as the source of the data in any and all public reports, publications, or presentations generated by the requester from these data;
 2. The investigator shall specify that the analyses, conclusions, and recommendations drawn from such data are solely those of the requester and are not necessarily those of the department;
 3. Any data or record copies provided shall not be used for any purpose other than that described in the application;
 4. The principal investigator and the research staff shall not disclose the identity of individuals revealed in the data or record copies to any persons except as is necessary to perform the research described in the application;
 5. The data record shall not be further released to any other person or organization without the written consent of the commissioner or his designee; and
 6. No form of information derived from the data or record copies that identify any individuals shall be made public;
- e. A written statement ensuring that the investigator shall hold all information confidential; and
- f. When contact with patients will occur, submission of an Institutional Review Board (IRB) approval for the study by an IRB formed in accordance with the requirements of the U.S. Department of Health and Human Services Code of Federal Regulations for Protection of Human Subjects, 45 CFR 46, June 23, 2005; or
- (6) In association with an audit as required under Title III of Public Health Services Act, 42 U.S.C. 241 et seq.

(d) Persons fraudulently requesting data or information shall be subject to penalty for unsworn falsification pursuant to RSA 641:3.

[Source.](#) #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.09 Approval Criteria for Release of Confidential Data for Research Purposes.

(a) The commissioner shall review applications for the use of confidential SCR data, based on the following criteria:

- (1) Completeness of application, pursuant to He-P 304.08(b)(5);
- (2) Documentation of adequate measures to insure confidentiality of patients, pursuant to He-P 304.08(b)(5);
- (3) Determination of whether the study, if carried out according to the application submitted pursuant to He-P 304.08(b)(5), will be able to answer the research hypothesis as stated in this application; and
- (4) Qualifications of investigator(s) and research staff, as indicated by:
 - a. Documentation of training and previous research, such as peer reviewed publications, in the proposed or related area; and
 - b. Affiliation with a university, medical center or other institution, which will provide sufficient research resources.

(b) The commissioner shall deny an application in accordance with RSA 541-A: 29, II (a) when it has been determined that one or more of the requirements of He-P 304.08(b)(5) or He-P 304.09(a) have not been met.

[Source.](#) #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.10 Aggregate Data. The number of cancer cases shall not be released in any document where the numbers of cancer cases are between 1 and 4.

[Source.](#) #9046, eff 12-5-07; ss by #11054, eff 3-15-16

APPENDIX G: Non-Analytic Tracking Form

New Hampshire State Cancer Registry Non-Analytic Tracking Form Instructions

BACKGROUND

NHSCR requires the collection of complete cancer data for every patient seen in NH with a cancer diagnosis and/or cancer-directed treatment. As such, NHSCR requires NH reporting facilities to accession and abstract all cases seen with evidence of a reportable cancer or for cancer treatment, on or after the NHSCR reference date (June 1986). This includes patients receiving transient care, patients with active cancer admitted for medical conditions other than cancer, patients with a history of cancer that are now undergoing cancer-directed treatment, as well as pathology-only, physician-only, and consult-only cases (i.e. class case 30-99). NHSCR does not require the reporting of historical cases when there is no active disease and no cancer treatment. Place of diagnosis, initial treatment, residence, and class of case are not determining factors for reportability.

We understand that most hospitals do not collect these cases, and that abstracting non-analytics creates a burden in cancer reporting. As a compromise, NHSCR has developed this Non-Analytic Tracking Form to identify cases that have not been reported by any other source, or where the non-analytic hospital's information may better help define a case.

GENERAL INSTRUCTIONS

This form is to be used for cases that are non-analytic (class case 30-99).

Information should be entered electronically on the form.

In the "Comments" section, please provide information about the case that may be helpful for NHSCR to determine if the case is needed.

Complete all fields with the exception of the last column. In this column, NHSCR staff will indicate whether the case should be completed.

The information that you provide will be checked against the NHSCR database. If the case is not in the state registry, or if you have additional information not available in the NHSCR abstract, you will be asked to abstract and transmit that case to the NHSCR.

The Non-Analytic Tracking Form should be uploaded to WebPlus only once a week, every other week, once a month, or once a quarter, depending on your caseload.

Forms received by Friday, 4:00p.m. are processed at the beginning of the following week and returned by Wednesday of that week via Web Plus. NHSCR staff will notify you when the form has been reviewed, completed, and available on WebPlus for you to download.

Please retain a copy of the completed form for your records.

NH STATE CANCER REGISTRY
Non-Analytic Tracking Form

Facility: _____

Date Facility Sent: _____

Date NHSCR Returned: _____

[illegible]

APPENDIX H: CASEFINDING LISTS

These lists are taken from the National Institutes of Health, Surveillance Epidemiology and End Results (SEER) program. Available at: <https://seer.cancer.gov/tools/casefinding/>

This appendix consists of ICD-10-CM codes used to screen prospective cases and identify reportable cancer cases for inclusion in the registry. The casefinding list is not the same as a reportable list. Some of these codes may contain conditions that are not considered reportable; however, these diagnoses may indicate a reportable cancer associated with the condition. Casefinding must include both primary and up to four (4) secondary diagnoses. At a minimum, cases with the codes listed under the “Reportable Neoplasms” should be screened. The patient medical record should be reviewed to verify whether or not the case is a reportable cancer to the NHSCR.

ICD-10-CM Casefinding List, 2026
Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

For the full list of eligible individual ICD-10-CM codes, please refer to the Excel Format.

Insert link

COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2025-9/30/2026) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
C00- C43, C4A.-, C45- C96	Malignant neoplasms (excluding C44), stated or presumed to be primary (of specified site) or secondary cancers and certain specified histologies
C50.A (C50.A0, C50.A1, C50.A2)	Malignant inflammatory neoplasm of breast Note: New codes effective 10/1/25
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10_, C44.19_	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
D00.-- D05.-, D07.-- D09	In-situ neoplasms <i>Note 1: Excludes carcinoma in situ tumors of the cervix (D06._)</i> <i>Note 2: Excludes prostatic intraepithelial neoplasia (PIN III) (8148/2) of the prostate. Other prostate in situ histologies are reportable</i> <i>Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions</i>
D18.02	Hemangioma of intracranial structures and any site
D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.-, D43.-	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9993)
D47.02	Systemic mastocytosis

ICD-10-CM Casefinding List, 2026
Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2025-9/30/2026) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82)
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia Secondary myelofibrosis in myeloproliferative disease
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) <i>Note: Effective 1/1/2021, PTLD (9971/3) is no longer reportable (9971/1)</i>
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
D72.11-	Hypereosonophilic syndrome [HES] (9964/3)
K31.A22	Gastric intestinal metaplasia with high grade dysplasia
N85.02	Endometrial intraepithelial neoplasia [EIN]
R85.613	High grade squamous intraepithelial lesion on cytologic smear of anus (HGSIL)
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.623	High grade squamous intraepithelial lesion on cytologic smear of vagina (HGSIL)
R87.624	Cytologic evidence of malignancy on smear of vagina
R90.0	Intracranial space-occupying lesion found on diagnostic imaging of central nervous system

ICD-10-CM Casefinding List, 2026

Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

NOTE: Cases with the codes in the Supplemental list below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental lists increases casefinding for benign brain and CNS, hematopoietic neoplasms, other reportable diseases and treatment related information

SUPPLEMENTAL LIST (PART I) ICD-10-CM (EFFECTIVE DATES: 10/1/2025-9/30/2026) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
D06.-	Carcinoma in situ of the cervix
D13.7	Benign neoplasm of endocrine pancreas <i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> • Islet cell adenoma • Nesidioblastoma • Islet cell adenomatosis • Insulinoma • Beta cell adenoma
D21.4	Benign neoplasm of connective and other soft tissue of abdomen <i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)
D23.9	Other benign neoplasm of skin Benign carcinoid tumors of other sites <i>Note: Effective 1/1/2021: Review these code to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i> • Aggressive digital papillary adenoma (c44_) (8408/1, but now 8408/3)
D35.0-	Benign neoplasm of adrenal gland <i>Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3)</i> • Pheochromocytoma • Adrenal medullary paraganglioma • Chromaffin paraganglioma • Chromaffin tumor • Chromaffinoma

ICD-10-CM Casefinding List, 2026

Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

SUPPLEMENTAL LIST (PART I) ICD-10-CM (EFFECTIVE DATES: 10/1/2025-9/30/2026) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
D37.8	Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas) <i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i> • Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3) • Islet cell tumor, NOS (C259, 8150/1, now 8150/3) • Glucagonoma, NOS (C259, 8152/1, now 8152/3) • Alpha cell tumor, NOS (C259, 8152/1, now 8152/3) • Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3) • Somatostatinoma, NOS (8156/1, now 8156/3) • Somatostatin cell tumor, NOS (8156/1, now 8156/3) • Endocrine tumor, functioning, NOS (8158/1, now 8158/3) ACTH-producing tumor (8158/1, now 8158/3)
D3A.-	Benign carcinoid tumors <i>Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i> • Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3) • Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)
D44.6	Neoplasm of uncertain behavior of carotid body <i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i> • Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3)
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia <i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i> • Paraganglioma, NOS (8680/1, now 8680/3) • Sympathetic paraganglioma (8681/1, now 8681/3) • Parasympathetic paraganglioma (8682/1, now 8682/3) • Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3) • Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3) • Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3)
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage <i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i> • Clear cell odontogenic tumor (9341/1, now 9341/3)

ICD-10-CM Casefinding List, 2026

Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

SUPPLEMENTAL LIST (PART I) ICD-10-CM (EFFECTIVE DATES: 10/1/2025-9/30/2026)	
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue of abdomen <i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)
D49.2	Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas) <i>Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3)</i> • Pancreatic endocrine tumor, NOS • Islet cell tumor, NOS
D61.810	Antineoplastic chemotherapy induced pancytopenia
D64.81	Anemia due to antineoplastic chemotherapy
D70.1	Agranulocytosis secondary to cancer chemotherapy
D72.10	Eosinophilia, NOS (<i>Note: Screen for incorrectly coded Chronic eosinophilic leukemia, 9964/3</i>)
D75.81	Myelofibrosis (<i>note: this is not primary myelofibrosis [9961/3]</i>)
E31.2-	Multiple endocrine neoplasia [MEN] syndromes
E34.0-	Carcinoid syndrome
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G89.3	Neoplasm related pain (acute)(chronic)
H47.42	Disorders of optic chiasm in (due to) neoplasm
H47.52-	Disorders of visual pathways in (due to) neoplasm
H47.63-	Disorders of visual cortex in (due to) neoplasm
I31.31	Malignant pericardial effusion in diseases classified elsewhere
J70.0	Acute pulmonary manifestations due to radiation
J70.1	Chronic and other pulmonary manifestations due to radiation
J91.0	Malignant pleural effusion
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
K12.33	Oral mucositis (ulcerative) due to radiation
K52.0	Gastroenteritis and colitis due to radiation
K62.7	Radiation proctitis
K62.82	Dysplasia of anus (AIN I and AIN II)
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)
L58.-	Radiodermatitis
L59.8	Other disorders of skin and subcutaneous tissue related to radiation
L59.9	Disorder of the skin and subcutaneous tissue related to radiation, unspecified
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy
M96.2	Postradiation kyphosis

ICD-10-CM Casefinding List, 2026

Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

SUPPLEMENTAL LIST (PART I) ICD-10-CM (EFFECTIVE DATES: 10/1/2025-9/30/2026) Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
M96.5	Postradiation scoliosis
N30.4-	Irradiation cystitis
N46.024	Azoospermia due to radiation
N46.124	Oligospermia due to radiation
N52.31-N52.32, N52.34-N52.36	Post procedural erectile dysfunction (due to prostatectomy, cystectomy, radiation)
O35.6-	Maternal care for (suspected) damage to fetus by radiation
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium
P04.11	Newborn affected by maternal antineoplastic chemotherapy
P04.12	Newborn affected by maternal cytotoxic drugs
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) <i>Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable</i>
R18.0	Malignant ascites
R53.0	Neoplastic (malignant) related fatigue
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes
T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified
T45.AX-	Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs
T66.-	Unspecified effects of radiation
T80.81-	Extravasation of vesicant agent
T80.82-	Complication of immune effector cellular therapy - Complication of chimeric antigen receptor (CAR-T) cell therapy
T86.0-	Complications of bone marrow transplant
Y63.2	Overdose of radiation given during therapy
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment)
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms
Z42.1	Encounter for breast reconstruction following mastectomy
Z48.290	Encounter for aftercare following bone marrow transplant
Z48.3	Aftercare following surgery for neoplasm
Z51.0	Encounter for antineoplastic radiation therapy

ICD-10-CM Casefinding List, 2026
Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2026

SUPPLEMENTAL LIST (PART I) ICD-10-CM (EFFECTIVE DATES: 10/1/2025-9/30/2026)	
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare
Z79.63-	Long term (current) use of chemotherapeutic agent
Z79.64	Long term (current) use of myelosuppressive agent (hydroxyurea)
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels
Z85.-	Personal history of malignant neoplasm
Z85.4A	<i>Personal history of malignant neoplasm of fallopian tube(s)</i> Note: New code effective 10/1/25
Z86.00-	Personal history of in situ neoplasm
Z86.00A	<i>Personal history of in-situ neoplasm of the fallopian tube(s)</i> Note: New code effective 10/1/25
Z86.010	Personal history of colonic polyps
Z86.011	Personal history of benign neoplasm of the brain
Z86.012	Personal history of benign carcinoid tumor
Z92.21, Z92.23, Z92.25, Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z92.26	Personal history of immune checkpoint inhibitor (ICI) (drug) therapy
Z92.850	Personal history of Chimeric Antigen Receptor T-cell therapy - Personal history of CAR-T-cell therapy
Z94.81, Z94.84	Bone marrow and stem cell transplant status

APPENDIX I: NHSCR TABLE OF REQUIRED DATA ITEMS

At a minimum, reporting facilities must collect the NHSCR required data items.

**New Hampshire State Cancer Registry
Table of Required Data Items**

Code Description

R = Required
 R* = Required, when available
 R# = Required, SEER or CoC
 RH = Historically collected and currently transmitted
 RH* = Historically collected & transmitted when available
 RS = Required, site-specific
 RS* = Required, site specific; when available

RC = Collected by SEER from CoC-approved hospitals
 R^ = Required, these text requirements may be met with one or several text block field:
 S = Supplemental/recommended
 D = Derived
 DH = Historically derived and currently transmitted
 D* = Derived, when available

Required data items are in accordance with RSA 141B and part He-P 304.0 of the New Hampshire Administrative Rules.

Thornton ML, (ed). *Data Standards and Data Dictionary, Version 26, 27th ed. Springfield, Ill.: North American Association of Central Cancer Registries, June 2025.*
 (Rev. July 2025, Aug. 2025, Sept. 2025, Oct. 2025) Available at <https://apps.naaccr.org/data-dictionary/home> (Accessed

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
10	Record Type	R	R	.	.	NAACCR	Record ID		Auto-coded by software
20	Patient ID Number	R	R	.	R	Reporting Facility	Record ID		NHSCR-use only; auto-coded by software
21	Patient System ID--Hosp	.	.	.	.	NAACCR	Record ID		For cases diagnosed 2006+
30	Registry Type	.	.	.	.	NAACCR	Record ID		
40	Registry ID	R	R	.	R	NAACCR	Record ID		Auto-coded by software
45	NPI--Registry ID	.	.	.	R*	CMS	Record ID		Auto-coded by software; For cases diagnosed 2007+
50	NAACCR Record Version	R	R	.	R	NAACCR	Record ID	Revised v24 & v25	Auto-coded by software
60	Tumor Record Number	R	R	.	R	NAACCR	Record ID	NPCR Revised 8/23/2023	NHSCR-use only
70	Addr at DX--City	R	R	R	R	CoC	Demographic		
80	Addr at DX--State	R	R	R	R	CoC	Demographic		
81	State at DX Geocode 1970/80/90	RH*	RH*	.	R	NAACCR	Demographic		NHSCR-use only
82	State at DX Geocode 2000	D	D	.	D	NAACCR	Demographic		NHSCR-use only
83	State at DX Geocode 2010	D	D	.	D	NAACCR	Demographic		NHSCR-use only
84	State at DX Geocode 2020	D	D	.	D	NAACCR	Demographic		NHSCR-use only
86	Geocoding Quality Code	D*	D*	.	D	NAACCR	Demographic	New v24; Revised v26	NHSCR-use only; For cases diagnosed 2024+
87	Geocoding Quality Code Detail	D*	D*	.	D	NAACCR	Demographic	New v24; Revised v26	NHSCR-use only; For cases diagnosed 2024+
89	County at DX Analysis	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2018+
90	County at DX Reported	R	R	R	R	FIPS/SEER	Demographic		
94	County at DX Geocode 1970/80/90	RH*	RH*	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2016+
95	County at DX Geocode2000	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2016+
96	County at DX Geocode2010	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2016+
97	County at DX Geocode2020	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2016+
100	Addr at DX--Postal Code	R	R	R	R	CoC	Demographic		
102	Addr at DX--Country	R	.	R	R	NAACCR	Demographic		For cases diagnosed 2013+
110	Census Tract 1970/80/90	RH*	RH*	.	RH	SEER	Demographic		NHSCR-use only
120	Census Cod Sys 1970/80/90	RH*	RH*	.	RH	SEER	Demographic		NHSCR-use only
125	Census Tract 2020	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2018+
130	Census Tract 2000	RH	RH	.	RH	NAACCR	Demographic		NHSCR-use only
135	Census Tract 2010	R	R	.	R	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2011+
145	Census Tr Poverty Indict	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2013+
150	Marital Status at DX	R	.	.	R	SEER	Demographic		
160	Race 1	R	R	R	R	SEER/CoC	Demographic		
161	Race 2	R	R	.	R	SEER	Demographic		May be auto-coded by software
162	Race 3	R	R	.	R	SEER	Demographic		May be auto-coded by software
163	Race 4	R	R	.	R	SEER	Demographic		May be auto-coded by software
164	Race 5	R	R	.	R	SEER	Demographic		May be auto-coded by software
170	Race Coding Sys--Current	.	.	.	.	NAACCR	Demographic	Retired v25	Retired v25
180	Race Coding Sys--Original	.	.	.	.	NAACCR	Demographic	Retired v25	Retired v25
190	Spanish/Hispanic Origin	R	R	R	R	SEER/CoC	Demographic		
191	NHIA Derived Hisp Origin	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2005+
192	IHS Link	R*	R*	.	R	NPCR	Demographic		NHSCR-use only; For cases diagnosed 2006+
193	Race--NAPIA(derived API)	R	R	.	.	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2009+
194	IHS Purchased/Referred Care Delivery Area	D	D	.	D	NPCR	Demographic	Revised v24	NHSCR-use only; For cases diagnosed 2022+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
200	Computed Ethnicity	.	.	.	D	SEER	Demographic		NHSCR-use only; For cases diagnosed 1995+
210	Computed Ethnicity Source	.	.	.	R	SEER	Demographic		NHSCR-use only
220	Sex							Retired v26	Replaced with #225 for all cases; Retired v26
225	Sex Assigned at Birth	R	R	R	R	NAACCR	Demographic	New v26	For cases diagnosed 2026+; Replaces #220 for all cases effective 2026
230	Age at Diagnosis	R	R	R	R	SEER/CoC	Demographic		Auto-calculated by software
240	Date of Birth	R	R	R	R	SEER/CoC	Demographic		
250	Birthplace					SEER/CoC	Demographic	Retired v24	For cases diagnosed ≤2012; replaced with #252 & #254 effective 2013
252	Birthplace--State	R	R*	R	R	NAACCR	Demographic		For cases diagnosed 2013+
254	Birthplace--Country	R	R*	R	R	NAACCR	Demographic		For cases diagnosed 2013+
270	Census Occ Code 1970-2000	R*	R*	.	.	Census/NPCR	Demographic	Retired v25	NHSCR-use only
272	Census Ind Code CDC	R*	R*	.	.	Census/NPCR	Demographic	Revised v25	NHSCR-use only; For cases diagnosed 2013+
280	Census Ind Code 1970-2000	R*	R*	.	.	Census/NPCR	Demographic	Retired v25	NHSCR-use only
282	Census Occ Code CDC	R*	R*	.	.	Census/NPCR	Demographic	Revised v25	NHSCR-use only; For cases diagnosed 2013+
284	Urban Indian Organization (UIO)	D	D	.	D	NPCR	Demographic	Revised v24	NHSCR-use only; For cases diagnosed 2022+
285	Urban Indian Organization (UIO) Service Area	D	D	.	D	NPCR	Demographic	Revised v24	NHSCR-use only; For cases diagnosed 2022+
290	Occupation Source	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
300	Industry Source	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
310	Text--Usual Occupation	R*	R*	.	.	NPCR	Demographic		
320	Text--Usual Industry	R*	R*	.	.	NPCR	Demographic		
330	Census Occ/Ind Sys 70-00	R*	R*	.	.	NPCR	Demographic	Retired v25	NHSCR-use only
331	Geocoding Accuracy Score	D*	D*	.	D	NAACCR	Demographic	New v26	NHSCR-use only; For cases diagnosed 2026+
332	Geocoding Accuracy Type	D*	D*	.	D	NAACCR	Demographic	New v26	NHSCR-use only; For cases diagnosed 2026+
339	RUCA 2000	D	D	.	D	NAACCR	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2018+
341	RUCA 2010	D	D	.	D	NAACCR	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2018+
342	RUCA 2020	D	D	.	D	NAACCR	Demographic	New v26	NHSCR-use only; For cases diagnosed 2026+
344	Tobacco Use Smoking Status	R*	R*	R	R*	NPCR	Demographic	Revised v24	For cases diagnosed 2022+
345	URIC 2000	D	D	.	D	NAACCR	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2018+
346	URIC 2010	D	D	.	D	NAACCR	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2018+
347	URIC 2020	D	D	.	D	NAACCR	Demographic	New v26	For cases diagnosed 2026+
361	Census Block Group 2020	.	.	.	.	Census	Demographic		NHSCR-use only; For cases diagnosed 2018+
362	Census Block Group 2000	.	.	.	D	Census	Demographic	Revised v26	NHSCR-use only
363	Census Block Group 2010	.	.	.	R	Census	Demographic		NHSCR-use only; For cases diagnosed 2011+
364	Census Tr Cert 1970/80/90	RH*	RH*	.	RH	SEER	Demographic		NHSCR-use only; For cases diagnosed 1997+
365	Census Tr Certainty 2000	RH	RH	.	RH	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2003+
366	GIS Coordinate Quality	R*	R*	.	D	NAACCR	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2011+
367	Census Tr Certainty 2010	R	R	.	R	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2011+
368	Census Block Grp 1970/80/90	.	.	.	D	Census	Demographic	Revised v26	NHSCR-use only; For cases diagnosed 2008+
369	Census Tract Certainty 2020	D	D	.	D	NAACCR	Demographic		NHSCR-use only; For cases diagnosed 2018+
380	Sequence Number--Central	R	R	.	R	SEER	Cancer Identification		NHSCR-use only
390	Date of Diagnosis	R	R	R	R	SEER/CoC	Cancer Identification		
400	Primary Site	R	R	R	R	SEER/CoC	Cancer Identification		
410	Laterality	R	R	R	R	SEER/CoC	Cancer Identification		
420	Histology (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed 1992-2000
430	Behavior (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed 1992-2000
440	Grade	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed ≤2017
441	Grade Path Value	RH*	RH*	RH	RH	AJCC	Cancer Identification		For cases diagnosed 2010-2013
442	Ambiguous Terminology DX	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
443	Date Conclusive DX	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
444	Mult Tum Rpt as One Prim	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
445	Date of Mult Tumors	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
446	Multiplicity Counter	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
449	Grade Path System	RH*	RH*	RH	RH	AJCC	Cancer Identification		For cases diagnosed 2010-2013
450	Site Coding Sys--Current	R	R	.	.	NAACCR	Cancer Identification		Auto-coded by software
460	Site Coding Sys--Original	.	.	.	.	NAACCR	Cancer Identification		Auto-coded by software
470	Morph Coding Sys--Current	R	R	.	.	NAACCR	Cancer Identification	Revised v24	Auto-coded by software
480	Morph Coding Sys--Originl	.	.	.	.	NAACCR	Cancer Identification	Revised v24	Auto-coded by software
490	Diagnostic Confirmation	R	R	R	R	SEER/CoC	Cancer Identification		
500	Type of Reporting Source	R	R	.	R	SEER	Cancer Identification		
501	Casefinding Source	R*	R*	.	.	NAACCR	Cancer Identification		For cases diagnosed 2006+
522	Histologic Type ICD-O-3	R	R	R	R	SEER/CoC	Cancer Identification		For cases diagnosed 2001+
523	Behavior Code ICD-O-3	R	R	R	R	SEER/CoC	Cancer Identification		For cases diagnosed 2001+
530	EDP MDE Link Date	RS	RS	.	.	NPCR	Demographic	Revised v24	NHSCR-use only; For cases diagnosed 2022+
531	EDP MDE Link	RS	RS	.	.	NPCR	Demographic	Revised v24	NHSCR-use only; For cases diagnosed 2022+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
540	Reporting Facility	R	R	R	R	CoC	Hospital-Specific		Auto-coded by software
545	NPI--Reporting Facility	R*	R*	R	R*	CMS	Hospital-Specific		Auto-coded by software; For cases diagnosed 2007+
550	Accession Number--Hosp	R	.	R	R	CoC	Hospital-Specific		
560	Sequence Number--Hospital	R	.	R	R	CoC	Hospital-Specific		
570	Abstracted By	R	.	R	R	CoC	Hospital-Specific		
580	Date of 1st Contact	R	R*	R	.	CoC	Hospital-Specific		
590	Date of Inpt Adm	.	.	.	.	NAACCR	Hospital-Specific		
600	Date of Inpt Disch	.	.	.	.	NAACCR	Hospital-Specific		
605	Inpatient Status	.	.	.	.	NAACCR	Hospital-Specific	Retired v25	Retired v25
610	Class of Case	R	R	R	R	CoC	Hospital-Specific		
630	Primary Payer at DX	R	R*	R	R	CoC	Hospital-Specific		
668	RX Hosp--Surg App 2010	RH	.	R	.	CoC	Hospital-Specific		For cases diagnosed 2010+
670	RX Hosp--Surg Prim Site 03-2022	RH	.	R	RH	CoC	Hospital-Specific		For cases diagnosed ≤2022
671	RX Hosp--Surg Prim Site 2023	R	.	R	R	CoC	Hospital-Specific		For cases diagnosed 2023+
672	RX Hosp--Scope Reg LN Sur	R	.	R	R	CoC	Hospital-Specific		
674	RX Hosp--Surg Oth Reg/Dis	R	.	R	R	CoC	Hospital-Specific		
676	RX Hosp--Reg LN Removed	RH	.	RH	.	CoC	Hospital-Specific		
682	Date Regional Lymph Node Dissection	R	.	R	RC	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2018+
690	RX Hosp--Radiation	RH	.	.	RH	SEER	Hospital-Specific		
700	RX Hosp--Chemo	R	.	R	R	CoC	Hospital-Specific		
710	RX Hosp--Hormone	R	.	R	R	CoC	Hospital-Specific		
720	RX Hosp--BRM	R	.	R	R	CoC	Hospital-Specific		
730	RX Hosp--Other	R	.	R	R	CoC	Hospital-Specific		
740	RX Hosp--DX/Stg Proc	.	.	R	.	CoC	Hospital-Specific		
746	RX Hosp--Surg Site 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
747	RX Hosp--Scope Reg 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
748	RX Hosp--Surg Oth 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
751	RX Hosp--Recon Breast	R	.	R	R	CoC	Hospital-Specific	New v24; Revised v26	For cases diagnosed 2024+
752	Tumor Size Clinical	RH	.	.	RH	SEER	Stage/Prognostic Factors	Updated SEER v24	For cases diagnosed 2016-2023
754	Tumor Size Pathologic	RH	.	.	RH	SEER	Stage/Prognostic Factors	Updated SEER v24	For cases diagnosed 2016-2023
756	Tumor Size Summary	R	R	R	R	NPCR/CoC	Stage/Prognostic Factors	Updated SEER v26	For cases diagnosed 2016+
759	SEER Summary Stage 2000	RH	RH	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed 2001-2003 & 2015-2017
760	SEER Summary Stage 1977	RH	RH	RH	.	SEER	Stage/Prognostic Factors		For cases diagnosed ≤2000
762	Derived Summary Stage 2018	D	.	.	D	SEER	Stage/Prognostic Factors		For cases diagnosed 2018+
764	Summary Stage 2018	R	R	.	R*	SEER	Stage/Prognostic Factors		For cases diagnosed 2018+
772	EOD Primary Tumor	.	.	.	R	SEER	Stage/Prognostic Factors		
774	EOD Regional Nodes	.	.	.	R	SEER	Stage/Prognostic Factors		
776	EOD Mets	.	.	.	R	SEER	Stage/Prognostic Factors		
780	EOD--Tumor Size	.	.	RH	RH	SEER/CoC	Stage/Prognostic Factors		For cases diagnosed ≤2003
785	Derived EOD 2018 T	.	.	.	D	SEER	Stage/Prognostic Factors		
790	EOD--Extension	.	.	.	RH	SEER	Stage/Prognostic Factors		
795	Derived EOD 2018 M	.	.	.	D	SEER	Stage/Prognostic Factors		
800	EOD--Extension Prost Path	.	.	.	RH	SEER	Stage/Prognostic Factors		
810	EOD--Lymph Node Involv	.	.	.	RH	SEER	Stage/Prognostic Factors		
815	Derived EOD 2018 N	.	.	.	D	SEER	Stage/Prognostic Factors		
818	Derived EOD 2018 Stage Group	.	.	.	D	SEER	Stage/Prognostic Factors		
820	Regional Nodes Positive	R	R	R	R	SEER/CoC	Stage/Prognostic Factors		
830	Regional Nodes Examined	R	R	R	R	SEER/CoC	Stage/Prognostic Factors		
832	Date of Sentinel Lymph Node Biopsy	RS	.	RS	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+
834	Sentinel Lymph Nodes Examined	RS	.	RS	RS	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+; Breast & Melanoma only
835	Sentinel Lymph Nodes Positive	RS	.	RS	RS	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+; Breast & Melanoma only
840	EOD--Old 13 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
850	EOD--Old 2 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
860	EOD--Old 4 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
870	Coding System for EOD	.	.	.	RH	SEER	Stage/Prognostic Factors		
880	TNM Path T	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017
890	TNM Path N	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017
900	TNM Path M	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017
910	TNM Path Stage Group	RH	.	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017
920	TNM Path Descriptor	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017
930	TNM Path Staged By	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
940	TNM Clin T	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
950	TNM Clin N	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
960	TNM Clin M	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
970	TNM Clin Stage Group	RH	.	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
980	TNM Clin Descriptor	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
990	TNM Clin Staged By	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed ≤2003 & 2015-2017; Breast & Rectum 2011-2014
995	AJCC ID	D	.	D	D	NAACCR	Stage/Prognostic Factors	NPCR Revised v26	For cases diagnosed 2018+
1001	AJCC TNM Clin T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1002	AJCC TNM Clin N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1003	AJCC TNM Clin M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1004	AJCC TNM Clin Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1011	AJCC TNM Path T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1012	AJCC TNM Path N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1013	AJCC TNM Path M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1014	AJCC TNM Path Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1021	AJCC TNM Post Therapy Path (yp) T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1022	AJCC TNM Post Therapy Path (yp) N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1023	AJCC TNM Post Therapy Path (yp) M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1024	AJCC TNM Post Therapy Path (yp) Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1031	AJCC TNM Clin T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1032	AJCC TNM Path T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1033	AJCC TNM Post Therapy Path (yp) T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1034	AJCC TNM Clin N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1035	AJCC TNM Path N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1036	AJCC TNM Post Therapy Path (yp) N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1060	TNM Edition Number	R	.	R	RH	CoC	Stage/Prognostic Factors		Auto-coded by software
1062	AJCC TNM Post Therapy Clin (yc) T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1064	AJCC TNM Post Therapy Clin (yc) N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1066	AJCC TNM Post Therapy Clin (yc) M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	R	.	.	.	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1068	Grade Post Therapy Clin (yc)	R	R*	R	RS	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2021+
1112	Mets at DX-Bone	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1113	Mets at DX-Brain	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1114	Mets at Dx-Distant LN	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1115	Mets at DX-Liver	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1116	Mets at DX-Lung	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1117	Mets at DX-Other	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1120	Pediatric Stage	.	.	.	.	CoC	Stage/Prognostic Factors	Retired v26	Retired v26
1130	Pediatric Staging System	.	.	.	.	CoC	Stage/Prognostic Factors	Retired v26	Retired v26
1132	Pediatric ID	.	.	.	RS*	NAACCR	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1133	Pediatric ID Version Current	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1134	Pediatric ID Version Original	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1135	Toronto Version Number	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1136	Pediatric Primary Tumor	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1137	Pediatric Regional Nodes	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1138	Pediatric Mets	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1140	Pediatric Staged By	.	.	.	.	CoC	Stage/Prognostic Factors	Retired v26	Retired v26
1142	Derived Pediatric T	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1143	Derived Pediatric N	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1144	Derived Pediatric M	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1145	Derived Pediatric Stage Group	.	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1146	Toronto T	.	.	.	R*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1147	Toronto N	.	.	.	R*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1148	Toronto M	.	.	.	R*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1149	Toronto Stage Group	.	.	.	R*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1150	Tumor Marker 1	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed ≤2003; Site-specific
1160	Tumor Marker 2	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed ≤2003; Site-specific
1170	Tumor Marker 3	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed ≤2003; Site-specific
1172	Post Transplant Lymphoproliferative Disorder-PTLD	RS*	RS*	R	RS	NAACCR	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; Site-specific
1174	PD-L1	RS*	RS*	RS	RS	NAACCR	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; Site-specific
1176	Spread Through Air Spaces (STAS)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	New v26	For cases diagnosed 2026+; Site-specific

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1178	Residual Cancer Burden (RCB)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	New v26	For cases diagnosed 2026+; Site-specific
1179	Residual Cancer Burden Class	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	New v26	For cases diagnosed 2026+; Site-specific
1182	Lymphovascular Invasion	R	R*	R	RS	AJCC	Stage/Prognostic Factors		For cases diagnosed 2010+
1184	White Blood Cell Count	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1185	Intl Neuroblastoma Risk Grp Stag Sys (INRGSS)	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1186	n-MYC Amplification	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1187	Intl Neuroblastoma Path Prog Class (INPC)	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1188	IRSS Stage for Eye-2	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1189	Chromosome 16q: Loss of Heterozygosity	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1190	Chromosome 1q Status	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1191	EWSR1-FLI1 fusion	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1192	Pretext Clinical Staging	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1193	FOXO1 Gene Rearrangements	RS*	.	.	RS*	NAACCR/SEER	Stage/Prognostic Factors	New v25	For cases diagnosed 2025+; SEER Pediatric Data Collection System
1200	RX Date Surgery	R	R*	R	R	CoC	Treatment-1st Course		
1210	RX Date Radiation	R	R*	R	R	CoC	Treatment-1st Course		
1220	RX Date Chemo	R	R*	R	R	CoC	Treatment-1st Course		
1230	RX Date Hormone	R	R*	R	R	CoC	Treatment-1st Course		
1240	RX Date BRM	R	R*	R	R	CoC	Treatment-1st Course		
1250	RX Date Other	R	R*	R	R	CoC	Treatment-1st Course		
1260	Date Initial RX SEER	R#*	R#*	.	R	SEER	Treatment-1st Course		
1270	Date 1st Crs RX CoC	R#*	R#*	R	.	CoC	Treatment-1st Course		
1280	RX Date DX/Stg Proc	R	.	R	.	CoC	Treatment-1st Course		
1285	RX Summ--Treatment Status	R	R#	R	R	SEER/CoC	Treatment-1st Course		For cases diagnosed 2010+
1290	RX Summ--Surg Prim Site 03-2022	RH	RH	R	RH	SEER/CoC	Treatment-1st Course	Updated NPCR v26	For cases diagnosed ≤2022
1291	RX Summ--Surg Prim Site 2023	R	R	R	R	SEER/CoC	Treatment-1st Course	Updated NPCR v26	For cases diagnosed 2023+
1292	RX Summ--Scope Reg LN Sur	R	R	R	R	SEER/CoC	Treatment-1st Course		
1294	RX Summ--Surg Oth Reg/Dis	R	R	R	R	SEER/CoC	Treatment-1st Course		
1296	RX Summ--Reg LN Examined	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1310	RX Summ--Surgical Approch	RH	.	RH	.	CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1320	RX Summ--Surgical Margins	R	.	R	R*	CoC	Treatment-1st Course		
1330	RX Summ--Reconstruct 1st	RH	.	RH	.	SEER	Treatment-1st Course		For cases diagnosed 1998-2002
1335	RX Summ--Recon Breast	R	.	R	R	CoC	Treatment-1st Course	New v24; Revised v26	For cases diagnosed 2024+
1340	Reason for No Surgery	R	R	R	R	SEER/CoC	Treatment-1st Course		
1350	RX Summ--DX/Stg Proc	R	.	R	.	CoC	Treatment-1st Course		
1360	RX Summ--Radiation	RH	RH	.	RH	SEER	Treatment-1st Course		For cases diagnosed <2003
1370	RX Summ--Rad to CNS	RH	.	.	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed <1998
1380	RX Summ--Surg/Rad Seq	R	R	R	R	SEER/CoC	Treatment-1st Course		
1390	RX Summ--Chemo	R	R	R	R	SEER/CoC	Treatment-1st Course		
1400	RX Summ--Hormone	R	R	R	R	SEER/CoC	Treatment-1st Course		
1410	RX Summ--BRM	R	R	R	R	SEER/CoC	Treatment-1st Course		
1420	RX Summ--Other	R	R	R	R	SEER/CoC	Treatment-1st Course		
1430	Reason for No Radiation	R	R	R	R	CoC	Treatment-1st Course		
1460	RX Coding System--Current	R	R	.	.	NAACCR	Treatment-1st Course		May be auto-coded by software
1501	Phase I Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1502	Phase I Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1503	Phase I Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1504	Phase I Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1505	Phase I Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1506	Phase I Radiation Treatment Modality	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1507	Phase I Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1510	Rad--Regional Dose: cGy	.	.	.	.	CoC	Treatment-1st Course	Retired v25	
1511	Phase II Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1512	Phase II Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1513	Phase II Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1514	Phase II Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1515	Phase II Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1516	Phase II Radiation Treatment Modality	R	.	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1517	Phase II Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1520	Rad--No of Treatment Vol	.	.	.	.	CoC	Treatment-1st Course	Retired v25	
1521	Phase III Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1522	Phase III Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1523	Phase III Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1524	Phase III Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1525	Phase III Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1526	Phase III Radiation Treatment Modality	R	.	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1527	Phase III Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1531	Radiation Treatment Discontinued Early	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1532	Number of Phases of Rad Treatment to this Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1533	Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1540	Rad--Treatment Volume	.	.	.	.	CoC	Treatment-1st Course	Retired v25	
1550	Rad--Location of RX	R	.	R	.	CoC	Treatment-1st Course	Revised v24	
1570	Rad--Regional RX Modality	RH	RH	.	.	CoC	Treatment-1st Course		For cases diagnosed <2003
1632	Neoadjuvant Therapy	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1633	Neoadjuvant Therapy-Clinical Response	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1634	Neoadjuvant Therapy-Treatment Effect	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1639	RX Summ--Systemic/Sur Seq	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2006+
1640	RX Summ--Surgery Type	RH	.	.	RH	SEER	Treatment-1st Course		For cases diagnosed <1996; Derived
1646	RX Summ--Surg Site 98-02	RH	.	RH	.	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1647	RX Summ--Scope Reg 98-02	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1648	RX Summ--Surg Oth 98-02	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1660	Subsq RX 2nd Course Date	.	.	.	.	CoC	Treatment-Subsq & Other		For Breast, Colorectal, CML cases diagnosed 2011
1671	Subsq RX 2nd Course Surg	.	.	.	.	CoC	Treatment-Subsq & Other		
1672	Subsq RX 2nd Course Rad	.	.	.	.	CoC	Treatment-Subsq & Other		
1673	Subsq RX 2nd Course Chemo	.	.	.	.	CoC	Treatment-Subsq & Other		
1674	Subsq RX 2nd Course Horm	.	.	.	.	CoC	Treatment-Subsq & Other		
1675	Subsq RX 2nd Course BRM	.	.	.	.	CoC	Treatment-Subsq & Other		
1676	Subsq RX 2nd Course Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1677	Subsq RX 2nd--Scope LN SU	.	.	.	.	CoC	Treatment-Subsq & Other		
1678	Subsq RX 2nd--Surg Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1679	Subsq RX 2nd--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsq & Other		
1680	Subsq RX 3rd Course Date	.	.	.	.	CoC	Treatment-Subsq & Other		
1691	Subsq RX 3rd Course Surg	.	.	.	.	CoC	Treatment-Subsq & Other		
1692	Subsq RX 3rd Course Rad	.	.	.	.	CoC	Treatment-Subsq & Other		
1693	Subsq RX 3rd Course Chemo	.	.	.	.	CoC	Treatment-Subsq & Other		
1694	Subsq RX 3rd Course Horm	.	.	.	.	CoC	Treatment-Subsq & Other		
1695	Subsq RX 3rd Course BRM	.	.	.	.	CoC	Treatment-Subsq & Other		
1696	Subsq RX 3rd Course Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1697	Subsq RX 3rd--Scope LN Su	.	.	.	.	CoC	Treatment-Subsq & Other		
1698	Subsq RX 3rd--Surg Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1699	Subsq RX 3rd--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsq & Other		
1700	Subsq RX 4th Course Date	.	.	.	.	CoC	Treatment-Subsq & Other		
1711	Subsq RX 4th Course Surg	.	.	.	.	CoC	Treatment-Subsq & Other		
1712	Subsq RX 4th Course Rad	.	.	.	.	CoC	Treatment-Subsq & Other		
1713	Subsq RX 4th Course Chemo	.	.	.	.	CoC	Treatment-Subsq & Other		
1714	Subsq RX 4th Course Horm	.	.	.	.	CoC	Treatment-Subsq & Other		
1715	Subsq RX 4th Course BRM	.	.	.	.	CoC	Treatment-Subsq & Other		
1716	Subsq RX 4th Course Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1717	Subsq RX 4th--Scope LN Su	.	.	.	.	CoC	Treatment-Subsq & Other		
1718	Subsq RX 4th--Surg Oth	.	.	.	.	CoC	Treatment-Subsq & Other		
1719	Subsq RX 4th--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsq & Other		
1741	Subsq RX--Reconstruct Del	.	.	.	.	CoC	Treatment-Subsq & Other	Retired v25	
1750	Date of Last Contact	R	R	R	R	SEER/CoC	Follow-up/Recurrence/Death		
1755	Date of Death--Canada	.	.	.	.	CCCR	Follow-up/Recurrence/Death		
1760	Vital Status	R	R	R	R	SEER/CoC	Follow-up/Recurrence/Death		
1762	Vital Status Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1770	Cancer Status	R	.	R	R*	CoC	Follow-up/Recurrence/Death		
1772	Date of Last Cancer (tumor) Status	R	.	R	R*	CoC	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1775	Record Number Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1780	Quality of Survival	.	.	.	.	CoC	Follow-up/Recurrence/Death	Retired v25	
1782	Surv-Date Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1783	Surv-Flag Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1784	Surv-Mos Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1785	Surv-Date Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1786	Surv-Flag Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1787	Surv-Mos Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1788	Surv-Date DX Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1790	Follow-Up Source	R*	R*	R	R*	CoC	Follow-up/Recurrence/Death	Updated SEER v26	
1791	Follow-up Source Central	R	R	.	R	NAACCR	Follow-up/Recurrence/Death	Revised v24; Updated SEER v26	NHSCR-use only
1800	Next Follow-Up Source	S	.	R	.	CoC	Follow-up/Recurrence/Death	Updated SEER v26	
1810	Addr Current--City	S	.	.	R	SEER	Follow-up/Recurrence/Death		
1820	Addr Current--State	S	.	.	R	SEER	Follow-up/Recurrence/Death		
1830	Addr Current--Postal Code	S	.	.	R	SEER	Follow-up/Recurrence/Death		
1832	Addr Current--Country	S	.	.	R	NAACCR	Demographic		
1840	County--Current	S	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1842	Follow-Up Contact--City	.	.	.	.	SEER	Follow-up/Recurrence/Death		
1844	Follow-Up Contact--State	.	.	.	.	SEER	Follow-up/Recurrence/Death		
1846	Follow-Up Contact--Postal	.	.	.	.	SEER	Follow-up/Recurrence/Death		
1847	FollowUp Contact--Country	.	.	.	.	NAACCR	Demographic		
1850	Unusual Follow-Up Method	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1854	No Patient Contact Flag	.	.	.	R	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2023+
1856	Reporting Facility Restriction Flag	.	.	.	R	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2023+
1860	Recurrence Date--1st	R*	.	R	R*	CoC	Follow-up/Recurrence/Death	Updated SEER v26	
1880	Recurrence Type--1st	R*	.	R	R*	CoC	Follow-up/Recurrence/Death	Updated SEER v26	
1910	Cause of Death	R	R	.	R	SEER	Follow-up/Recurrence/Death		Reporting registries use 7777 or 7797
1914	SEER Cause Specific COD	D	D	.	D	SEER	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1915	SEER Other COD	D	D	.	D	SEER	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1920	ICD Revision Number	R	R	.	R	SEER	Follow-up/Recurrence/Death		Auto-coded by software
1930	Autopsy	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1940	Place of Death	RH	RH	.	.			Retired v23	For cases diagnosed ≤2012; replaced with #1942 & #1944 effective 2013
1942	Place of Death--State	R	R	.	R	NAACCR	Demographic		For cases diagnosed 2013+
1944	Place of Death--Country	R	R*	.	R	NAACCR	Demographic		For cases diagnosed 2013+
1960	Site (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides		
1971	Histology (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides		
1972	Behavior (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides		
1973	Grade (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides		
1975	Derived Summary Grade 2018	D	D	.	D	SEER	Stage/Prognostic Factors	New v24; Revised v26	For cases diagnosed 2024+
1981	Over-ride SS/NodesPos	RH	.	.	RH	NAACCR	Edit Overrides		
1982	Over-ride SS/TNM-N	RH	.	.	RH	NAACCR	Edit Overrides		
1983	Over-ride SS/TNM-M	RH	.	.	RH	NAACCR	Edit Overrides		
1985	Over-ride Acsn/Class/Seq	.	.	.	.	NAACCR	Edit Overrides		
1986	Over-ride HospSeq/DxConf	.	.	.	.	NAACCR	Edit Overrides		
1987	Over-ride CoC-Site/Type	.	.	.	.	NAACCR	Edit Overrides		
1988	Over-ride HospSeq/Site	.	.	.	.	NAACCR	Edit Overrides		
1989	Over-ride Site/TNM-StgGrp	R	.	.	R	NAACCR	Edit Overrides		
1990	Over-ride Age/Site/Morph	R	R	.	R	SEER	Edit Overrides		
1992	Over-ride TNM Stage	.	.	.	.	NAACCR	Edit Overrides		For cases diagnosed 2018+
1993	Over-ride TNM Tis	.	.	.	R	NAACCR	Edit Overrides		For cases diagnosed 2018+
1994	Over-ride TNM 3	.	.	.	.	NAACCR	Edit Overrides		For cases diagnosed 2018+
2000	Over-ride SeqNo/DxConf	R	R	.	R	SEER	Edit Overrides		
2010	Over-ride Site/Lat/SeqNo	R	R	.	R	SEER	Edit Overrides		
2020	Over-ride Surg/DxConf	R	R	.	R	SEER	Edit Overrides		
2030	Over-ride Site/Type	R	R	.	R	SEER	Edit Overrides		
2040	Over-ride Histology	R	R	.	R	SEER	Edit Overrides		
2050	Over-ride Report Source	R	R	.	R	SEER	Edit Overrides		
2060	Over-ride Ill-define Site	R	R	.	R	SEER	Edit Overrides		
2070	Over-ride Leuk, Lymphoma	R	R	.	R	SEER	Edit Overrides		
2071	Over-ride Site/Behavior	R	R	.	R	SEER	Edit Overrides		
2072	Over-ride Site/EOD/DX Dt	.	.	.	R	SEER	Edit Overrides		
2073	Over-ride Site/Lat/EOD	.	.	.	R	SEER	Edit Overrides		
2074	Over-ride Site/Lat/Morph	R	R	.	R	SEER	Edit Overrides		
2078	Over-ride Name/Sex Assigned at Birth	R	R	.	R	NAACCR	Edit Overrides	Revised v26	For cases diagnosed 2018+
2081	CRC CHECKSUM	S	.	.	S			Retired v24	Retired v24
2085	Date Case Initiated	.	.	.	.	NAACCR	Edit Overrides		Auto-coded by software
2090	Date Case Completed	.	.	.	.	NAACCR	Edit Overrides		
2092	Date Case Completed--CoC	D	.	D	.	CoC	Edit Overrides		Auto-coded by software
2100	Date Case Last Changed	D	.	D	.	NAACCR	Edit Overrides		Auto-coded by software
2110	Date Case Report Exported	R	R	.	R	NPCR	Edit Overrides		Auto-coded by software
2111	Date Case Report Received	R	R	.	R	NPCR	Edit Overrides		Auto-coded by software
2112	Date Case Report Loaded	R	R	.	R	NPCR	Edit Overrides		Auto-coded by software

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
2113	Date Tumor Record Availbl	R	R	.	D	NPCR	Edit Overrides		Auto-coded by software
2116	ICD-O-3 Conversion Flag	R	R	.	R	SEER	Edit Overrides		May be auto-coded by software
2117	Schema ID Version Current	D	D	D	D	SEER	Edit Overrides	Revised v24; Revised v25	For cases diagnosed 2021+
2118	Schema ID Version Original	D	D	D	D	SEER	Edit Overrides	Revised v24; Revised v25	For cases diagnosed 2021+
2140	CoC Coding Sys--Current	.	.	.	.	CoC	Edit Overrides		
2150	CoC Coding Sys--Original	.	.	.	.	CoC	Edit Overrides		
2152	CoC Accredited Flag	R	R	.	R	NPCR	Edit Overrides		For cases diagnosed 2018+
2155	RQRS NCD8 Submission Flag	.	.	.	.	CoC	Edit Overrides	Retired v25	For cases diagnosed 2018-2020
2156	AJCC API Version Current	D*	.	D	D*	AJCC	Edit Overrides	Revised v24; Revised v25	For cases diagnosed 2021+
2157	AJCC API Version Original	D*	.	D	D*	AJCC	Edit Overrides	Revised v24; Revised v25	For cases diagnosed 2021+
2158	AJCC Cancer Surveillance DLL Version Current	D	D	D	.	AJCC	Edit Overrides	Revised v24; Revised v25	Auto-coded by software; For cases diagnosed 2021+
2159	AJCC Cancer Surveillance DLL Version Original	D	D	D	.	AJCC	Edit Overrides	Revised v24; Revised v25	Auto-coded by software; For cases diagnosed 2021+
2170	Vendor Name	.	.	R	.	NAACCR	Edit Overrides		Auto-coded by software
2200	Diagnostic Proc 73-87	.	.	.	.	SEER	Edit Overrides	Retired v25	
2230	Name--Last	R	R	S	R	SEER	Patient-Confidential	Revised v26; CoC revised 10/15/2025	
2232	Name--Birth Surname	R	R	S	R	NAACCR	Patient-Confidential	Revised v26	For cases diagnosed 2021+
2240	Name--First	R	R	S	R	SEER	Patient-Confidential	Revised v26	
2250	Name--Middle	R	R	S	R	SEER	Patient-Confidential	Revised v26; CoC revised 10/15/2025	
2260	Name--Prefix	.	.	.	.	NAACCR	Patient-Confidential		
2270	Name--Suffix	R	.	.	R	NAACCR	Patient-Confidential		
2280	Name--Alias	R	R	S	R	NAACCR	Patient-Confidential	Revised v26; CoC revised 10/15/2025	
2290	Name--Spouse/Parent	.	.	.	.	NAACCR	Patient-Confidential		
2300	Medical Record Number	R	R	.	R	NAACCR	Patient-Confidential		
2310	Military Record No Suffix						Patient-Confidential	Retired v25	
2315	Medicare Beneficiary Identifier	R*	R*	.	.	NAACCR	Patient-Confidential		For cases diagnosed 2018+
2320	Social Security Number	R	R	.	R	SEER	Patient-Confidential		
2330	Addr at DX--No & Street	R	R	.	R	SEER	Patient-Confidential		
2335	Addr at DX--Supplementl	R	R	.	R	SEER	Patient-Confidential		
2350	Addr Current--No & Street	.	.	.	R	SEER	Patient-Confidential		
2352	Latitude	R*	R*	.	D	NAACCR	Patient-Confidential	Revised v23	NHSCR-use only
2354	Longitude	R*	R*	.	D	NAACCR	Patient-Confidential	Revised v23	NHSCR-use only
2355	Addr Current--Supplementl	.	.	.	R*	SEER	Patient-Confidential		
2360	Telephone	.	.	.	R	SEER	Patient-Confidential		
2380	DC State File Number	R	R	.	R*	State	Patient-Confidential		NHSCR-use only
2390	Name--Maiden	.	.	.	.		Patient-Confidential	Retired v24	For cases diagnosed <2021; replaced with #2232 effective 2021+
2392	Follow-Up Contact--No&St	.	.	.	.	SEER	Patient-Confidential		
2393	Follow-Up Contact--Suppl	.	.	.	.	SEER	Patient-Confidential		
2394	Follow-Up Contact--Name	.	.	.	.	SEER	Patient-Confidential		
2410	Institution Referred From	.	.	.	.	CoC	Hospital-Confidential		
2415	NPI--Inst Referred From	.	.	R	.	CMS	Hospital-Confidential		
2420	Institution Referred To	.	.	.	.	CoC	Hospital-Confidential		
2425	NPI--Inst Referred To	.	.	R	.	CMS	Hospital-Confidential		
2440	Following Registry	.	.	.	.	RH	CoC	Hospital-Confidential	
2445	NPI--Following Registry	.	.	.	.	RH*	CMS	Hospital-Confidential	
2460	Physician--Managing	.	.	.	.	NAACCR	Other-Confidential		
2465	NPI--Physician--Managing	R*	.	.	.	CMS	Other-Confidential		
2470	Physician--Follow-Up	R	.	.	R	CoC	Other-Confidential		
2475	NPI--Physician--Follow-Up	R*	.	.	R*	CMS	Other-Confidential		
2480	Physician--Primary Surg	.	.	.	.	CoC	Other-Confidential		
2485	NPI--Physician--Primary Surg	R*	.	R	.	CMS	Other-Confidential		
2490	Physician 3	.	.	.	.	CoC	Other-Confidential		
2495	NPI--Physician 3	R*	.	R	.	CMS	Other-Confidential		
2500	Physician 4	.	.	.	.	CoC	Other-Confidential		
2505	NPI--Physician 4	R*	.	R	.	CMS	Other-Confidential		
2508	EHR Reporting	.	.	.	.	NAACCR	Other-Confidential		
2520	Text--DX Proc--PE	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2530	Text--DX Proc--X-ray/Scan	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2540	Text--DX Proc--Scopes	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2550	Text--DX Proc--Lab Tests	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2560	Text--DX Proc--Op	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2570	Text--DX Proc--Path	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2580	Text--Primary Site Title	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2590	Text--Histology Title	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
2600	Text--Staging	R^	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2610	RX Text--Surgery	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2620	RX Text--Radiation (Beam)	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2630	RX Text--Radiation Other	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2640	RX Text--Chemo	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2650	RX Text--Hormone	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2660	RX Text--BRM	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2670	RX Text--Other	R^	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2680	Text--Remarks	.	.	.	R	NPCR	Text-Miscellaneous		May be met with one or several text block fields
2690	Text--Place of Diagnosis	.	.	.	.	NPCR	Text-Miscellaneous		
2800	CS Tumor Size	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2810	CS Extension	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2820	CS Tumor Size/Ext Eval	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2830	CS Lymph Nodes	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2840	CS Lymph Nodes Eval	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2850	CS Mets at DX	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2851	CS Mets at Dx-Bone	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2852	CS Mets at Dx-Brain	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2853	CS Mets at Dx-Liver	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2854	CS Mets at Dx-Lung	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2860	CS Mets Eval	RH*	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2861	CS Site-Specific Factor 7	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2862	CS Site-Specific Factor 8	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2863	CS Site-Specific Factor 9	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2864	CS Site-Specific Factor10	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2865	CS Site-Specific Factor11	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2866	CS Site-Specific Factor12	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2867	CS Site-Specific Factor13	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2868	CS Site-Specific Factor14	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2869	CS Site-Specific Factor15	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2870	CS Site-Specific Factor16	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2871	CS Site-Specific Factor17	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2872	CS Site-Specific Factor18	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2873	CS Site-Specific Factor19	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2874	CS Site-Specific Factor20	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2875	CS Site-Specific Factor21	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2876	CS Site-Specific Factor22	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2877	CS Site-Specific Factor23	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2878	CS Site-Specific Factor24	RH*	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2879	CS Site-Specific Factor25	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2880	CS Site-Specific Factor 1	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2890	CS Site-Specific Factor 2	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2900	CS Site-Specific Factor 3	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2910	CS Site-Specific Factor 4	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2920	CS Site-Specific Factor 5	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2930	CS Site-Specific Factor 6	RH*	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2935	CS Version Input Original	R*	R*	RH	RH*	AJCC	Stage/Prognostic Factors		
2936	CS Version Derived	RH*	RH*	DH	D*	AJCC	Stage/Prognostic Factors		
2937	CS Version Input Current	R*	R*	RH	RH*	AJCC	Stage/Prognostic Factors		
2940	Derived AJCC-6 T	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2950	Derived AJCC-6 T Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2960	Derived AJCC-6 N	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2970	Derived AJCC-6 N Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2980	Derived AJCC-6 M	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2990	Derived AJCC-6 M Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3000	Derived AJCC-6 Stage Grp	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3010	Derived SS1977	DH	.	DH	DH	AJCC	Stage/Prognostic Factors	Updated SEER v26	
3020	Derived SS2000	DH	RH*	DH	DH	AJCC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3030	Derived AJCC--Flag	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3040	Derived SS1977--Flag	DH	.	DH	DH	AJCC	Stage/Prognostic Factors	Updated SEER v26	
3050	Derived SS2000--Flag	DH	RH*	DH	DH	AJCC	Stage/Prognostic Factors	Updated SEER v26	
3100	Archive FIN	.	.	R	.	CoC	Hospital-Specific		
3105	NPI--Archive FIN	.	.	R	.	CMS	Hospital-Specific		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3110	Comorbid/Complication 1	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3120	Comorbid/Complication 2	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3130	Comorbid/Complication 3	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3140	Comorbid/Complication 4	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3150	Comorbid/Complication 5	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3160	Comorbid/Complication 6	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3161	Comorbid/Complication 7	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3162	Comorbid/Complication 8	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3163	Comorbid/Complication 9	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3164	Comorbid/Complication 10	RH	.	RH	.	CoC	Stage/Prognostic Factors	Retired v26	For cases diagnosed 1/1/2010-09/30/2015
3165	ICD Revision Comorbid	.	.	.	.	CoC	Stage/Prognostic Factors		May be auto-coded by software
3170	RX Date Mst Defn Srg	R*	R*	R	R*	CoC	Treatment-1st Course	Updated SEER v26	
3180	RX Date Surg Disch	R	.	R	.	CoC	Treatment-1st Course		
3190	Readm Same Hosp 30 Days	.	.	R	.	CoC	Treatment-1st Course		
3200	Rad--Boost RX Modality	.	.	.	.	CoC	Treatment-1st Course	Retired v25	
3210	Rad--Boost Dose cGy	.	.	.	.	CoC	Treatment-1st Course	Retired v25	
3220	RX Date Rad Ended	R	.	R	.	CoC	Treatment-1st Course		
3230	RX Date Systemic	R	.	R	RC	CoC	Treatment-1st Course		
3250	RX Summ--Transplnt/Endocr	R	R	R	R	CoC	Treatment-1st Course		
3270	RX Summ--Palliative Proc	R	.	R	.	CoC	Treatment-1st Course		
3280	RX Hosp--Palliative Proc	R	.	R	.	CoC	Hospital-Specific		
3300	RuralUrban Continuum 1993	D	D	.	D	NAACCR	Demographic		NHSCR-use only
3310	RuralUrban Continuum 2003	D	D	.	D	NAACCR	Demographic		NHSCR-use only
3312	RuralUrban Continuum 2013	D	D	.	D	NAACCR	Demographic		NHSCR-use only
3400	Derived AJCC-7 T	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3402	Derived AJCC-7 T Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3410	Derived AJCC-7 N	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3412	Derived AJCC-7 N Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3420	Derived AJCC-7 M	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3422	Derived AJCC-7 M Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3430	Derived AJCC-7 Stage Grp	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3440	Derived PreRx-7 T	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3442	Derived PreRx-7 T Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3450	Derived PreRx-7 N	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3452	Derived PreRx-7 N Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3460	Derived PreRx-7 M	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3462	Derived PreRx-7 M Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3470	Derived PreRx-7 Stage Grp	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3480	Derived PostRx-7 T	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3482	Derived PostRx-7 N	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3490	Derived PostRx-7 M	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3492	Derived PostRx-7 Stge Grp	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3600	Derived Neoadjuv Rx Flag	.	.	.	.	AJCC	Stage/Prognostic Factors	Retired v25	
3605	Derived SEER Path Stg Grp	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3610	Derived SEER Clin Stg Grp	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3614	Derived SEER Cmb Stg Grp	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3616	Derived SEER Combined T	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3618	Derived SEER Combined N	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3620	Derived SEER Combined M	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3622	Derived SEER Cmb T Src	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3624	Derived SEER Cmb N Src	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3626	Derived SEER Cmb M Src	DH*	.	.	DH	SEER	Stage/Prognostic Factors		
3645	NPCR Derived AJCC 8 TNM Clin Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors	Retired v26	
3646	NPCR Derived AJCC 8 TNM Path Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors	Retired v26	
3647	NPCR Derived AJCC 8 TNM Post Therapy Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors	Retired v26	
3650	NPCR Derived Clin Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors	Retired v25	
3655	NPCR Derived Path Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors	Retired v25	
3700	SEER Site-Specific Fact 1	.	.	.	R	SEER	Stage/Prognostic Factors	Revised v24	
3702	SEER Site-Specific Fact 2	.	.	.	.	SEER	Stage/Prognostic Factors		
3704	SEER Site-Specific Fact 3	.	.	.	.	SEER	Stage/Prognostic Factors		
3706	SEER Site-Specific Fact 4	.	.	.	.	SEER	Stage/Prognostic Factors		
3708	SEER Site-Specific Fact 5	.	.	.	.	SEER	Stage/Prognostic Factors		
3710	SEER Site-Specific Fact 6	.	.	.	.	SEER	Stage/Prognostic Factors		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3750	Over-ride CS 1	.	.	RH	.	AJCC	Edit Overrides		
3751	Over-ride CS 2	.	.	RH	.	AJCC	Edit Overrides		
3752	Over-ride CS 3	.	.	RH	.	AJCC	Edit Overrides		
3753	Over-ride CS 4	.	.	RH	.	AJCC	Edit Overrides		
3754	Over-ride CS 5	.	.	RH	.	AJCC	Edit Overrides		
3755	Over-ride CS 6	.	.	RH	.	AJCC	Edit Overrides		
3756	Over-ride CS 7	.	.	RH	.	AJCC	Edit Overrides		
3757	Over-ride CS 8	.	.	RH	.	AJCC	Edit Overrides		
3758	Over-ride CS 9	.	.	RH	.	AJCC	Edit Overrides		
3759	Over-ride CS 10	.	.	RH	.	AJCC	Edit Overrides		
3760	Over-ride CS 11	.	.	RH	.	AJCC	Edit Overrides		
3761	Over-ride CS 12	.	.	RH	.	AJCC	Edit Overrides		
3762	Over-ride CS 13	.	.	RH	.	AJCC	Edit Overrides		
3763	Over-ride CS 14	.	.	RH	.	AJCC	Edit Overrides		
3764	Over-ride CS 15	.	.	RH	.	AJCC	Edit Overrides		
3765	Over-ride CS 16	.	.	RH	.	AJCC	Edit Overrides		
3766	Over-ride CS 17	.	.	RH	.	AJCC	Edit Overrides		
3767	Over-ride CS 18	.	.	RH	.	AJCC	Edit Overrides		
3768	Over-ride CS 19	.	.	RH	.	AJCC	Edit Overrides		
3769	Over-ride CS 20	RH	RH	RH	RH	AJCC/NPCR	Edit Overrides		
3780	Secondary Diagnosis 1	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3782	Secondary Diagnosis 2	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3784	Secondary Diagnosis 3	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3786	Secondary Diagnosis 4	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3788	Secondary Diagnosis 5	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3790	Secondary Diagnosis 6	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3792	Secondary Diagnosis 7	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3794	Secondary Diagnosis 8	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3796	Secondary Diagnosis 9	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3798	Secondary Diagnosis 10	R*	.	R	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 10/01/2015+
3800	Schema ID	D	D	D	D	NAACCR	Stage/Prognostic Factors		
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3803	Adenoid Cystic Basaloid Pattern	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3804	Adenopathy	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3805	AFP Post-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3806	AFP Post-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3807	AFP Pre-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3808	AFP Pre-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3809	AFP Pretreatment Interpretation	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3810	AFP Pretreatment Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3811	Anemia	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3812	B symptoms	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3813	Bilirubin Pretreatment Total Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3814	Bilirubin Pretreatment Unit of Measure	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3815	Bone Invasion	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3816	Brain Molecular Markers	RS	RS	.	RS	NAACCR	Stage/Prognostic Factors	Revised v24	Site-specific; For cases diagnosed 2018+
3817	Breslow Tumor Thickness	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3818	CA-125 Pretreatment Interpretation	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3819	CEA Pretreatment Interpretation	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3820	CEA Pretreatment Lab Value	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3821	Chromosome 3 Status	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3822	Chromosome 8q Status	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3823	Circumferential Resection Margin (CRM)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3824	Creatinine Pretreatment Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3825	Creatinine Pretreatment Unit of Measure	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3826	Estrogen Receptor Percent Positive or Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3827	Estrogen Receptor Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3828	Estrogen Receptor Total Allred Score	RS	.	RS	RH	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3829	Esophagus and EGJ Tumor Epicenter	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3830	Extranodal Extension Clin (non-Head and Neck)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3831	Extranodal Extension Head and Neck Clinical	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3832	Extranodal Extension Head and Neck Pathological	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3833	Extranodal Extension Path (non-Head and Neck)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3834	Extravascular Matrix Patterns	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3835	Fibrosis Score	RS	RS	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3836	FIGO Stage	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3837	Gestational Trophoblastic Prognostic Scoring Index	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3838	Gleason Patterns Clinical	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3839	Gleason Patterns Pathological	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3840	Gleason Score Clinical	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3841	Gleason Score Pathological	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3842	Gleason Tertiary Pattern	RS*	RS*	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3843	Grade Clinical	R	R	R	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3844	Grade Pathological	R	R	R	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3845	Grade Post Therapy Path (yp)	R*	R*	R	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3846	hCG Post-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3847	hCG Post-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3848	hCG Pre-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3849	hCG Pre-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3850	HER2 IHC Summary	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3851	HER2 ISH Dual Probe Copy Number	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3852	HER2 ISH Dual Probe Ratio	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3853	HER2 ISH Single Probe Copy Number	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3854	HER2 ISH Summary	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3855	HER2 Overall Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3856	Heritable Trait	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3857	High Risk Cytogenetics	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3858	High Risk Histologic Features	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3859	HIV Status	.	.	.	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3860	International Normalized Ratio Prothrombin Time	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3861	Ipsilateral Adrenal Gland Involvement	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3862	JAK2	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3863	Ki-67	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3864	Invasion Beyond Capsule	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3865	KIT Gene Immunohistochemistry	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3866	KRAS	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3867	LDH Post-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3868	LDH Pre-Orchiectomy Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3869	LDH Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3870	LDH Upper Limits of Normal	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3871	LN Assessment Method Femoral-Inguinal	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3872	LN Assessment Method Para-Aortic	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3873	LN Assessment Method Pelvic	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3874	LN Distant Assessment Method	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3875	LN Distant: Mediastinal, Scalene	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3876	LN Head and Neck Levels I-III	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3877	LN Head and Neck Levels IV-V	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3878	LN Head and Neck Levels VI-VII	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3879	LN Head and Neck Other	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3880	LN Isolated Tumor Cells (ITC)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3881	LN Laterality	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3882	LN Positive Axillary Level I-II	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3883	LN Size	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3884	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	.	.	.	.		Stage/Prognostic Factors	Retired v24	Site-specific; For cases diagnosed 2018-2021
3885	Lymphocytosis	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3886	Major Vein Involvement	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3887	Measured Basal Diameter	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3888	Measured Thickness	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3889	Methylation of O6-Methylguanine-Methyltransferase	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3890	Microsatellite Instability (MSI)	RS*	RS*	RS	RS	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3891	Microvascular Density	RS	.	RS	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3892	Mitotic Count Uveal Melanoma	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3893	Mitotic Rate Melanoma	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3894	Multigene Signature Method	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3895	Multigene Signature Results	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3896	NCCN International Prognostic Index (IPI)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3897	Number of Cores Examined	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3898	Number of Cores Positive	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3899	Number of Examined Para-Aortic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3900	Number of Examined Pelvic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3901	Number of Positive Para-Aortic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3902	Number of Positive Pelvic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3903	Oncotype Dx Recurrence Score-DCIS	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3904	Oncotype Dx Recurrence Score-Invasive	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3905	Oncotype Dx Risk Level-DCIS	.	.	.	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3906	Oncotype Dx Risk Level-Invasive	.	.	.	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3907	Organomegaly	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3908	Percent Necrosis Post Neoadjuvant	.	.	.	.	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3909	Perineural Invasion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3910	Periphereal Blood Involvement	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3911	Peritoneal Cytology	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3913	Pleural Effusion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3914	Progesterone Receptor Percent Positive or Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3915	Progesterone Receptor Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3916	Progesterone Receptor Total Allred Score	RS	.	RS	RH	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3917	Primary Sclerosing Cholangitis	RS	.	RS	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3918	Profound Immune Suppression	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3919	EOD Prostate Pathologic Extension	RS	.	.	RS	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3920	PSA (Prostatic Specific Antigen) Lab Value	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3921	Residual Tumor Volume Post Cytorreduction	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3922	Response to Neoadjuvant Therapy	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3923	S Category Clinical	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3924	S Category Pathological	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3925	Sarcomatoid Features	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3926	Schema Discriminator 1	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3927	Schema Discriminator 2	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3928	Schema Discriminator 3	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3929	Separate Tumor Nodules	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3930	Serum Albumin Pretreatment Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3931	Serum Beta-2 Microglobulin Pretreatment Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3932	LDH Lab Value	RS	RS	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3933	Thrombocytopenia	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3934	Tumor Deposits	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3935	Tumor Growth Pattern	RS	.	RS	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3936	Ulceration	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3937	Visceral and Parietal Pleural Invasion	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2018+
3938	ALK Rearrangement	RS	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3939	EGFR Mutational Analysis	RS	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3940	BRAF Mutational Analysis	RS	.	RS	R	NAACCR	Stage/Prognostic Factors	Revised v25	Site-specific; For cases diagnosed 2021+
3941	NRAS Mutational Analysis	RS	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3942	CA 19-9 PreTX Lab Value	RS	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3943	NCDB--SARSCoV2--Test	RH*	.	RH	RH*	CoC	Special Use		For cases diagnosed 2020-2022
3944	NCDB--SARSCoV2--Pos	RH*	.	RH	RH*	CoC	Special Use		For cases diagnosed 2020-2022
3945	NCDB--SARSCoV2--Pos Date	RH*	.	RH	RH*	CoC	Special Use		For cases diagnosed 2020-2022
3946	NCDB--COVID19--Tx Impact	RH*	.	RH	RH*	CoC	Special Use		For cases diagnosed 2020-2022
3950	Macroscopic Evaluation of Mesorectum	R	.	R	RC	CoC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2022+
3955	Derived Rai Stage	.	.	.	D	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2022+
3956	p16	RS	RS	RS	RS	SEER	Stage/Prognostic Factors	Revised v24	Site-specific; For cases diagnosed 2022+
3957	LN Status Pelvic	RS	.	RS	RC	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2022+
3958	LN Status Para-Aortic	RS	.	RS	RC	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2022+
3959	LN Status Femoral-Inguinal	RS	.	RS	RC	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2022+
3960	Histologic Subtype	RS	RS*	RS	RS	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2023+
3961	Clinical Margin Width	RS	.	RS	RC	CoC	Stage/Prognostic Factors	Revised v26	Site-specific; For cases diagnosed 2023+
3964	Brain Primary Tumor Location	RS	RS	R	RS	SEER	Stage/Prognostic Factors	New v24; Revised v26	Site-specific; For cases diagnosed 2024+
7010	Path Reporting Fac ID 1	.	.	.	.	HL7	Pathology		
7011	Path Reporting Fac ID 2	.	.	.	.	HL7	Pathology		
7012	Path Reporting Fac ID 3	.	.	.	.	HL7	Pathology		
7013	Path Reporting Fac ID 4	.	.	.	.	HL7	Pathology		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
7014	Path Reporting Fac ID 5	-	-	-	-	HL7	Pathology		
7090	Path Report Number 1	-	-	-	-	HL7	Pathology		
7091	Path Report Number 2	-	-	-	-	HL7	Pathology		
7092	Path Report Number 3	-	-	-	-	HL7	Pathology		
7093	Path Report Number 4	-	-	-	-	HL7	Pathology		
7094	Path Report Number 5	-	-	-	-	HL7	Pathology		
7100	Path Order Phys Lic No 1	-	-	-	-	HL7	Pathology		
7101	Path Order Phys Lic No 2	-	-	-	-	HL7	Pathology		
7102	Path Order Phys Lic No 3	-	-	-	-	HL7	Pathology		
7103	Path Order Phys Lic No 4	-	-	-	-	HL7	Pathology		
7104	Path Order Phys Lic No 5	-	-	-	-	HL7	Pathology		
7190	Path Ordering Fac No 1	-	-	-	-	HL7	Pathology		
7191	Path Ordering Fac No 2	-	-	-	-	HL7	Pathology		
7192	Path Ordering Fac No 3	-	-	-	-	HL7	Pathology		
7193	Path Ordering Fac No 4	-	-	-	-	HL7	Pathology		
7194	Path Ordering Fac No 5	-	-	-	-	HL7	Pathology		
7320	Path Date Spec Collect 1	-	-	-	-	HL7	Pathology	Revised v25	
7321	Path Date Spec Collect 2	-	-	-	-	HL7	Pathology	Revised v25	
7322	Path Date Spec Collect 3	-	-	-	-	HL7	Pathology	Revised v25	
7323	Path Date Spec Collect 4	-	-	-	-	HL7	Pathology	Revised v25	
7324	Path Date Spec Collect 5	-	-	-	-	HL7	Pathology	Revised v25	
7480	Path Report Type 1	-	-	-	-	HL7	Pathology		
7481	Path Report Type 2	-	-	-	-	HL7	Pathology		
7482	Path Report Type 3	-	-	-	-	HL7	Pathology		
7483	Path Report Type 4	-	-	-	-	HL7	Pathology		
7484	Path Report Type 5	-	-	-	-	HL7	Pathology		
8000	Active Follow Up Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8001	Completion 1st Course Therapy Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8002	Completion 1st Course Therapy Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8003	Completion 1st Course Therapy Data Source	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8004	Documented Disease Free Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8005	First Disease Free Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8006	First Disease Free Status Data Sources Used	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8007	Additional Disease Free Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8008	Last Disease Free Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8009	Additional Disease Free Status Data Sources Used	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8010	Recurrence Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8011	First Recurrence Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8012	Type of Recurrence	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8013	Recurrence Status Data Sources Used	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8014	Progression/Residual Disease Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8015	Progression Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8016	Progression Residual Disease Status Sources Used	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8017	Subsequent Primary Status	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8018	Subsequent Primary Date	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
8019	Subsequent Primary Data Sources Used	RS*	RS*			NPCR/PCO	Follow-up/Recurrence/Death		For Breast & Colorectal cases diagnosed 2011
9751	Chemo 1 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9752	Chemo 2 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9753	Chemo 3 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9754	Chemo 4 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9755	Chemo 5 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9756	Chemo 6 NSC Number	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9761	Chemo 1 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9762	Chemo 2 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9763	Chemo 3 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9764	Chemo 4 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9765	Chemo 5 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9766	Chemo 6 Num Doses Planned	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9771	Chemo 1 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9772	Chemo 2 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9773	Chemo 3 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9774	Chemo 4 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9775	Chemo 5 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
9776	Chemo 6 Planned Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9781	Chemo 1 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9782	Chemo 2 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9783	Chemo 3 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9784	Chemo 4 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9785	Chemo 5 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9786	Chemo 6 Planned Dose Unit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9791	Chemo 1 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9792	Chemo 2 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9793	Chemo 3 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9794	Chemo 4 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9795	Chemo 5 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9796	Chemo 6 Num Doses Receivd	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9801	Chemo 1 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9802	Chemo 2 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9803	Chemo 3 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9804	Chemo 4 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9805	Chemo 5 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9806	Chemo 6 Received Dose	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9811	Chemo 1 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9812	Chemo 2 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9813	Chemo 3 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9814	Chemo 4 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9815	Chemo 5 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9816	Chemo 6 Received DoseUnit	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9821	Chemo 1 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9822	Chemo 2 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9823	Chemo 3 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9824	Chemo 4 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9825	Chemo 5 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9826	Chemo 6 Start Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9831	Chemo 1 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9832	Chemo 2 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9833	Chemo 3 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9834	Chemo 4 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9835	Chemo 5 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9836	Chemo 6 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9841	Chemo 1 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9842	Chemo 2 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9843	Chemo 3 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9844	Chemo 4 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9845	Chemo 5 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9846	Chemo 6 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9851	Chemo 1 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9852	Chemo 2 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9853	Chemo 3 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9854	Chemo 4 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9855	Chemo 5 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9856	Chemo 6 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9859	Chemo Completion Status	RS	RS			NPCR/CER	Treatment-1st Course		For Breast, Colorectal, CML cases diagnosed 2011
9861	Hormone 1 NSC Number	RS	RS			NPCR/CER	Hormone Therapy		For Breast, Colorectal, CML cases diagnosed 2011
9862	Hormone 2 NSC Number	RS	RS			NPCR/CER	Hormone Therapy		For Breast, Colorectal, CML cases diagnosed 2011
9871	BRM 1 NSC Number	RS	RS			NPCR/CER	Biological Response Modifier		For Breast, Colorectal, CML cases diagnosed 2011
9872	BRM 2 NSC Number	RS	RS			NPCR/CER	Biological Response Modifier		For Breast, Colorectal, CML cases diagnosed 2011
9880	Granulocyte CSF Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9881	Erythrocyte Growth Factor Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9882	Thrombocyte Growth Factor Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9900	BCR-ABL Cytogenetic	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9901	BCR-ABL Cytogenetic Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9902	BCR-ABL Cytogenetic Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9903	BCR-ABL FISH	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9904	BCR-ABL FISH Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9905	BCR-ABL FISH Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
9906	BCR-ABL RT-PCR Qualitative	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9907	BCR-ABL RT-PCR Qual Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9908	BCR-ABL RT-PCR Qual Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9909	BCR-ABL RT-PCR Quantitative	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9910	BCR-ABL RT-PCR Quant Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9911	BCR-ABL RT-PCR Quant Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9920	Reason Subsq RX	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9921	Subsq RX 2nd Course Surgery	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9922	Subsq RX 2nd Course Radiation	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9923	Subsq RX 2nd Course Chemotherapy	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9924	Subsq RX 2nd Course Hormone	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9925	Subsq RX 2nd Course BRM	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9926	Subsq RX 2nd Course Other	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9927	Subsq RX 2nd Course Trans/End	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9931	Subsq RX 2nd Chemo 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9932	Subsq RX 2nd Chemo 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9933	Subsq RX 2nd Chemo 3 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9934	Subsq RX 2nd Chemo 4 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9935	Subsq RX 2nd Chemo 5 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9936	Subsq RX 2nd Chemo 6 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9941	Subsq RX 2nd Horm 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9942	Subsq RX 2nd Horm 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9951	Subsq RX 2nd BRM 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9952	Subsq RX 2nd BRM 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9955	Subsq RX 2nd Date Flag CER	RS	RS			NPCR/CER/PCO	Treatment-Subsq & Other		For Breast, Colorectal, CML cases diagnosed 2011
9960	Height	R	R			NPCR/CER	Work Up		For cases diagnosed 2011+
9961	Weight	R	R			NPCR/CER	Work Up		For cases diagnosed 2011+
9965	Tobacco Use Cigarettes	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9966	Tobacco Use Other Smoke	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9967	Tobacco Use Smokeless	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9968	Tobacco Use NOS	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9970	Source Comorbidity	R	R			NPCR/CER	Comorbidities		For cases diagnosed 2011
9980	NBCCEDP Linkage Results	RS	RS			NPCR/CER	NBCCEDP		NHSCR-use only; For Breast & Cervix cases
9981	NBCCEDP Linkage Date	RS	RS			NPCR/CER	NBCCEDP		NHSCR-use only; For Breast & Cervix cases

APPENDIX M: Case Studies for Coding Melanoma in STORE

Case Studies for Coding Melanoma in STORE

May 29, 2024

Introduction

The coding of examples in this document have been verified by multiple standard setters as well as the Synoptic Operative Reports physicians.

Note: If registry software allows coding of multiple procedures, registrars are encouraged to capture all procedures. However, only the most definitive (most invasive) surgical procedure will be submitted to NCDB. In the provided examples, only the most definitive (most invasive) procedure is coded.

This guide is to provide added clarification when coding the data items for melanoma skin primaries per STORE rules.

The clinical surgical melanoma margin is captured separately under a Site-Specific Data Item [3961] effective for diagnosis years 2023+. The clinical surgical margin should be coded from the operative report or physician documentation. Do not code clinical surgical margins from the pathology report.

If the primary site is not skin (C44.X) assign the SSDI Clinical Margins [3961] to code XX.9 (unknown).

Where to find the data to code

- To accurately code the melanoma/skin procedure codes, registrars should review all available operative notes, pathology notes, and clinical notes pertaining to the case.
- If needed, communicate to obtain additional information from internal divisions (pathology department) as well as outside facilities (referring facility) to ensure the most accurate and complete data is being captured.
- Review the current STORE manual for the specific data item. Your review should include the description, the rationale for capturing and the complete coding instructions.
- This manual should be used in conjunction with the STORE rules for coding the skin/Melanoma surgical data items.
- One significant change to the coding rules for cases diagnosed 2023 and after is that shave, punch, or elliptical biopsies are coded as surgical procedure regardless of margin status.
- Melanoma procedure questions should be directed to the CANSWER Forum STORE at <https://cancerbulletin.facs.org/forums/forum/fords-national-cancer-data-base/store>
- Site specific questions (including questions regarding melanoma clinical margin #3961) should be directed to SSDI CANSWER Forum at <https://cancerbulletin.facs.org/forums/forum/site-specific-data-items-grade-2018>

Case Studies: 1 Punch Biopsy Followed by WLE with SLN Biopsy and LN Dissection Performed on the Same Day

Clinical

- 1/1/2023 PE: 59-year-old male presented to dermatology office with a 1.5 cm area of concern on right forearm.

Procedures/Operative Report

- 1/1/2023 Punch biopsy Rt forearm: residual melanoma left at margins (reporting facility)
- 1/25/2023 Wide Local Excision (WLE) performed at an outside facility. Lesion on Rt forearm Size of specimen was 2.5 cm, clinical margin 1.5cm. SLN bx: Due to the positive SLN on frozen section, an axillary LN dissection was performed.

Pathology

- 1/1/2023 Punch bx skin of Rt forearm: Malignant Melanoma, Breslows thickness 1.2 mm
- 1/25/2023 Wide Local Excision lesion on Rt forearm: Histopathological examination of the excised 2.5cm specimen confirms complete removal of the melanoma with clear surgical margins. No evidence of residual disease. The Breslow thickness is consistent with the findings from the initial biopsy, measuring 1.2 mm. 1+/3 SLN, 0+/7 Ax LN.

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	01012023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	01252023
	5	RX Hosp- Surg 2023 [671]	B230
	6	RX Summ -Surg 2023 [1291]	B530
	7	SSDI Clinical Margins [3961]	1.5
	8	Date of SLN Biopsy [832]	01252023
	9	Date of Regional LN Dissection [682]	01252023

Coding Logic

- #1: Code biopsy procedures to the Surgical Diagnostic and Staging Procedure (SDSP) ONLY when there is a small specimen of tissue taken from the melanoma tumor, such as a core biopsy. This is a change from diagnosis year 2022. For diagnosis year 2023, melanoma primary will rarely have a code other than 00 in the SDSP data item. For this scenario, a punch biopsy was performed with positive margins so code SDSP to code 00.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00. Blanks are allowed for cases that are applicable.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility. In this scenario, code the date of the punch biopsy, performed on 1/1/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment. In this scenario it would be the date of the WLE, 1/25/23.
- #5: Rx Hosp-Surg 2023 is assigned code B230: punch biopsy performed at reporting facility.
- #6: Rx Summ-Surg 2023 is assigned code B530: punch biopsy followed by a WLE performed at an outside facility.
- #7: SSDI Clinical Margins is taken from the 1/25/2023 procedure note (1.5cm clinical margin from the WLE).
- #8 and #9: Date of SLN bx [832] records the date of the sentinel lymph node(s) biopsy procedure and Date of Regional Lymph Node Dissection [682] records the date of LN dissection. Both the SLN bx and the RLN dissection were performed on the same day; enter the date 1/25/2023 for both data items.

2 Shave Biopsy followed by WLE

Clinical

- 1/17/2023 PE: Patient presents with an irregular pigmented macule on the left upper arm. The macule measures 6 mm. The exam was normal other than the 6 mm macule on the left arm.

Procedures

- 1/17/2023 shave biopsy left upper arm (reporting facility)
- 2/9/2023 Wide local excision of 6 mm melanoma of left upper arm for Breslow 0.4 mm as determined by previously excised melanoma: Excision with 1 cm clinical margin (outside facility)

Pathology

- 1/17/2023 Shave bx Lt upper arm: Malignant melanoma, superficially invasive, depth of invasion (Breslow's thickness) 0.4 mm, Margins negative
- 2/9/2023 WLE lesion Lt upper arm: margins clear, consistent with previous biopsy site

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	01172023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	02092023
	5	RX Hosp- Surg 2023 [671]	B220
	6	RX Summ-Surg 2023 [1291]	B520
	7	SSDI Clinical Margins [3961]	1.0
	8	Date of SLN Biopsy [832]	Blank
	9	Date of Regional LN Dissection [682]	Blank

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item: assign 00 since there was no core biopsy performed.
- #2: Date of SDSP Procedure [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
In this scenario, the data item would be coded to the date of the shave biopsy, 01/17/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed. In this scenario, the date would be coded to the date of the WLE, 02/9/2023.
- #5: Rx Hosp- Surg 2023 is assigned code B220: Shave biopsy, NOS performed at reporting facility
- #6: Rx Summ-Surg 2023 is assigned code B520: Shave Biopsy followed by wide excision performed at an outside facility (WLE and re-excision are equivalent when assigning surgical codes.)
- #7: SSDI Clinical Margins is assigned 1.0 from WLE procedure note.
- #8 and #9: No LNs were taken so both Date of SLN Biopsy and Date of Regional LN Dissection would be blank.

3 Elliptical Biopsy Followed by WLE with SLN Biopsy and Lymph Node Dissection Performed on the Same Day

Clinical

- 11/5/23 CC: Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5 cm suspicious-looking mole was noted on the dorsal upper left arm, just proximal to the elbow. Head, neck, thorax, and abdominal exams were normal, except for a hard, enlarged, non-tender mass felt in the left axillary region

Procedures

- 11/13/23 Elliptical Biopsy lesion Lt upper arm (reporting facility)
- 12/15/23 Re- excision lesion of Lt upper arm with 2 cm peripheral margins, sentinel node biopsy, axillary lymphadenectomy (outside facility)

Pathology

- 11/13/23 Elliptical bx lesion Lt upper arm: Superficial spreading melanoma with vertical level V invasion; Breslow's thickness approximately 6.0 mm, ulcerated; lesion present at the lateral edge; 12/15/23 Wide excision lesion Lt upper arm: Residual melanoma margins of resection are negative; 2+/4 SLNs; 8+/27 AxLNs

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item: assign 00 since there was no core biopsy performed.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
In this scenario, the data item would be coded to the date of the elliptical biopsy, 11/13/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed. In this scenario, the date would be coded to the date of the WLE, 12/15/2023.
- #5: Rx Hosp-Surg 2023 is assigned code B240: Elliptical biopsy performed at reporting facility
- #6: Rx Summ-Surg 2023 is assigned code B540: Elliptical Biopsy (aka fusiform) followed by re-excision (WLE) at an outside facility.
 - NOTE: WLE and re-excision are equivalent when assigning surgical codes.
- #7: SSDI Clinical Margins is assigned 2.0 since documented as 2cm in the WLE procedure note.
- #8 and #9: SLN and LAD performed same day, 12/15/2023 entered for Date of SLN Biopsy [832] and Date of Regional LN Dissection [682].

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	11132023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	12152023
	5	RX Hosp-Surg 2023 [671]	B240
	6	RX Summ-Surg 2023 [1291]	B540
	7	SSDI Clinical Margins [3961]	2.0
	8	Date of SLN Biopsy [832]	12152023
	9	Date of Regional LN Dissection [682]	12152023

4 Case Study Slow Mohs

Clinical

- 6/25/23 Physical Exam: A 77-year-old white male presents for Mohs surg for melanoma in-situ of the left nasolabial fold diagnosed on routine skin exam. Exam demonstrates a 11x9 mm ill-defined erythematous patch on the left nasolabial fold. Lymph node exam negative.

Procedures

- 5/22/23 Shave bx lesion left nasolabial fold (reporting facility)
- 6/25/23 Mohs exc. lesion Lt nasolabial fold (layer 1): Entire gross spec with 5 mm margins excised to subq. plane. (outside facility)
- 6/27/23 Mohs exc. lesion left nasolabial fold (layer 2): Re-exc. w/add 3 mm margins to subq. plane. (outside facility)

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	05222023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	06272023
	5	RX Hosp-Surg 2023 [671]	B220
	6	RX Summ- Surg 2023 [1291]	B320
	7	SSDI Clinical Margins [3961]	XX.9
	8	Date of SLN Biopsy [832]	Blank
	9	Date of Regional LN Dissection [682]	Blank

Pathology

- 5/22/23 Shave bx lesion left nasolabial fold: Melanoma in situ; Invasive melanoma not present; Melanoma in situ present at transected lateral margins
- 6/25/23 Mohs excision left nasolabial fold: Residual melanoma in situ with associated biopsy site changes; Multiple peripheral margins positive; Deep margin clear
- 6/27/23 Mohs excision left nasolabial fold (layer 2): Bx site changes w/actinic keratoses & solar lentigines; no residual atypical melanocytic proliferation

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item, assign 00 since no core biopsy performed.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility. In this scenario, it would be coded to the date of the shave biopsy, 5/22/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed. In this scenario use the date of the Mohs, 6/27/2023.
- #5: Rx Hosp-Surg 2023 is assigned code B220 Shave biopsy, NOS per documentation in the op report at the reporting facility.
- #6: Rx Summ-Surg 2023 is assigned code B320 for Mohs surgery performed on different days.
- #7: SSDI Clinical Margins is only assigned if a wide excision is performed.
- Assign code to XX.9 because the clinical margin width from the Mohs procedure should not be documented in this data item.
- #8 and #9: No SLN Biopsy or LAD performed, Date of SLN Biopsy [832] and Date of Regional LN Dissection [682] should be blank.

5 Core Biopsy followed by WLE with SLN Biopsy

Clinical

- 01/2/2023 PE: Left upper chest with 0.8 cm flesh colored waxy papule exhibiting dark brown and light brown pigmentation.

Procedure

- 1/2/2023 Core biopsy papule on left chest (Reporting facility)
- 1/15/2023 Wide excision Lt upper chest papule with 1.0 cm peripheral margin, sentinel node biopsy, (outside facility)

Pathology

- 1/2/2023 core biopsy papule Left upper chest: 0.5 mm core of tissue; 0.3 mm invasive melanoma
- 1/15/2023 WLE papule Lt upper chest invasive malignant melanoma; excised specimen with clear surgical margins. No evidence of residual disease or lymphovascular invasion is identified. The Breslow thickness is consistent with the findings from the initial biopsy, measuring .3mm. Sentinel lymph node analysis reveals no evidence of metastatic disease. ; 0+/1 SLN

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	02
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	01022023
	3	Date of First Surgical Procedure [1200]	01152023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	01152023
	5	RX Hosp-Surg 2023 [671]	B000
	6	RX Summ-Surg 2023 [1291]	B510
	7	SSDI Clinical Margins [3961]	1.0
	8	Date of SLN Biopsy [832]	01152023
	9	Date of Regional LN Dissection [682]	Blank

Coding Logic

- #1: Code biopsy procedures to the Surgical Diagnostic and Staging Procedure (SDSP) ONLY when there is small specimen of tissue taken from the melanoma tumor, such as a core biopsy. This is a change from diagnosis year 2022.
For diagnosis year 2023, melanoma primary will rarely have a code other than 00 in the SDSP data item. For this scenario, a core biopsy was done; capture the core biopsy in the Surgical Diagnostic and Staging Procedure [1350] data item as code 02.
- #2: Code the Date of Surgical Diagnostic and Staging Procedure [1280] to the date of core biopsy.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
In this scenario; use the date of the WLE, 01/15/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed. In this scenario, the date would be coded to the date of the wide excision, 1/15/2023.
- #5: RX Hosp-Surg 2023 is assigned code B000: no surgical procedure performed at reporting facility.
- #6: RX Summ- Surg 2023 is assigned code B510: needle or core biopsy of tumor followed by a WLE.
- #7: SSDI Clinical Margins is 1.0 from the 01/15/2023 WLE note.
- #8: Date of SLN Biopsy [832] is the date of the SLN biopsy, 01/15/2023.
- #9: Date of Regional LN Dissection [682] would be left blank since no dissection was performed.

6 Biopsy followed by MOHs followed by WLE with SLN Biopsy

Clinical

- All information available is below.

Procedure

- 6/20/2023 Right cheek biopsy (reporting facility)
- 8/14/2023 Mohs right cheek (outside facility)
- 8/16/2023 WLE lesion right cheek w/ SLN biopsy (outside facility)

Pathology

- 6/20/2023 Rt cheek bx: Lentigo malignant melanoma; thickness 0.83 mm; anatomic level III- early IV; peripheral margins involved by MIS in both portions of tissue; deep margins not involved
- 8/14/2023 Mohs Rt cheek: Peripheral margins involved w/ MIS
- 8/16/2023 WLE lesion Rt cheek: no residual tumor appreciated on gross examination; all margins microscopically negative; 0+/2 SLN

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	06/20/2023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	08/16/2023
	5	RX Hosp-Surg 2023 [671]	B200
	6	RX Summ-Surg 2023 [1291]	B500
	7	SSDI Clinical Margins [3961]	XX.9
	8	Date of SLN Biopsy [832]	08/16/2023
	9	Date of Regional LN Dissection [682]	Blank

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item: assign 00 since no core biopsy was performed.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
In this scenario, use the date of the biopsy, 6/20/2023.
- #4: Date of Most Definitive Surgical Resection of the Primary Site [3170] records the date of the most definitive surgical procedure of the primary site performed. In this scenario, the date would be coded to the date of the WLE, 8/16/2023.
- #5: RX Hosp-Surg 2023 is assigned code B200 for biopsy NOS.
- #6: RX Summ-Surg 2023 is assigned code B500: Biopsy, NOS of primary tumor followed by WLE.
- #7: SSDI Clinical Margins is assigned XX.9: Wide Excision performed but clinical margin width not documented.
- #8: Date of SLN Biopsy [832] is the date the SLN was performed, 8/16/2023.
- #9: Date of Regional LN Dissection [682] is left blank since no LN dissection was performed.

7 Excisional Biopsy followed by WLE, SLN and LAD performed on different days

Clinical

- All information available is below.

Procedure

- 10/1/2023 excisional biopsy of right shoulder lesion (reporting facility)
- 10/25/2023 wide local excision with 2 cm margins and SLN biopsy (outside facility)
- 11/4/2023 Regional lymph node dissection (outside facility)

Pathology

- 10/1/2023 Excisional bx: superficial spreading melanoma; all margins uninvolved; closest peripheral margin was 2.4 mm; deep margin was 2.25 mm
- 10/25/2023 WLE: negative for residual melanoma; 1+/2 SLN.
- 11/4/2023 RLND: 1+/7 regional lymph nodes

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	10/01/2023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	10/25/2023
	5	RX Hosp-Surg 2023 [671]	B200
	6	RX Summ-Surg 2023 [1291]	B500
	7	SSDI Clinical Margins [3961]	2.0
	8	Date of SLN Biopsy [832]	10/25/2023
	9	Date of Regional LN Dissection [682]	11/04/2023

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item: assign code 00 since no core biopsy was performed.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
In this scenario, it would be coded to the date of the excisional biopsy, 10/01/2023.
- #4: Date of Most Definitive Surgical Resection of Primary Site [3170] records the date the most definitive surgical procedure of the primary site was performed. In this scenario, use 10/25/2023.
- #5: RX Hosp-Surg 2023 is assigned B200: Excisional biopsy NOS.
- #6: RX Summ- Surg 2023 is assigned B500: Biopsy of primary tumor followed by WLE.
- #7: SSDI Clinical Margins is coded 2.0 per the 10/25/2023 WLE procedure note.
- #8: Date of SLN Biopsy [832] is the date the SLN biopsy was performed, 10/25/2023.
- #9: Date of Regional LN Dissection [682] is the date the regional lymph node dissection was performed, 11/04/2023.

8 Excisional Biopsy Followed by WLE with SLN Biopsy

Clinical

- All information available is below.

Procedure

- 2/20/23 EXC of 20 mm Left Abdominal Skin Lesion; lesion excised in Wide Local Elliptical fashion with 0.5 cm Margin (reporting facility)
- 3/30/23 WLE Malignant Melanoma of Left Side ABD Wall w/ SLN BXs: Margins measuring 3.1 cm x 5.2 cm (outside facility)

Pathology

- 2/20/23 EXC LT Abdominal Skin Lesion: Malignant Melanoma Unclassified; TS 4.5 mm; DOI Clark Level IV; 0.8 mm; Ulceration absent; Mitosis 1.5/mm²; Brisk TIL; No regression; No satellites; No PNI; No LVI; ALL SURG MARGINS FREE OF TUMOR (tumor is 3.5 mm from closest circumference surgical margin and 5 mm from deep surgical margin); CAP=Incisional BX, Skin of Trunk
- 3/30/23 WLE Left ABD Wall Melanoma: No Residual Melanoma; 0+/1 left Groin LN; 0+/2 Left AX LNs

Seg	#	Field	Code/Definition
Summary	1	Surgical Diagnostic and Staging Procedure [1350]	00
	2	Date of Surgical Diagnostic and Staging Procedure [1280]	Blank
	3	Date of First Surgical Procedure [1200]	02/20/2023
	4	Date of Most Definitive Surgical Resection of Primary Site [3170]	03/30/2023
	5	RX Hosp-Surg 2023 [671]	B240
	6	RX Summ-Surg 2023 [1291]	B540
	7	SSDI Clinical Margins [3961]	XX.9
	8	Date of SLN Biopsy [832]	03/30/2023
	9	Date of Regional LN Dissection [682]	Blank

Coding Logic

- #1: Surgical Diagnostic and Staging Procedure [1350] data item, assign 00 since no core biopsy was performed.
- #2: Date of SDSP [1280] is blank since SDSP procedure [1350] is 00.
- #3: Date of First Surgical Procedure [1200] records the earliest date on which any first course surgical procedure was performed including Scope of Regional Lymph Node Surgery [1292] (except for code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility. In this scenario, it would be coded to the date of the excision of the left abdominal skin lesion, 2/20/2023.
- #4: Date of Most Definitive Surgical Resection of Primary Site [3170] records the date the most definitive surgical procedure of the primary site was performed. In this scenario use the date of the WLE, 3/30/2023.
- #5: RX Hosp-Surg 2023 is assigned B240: Elliptical Biopsy
- #6: RX Summ-Surg 2023 is assigned code B540: Elliptical Biopsy followed by WLE
- #7: SSDI Clinical Margins is coded to XX.9 as the margin is not documented in the 3/30/2023 WLE Op Report. Do not use the clinical margins (e.g., 3.1 cm x 5.2 cm) for this data item. This margin is documented by the surgeon in the CoC operative note as a single measurement, which if missing, is coded as XX.9 by the registrar.
- #8: Date of SLN Biopsy [832] is 03/30/2023, the date the SLN bx was performed.
- #9: Date of Regional LN Dissection [682] should be left blank since no LAD performed.

Appendix M Summary of Coding Rules

Data items Surgical Procedure of Primary Site at this Facility [NAACCR data item #670] and Surgical Procedure of Primary Site [NAACCR data item #1290] are no longer collected beginning with diagnosis year 2023.

Do not re-assign codes previously coded for diagnosis years 2022 and prior for data items #670 and #1290.

Margins are collected under a new SSDI and are no longer factored into the surgical code.

Assign biopsy procedures to the Surgical Diagnostic and Staging Procedure (SDSP) **ONLY** when there is small specimen of tissue taken from the melanoma tumor, such as a core biopsy. This is a change from diagnosis year 2022. For diagnosis year 2023, melanoma primary will rarely have a code other than 00 in the SDSP data item.

Code the procedure and not the results of the procedure.

For coding SSDI Clinical Margins [3961] , this margin is documented by the surgeon in the CoC operative note as a single measurement:

- If the margin documentation is missing, the SSDI Clinical Margin should be coded as XX.9, do not use other measurements.
- Do not use any clinical margin measurements (e.g., 3.1 cm x 5.2 cm) for this data item as this describes the specimen measurements and not the clinical margin width.
- If multiple WLE procedures are performed, record the documented margin from the op note with the largest margin.
- Do not record the deep , circumferential, or peripheral/lateral margin in this data item as these terms are not interchangeable with the clinical margin width.
- Margins should not be added together.
- Clinical margin width is the planned, visible boundary of normal skin removed around the tumor during surgery and should be specified in the operative report as a single measurement i.e. (0.5, 1, 2cm).

Additional information can be located in the CoC QPort Operative Standards Toolkit.

APPENDIX R: CTR Guide to Coding Radiation Therapy Treatment in the STORE

CTR Guide to Coding Radiation Therapy Treatment in the STORE

Version 6.0 January 2024

Prepared by

Ted Williamson, MD, PhD, CTR
Salem Health Radiation Oncology (Emeritus)
Medical Director, Onco, Inc.

Wilson Apollo, MS, CTR
WHA Consulting

Susanne Kessler, MSM, RHIT, CTR
Manager, NCDB Information and Data Standards,
Commission on Cancer

John Christodouleas, MD, MPH
Department of Radiation Oncology,
Hospital of the University of Pennsylvania
Medical Affairs, Elekta Inc.

Kimberly Taintor, RTT
Cancer Registrar
Department of Veterans Affairs

Ashley Maxey, BRST(T), CTR
Cancer Registrar II
Inova Schar Cancer Institute

On behalf of the Commission on Cancer
Radiation Oncology Working Group

A Word from the Editors

The work you do collecting radiotherapy data elements matters a lot. Over the last 5 years, over 2,000 manuscripts have been published utilizing radiotherapy data from the National Cancer Database or SEER. These manuscripts, in small ways and large, help clinicians take better care of patients, policy makers take better care of communities, and academics and entrepreneurs develop more impactful innovations. All these benefits to radiotherapy patients and society start with you. We hope you take enormous personal satisfaction knowing how important this work is to the radiotherapy community and our patients.

The work you do collecting radiotherapy data elements is not easy. Radiotherapy is delivered in a wide variety of settings, radiotherapy technology is constantly changing, and clinicians often describe their treatments using informal, seemingly inconsistent terminology. Despite these challenges, the CTR community has been extraordinary successful at capturing complete and accurate information. As members of the CoC Radiation Oncology Working Group, we review analyses of completeness. We can confirm that the transition to STORE from FORDS has been an enormous success. We want you to know that we are committed to you like you are committed to the cancer community. This Guide is our best attempt to provide an easy-to-use resource for clarifying how to code radiotherapy courses, but it is not perfectly accurate or complete. If you see errors or find gaps, do not hesitate to let us know. We are eager to make this better.

Revision History

Date	Version	Remarks
03/15/2019	1.0	Initial release
02/2020	2.0	First revision
02/2021	3.0	Third revision
02/2022	4.0	Fourth revision, 3 new case studies
01/2023	5.0	Fifth revision
01/2024	6.0	Sixth revision

Changes

Date	Page	Remarks
12/15/2023	409	Removed outdated note regarding changes in the STORE 2021

Introduction

By now you undoubtedly know that, with the STORE, coding for radiation treatment has changed significantly. These changes were introduced to provide the NCDB with a more complete and accurate description of contemporary radiation treatment. Consistent coding and reporting of treatment across multiple registry platforms is critical in many dimensions:

- Optimizing quality measure performance scores
- Providing meaningful outcome results for future analysts of NCDB data
- Allowing accurate comparisons of patterns of care by type, size, and location of treating facilities
- Monitoring practice patterns over time
- Offering in-house reports of service utilization, and predictions of growth for facility planning.

While the STORE changes offer a significant improvement in the value of radiation treatment data, they also present a challenge for the cancer registrar charged with translating the radiation record into the 31 data fields defined by STORE. To that end, this document has been prepared as a platform for “learning by example”. It is our hope that the clinical examples provided will lead the way to efficient and uniform reporting of radiation data. This third edition contains several new examples drawn from contact with registrars at meetings and webinars, as well as questions submitted to CAnswer. We expect this to continue to be a living document that evolves as technology changes, or we are presented with new clinical situations. To that end, we invite the CTR community to continue submit cases that do not seem to be covered within to the Commission on Cancer CAnswer.

Where is the Data?

Note to Cancer Registry Software Developers and Vendors

You will observe that (a) this document does not bear a copyright statement, and (b) it has been provided in a standard, editable, word processing platform. We encourage you to supplement the document with text and graphics that will assist your client registrars in applying the coding standards provided in these case studies to your particular implementation of the radiation data fields. However, in doing so please do not alter the coding guidance of the individual case studies without consulting with the Commission on Cancer.

If you have years of experience abstracting radiation data, you probably “know the ropes” and can skip this short section. There are a few principles here that will help you towards the goal of complete and accurate data collection.

1. Start early in the patient’s course. Much of the data you need will be available once the treatment prescriptions have been written if you have read access to the radiation therapy department “record and verify” system. Most courses of radiation therapy are completed as initially prescribed. For these, when treatment is completed, all you should have to do is confirm or update the dates.
2. The ultimate source of data should be the mandatory treatment summary letter created by the radiation oncologist. Most radiation oncologists are very supportive of the registry’s contribution but not all speak the language of STORE so you may have to train them a bit.
3. Get to know your radiation oncologists. They tend to be active participants in cancer conferences. Take your questions to them in or after that venue. They are a friendly bunch.
4. If you abstract remotely, particularly if you are employed by an outside contractor, find a way to contact the radiation oncologists directly, introduce yourself, and let them know you want to work with them in support of the cancer program.

Summary of Coding Principles

1. **First Course:** You are responsible for, and the NCDB wants, documentation only of treatment given in the “first course of treatment for this cancer”. Nothing more. Nothing less. Forget the old 4-month rule. The first course of treatment is clearly defined in the STORE as this snippet from STORE2021, page 52, shows.

First Course of Treatment

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.

This doesn’t mean you can’t collect data from subsequent courses. Just don’t put it in the first three (reportable) phases. For an example of treatment that you would not document in these three sets of fields, see Case #10.

We know that, in some cases, you, or your administration, or your radiation oncology team (often the registrar’s best friend) may want to collect data on additional first course phases, or treatment given in later courses. If your registry software can support this data, you should put it outside the set of three phases designated by your software vendor as reportable.

2. **Words:** There are few words in the oncology treatment lexicon with more possible interpretations than “course”. To the medical oncologist it typically means a series of treatments with a specific combination of drugs, including periodic dose adjustments. To some radiation oncologists, it describes a series of treatments to one specific target irrespective of possible changes along the way. As we have just seen, STORE has its own definition. This is the one you should use. We are working to get everyone else on board.

“Phase” is another term with confusion potential. It appears briefly in the ROADS radiation treatment discussions, and with more conviction in the FORDS, but has now become an anchor term for separating the distinct components of a “course” of radiation. Each phase is meant to reflect a “delivered radiation prescription”. At the start of the radiation planning process, physicians write radiation prescriptions to treatment volumes and specify the dose per fraction (session), the number of fractions, the modality, and the planning technique. A phase simply represents the radiation prescription that has actually been delivered (as sometimes the intended prescription differs from the delivered prescription.) The STORE 2021 definition on page 50 is quite specific:

Note that phases can be delivered sequentially or simultaneously. In sequential phases, a new phase begins when there is a change in the anatomic target volume of a body site, treatment fraction size, modality or technique.

Many of the case examples that follow are designed to emphasize this definition. Please note that phases can be delivered sequentially or simultaneously which can generate confusion. Case # 9 and #13 highlight potential areas of confusion with this definition of phase.

With respect to the order in which phases should be summarized, our recommendation is:

- Phases should be summarized first in chronological order.
- If multiple phases start on the same date, then list the phases in order from highest ‘Total Phase Dose’ to lowest ‘Total Phase Dose’.
- If multiple phases start on the same date and have the same Total Phase Dose, then any order is acceptable.

3. **When there are more than three phases:** In most treatment settings this will occur in a relatively small number of cases, typically with unusually complex treatment plans, occasionally with cases with multiple metastatic sites treated simultaneously. The STORE guidelines are clear. Collect and report details of the first three phases but report the actual number of first course phases treated in the field “Number of Phases of Radiation Treatment in this Course”.
4. **Phase Total Dose:** The upcoming STORE manual will make an important clarification as follows: Doses should ONLY be summed across phases to create a Total Dose when all of the phases were delivered *using the same major modality type (External Beam, Brachytherapy or Radioisotopes)*. If phases were delivered using two or more different major modalities (e.g. external beam and brachytherapy to the same body site), then code 999998, Not applicable.
5. **Phase N Radiation Primary Treatment Volume:** Don’t let the word “primary” confuse you. In a large percentage of cases, you will be choosing an item from the list that closely matches the diagnostic primary site code. But not always. The first volume treated may be metastatic and remote from the site of origin of the tumor. From the list presented for this data field, choose the best match to the treatment target volume.
6. **Brachytherapy, radioisotopes, and infusion therapy:** Early reports from registrars indicate some confusion here in part because the initial version of this guidance document differed from the STORE manual. Herein we attempt to correct and clarify.

If any phase of treatment to a volume has the Treatment Modality coded to anything between 07 and 16, the dose for that phase should be coded in cGy, when available. If there is only one phase in the entire course of radiation, then the phase total dose can be used to record the Radiation Course Total Dose.

However, if there are multiple phases in a radiation course and any of the phases use a brachytherapy, radioisotopes or infusion therapy, then the Radiation Course Total Dose should be coded to 999998 (five 9’s). This is because there is no agreed upon standard for summing doses across radiation modalities. For example, it is not biologically meaningful to sum dose from a brachytherapy treatment with dose from an external beam treatment (EBRT). If a radiation phase dose is not prescribed in cGy or Gy, then code the Dose per Fraction 99998(four 9’s), the Total Phase Dose to 999998 (five 9’s) and the Radiation Course Total Dose to 999998 (five 9’s).

7. **Where to find the data:** Hopefully, in most cases, you will find all the information you need in the treatment summary letter written by the Radiation Oncologist and generally available promptly after completion of treatment to a volume. Unfortunately, at this time, there is no standard for the content of these letters. There may be times when you must look at more detailed radiation records or need expert guidance. Happily, there are usually several resources within the radiation department. Certainly, the radiation oncologist is a consideration but think also of the physicist(s) and dosimetrist(s). They speak the language and may be more available.

Sources

This edition draws on four sources for case studies:

1. The original set of cases (Case 1 and Cases 4-15) with adjustments for changes in coding policy.
2. Situations posed to the CAnswer staff in the interim since the 1st Edition was published (Cases 17-28). These are identified as such in the Clinical description and information provided to CAnswer is in italics (with occasional additions by editorial staff for clarity)
3. Examples provided in Webinars delivered by the authors (for example, Case 29).
4. The authors imaginations (Cases 2 and 3).

Looking to the Future

Someday most of the radiation data may be automatically downloaded into the registry from the “record and verify” computer systems that control the treatment machines. But don’t go making retirement arrangements just yet. For the more immediate future a plan is afoot.

Inspired by the work of Dr. James Connolly and his team in developing the “synoptic pathology report”, the CoC Radiation Therapy Data Standards Committee organized a diverse group of oncology, physics, and data specialists to develop a model for synoptic radiation treatment reporting based on the STORE data set. The result was published in the November-December 2020 journal “Practical Radiation Oncology” (PMID: 31988040).

We hope that, if this model is adopted widely, it will greatly simplify the registrar’s task and at the same time proved a template for standardized electronic transfer.

Case Studies:

1 No Radiation Therapy

Clinical

- 87-year-old man with mild fatigue is found to have an elevated lymphocyte count on CBC.
- Bone marrow biopsy in your facility confirms a diagnosis of chronic lymphocytic leukemia.
- Physician and patient agree that no treatment is indicated at this time.

Coding Logic

- #2: Though not required by EDITS, this field has research value, and we encourage everyone to apply the appropriate code for all untreated cases.
- #9: SEER registries only: Code Phase I Modality to 00.
- #9: All other registries, code the Volume for Phase I to 00.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	
	2	Reason No Rad	1 Not part of planned 1st
	3	Location of Rad	
	4	Date Started	
	5	Date Ended	
	6	Number of Phases	
	7	Discontinued Early	
	8	Course Total Dose	
Phase 1	9	Volume	00 No Radiation Treatment
	10	Rad to Nodes	
	11	Modality	00 No Rad Treatment (SEER)
	12	Planning Technique	
	13	Number of Fractions	
	14	Dose per Fraction	
	15	Total Phase 1 Dose	
Phase 2	16	Volume	
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

2 Radiation Given – Details Unknown

Clinical

- A 56-year-old man is first seen in your emergency room with a history of rapid onset of weight loss, and inability to swallow solids.
- He is scoped and a tight mid-esophagus lesion is identified. Biopsy shows adenocarcinoma.
- He is treated with neo-adjuvant chemotherapy at your facility and then referred to a nearby university for surgery. He chooses to have all further care and follow-up at the university.
- Sometime later you notice a letter from someone at the university to your medical oncologist. The letter mentions post-operative radiation but provides no details.
- You contact the university for information but the clerk you speak to pleads HIPAA and refuses to provide any information.

Coding Logic

It is important to code anything you have available and, hopefully, enough information so that any future reviewer or analyst will have a clear picture of what is going on.

- #1, #2: Because you know these to be true.
- #3: This tells much of the story.
- #9: It might be tempting, given the available history, to code the volume to esophagus but we don't know that for sure so 99 is the honest and safest choice.
- #11: Code 98, new in STORE2021, resolves the ambiguity in #9. This is useful because analysis of Phase data, in the proper context, can stand alone from Summary data.
- #16: It is standard to code the first untreated volume this way (of course, if the information was available, we might learn that the radiation required 2 or more phases).

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 RT administered
	3	Location of Rad	4 All RT elsewhere
	4	Date Started	
	5	Date Ended	
	6	Number of Phases	
	7	Discontinued Early	
	8	Course Total Dose	
Phase 1	9	Volume	99 Unknown
	10	Rad to Nodes	
	11	Modality	98 RT given, modality unk.
	12	Planning Technique	
	13	Number of Fractions	
	14	Dose per Fraction	
	15	Total Phase 1 Dose	
Phase 2	16	Volume	
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

3 Bladder Cancer – Patient Takes a Flyer

Clinical

- A 42-year-old vegetarian of Austrian decent, has enjoyed fiddlehead and bracken fern salads nightly for years.
- When she tells her naturopath she is having painful urination with blood, he wisely refers her to a urologist on your hospital's staff.
- Cystoscopy shows a large, invasive bladder cancer, stage III.
- She is advised to have surgery and warned that she will likely need post-operative radiation and chemotherapy.
- Like so many patients, she turns to the internet for advice and finds a clinic in Bermuda that reports a high cure rate with infusions of Vitamin C during radiation treatment with their 1956 vintage Picker Cobalt machine.
- She tells the urologist she is going for alternative therapy and is never heard from again.

Coding Logic

Some Class 00 patients can be a frustrating challenge, so we just have to go with what we know.

- #2: Tells most of the story
- #9: A code of 00 is technically not correct since we don't know if she was ever treated.
- #16: It is reasonable to leave this blank when field #9 is coded to 99.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	9 Unknown
	2	Reason No Rad	8 Recommended, unknown if administered
	3	Location of Rad	9 Unknown
	4	Date Started	
	5	Date Ended	
	6	Number of Phases	
	7	Discontinued Early	
	8	Course Total Dose	
Phase 1	9	Volume	99 Unknown
	10	Rad to Nodes	
	11	Modality	
	12	Planning Technique	
	13	Number of Fractions	
	14	Dose per Fraction	
	15	Total Phase 1 Dose	
Phase 2	16	Volume	
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

4 Single Target Volume – Single Phase

Clinical

- 78 y/o female with new diagnosis of multiple myeloma
- R hip pain
- Lytic lesion, threatening fracture

Treatment

- Treated locally using opposed conformal¹ 15Mv photons
- 5 fractions at 400 cGy per day - 4/5/18 to 4/9/18
- Chemo started on completion of radiation treatment

Coding Logic

- #1: Code 0 in this field because there was no surgery.
- #8: Simple math, 400 x 5, but you should always find the total dose in the summary letter.
- #10: Inguinal lymph nodes may be exposed to radiation during treatment of the hip, but they are not being intentionally targeted.
- #12: Here you need to read the record carefully. However, the hip is a complex structure adjacent to radiosensitive organs (bowel and bladder) so, even for palliative treatment, the radiation “ports” (the radiation oncologist’s term for radiation beams, a.k.a. “fields”) for hip treatment are usually conformally shaped to avoid adjacent soft tissue and organs as much as possible.
- #16: STORE rules say you must code the Volume of the first unused phase to 00. In this case all the fields in phase 3 can be left blank.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was admin..
	3	Location of Rad	1 All RT at this facility
	4	Date Started	04/05/2018
	5	Date Ended	04/09/2018
	6	Number of Phases	01
	7	Discontinued Early	01 Radiation completed
	8	Course Total Dose	002000
Phase 1	9	Volume	84 Hip
	10	Rad to Nodes	00 No RT to nodes
	11	Modality	02 External beam, photons
	12	Planning Technique	04 Conformal or 3D
	13	Number of Fractions	005
	14	Dose per Fraction	00400*
	15	Total Phase 1 Dose	002000
Phase 2	16	Volume	00 No Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

¹ “Conformal” simply means that the fields were shaped to was created to “conform” the radiation dose to the target and/or avoid normal tissue. With “3D Conformal” treatment a CT simulation is obtained and a plan generated using 3-dimensional information. In conformal treatments, beams are shaped using lead blocks or a multi-leafed collimator to something other than the basic rectangular beams used in 2D therapy.

*Vendor software generally populates leading zeros.

5 Thyroid Cancer Treated with Radioiodine

Clinical

- Thirty-seven-year-old female
- Painless lump in her right lower neck (level VI)
- Ultrasound guided needle biopsy
- Follicular carcinoma, clinical T1bN0M0.

Treatment

- Thyroidectomy, pathologic T2N0M0
- Radiation treatment is delivered with a single injection of 150 millicuries of radioiodine (I-131) on August 7, 2018.

Coding Logic

- #5: Our recommendation is to consider the injection of a radioisotope as the treatment and thus to set the Date Finished equal to the Date Started.² STORE makes a similar recommendation for brachytherapy treatments; however, with some brachytherapy procedures, the radioactive seeds are left in place for two or three days then removed. In those situations, code the date of removal as the Date Finished.
- #9: Technically I-131 may be effective wherever there are thyroid cancer cells in the body, so there is no specific anatomic treatment volume here. Therefore, we recommend coding radioisotope treatments as “98 Other”. You might think another reasonable option would be to code the volume as “93 Whole Body”. Traditionally, however, the code 93 (Whole Body) has been reserved for whole body treatment with external beam radiation such as is done prior to bone marrow transplantation. So, for the sake of historic consistency, our preference is “98 Other”.
- #8, 14, 15: These dose fields are coded as 99998 and 999998 because dose was not prescribed in cGy or Gy.
- #12: We code this to “88 Not applicable” because with I-131 and other systemic isotopes there is no planning in the conventional sense. The physician selects a dose level based on risks of residual disease and the risk of complications.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	08/07/2018
	5	Date Ended	08/07/2018
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	999998
Phase 1	9	Volume	98 Other
	10	Rad to Nodes	00 No RT to draining nodes
	11	Modality	13 Radioisotopes, NOS
	12	Planning Technique	88 Not applicable
	13	Number of Fractions	1
	14	Dose per Fraction	99998
	15	Total Phase 1 Dose	999998
Phase 2	16	Volume	00 No Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

² Like other radioisotopes, I-131 “decays” with a “half-life”. That means that, from any given point in time, only half as much will remain after an elapsed time equal to the half-life. The half-life of I -131 is 8.06 days. With a typical injection it will be between 21 and 24 months before the last I-131 atom spits out its radiation.

6 Prostate Cancer, Boost First, Elsewhere

Clinical

- Otherwise healthy 69 y/o man
- Gleason 9, cT1c prostate Ca.

Treatment

- Treated with iodine seed implant (2/21/2018) at a university hospital
- Returned home for additional treatment.
- 4-field conformal pelvic radiation with 15Mv photons (3/5/2018 to 4/6/2018, 4500cGy in 25 fractions) at your facility.

Coding Logic

- #4: The date of the implant marks the beginning of treatment.³
- #5: The last date of external beam is the only logical choice. For permanent implants and systemic radioisotopes, there is no good choice for a Date Finished. See Case #5.
- #8: There is no standard for summing a dose from brachytherapy with an external beam dose, so always code a mixed modality treatment using 999998 (5 9's) for Total Dose in this situation.
- #11: With an iodine implant, seeds are permanently placed in the prostate tissue and radiation is emitted continuously over a long period of time as described in Case 6. The "dose rate" is much lower with iodine implants than it is with iridium-192 seeds, which are in tubes that are removed after a day or two.
- #12: There is actually a lot of planning involved with prostate implants, both before and after the procedure, but code 88 is the only reasonable option from the choices available.
- #14, 15: Four 9's before the terminal "8" because no dose for brachytherapy is provided in the treatment summary. If a brachytherapy dose was given, then it can be entered here.
- #16: The prostate is still the primary target. The next field tells us that pelvic lymph nodes were treated. In FORDS you would have used Volume code 35, "Prostate and pelvis."

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	2 Regional RT at this Facility
	4	Date Started	02/21/2018
	5	Date Ended	04/06/2018
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	999998
Phase 1	9	Volume	64 Prostate - whole
	10	Rad to Nodes	00 No RT to draining nodes
	11	Modality	10 Brachy Tx, Interstitial, LDR
	12	Planning Technique	88 Not applicable
	13	Number of Fractions	001
	14	Dose per Fraction	99998
	15	Total Phase 1 Dose	99998
Phase 2	16	Volume	64 Prostate - whole
	17	Rad to Nodes	06 Pelvic lymph nodes
	18	Modality	02 External beam, photons
	19	Planning Technique	04 Conformal or 3D...
	20	Number of Fractions	025
	21	Dose per Fraction	00180
	22	Total Phase 2 Dose	04500
Phase 3	23	Volume	00 No Treatment
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

³ Registrars have asked us why the STORE did not include date ranges for each phase. There are two good reasons:

- Limited clinical or analytic value,
- Avoid unnecessary work for registrars.

7 Breast and Regional Nodes with Breast and Axillary Boost

Clinical

- 46 y/o female with T2N1M0 breast cancer, and conservation surgery. 3 of 5 axillary nodes positive. ER 100%, PR 10%, Her-2 negative.

Treatment

- Whole breast RT, 5040 cGy in 28 fractions given between 8/13/2018 and 9/19/2018 using 6Mv photons, conformal fields.
- Axillary and supraclavicular (SC) nodes treated concurrently with 6Mv photons using an anterior field covering both regions to deliver a daily dose of 180 cGy to a depth of 3 cm. Because the radiation intensity diminishes with depth, a posterior axillary field (PAB) was added delivering 30cGy per day to the midplane of the axilla so this region also received the prescribed daily dose of 180cGy.
- The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury.
- Between 9/20 and 9/26 the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins.

Coding Logic

- #8: The sum the doses reported in Phase 1 2 and 3 (#15 + #22 + #29). In general, the “total dose” to be reported will be the dose at the point in the volume receiving the most radiation. This dose is meant to represent the “cumulative” dose across phases to the same point or region (receiving the highest dose). Importantly, this field should report the cumulative dose to the highest dose treatment volume so long as the phases were performed using the same modality (i.e. external beam, brachytherapy, etc.).
- #10: In this phase the code “04” represents both axillary and SC regions as a single target. STORE coding does not provide enough granularity to distinguish between the possible combination of targets in this region.
- #17: In this field, code 04 represents just the axilla as it receives three additional treatments. Note that the PAB is simply regarded as part of the axillary plan and not coded as a phase.
- #23: This is what is commonly called the “boost” or “cone down” to deliver additional radiation to the region at greatest risk for recurrence, the surgical bed.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	08/13/2018
	5	Date Ended	09/26/2018
	6	Number of Phases	3
	7	Discontinued Early	01 Completed
	8	Course Total Dose	006040
Phase 1	9	Volume	40 Breast - whole
	10	Rad to Nodes	04 Breast/chest wall LN region
	11	Modality	02 External beam photon
	12	Planning Technique	04 Conformal or 3D Conformal
	13	Number of Fractions	025
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	004500
Phase 2	16	Volume	40 Breast - whole
	17	Rad to Nodes	04 Breast/chest wall LN region
	18	Modality	02 External beam photon
	19	Planning Technique	04 Conformal
	20	Number of Fractions	003
	21	Dose per Fraction	00180
	22	Total Phase 2 Dose	000540
Phase 3	23	Volume	41 Breast - partial
	24	Rad to Nodes	00 No RT to draining nodes
	25	Modality	04 External beam, electrons
	26	Planning Technique	04 Conformal
	27	Number of Fractions	005
	28	Dose per Fraction	00200
	29	Total Phase 3 Dose	001000

8 Prostate Cancer: Concurrent Prostate and SV Boost

Clinical

- 76 y/o man with T3b prostate cancer.

Treatment

- 7/9/2018 to 8/10/2018: Treated initially with whole pelvis RT to 4500 cGy in 25 fractions of 180 cGy using a four-field approach, all fields shaped conformally to pelvic anatomy.
- 8/13/2018 to 9/07/2018: IMRT boost of 19 fractions in which the seminal vesicles receive an additional 3420 cGy while the prostate receives 3800 cGy.

Coding Logic

- #6: Although the volumes described in Phase 2 and Phase 3 were delivered at the same time with the same beams, they represent different organs receiving different daily and total doses and, under STORE rules, are treated as separate but concurrent phases. This is typically accomplished using an IMRT capability known as “dose painting” or “simultaneous integrated boosts” (SIB).
- #8: Add the regional dose from Phase 1 to the highest dose delivered within the boost target volumes. That would be the prostate dose. $4500 + 3800 = 8300\text{cGy}$
- #23: The standard setters had to draw the line somewhere for the list of volumes and, since seminal vesicles are very rarely the primary target volume, they were not included as a separate volume. That is why we have always (ROADS -> FORDS -> STORE) had a code 98. For the benefit of future local⁴ users of the data it would be a good idea to document treatment of seminal vesicles in the radiation comments field.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or surg
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	07/09/2018
	5	Date Ended	09/07/2018
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	008300
Phase 1	9	Volume	64 Prostate - whole
	10	Rad to Nodes	06 Pelvic lymph nodes
	11	Modality	02 External beam photons
	12	Planning Technique	04 Conformal or 3-D
	13	Number of Fractions	025
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	004500
Phase 2	16	Volume	64 Prostate - whole
	17	Rad to Nodes	00 No Treatment to Nodes
	18	Modality	02 External beam photons
	19	Planning Technique	05 IMRT
	20	Number of Fractions	019
	21	Dose per Fraction	00200
	22	Total Phase 2 Dose	003800
Phase 3	23	Volume	98 Other
	24	Rad to Nodes	00 No Treatment to Nodes
	25	Modality	02 External beam photons
	26	Planning Technique	05 IMRT
	27	Number of Fractions	019
	28	Dose per Fraction	00180
	29	Total Phase 3 Dose	003420

⁴ Comments in NAACCR text fields are transmitted to state registries (primarily for quality control purposes) but are not transmitted to NCDB and therefore not useful for PUF file analysis.

9 Multiple Metastatic Sites Treated Concurrently

Clinical

65-year-old male smoker presents with Stage IV adenocarcinoma of the lung and multiple symptomatic sites of metastases:

- Proximal right humerus, lytic, painful, but not thought to be at risk of fracture.
- Left hip, minimal radiographic changes but positive on bone scan and painful.
- Mid-shaft right femur, minimal pain but judged to be at risk for path fracture
- T7 lesion with no fracture but extension of tumor into spinal canal and rapid onset of lower extremity weakness.

Treatment

1. Treatment to thoracic spine was initiated evening of Saturday, 11/10/2018 and continued until 11/21/2018. Unblocked photon field, 3000 cGy in 10 fractions
2. 11/12/2018 to 11/23/2018: Treatment to right femur, unblocked photon field, 3000 cGy in 10 fractions
3. 11/12/2018 to 11/16/2018: Left hip treated with conformal fields designed to spare adjacent bowel, bladder, and soft tissues. 2000 cGy in 5 equal fractions.
4. 11/12/2018 to 11/16/2018: Right humerus, open square field, 2000cGy in 5 equal fractions.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All treatment at this facility
	4	Date Started	11/10/2018
	5	Date Ended	11/23/2018
	6	Number of Phases	04 '4 or more phases'
	7	Discontinued Early	01 Completed
	8	Course Total Dose	003000
Phase 1	9	Volume	81 Spine
	10	Rad to Nodes	00 No RT to nodes
	11	Modality	02 External beam, photons
	12	Planning Technique	03 2-D therapy
	13	Number of Fractions	10
	14	Dose per Fraction	00300
	15	Total Phase 1 Dose	003000
Phase 2	16	Volume	88 Extremity Bone, NOS
	17	Rad to Nodes	00 No RT to nodes
	18	Modality	02 External beam, photons
	19	Planning Technique	03 2-D therapy
	20	Number of Fractions	010
	21	Dose per Fraction	00300
	22	Total Phase 2 Dose	003000
Phase 3	23	Volume	84 Hip
	24	Rad to Nodes	00 No RT to nodes
	25	Modality	02 External beam, photons
	26	Planning Technique	04 Conformal or 3-D
	27	Number of Fractions	05
	28	Dose per Fraction	00400
	29	Total Phase 3 Dose	002000

Coding Logic

- #4: The earliest date of treatment in the first course.
- #5: The last date of treatment in the first course even though it may not be associated with any of the radiation phases that have been documented here.
- #6: Four distinct volumes treated with each treatment represented by a distinct phase.
- #8 Record the maximum dose to first volume/phase. Do not add doses to different treatment volumes.
- #9: Chronology is the primary determinant of phase. The spine was treated first
- #16: After chronology we look at dose. The femur received a higher dose than either the hip or the humerus.
- #23: Two targets with the same dose. Toss a coin.

10 Lung: How Many Phases?

Clinical

72-year-old male diagnosed with small cell lung cancer on 2/22/2018.

- PET-CT scan shows activity limited to the right upper lobe and right hilum.
- Brain MRI is interpreted as showing a pattern consistent with scattered, age-related microvascular infarcts.
- The patient refuses chemotherapy.

Treatment

- 3/5 – 4/6/2018: Area of PET activity treated with 6 MV photons using an IMRT plan to minimize esophagitis, 180 cGy per day, 25 fractions, 4500 cGy.
- 4/6/2018: Repeat simulation CT scan shows greater than 50% reduction in gross tumor volume. A new plan is developed.
- 4/10 – 4/16/2018: IMRT to upper lobe and hilar nodes (same target as before), 180cGy per day, 900cGy in 5 fractions
- 6/5/2018: Patient presents with confusion and aphasia. Brain MRI shows numerous sub-centimeter lesions consistent with metastases, most at locations previously interpreted as infarcts.
- 6/7 – 6/13/2018: Whole brain radiation, conformal opposed photon fields. 2000cGy in 5 fractions.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	03/05/2018
	5	Date Ended	04/16/2018
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	005400
Phase 1	9	Volume	30 Lung or bronchus
	10	Rad to Nodes	02 Thoracic lymph nodes
	11	Modality	02 External beam, photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	030
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	005400
Phase 2	16	Volume	00 No Radiation Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Planning Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

Coding Logic

- #6 and #16: We have coded only one phase for chest treatment. The patient had a new plan developed in the middle of therapy; but, because the treatment was to the same target volumes (primary and node) using the same modality, planning technique and dose per fraction, the new plan does NOT represent a new phase of radiation. This patient had “off-line” plan adaptation, which adapted the radiation targeting to changes in shape of the tumor or surrounding normal tissues. In some cases, this can occur several times throughout the course of radiation. So long as there is no change of targeted organs, modality, planning technique and dose per fraction, all of the adapted plans should be considered one phase. The second important consideration in this case is that treatment to the brain is not coded under STORE rules because treatment to the brain did not occur until after progression occurred in the brain.

STORE collects only first course treatment data where first course is defined as:

First Course of Treatment

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.

11 Prophylactic Cranial Irradiation (PCI): How Many Phases?

Clinical

72-year-old male diagnosed with small cell lung cancer on 2/22/2018.

- PET-CT scan shows activity limited to the right upper lobe and right hilum.
- He was treated with concurrent cisplatin, etoposide and radiation as summarized below.
- After completion of his thoracic radiation, he had follow-up imaging including brain MRI which showed no evidence of disease. He then had prophylactic cranial irradiation.

Treatment

- 3/5 – 4/13/2018: Area of PET activity treated with 6MVphotons using an IMRT plan to minimize esophagitis, 200 cGy per day, 30 fractions, 6000 cGy.
- 5/7 – 5/18/2018: whole brain radiation at 25Gy in 10 fractions.

Coding Logic:

- #5: Date finished should be the last day of the last phase of the entire radiation course even if there are gaps between phases, as in this case.
- #10: When the hilum of the lung is listed as a target, it almost invariably means that the lymph nodes of the hilar region are the targets.
- #8: It is a universal rule that you should NEVER add doses from different target volumes. In the Total Dose field, you will most often be simply recording the phase 1 dose. If the target volume in phase 1 is given a boost, in phase 2 you should add the doses. You should rarely have to add the phase 3 dose, unless it represents a further change in the size or technique used to give additional radiation within the first boost.
- #6 and #16: We have coded two phases in the first course of therapy, one for the chest treatment and another for the brain treatment. In this case, the whole brain radiation treatment is coded as part of the first course of therapy because it occurred prior to any evidence of progression or recurrence (i.e. it was done prophylactically).

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	03/05/2018
	5	Date Ended	5/18/2018
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	006000
Phase 1	9	Volume	30 Lung or bronchus
	10	Rad to Nodes	02 Thoracic lymph nodes
	11	Modality	02 External beam, photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	030
	14	Dose per Fraction	00200
	15	Total Phase 1 Dose	006000
Phase 2	16	Volume	12 Brain
	17	Rad to Nodes	00 No RT to nodes
	18	Modality	02 External beam, photons
	19	Planning Technique	01 External beam, NOS
	20	Number of Fractions	010
	21	Dose per Fraction	00250
	22	Total Phase 2 Dose	002500
Phase 3	23	Volume	00 No Radiation Treatment
	24	Rad to Nodes	
	25	Modality	
	26	Planning Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

12 Total Body Irradiation for Transplant

Clinical

43-year-old woman with advanced multiple myeloma is referred for total body irradiation in preparation for a bone marrow transplant.

Treatment

- 11/14 – 11/16/2018: Treated twice daily for three consecutive days in a total body stand at extended distance with open rectangular photon fields, 200cGy to mid-body per treatment.

Coding Logic:

- #9: Volume code 93 is reserved for this circumstance and the now somewhat rare whole-body treatment for bone metastases. Use code 98 for systemic treatment with radioisotopes.
- #10: Obviously lymph nodes are included in a whole-body beam, but they are not the primary target and there is no code describing total lymph node irradiation.
- #12: With the data available (no mention of secondary shielding) it is reasonable to describe this as 2-D planning (open field, no blocks) was used. In some centers, particularly if the total dose is greater than 1200cGy, the record may describe lung, liver, or kidney blocks. In these situations, it is appropriate to code planning technique to 3-D conformal.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/14/2018
	5	Date Ended	11/16/2018
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	001200
Phase 1	9	Volume	93 Whole Body
	10	Rad to Nodes	00 No RT to draining nodes
	11	Modality	02 External beam, photons
	12	Technique	03 2-D therapy
	13	Number of Fractions	006
	14	Dose per Fraction	00200
	15	Total Phase 1 Dose	001200
Phase 2	16	Volume	00 No Radiation Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

13 Head and Neck: Simultaneous Integrated Boost (SIB)

Clinical

61-year-old man with stage IVa, T3N2cM0, HPV-negative squamous cell carcinoma of the tonsil completed his course of radiation therapy (delivered with concurrent weekly cisplatin and, on study, with concurrent nelfinavir for hypoxia modification).

Treatment

- Dates of treatment: 9/10/2018 to 10/29/2018.
- Proton pencil beam scanning
- Area: Primary site + bilateral neck.
- Over the course of 35 treatments areas of gross disease received 7000 cGy, high risk elective neck regions received 6300 cGy, low-risk elective neck including the supraclavicular regions received 5600 cGy.

Coding Logic

- #6: This course of RT is an example of a simultaneous integrated boost. Three regions of the neck (gross disease, high risk neck nodes, low risk neck nodes) were treated simultaneously using different daily fractions of radiation. In the past, these three regions were usually treated using sequential radiation phases (the first radiation plan treated gross disease, high- and low-risk neck regions to 5000 cGy in 25 fractions; then, the second plan treated gross disease and high-risk neck regions to 6000 cGy in 30 fractions; finally, the third plan treated gross disease to 7000cGy in 35 fractions). The sequential approach requires three separate radiation plans to be made by the physics team, which is a lot of work! More and more, simultaneous integrated boost (or dose painting) treatments are being used because this approach requires only one radiation plan to be developed.
- #10: Note that we coded "01 neck lymph node regions" in this phase. We know from his nodal staging (N2c) that he had gross disease in his neck nodes and the treatment summary that areas of gross disease received 7000cGy in 35 fractions.
- #12: We recommend that protons should be coded as conformal planning technique unless intensity modulated proton therapy (IMPT) is explicitly referenced. IMPT is just a version of IMRT using protons instead of X-rays and would be coded as such for Technique.
- #17 and #24: In phase 2 and 3, neck nodal regions were the primary treatment volume so there is no secondary nodal treatment volume. Radiation to Nodes code 88 is reserved for this.
- #24: Because the summary states that the low-risk neck volume includes the supraclavicular regions, this is coded as 03 Neck and thoracic lymph node regions.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	9/10/2018
	5	Date Ended	10/29/2018
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	007000
Phase 1	9	Volume	22 Oropharynx
	10	Rad to Nodes	01 Neck lymph node regions
	11	Modality	03 External beam, protons
	12	Technique	04 Conformal
	13	Number of Fractions	035
	14	Dose per Fraction	00200
	15	Total Phase 1 Dose	007000
Phase 2	16	Volume	01 Neck lymph node regions
	17	Rad to Nodes	88 N/A, nodes are primary vol
	18	Modality	03 External beam, protons
	19	Technique	04 Conformal
	20	Number of Fractions	035
	21	Dose per Fraction	00180
	22	Total Phase 2 Dose	006300
Phase 3	23	Volume	03 Neck and thoracic LN reg
	24	Rad to Nodes	88 N/A, nodes are primary vol
	25	Modality	03 External beam, protons
	26	Technique	04 Conformal
	27	Number of Fractions	035
	28	Dose per Fraction	00160
	29	Total Phase 3 Dose	005600

14 Lung: Off-line Adaptive Re-plan

Clinical


72 y/o man with NSCLC diagnosed on 2/22/2018 with a mass limited to the right upper lobe and right hilum. Patient was treated with radiation alone. He refused chemotherapy.

Treatment

- 03/5/2018-4/6/2018: Area of PET activity was treated with 6MV photons using an IMRT plan to minimize esophagitis, 180cGy per day, 25 fractions, 4500 cGy.
- 4/6/2018: at 4500 cGy a repeat CT simulation showed dramatic shrinkage of the primary tumor volume, so a new plan was generated.
- 4/10/2018- 4/12/2018: IMRT to right upper lobe and right hilar nodes was restarted with new plan, 180cGy per day, 3 fractions to 540cGy.
- 4/14/2018 – 4/16/2018: Third CT simulation scan showed even further shrinkage of the primary tumor and no evidence of the peritracheal node. Field revised to an opposed pair of ports angled off esophagus and spinal cord and reduced to include only the primary tumor and residual hilar node. 900 cGy prescribed and delivered in 5 fractions


The concept of off-line adaptive planning is illustrated below. Note that in Phase I, there is a change in the shape of the radiation field but the target volume (primary + hilar node + peritracheal node) does not change.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	03/05/2018
	5	Date Ended	04/16/2018
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	005940
Phase 1	9	Volume	30 Lung or bronchus
	10	Rad to Nodes	02 Thoracic lymph nodes
	11	Modality	02 External beam, photons
	12	Technique	05 IMRT
	13	Number of Fractions	028
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	005040
Phase 2	16	Volume	30 Lung or bronchus
	17	Rad to Nodes	02 Thoracic lymph nodes
	18	Modality	02 External beam, photons
	19	Technique	04 – Conformal
	20	Number of Fractions	005
	21	Dose per Fraction	00180
	22	Total Phase 2 Dose	000900
Phase 3	23	Volume	00 No Radiation Treatment
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	



In the diagram below we illustrate the workflow for conventional and off-line plans.

- In the majority of cases, a patient will have a single CT scan and over the course of a few days a treatment plan will be generated and then applied daily for several days or weeks.
- In an off-line adaptive plan, the scan-plan-treat sequence may be repeated two or three times on the same time scales. Short treatment interruptions may occur to allow time for planning. Off-line planning has been part of the radiation oncologists play book for decades. It has been most frequently employed with tumors that respond very quickly to radiation, such as lymphomas and small cell lung cancer.



Coding Logic

- During the first adaptation, the physical volume has changed but the target volume (diseased organs), modality, planning technique and daily fraction size have not changed. Therefore, we do not code a second phase at this point.
- In the second adaptation, the target volume changes and paratracheal nodes are now excluded. This alone is reason for a second phase, as is the change to conformal therapy.

15 Bladder: On-line Adaptive Therapy with an MR-Linac

Clinical

75-year-old woman with average risk muscle-invasive bladder cancer treated with selective bladder preservation. She had a complete transurethral resection followed by neoadjuvant chemotherapy with gemcitabine and cisplatin and finally concurrent mitomycin/5FU and radiation.

Treatment

- Dates of treatment: 9/10/2018 to 10/30/2018.
- She received 180 cGy x 36 to 6480cGy to the whole bladder.
- Her radiation was performed on the MR-linac with IMRT and daily on-line treatment adaptation to account for changes in bladder filling. Seventeen of 36 fraction required a full re-plan.

Coding Logic

- #12: Some new linear accelerators are attached to such high-quality imaging devices that they can function as both simulation scanners for planning and radiation delivery systems. If a new radiation plan is created while the patient is on the radiation delivery table to take into account that day's anatomy, this is referred to "on-line" (or on-table) adaptive radiation. If a new radiation plan is created while the patient is elsewhere, then it is referred to as "off-line" adaptive therapy.

Off-line adaptive therapy treatments are relatively common, but MR-guided and CT-guided online adaptive therapy treatments are just emerging. Applicability is limited to situations where tumor anatomy is variable with time as can be the case with bladder tumors. This case describes MR-guided online adaptive therapy⁵. If a treatment is described as both MR-guided (or CT-guided) on-line adaptive as well as another external beam planning technique (e.g. IMRT, SBRT, etc.), then it should be categorized as MR-guided online adaptive therapy. Online adaptive techniques are the most complex and usually include IMRT and/or SBRT techniques within them, so the online adaptive component is most important to capture.



Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	9/10/2018
	5	Date Ended	10/30/2018
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	006480
Phase 1	9	Volume	60 Bladder - whole
	10	Rad to Nodes	00 No radiation to nodes
	11	Modality	02 External beam, photons
	12	Technique	10 MR-guided on-line adaptive
	13	Number of Fractions	036
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	006480
Phase 2	16	Volume	00 No Radiation Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

⁵ For more information see: Apollo, W., "Online Adaptive Radiation Therapy", Journal of Registry Management, Summer 2018, Vol45 #2, page 91.

16 Gyn-Brachytherapy + External Beam Radiotherapy (EBRT)

Clinical

67 y/o patient, G2P2, presented with postmenopausal bleeding with positive findings on endometrial bx. Patient underwent TAH/BSO with pelvic lymphadenectomy, pT3b, pN0 w/ +margins, and then concurrent RT/cisplatin followed by carboplatin + paclitaxel.

Treatment

- 1/7/21-2/11/21, Whole pelvis RT w/ 6X/IMRT, 180 cGy x 25 fx⁶ to 45 Gy.
- 2/13/21-3/18/21, Vaginal cuff HDR brachytherapy via Ir-192 seeds, 600 cGy x 2 fx for a total of 1200 cGy.

Coding Logic

- #8: You cannot add dose from a brachytherapy phase with dose from EBRT phase.
- #9: When possible, phases are captured in chronological order based on phase start date. If a primary site in the pelvic region is surgically resected, code the primary irradiated volume to the primary site
- #10: RT treatment summary tells us that the whole pelvis was irradiated. This includes regional lymph nodes.
- #15 180 x 25 = 4500
- #16: When intracavitary HDR brachytherapy is administered to the vaginal cuff for endometrial or cervical cancer, post TAH/BSO, primary irradiated volume is vagina (72) because the vaginal surface is the organ at risk for recurrence. Note that in this setting, the effective range of the treatment is limited to the vaginal wall. This is an exception to general rule of coding to the organ of origin and a code 71 would be technically correct, just less informative.
- 21-22: If dose per fraction and total dose is given in cGy, code it as such in the abstract for that phase.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	01/07/2021
	5	Date Ended	03/18/2021
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	999998
Phase 1	9	Volume	71 Uterus or Cervix
	10	Rad to Nodes	06 Pelvic lymph nodes
	11	Modality	02 External beam, photons
	12	Technique	05 IMRT
	13	Number of Fractions	025
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	004500
Phase 2	16	Volume	72 Vagina
	17	Rad to Nodes	00 No RT to draining LNs
	18	Modality	09 Brachytherapy, intracavitary, HDR
	19	Technique	88 NA
	20	Number of Fractions	02
	21	Dose per Fraction	00600
	22	Total Phase 2 Dose	001200
Phase 3	23	Volume	00 No Radiation Treatment
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

⁶ "fx" is a common abbreviation for "fraction" which, in turn, simply means a treatment event.

17 Multiple Brain Mets: Treated with Gamma Knife

Clinical

67 y/o with a history of stage IV Lung adenocarcinoma (NSCLC), T2N0M1c, EGFR+, s/p left frontal craniotomy for resection of brain mets, now presents for Gamma Knife treatment to multiple (7) intracranial lesions.

Treatment

- On 11/4/19, patient was treated to 7 CNS lesions via Gamma Knife SRS. Dose ranged from 16-20 Gy prescribed to the 50% isodose line.
- # of shots: 51

Coding Logic

- #6/#13: The Gamma Knife teletherapy unit can target multiple CNS lesions simultaneously in a single session (1 fraction, 1 phase). Regardless of whether 4 or 15 CNS lesions are targeted by the Gamma Knife unit in a single session, consider this a single fraction and a single phase.
- #15: It is not unusual with Gamma Knife SRS for the dose to vary among the targeted CNS lesions. Select the highest delivered dose as the total dose for this single-phase treatment.

Historical Note

Gamma Knife treatment is an example of a very old concept that took a long time to reach general use. It was invented in 1951 by a Swedish physician, Dr. Lars Leksell and took advantage of a newly available source of gamma radiation, Cobalt-60. The first commercial Gamma Knife machine was not available until 1967 and general availability is much more recent.

In simple terms, the original Gamma Knife machine is spherical lead “helmet” with 210 holes distributed over the surface and drilled in a fashion such that they come to a common small focus in the open center of the helmet. Each hole contains a small source of Cobalt-60 (a radioactive metal with a long half-life). Ignoring the complexity of turning the radiation on and off, the net result is 210 narrow beams of radiation coming together to a small region with a very high dose rate.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	03 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/04/2019
	5	Date Ended	11/04/2019
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	002000
Phase 1	9	Volume	13 Brain-limited
	10	Rad to Nodes	00 No radiation to nodes
	11	Modality	02 External beam, photons
	12	Technique	08 SRS, Gamma Knife
	13	Number of Fractions	001
	14	Dose per Fraction	02000
	15	Total Phase 1 Dose	002000
Phase 2	16	Volume	00 No Radiation Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

18 Prostate and Rectal: Treated with One Plan

Clinical (This case was submitted to CAnswer.)

"In the course of a workup for prostate cancer (cT1c cN0 cM0, Gleason 6) the patient was also found to have an adjacent rectal cancer (cT2 cN1b cM0)."

Treatment

"The radiation record shows that the two malignancies were treated simultaneously within a single planned volume using SBRT (stereotactic body radiation therapy). 10Mv x-rays were utilized and treatment was completed in 5 fractions starting on 11/18/2021 and ending on 11/27/2021.

- The prostate received a dose of 3625 cGy.*
- Clinically suspicious nodes in the "neighborhood" received 2750 cGy*
- The rectal primary and remaining pelvic lymph nodes received 2500 cGy."*

Coding Logic

This is obviously a unique and very infrequent situation. The key fact here is that the patient has two primaries and each one must be reported separately to NCDB with a complete STORE compatible record (demographics / diagnostics / treatment / follow-up). Registry software may vary in how this is accomplished, but the end result should always be the same. Treatment will be reported twice, in one record for the prostate cancer and another for the rectal cancer since both were targeted by the plan. Because we can not arbitrarily attribute some aspects of the radiation course to the prostate cancer record and the rest to the rectal cancer record, the entire course is reported for both. This is an SIB treatment.

#8: As usual, record the maximum dose delivered to the primary tumor volume (prostate).

#10: Unlike case # 8, the target for this phase of the prescription is just the prostate.

#12: The summary explicitly references SBRT.

Prostate			
Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/18/2021
	5	Date Ended	11/27/2021
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	003625
Phase 1	9	Volume	64 Prostate - Whole
	10	Rad to Nodes	00 No Radiation to
	11	Modality	02 External Beam, Photons
	12	Planning Technique	06 Stereotactic
	13	Number of Fractions	5
	14	Dose per Fraction	00725
	15	Total Phase 1 Dose	003625
Phase 2	16	Volume	06 Pelvic lymph nodes
	17	Rad to Nodes	88 Not Applicable
	18	Modality	02 External Beam, Photons
	19	Planning Technique	06 Stereotactic radiotherapy, NOS
	20	Number of Fractions	5
	21	Dose per Fraction	00550
	22	Total Phase 2 Dose	002750
Phase 3	23	Volume	54 Rectum
	24	Rad to Nodes	06 Pelvic lymph nodes
	25	Modality	02 External Beam, Photons
	26	Planning Technique	06 Stereotactic
	27	Number of Fractions	5
	28	Dose per Fraction	00500
	29	Total Phase 3 Dose	002500

18 (Continued)

Clinical

- As above.

Treatment

- As above.

Coding Logic

- Because we cannot arbitrarily attribute some aspects of the radiation course to the prostate cancer record and the rest to the rectal cancer record, the entire course is reported for both.

Rectum

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	2 Radiation Before Surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/18/2021
	5	Date Ended	11/27/2021
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	003625
Phase 1	9	Volume	64 Prostate - Whole
	10	Rad to Nodes	00 No Radiation to Nodes
	11	Modality	02 External Beam, Photons
	12	Planning Technique	06 Stereotactic radiotherapy, NOS
	13	Number of Fractions	5
	14	Dose per Fraction	00725
	15	Total Phase 1 Dose	003625
Phase 2	16	Volume	06 Pelvic lymph nodes
	17	Rad to Nodes	88 Not Applicable
	18	Modality	02 External Beam, Photons
	19	Planning Technique	06 Stereotactic radiotherapy, NOS
	20	Number of Fractions	5
	21	Dose per Fraction	00550
	22	Total Phase 2 Dose	002750
Phase 3	23	Volume	54 Rectum
	24	Rad to Nodes	06 Pelvic lymph nodes
	25	Modality	02 External Beam, Photons
	26	Planning Technique	06 Stereotactic radiotherapy, NOS
	27	Number of Fractions	5
	28	Dose per Fraction	00500
	29	Total Phase 3 Dose	002500

19 Unknown Primary, Head and Neck: with Simultaneous Integrated Boost

Clinical⁷ (This case, amended to provide more detail - was submitted to CANSWER.)

The patient, fond of alcohol and cigarettes, presented with a large, bilateral, lymph nodes that appeared to originate at levels IIA and IIB (upper neck), pushing down into level III (mid-neck). Biopsy of the left neck mass showed squamous carcinoma. Examination under anesthesia by an otolaryngologist, with multiple biopsies, failed to identify the primary site.

Treatment

The radiation oncologist defined three areas of interest for planning and treatment was delivered using an IMRT class of plan (VMAT) with simultaneous integrated boosts (SIB's). Thirty-five identical treatments were delivered between 11/02/2020 and 12/17/2020.

- The palpable lymph nodes received 7000 CGy.
- Immediately adjacent lymph nodes, clinically negative but considered to be high risk, received 5950 cGy.
- Lymph nodes in the low neck, considered to be low risk, received 5600cGy

Coding Logic

While treatment was delivered simultaneously, there were dose prescriptions to 3 adjacent but separate volumes. As with Case #17, each prescription volume is considered a phase with the highest dose volume assigned to Phase I.

- #8 Document the highest dose delivered to any one volume; with SIB this would be the dose recorded for Phase I. With older techniques (See Case #17), it may be appropriate to add doses for each phase.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/02/2020
	5	Date Ended	12/17/2020
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	007000
Phase 1	9	Volume	01 Neck Lymph Node Regions
	10	Rad to Nodes	88 Not Applicable
	11	Modality	02 External Beam, Photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	35
	14	Dose per Fraction	200
	15	Total Phase 1 Dose	007000
Phase 2	16	Volume	01 Neck Lymph Node Regions
	17	Rad to Nodes	88 Not Applicable
	18	Modality	02 External Beam, Photons
	19	Planning Technique	05 IMRT
	20	Number of Fractions	35
	21	Dose per Fraction	170
	22	Total Phase 2 Dose	005950
Phase 3	23	Volume	01 Neck Lymph Node Regions
	24	Rad to Nodes	88 Not Applicable
	25	Modality	02 External Beam, Photons
	26	Planning Technique	05 IMRT
	27	Number of Fractions	35
	28	Dose per Fraction	160
	29	Total Phase 3 Dose	005600

⁷ Case originally presented to CANSWER with the question: "Is the total dose the sum of phase I and phase II doses (12950 cGy) or the sum for all 3 phases (18550 cGy)."

20 Head and Neck: Unknown Primary with Staged Boost

Clinical

The patient, twin brother of the patient in Case #19, is also fond of alcohol and cigarettes, and presented with a large, bilateral, lymph nodes that appeared to originate at levels IIA and IIB (upper neck), pushing down into level III (mid-neck). Biopsy of the left neck mass showed squamous carcinoma. Examination under anesthesia by an otolaryngologist, with multiple biopsies, failed to identify the primary site.

Treatment

The radiation oncologist defined three areas of interest for planning but, lacking the equipment for IMRT, he used a classic, time-proven, staged approach with 3-D conformal treatment in each phase:

- The entire neck, masses, adjacent high-risk nodes, and more distant nodes were treated to a uniform dose of 5600 cGy in 28 equal "fractions" of 200cGy each.
- The field was reduced and an additional 2 fractions of 200cGy were given to the masses and high-risk regions.
- Finally, the field was reduced again, and treatment continued for an additional 5 fractions bringing the palpable masses to a total dose of 7000cGy

Coding Logic

Unlike the situation with case #16, the three phases here are delivered consecutively, each with its own plan.

#8 Document the highest dose delivered to any one volume. That volume is the volume of Phase III which also has dose contributions from phases I and II. Here it is appropriate to add the doses across all three phases.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/02/2020
	5	Date Ended	12/17/2019
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	007000
Phase 1	9	Volume	01 Neck Lymph Node Regions
	10	Rad to Nodes	88 Not Applicable
	11	Modality	02 External Beam, Photons
	12	Planning Technique	04 – Conformal
	13	Number of Fractions	28
	14	Dose per Fraction	00200
Phase 2	15	Total Phase 1 Dose	005600
	16	Volume	01 Neck Lymph Node Regions
	17	Rad to Nodes	88 Not Applicable
	18	Modality	02 External Beam, Photons
	19	Planning Technique	04 – Conformal
	20	Number of Fractions	2
Phase 3	21	Dose per Fraction	00200
	22	Total Phase 2 Dose	000400
	23	Volume	01 Neck Lymph Node Regions
	24	Rad to Nodes	88 Not Applicable
	25	Modality	02 External Beam, Photons
	26	Planning Technique	04 – Conformal
	27	Number of Fractions	5
	28	Dose per Fraction	00200
	29	Total Phase 3 Dose	001000

21 Breast: Simultaneous Integrated Boost (SIB)

Clinical (This case was submitted to CAnswer.)

A 74-year-old woman underwent lumpectomy followed by breast irradiation for a pT2 (2.3cm) pN1a cM0, ER 100%, PR 90%, Her-2 negative, left breast cancer.

Treatment

- Dates of treatment: 5/20/20 to 6/8/2020 (hypo-fractionated).
- Cardiac sparing IMRT with simultaneous integrated boost.
- Regional (breast plus axillary lymph nodes) treatment to a prescribed dose of 4005 cGy (267 cGy per day) in 15 fractions.
- Simultaneous treatment of lumpectomy bed with margins to a prescribed dose of 320 cGy per day for a total of 4800cGy

Coding Logic

- While treatment to both prescription areas occurred simultaneously, there were two prescriptions and therefore two phases. The only question is which should be considered Phase I, the prescription with the larger volume or the prescription with the higher total dose. It is a bit of a chicken-egg thing, but for consistency the standard in this setting is to assign Phase I to the target volume receiving the highest dose.
- SIB is not a new technique. It was in use long before we had IMRT but it was a lot more bother with fixed fields.
- #17: Axillary treatment is a physical extension of breast treatment and therefore assigned to Phase II.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	3 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	5/20/2020
	5	Date Ended	6/8/2020
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	004800
Phase 1	9	Volume	41 Breast, partial
	10	Rad to Nodes	00 No radiation to nodes
	11	Modality	02 External beam, photons
	12	Technique	05 IMRT
	13	Number of Fractions	015
	14	Dose per Fraction	00320
	15	Total Phase 1 Dose	004800
Phase 2	16	Volume	40 Breast - whole
	17	Rad to Nodes	04 Breast/chest wall nodes
	18	Modality	02 External beam, photons
	19	Technique	05 IMRT
	20	Number of Fractions	015
	21	Dose per Fraction	00267
	22	Total Phase 2 Dose	004005
Phase 3	23	Volume	00 No Radiation
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

22 Prostate and Seminal Vesicles with IMRT

Clinical (This case was submitted to CAnswer.)

"This radiation was given at another facility. All I have is the treatment summary. The Rad Onc physician states in his note that "He was treated as per the above radiation chart" [provided below]. How would this be entered in the abstract? What is the Total Dose to Volume? (12,600? - doesn't seem right). Case #6 in the guide isn't quite the same. Here is the treatment summary:

Treatment

Treatment Site	Energy	Technique	Dose	Fractions	Dates	Elapsed Days
Prostate + SV	6 MV	RapidArc	2 Gy x28=56 Gy	28	3/18/19- 4/25/19	38
Prostate	6 MV	RapidArc	2.5 Gy x28= 70 Gy	28	3/18/19- 4/25/19	38"

- "RapidArc" is a marketing name (Varian) for one implementation of IMRT.
- STORE does not collect "Elapsed Days" because it is easily calculated from the start and end dates.

Coding Logic

- This case is problematic because it includes logical inconsistencies. In order to code it, one must decide what the error is. In this case, the most likely error is that treatment sites should be "Prostate" and "SV" not "Prostate + SV" and "Prostate". We know this because the prescriptions would be typical for such an approach.
- This case shares some elements with cases 8, 13, and 18 and 20. From a coding point of view, it presents the same issues as phases II and III of case 6. There, the "boost" was managed with IMRT in a manner such that the prostate received a higher dose than the adjacent seminal vesicles, i.e., two prescriptions, therefore two phases.
- #8 Following the general rule, when phases are given simultaneously, record the dose to the prescribed volume receiving the highest dose (prostate). Doses are added across phases only when they are attributed to the same target volume, and treatment was with some form of external beam.⁸
- #16: Here, as in case #8 we are regarding the seminal vesicles as a separate phase even though they are treated concurrently with the prostate. From a planning point of view, they are receiving a different dose. In principle the result is no different from a situation in which the prostate is treated with one set of fields at 250 CGy per day then the seminal vesicles are treated separately with additional fields at 200 CGy per day.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	4 All RT elsewhere
	4	Date Started	3/18/20
	5	Date Ended	4/25/20
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	007000
Phase 1	9	Volume	64 Prostate - whole
	10	Rad to Nodes	00 No Treatment to Nodes
	11	Modality	02 External beam photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	028
	14	Dose per Fraction	00250
	15	Total Phase 1 Dose	007000
Phase 2	16	Volume	98 Other
	17	Rad to Nodes	00 No Treatment to Nodes
	18	Modality	02 External beam photons
	19	Planning Technique	05 IMRT
	20	Number of Fractions	028
	21	Dose per Fraction	00200
	22	Total Phase 2Dose	005600
Phase 3	23	Volume	00 No Radiation
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

⁸ if your calculated Total Dose from external beam sources is greater than 10000 cGy it is probably wrong. This unusual way to summarize treatment could easily be misinterpreted.

23 Cervical Cancer: HDR Brachytherapy with Variable Dose per Fraction

Clinical (This case was submitted to CAnswer.)

“The end of treatment summary for HDR brachytherapy for cervical cancer states 5 fractions and dose per fraction for the first 3 fractions is 800 cGy and fraction 4 and 5 were 550 cGy. Volume, modality and treatment planning are the same. Due to the change in dose, would this be considered 2 phases? If considered same phase, can the doses be added together? Or would it be coded 999998?”

The text in italics was submitted by the CTR, but for completeness we will add that the assuming that treatment was done at the reporting facility between 11/9/2020 and 11/18/2020. No information is given about surgery so we only code using the radiation information.

Treatment

- As above.

Coding Logic

Under the 2021 guidelines a change in daily dose fraction constitutes a change in phase

- #3: Treatment was administered by the same modality (HDR) in each case so the doses for each phase can be added.
- #9,16: If the patient has had a hysterectomy, code the Volume to vagina, since it is the primary target.
- #9,16: If the patient has not had a hysterectomy, code the Volume to 71 Cervix.
- #10, 16: Lymph nodes are rarely the target of intracavitary therapy.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/9/2020
	5	Date Ended	11/18/2020
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	003500
Phase 1	9	Volume	71 – Cervix or 72 - Vagina
	10	Rad to Nodes	00 No Treatment to Nodes
	11	Modality	09 Brachy, intracavitary, HDR
	12	Planning Technique	88 NA
	13	Number of Fractions	003
	14	Dose per Fraction	00800
	15	Total Phase 2 Dose	002400
Phase 2	16	Volume	71 – Cervix or 72 - Vagina
	17	Rad to Nodes	00 No Treatment to Nodes
	18	Modality	09 Brachy, intracavitary, HDR
	19	Planning Technique	88 NA
	20	Number of Fractions	002
	21	Dose per Fraction	00550
	22	Total Phase 2 Dose	001100
Phase 3	23	Volume	00 No Treatment
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

24 Pelvis, Prostate and Seminal Vesicles with VMAT

Clinical (This case was submitted to CAnswer.)

“Is the following coded correctly into 3 phases?”

Ph 1: 10/4/19-11/8/19 6MV-VMAT Pelvis PTV1 180x25=4500cGy.

Ph 3: 11/11/19-11/15/19 6MV-VMAT Pelvis PTV2 (Prostate + SV) 180x5=900cGy.

Ph 2: 11/18/19-12/4/19 6MV-VMAT Pelvis PTV3 (Prostate) 180x12=2160cGy.
TOTAL 7560cGy.

Rad Onc Note = I will be following NCCN and [XYZ] guidelines and delivering 7560cGy in 42 fractions to Prostate + SV w/ at least 4500cGy to high-risk Pelvic LN region w/ IMRT/IGRT.”

Treatment

The short answer to their question is, “not quite”, with the only problem being the numbering of the phases. The record shows treatment divided into three consecutive date intervals with a different target volume definition (prescription) in each case. Each time interval defines a phase because the volume also changes. Phases to a common volume are recorded in the chronological order they are given and no on the bases of phase dose.

Coding Logic

- #4: Record first date of Phase I
- #5: Record last date of treatment (Phase III)
- #8: The prostate is included in all three phases so the doses can be summed across all three phases.
- #9,10: When a region like the pelvis is treated, code the primary site. Pelvic lymph nodes are identified as a target in field #10.
- #12: VMAT is just a form of IMRT (an “advanced” form for marketing purposes)
- #23: In the final phase, just the prostate is covered.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	10/4/2019
	5	Date Ended	12/4/2019
	6	Number of Phases	03
	7	Discontinued Early	01 Completed
	8	Course Total Dose	007560
Phase 1	9	Volume	64 Prostate - whole
	10	Rad to Nodes	06 Pelvic lymph nodes
	11	Modality	02 External beam photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	028
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	004500
Phase 2	16	Volume	64 Prostate - whole
	17	Rad to Nodes	00 No Treatment to Nodes
	18	Modality	02 External beam photons
	19	Planning Technique	05 IMRT
	20	Number of Fractions	005
	21	Dose per Fraction	00180
	22	Total Phase 2 Dose	000900
Phase 3	23	Volume	64 Prostate - whole
	24	Rad to Nodes	00 No Treatment to Nodes
	25	Modality	02 External beam photons
	26	Technique	05 IMRT
	27	Number of Fractions	012
	28	Dose per Fraction	00180
	29	Total Phase 3 Dose	002160

25 Breast: Treatment Interrupted – Big Time

Clinical (This case was submitted to CAnswer.)

Lumpectomy was done and path came back as 1/5 lymph nodes positive. Oncotype results led to a decision to omit chemotherapy. Radiation was started and the patient had received 3 of 16 planned fractions (hypo-fractionation, often referred to as the “Canadian protocol”) when word was received that the specimen had been re-examined and path report was amended to 5/5 lymph nodes positive.

Radiation treatment was stopped and chemotherapy initiated with a plan to have the patient return to Radiation Oncology to be re-simulated and treated upon completion of chemo.

How would I code this XRT? Would I code it as completed since they will be re-simulating and re-planning when the patient returns? Or would I code it as not completed due to other reasons?

Coding Logic

This patient is not going to be back in two weeks to complete radiation, it will be more like four to six months, by which time any tumoricidal benefit from the first radiation will have been lost and any tissue injury will have been largely repaired. Many, if not most, radiation oncologists would make little or no adjustment and simply treat the patient as though they had not had any prior radiation. That said, the right answer here is to code what occurred starting from the first fraction of radiotherapy, even if there is a very long break in the middle of the course or phase, because there has been no progression event.

With this strategy, any researcher should, from the elapsed time alone, determine that this treatment was interrupted.

26 Prostate: VMAT to Pelvis with SBRT Boost

Clinical

67 y.o. male with high-risk prostatic adenocarcinoma (cT3a by MRI(suspicious for EPE), Gleason 4+3=7, 14/17 total cores, PSA 14.5).He has been referred for radiation therapy. How would you code the VMAT (05) & SBRT/SRS (06)?

Treatment

Volume	First Tx	Last Tx	Frac	Dose/Fx	Dose	Technique
Pelvis (incl. Prostate)	5/14/19	6/18/19	25	180	4500	VMAT
Prostate	6/19/19	6/25/19	3	650	1950	SBRT

Coding Logic

VMAT (an IMRT variant) is typically used when the target is complex. In this case we have a pelvic organ, prostate, and pelvic lymph nodes of concern, and there is a desire to reduce the risk of injury to small bowel and bladder (with fixed fields, options for such protection are limited). SBRT is another IMRT variant with steps taken to maximize precision of targeting. It is generally reserved for small target volumes (less than 5cm in diameter – prostate dimensions are usually less than 5cm) often with large doses per fraction.

- #8: Since the two phases were consecutive, had a common target and modality we can add the two-phase doses. This sum of phase doses may seem a bit low for fractionated prostate treatment but the 3 fractions of 650 cGy have a biologic effect (cell kill) that is substantially greater than the same total dose at 180cGy per fraction.
- #9, #10: Code to the organ of diagnosis and let the coding for nodes show that the pelvis was treated.
- #19: Although closely related to IMRT, SBRT has it own set of codes. We use code 06 as the most likely form since the record does not mention Gamma Knife or robotics.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or sur
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	5/14/19
	5	Date Ended	6/25/19
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	006450
Phase 1	9	Volume	64 Prostate -
	10	Rad to Nodes	06 Pelvic lymph nodes
	11	Modality	02 External beam photons
	12	Planning Technique	05 IMRT
	13	Number of Fractions	025
	14	Dose per Fraction	00180
	15	Total Phase 1 Dose	004500
Phase 2	16	Volume	64 Prostate -
	17	Rad to Nodes	00 No Treatment to Nodes
	18	Modality	02 External beam photons
	19	Planning Technique	06 Stereotactic Radiotherapy
	20	Number of Fractions	003
	21	Dose per Fraction	00650
	22	Total Phase 2Dose	001950
Phase 3	23	Volume	00 No Radiation
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

27 Lung: Brain and Bone Metastases

Clinical (This case was submitted to CAnswer.)
 57 year-old patient with a history of 80 pack year smoker, presents with stage IV lung cancer with multiple brain metastases and a painful Left Scapular met.

Treatment

- 6/16/21 to 6/25/21: Brain, (mets 1,6,10), VMAT, 10 MV photons, 5 fractions of 600cGy, 3000cGy total.
- 6/16/21: Brain (mets 2-5), VMAT, 10MV, 1 fraction of 2000cGy, 2000cGy total.
- 6/21/21: Brain (mets 7-9), VMAT, 10MV, 1 fraction of 2000cGy, 2000cGy total.
- 6/23/21: Left Scapula, 3D, 10MV, 1 fraction of 800cGy, 800cGy total.

Coding Logic

- Assignment of phases for this case is easily determined by referring to the first two bullets on page 8 of this document:
 - Phases should be summarized first in chronological order.
 - If multiple phases start on the same date, then list the phases in order from highest 'Total Phase Dose' to lowest 'Total Phase Dose'.
- Here the first two treatment bullets begin on the same date, but the first delivers a higher dose to its targets, so it is assigned to Phase I. A logical question is, since there are three targets described in the first bullet, shouldn't that use up all three phases? Twenty-five years or so ago the answer would have been yes because with the technology available each target would have its own plan and they would have to be treated sequentially. Today, with VMAT and other derivatives of IMRT technology, it is possible to treat all three sites at the same time with the same plan delivering high doses to the metastases with much lower doses to the spaces in between. Bottom line, just one phase for the first bullet. Should this be coded as SBRT? Only if "SBRT" appears in the plan or treatment summary.
- The second bullet uses the same technology but with a different plan, 1 fraction instead of 5, 2000cGy total instead of 3000. This is Phase II because the fraction size and total dose is lower and a different plan and time of treatment are required.
- The treatment described in the third bullet occurs 5 days later and requires a new plan, Phase III!
- #6: The treatment to the scapula is Phase IV. It will not be reported to NCDB. Documenting Phase IV and higher in your registry is optional and probably of little if any value for outcomes studies.
- #8: When the phases target different volumes, the total dose recorded is the highest dose delivered to any one phase (STORE 2021, page 290). Doses to different targets are never added.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	0 No radiation and/or surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	6/16/21
	5	Date Ended	6/25/21
	6	Number of Phases	04
	7	Discontinued Early	01 Completed
	8	Course Total Dose	003000
Phase 1	9	Volume	13 Brain - Limited
	10	Rad to Nodes	00 No radiation to nodes
	11	Modality	02 External beam, photons
	12	Technique	05 IMRT
	13	Number of Fractions	005
	14	Dose per Fraction	00600
	15	Total Phase 1 Dose	003000
Phase 2	16	Volume	13 Brain - Limited
	17	Rad to Nodes	00 No radiation to nodes
	18	Modality	02 External beam, photons
	19	Technique	05 IMRT
	20	Number of Fractions	001
	21	Dose per Fraction	02000
	22	Total Phase 2 Dose	002000
Phase 3	23	Volume	13 Brain - Limited
	24	Rad to Nodes	00 No radiation to nodes
	25	Modality	02 External beam, photons
	26	Technique	05 IMRT
	27	Number of Fractions	001
	28	Dose per Fraction	02000
	29	Total Phase 3 Dose	002000

28 Breast: Lumpectomy, External Beam, Accuboot™

Clinical (This case was submitted to CAnswer.)

A 74-year-old woman underwent lumpectomy followed by breast irradiation for a pT1c (1.8cm, close margins) pN0 cM0, ER 40%, PR 10%, Her-2 negative, left breast cancer.

Treatment

- 01/10/2022 to 01/31/2022: Tangential opposed fields to left breast, 16 fractions, 4256 Gy (commonly called “the Canadian protocol”).
- 02/01/2022 – 02/04/2021: 1000 cGy boost to surgical bed in 4 fractions using Accuboot™ technology.

Note:

The person contacting CAnswer proposed the following for Phase 2 and wisely asked if it was correct: Modality – (13) Radioisotopes, NOS, Technique – (98) Other, Dose per Fraction – 99998, Total Dose -999998

Coding Logic

- The proposed phase II coding was incorrect, but it is easy to understand why they reached this conclusion. It demonstrates some of the challenge of dealing with the language of radiation oncology, a language that has been evolving since Dr. Emil H Grubbe administered the first x-ray treatment (for breast cancer, post-surgical recurrence) to Mrs. Rose Lee in Chicago, January 31, 1896
 - Accuboot is a mechanical device that can position an iridium-192 radiation source in multiple orientations in close proximity around the exterior of the breast. Iridium-192 is a radioisotope that produces a stew of low energy x-rays (old-timers might still call them gamma rays) that, with some tungsten shielding, can form a “beam”. Marketing material describes this as “Non-invasive Breast Brachytherapy” used both for surgical bed boosts, as in this case, and for accelerated partial breast irradiation (APBI). From a STORE coding perspective, it is just another form of external beam x-ray treatment, in a class with its predecessors, radium, cobalt-60 and Cesium 137. All these have been used as both external beam sources and for interstitial or intracavitary brachytherapy.
- Marketing sources also refer to it as a form of brachytherapy. “Brachy” simply means “slow”. The founding fathers of radiation oncology used prefix primarily to distinguish between external beam therapy which could be completed in less than an hour (radium), half-hour (Cobalt-60 with a tired source), or 5 to 10 minutes. (linear accelerators), and implants with the same isotopes that might take 2-3 days. An Accuboot treatment takes 20-25 minutes. So, with the long tradition of “brachy” usage in mind, we would not recommend coding this as any form of brachytherapy.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	03 Radiation after surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	1/10/2022
	5	Date Ended	2/4/2022
	6	Number of Phases	02
	7	Discontinued Early	01 Completed
	8	Course Total Dose	005256
Phase 1	9	Volume	40 Breast - whole
	10	Rad to Nodes	00 No radiation to nodes
	11	Modality	02 External beam, photons
	12	Technique	04 -Conformal
	13	Number of Fractions	016
	14	Dose per Fraction	00266
	15	Total Phase 1 Dose	004256
Phase 2	16	Volume	41 Breast -partial
	17	Rad to Nodes	00 No radiation to nodes
	18	Modality	02 External beam, photons
	19	Technique	02 Low energy X-ray
	20	Number of Fractions	004
	21	Dose per Fraction	00250
	22	Total Phase 2 Dose	001000
Phase 3	23	Volume	00 No Radiation
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

29 Prostate: Multifocal Bone Metastases Treated with Xofigo™

Clinical

A 95-year old retired logger, presented to the ER one afternoon with widespread bone pain (“...but I’ve had worse pain on the job a lot of times”). Evaluation revealed a PSA of 820 with widespread bone metastases. Initial treatment with hormones failed to improve his situation so a decision was made to treat him with Xofigo, the brand name for Radium-223 Dichloride, an agent that selectively deposits in areas of injured bone.

Treatment

Six injections of Xofigo at roughly 10-day intervals, with the first on 11/2/2021 and the last on 12/17/2021.

Coding Logic

- (6: A single planned phase consisting of 6 injections, analogous to six consecutive external beam treatments.
- 9: There is no code for “whole body bone” but researchers will know what the target is by the diagnosis and choice of treatment.
- 12: There is no planning in the sense that “planning” applies to external beam treatments where a computer is used to combine the effects of any number of beams to predict a dose distribution within the patient.

Background:

Xofigo is a relatively new (2013) option for treating this relatively rare condition of “global” symptomatic metastases. Other isotopes have been used for this purpose for a long time, including phosphorus-32, strontium-89 and samarium 153. Each has its advantages and disadvantages. Strontium-89 replaced its predecessor, phosphorus-32 because it was less toxic to bone marrow. Whereas the other isotopes are treating with x-rays and beta particles, radium-223 has a theoretical advantage in that it delivers the goods using energetic, charged, bulky (in the atomic sense) alpha particles that have a very short range (2 -10 cell diameters) but do a lot of local damage in that short distance.

Another treatment option is a procedure called “sequential hemi-body irradiation” in which very large x-ray fields are used to treat one half of the body at a time with a break in between for bone marrow recovery. Treatment is usually in multiple fractions. Palliative benefits are roughly comparable to the isotopes. Survival benefits are modest (a few months, at best). Coding is somewhat similar, but the modality would be external beam, planning technique could be 2-D or 3-D and there would be a meaningful dose per fraction and total dose. Also, it would most likely be done in two phases, upper hemi-body and lower hemi-body.

Seg	#	Field	Code/Definition
Summary	1	Rad/Surg Sequence	00 No Radiation /Surgery
	2	Reason No Rad	0 Radiation was administered
	3	Location of Rad	1 All RT at this facility
	4	Date Started	11/2/2021
	5	Date Ended	12/17/2021
	6	Number of Phases	01
	7	Discontinued Early	01 Completed
	8	Course Total Dose	999998
Phase 1	9	Volume	98 Other
	10	Rad to Nodes	00 No RT to draining nodes
	11	Modality	14 Radioisotopes, Radium 223
	12	Technique	88 Not applicable
	13	Number of Fractions	006
	14	Dose per Fraction	99998
	15	Total Phase 1 Dose	999998
Phase 2	16	Volume	00 No Radiation Treatment
	17	Rad to Nodes	
	18	Modality	
	19	Technique	
	20	Number of Fractions	
	21	Dose per Fraction	
	22	Total Phase 2 Dose	
Phase 3	23	Volume	
	24	Rad to Nodes	
	25	Modality	
	26	Technique	
	27	Number of Fractions	
	28	Dose per Fraction	
	29	Total Phase 3 Dose	

STORE Radiation Data Field Items

Summary Fields

Code	Location of Radiation Treatment
0	No radiation treatment
1	All radiation treatment at this facility
2	Regional treatment at this facility, boost elsewhere
3	Boost radiation at this facility, regional elsewhere
4	All radiation treatment elsewhere
8	Other
9	Unknown

Code	Radiation/Surgery Sequence
0	No radiation therapy and/or surgical procedures
2	Radiation therapy before surgery
3	Radiation therapy after surgery
4	Radiation therapy both before and after surgery
5	Intraoperative radiation therapy
6	Intraoperative radiation therapy with other therapy administered before or after surgery
7	Surgery both before and after radiation
9	Sequence unknown

Code	Reason for No Radiation
0	Radiation therapy was administered.
1	Radiation therapy was not administered because it was not part of the planned first course treatment. Diagnosed at autopsy.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).
5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.
6	Radiation therapy was not administered; it was recommended by the patient's physician but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered. Death certificate cases only.

Code	Radiation Treatment Discontinued Early
00	No radiation treatment
01	Radiation treatment completed as prescribed
02	Radiation treatment discontinued early - toxicity
03	Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)
04	Radiation treatment discontinued early - patient decision
05	Radiation discontinued early - family decision
06	Radiation discontinued early - patient expired
07	Radiation discontinued early - reason not documented
99	Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered

Phase Fields

Phase N Volume	
Value	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/chestwall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
09	Lymph node primary, NOS
10	Eye/orbit/optic nerve
11	Pituitary
12	Brain
13	Brain (limited)
14	Spinal cord
20	Nasopharynx
21	Oral cavity
22	Oropharynx
23	Larynx (glottis) or hypopharynx
24	Sinuses/nasal tract
25	Parotid or other salivary glands
26	Thyroid
29	Head and neck (NOS)
30	Lung or bronchus
31	Mesothelium
32	Thymus
39	Chest/lung (NOS)
40	Breast - whole
41	Breast - partial
42	Chest wall
50	Esophagus
51	Stomach
52	Small bowel
53	Colon
54	Rectum
55	Anus
56	Liver
57	Biliary tree or gallbladder
58	Pancreas or hepatopancreatic ampulla
59	Abdomen (NOS)
60	Bladder - whole
61	Bladder - partial
62	Kidney
63	Ureter
64	Prostate - whole
65	Prostate - partial
66	Urethra
67	Penis
68	Testicle or scrotum
70	Ovaries or fallopian tubes
71	Uterus or cervix
72	Vagina
73	Vulva
80	Skull
81	Spine/vertebral bodies
82	Shoulder
83	Ribs
84	Hip
85	Pelvic bones
86	Pelvis (NOS, non-visceral)
88	Extremity bone, NOS
90	Skin
91	Soft tissue
92	Hemibody
93	Whole body
94	Mantle, mini-mantle (obsolete after 2017)
95	Lower extended field (obsolete after 2017)
96	Inverted Y (obsolete after 2017)
98	Other
99	Unknown

Phase N Radiation to Draining Lymph Nodes	
Value	Description
00	No radiation treatment to draining lymph nodes
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/chestwall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
08	Lymph node region, NOS
88	Not applicable; Radiation Primary Treatment Volume is lymph nodes
99	Unknown if any radiation to draining lymph nodes

Phase N Modality	
Code	Label
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-223
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
98	Treatment administered, modality unknown
99	Unknown if radiation treatment administered

Phase N Planning Technique	
Value	Description
00	No radiation treatment
01	External beam, NOS
02	Low energy x-ray/photon therapy
03	2-D therapy
04	Conformal or 3-D conformal therapy
05	Intensity modulated therapy
06	Stereotactic radiotherapy or radiosurgery, NOS
07	Stereotactic radiotherapy or radiosurgery, robotic
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife?
09	CT-guided online adaptive therapy
10	MR-guided online adaptive therapy
88	Not applicable
98	Other, NOS
99	Unknown

Coding Modality for the Heavy Equipment of Modern Radiation Therapy

Associating the Radiation Modality and Radiation Planning Techniques can be confusing when all you have is the name of the piece of “heavy equipment” used to deliver the treatment. We present the following table to help you find the correct codes. Many thanks to Wilson Apollo, MS, CTR, RTT, for sharing his heavy equipment research.

Product	Modality	Applicable Planning Technique(s)
Varian TrueBeam, Halcyon or Ethos	02	03,04,05, 06, 09
ViewRay MRIdian MR-Linac	02	10
Elekta Unity MR-Linac	02	10
Elekta VersaHD, Infinity, Synergy	02	03,04,05, 06, 09
GammaKnife	02	08
GammaPod	02	06
Cyberknife	02	07
Tomotherapy	02	05, 06, 09
VMAT, RapidArc, Hyperarc	02	05, 06
Zeiss, Xoft, Esteya	02	02
Accuboot	02	02
LIAC, NOVAC	04	03, 04
MammoSite, SAVI, Contura	09	88

Radiation Therapy Useful Abbreviations

Abbreviation	Term	Abbreviation	Term
AP	Anterior-Posterior	LAO	Left Anterior Oblique
BED	Biological Equivalent Dose	LET	Linear Energy Transfer
BID	Twice a day	LL	Left Lateral
BT	Brachytherapy	LPO	Left Posterior Oblique
CAX	Central Axis	M-IMRT	Multifield IMRT
cGy	Centigray, 1/100 th of a Gy	MP	Midplane
CIRT	Carbon Ion Radiation Therapy	MU	Monitor Unit
CTV	Clinical Tumor Volume	MV	Megavoltage
CW	Chest wall	OAR	Organs at Risk
DART	Dynamic Adaptive Radiation Therapy	OBI	On-Board Imaging
Dmax	Depth of Maximum Dose	ODI	Optical Distance Indicator
DMLC	Dynamic Multileaf Collimator	OTT	Overall Treatment Time
DRR	Digitally Reconstructed Radiograph	PA	Posterior-Anterior
DVH	Dose-Volume Histogram	PRRT	Peptide Receptor Radionuclide Therapy
Dx	Diagnosis	PSA	Patient Support Assembly (treatment couch)
EBRT	External Beam Radiation Therapy	PTV	Planning Tumor Volume
e-comp	Electronic compensator: describes 3D-conformal technique	R&V	Record and Verify
EFRT	Extended Field Radiation Therapy	RAO	Right Anterior Oblique
ENLs	Extranodal Lymphomas	RBE	Relative Biological Effect
EPID	Electronic Portal Imaging Device	RL	Right Lateral
FF	Filter-Flattened	RPO	Right Posterior Oblique
FFF	Flattening-Filter-Free	Rx	Prescription
FiF	Field-in-Field Technique (3D)	SAD	Source-to-Axis Distance
Fx	Fraction		
GTV	Gross Tumor Volume	SART	Stereotactic Ablative RT
Gy	Gray, unit of absorbed dose	SBPT	Stereotactic Body Proton Therapy
H-IMRT	Hybrid IMRT	SBRT	Stereotactic Body RT
HR-CTV	High-Risk Clinical Target Volume	SCT	Stem Cell Transplant
HT	Helical Tomotherapy	SCV (S'clav)	Supraclavicular
IC-BT	Intracavitary Brachytherapy	SDD	Source-to-Diaphragm Distance
IC/IS BT	Intracavitary/Interstitial Brachytherapy	SGRT	Surface Guided RT

IFD	Intra-field Distance	SIB	Simultaneous Integrated Boost
IFRT	Involved Field Radiation Therapy	SIRMIT	Single Isocenter Radiosurgery for Multiple Intracranial Targets
IGART	Image-guided Adaptive RT	SMART	Simultaneous Accelerated RT
IGRT	Image-guided RT	SSD	Source-to-Skin Distance
IMPT	Intensity Modulated Proton Therapy	STD	Source-to-Target Distance
INRT	Involved Nodal RT	T-IMRT	Tangential IMRT
IOERT	Intraoperative Electron RT	T-VMAT	Tangential Volumetric Modulated Arc Therapy
IORT	Intraoperative RT	TBI	Total Body Irradiation
IS-BT	Interstitial Brachytherapy	TID	Three times a day
ISRT	Involved Site RT	TSEB	Total Skin Electron Boost
ITV	Irradiated Tumor Volume		
KV	Kilovoltage		

Summary of Radiation Coding Rules

1. **First Course of Treatment:** The first course of treatment includes all treatments recorded in the treatment plan and administered to the patient before disease progression or recurrence.
2. **Fraction:** One radiation treatment to one target volume.
3. **Target Volume:** The anatomic content being treated, for example, primary lung tumor and adjacent regional nodes. Note that space occupied by the target volume may diminish (hopefully by shrinking) as treatment progresses, but that alone does not change the phase. However, if the anatomic content being treated changes (i.e. the field is modified to exclude some of the lymph node regions), a new phase begins.
4. **Treatment Volume:** The three-dimensional space around and including the target volume that is receiving therapeutic doses of radiation. A change in target volume (because of tumor shrinkage) does not by itself mean a new phase.
5. **Phase:** A phase of treatment is a set of treatments delivered with a unique combination of target volume, treatment fraction size, treatment modality, and treatment technique. Phases can be delivered sequentially or simultaneously. A new phase begins when there is a change in any of these four parameters.
6. **Phase Order Rules:**
 - a. First phase first. Phases should be summarized first in chronological order.
 - b. If multiple phases start on the same date, then list the phases in order from highest 'Total Phase Dose' to lowest 'Total Phase Dose',
 - c. If multiple phases start on the same date and have the same Total Phase Dose, then any order is acceptable.
 - d. If there are more than three phases you only need to document the first three (additional phases will not be reported to NCDB) but be sure to record the actual total number of phases.
7. **Unknown Modality:** If patient had treatment but Modality details are not available code Modality to 98.
8. **When a Patient Has No Treatment:**
 - a. **Non-SEER** facilities code Phase I Volume to 00. Leave other fields blank.
 - b. **SEER** Facilities code Modality to 00. Leave other fields blank.
 - c. Code the Reason for No Radiation field. It is not required by EDITS but it might be useful to future researchers.
9. **First Untreated Phase:**
 - a. **Non-SEER** facilities code Volume to 00. Leave other fields blank.
 - b. **SEER** Facilities code Modality to 00. Leave other fields blank.
10. **Adding Doses**
 - a. If multiple phases are directed at the same target volume using an external beam modality, you can add the doses.
 - b. If multiple phases are directed at the same target volume using brachytherapy you can add the doses.
 - c. If treatment uses a mix of external beam and brachytherapy you cannot add doses. Code Course Total Dose to 999998.
11. **Coding Volume when the Site of Cancer Organ has been Removed:**
 - a. In most cases code the volume to the organ removed. After prostatectomy, code the volume to prostate. If the whole pelvis is treated after prostatectomy, hysterectomy or cystectomy, code the volume to the organ of origin and lymph nodes to pelvic.

- b. Important clarification: Brachytherapy after hysterectomy is a grey area. We advise that if the vaginal apex is treated with brachytherapy after hysterectomy for cervical or uterine cancer, code the volume to 72 – Vagina because that is the target organ for treatment.

12. When Treatment is Interrupted

- a. Treatment may be interrupted as part of a plan, or because of unplanned circumstances.
- b. For treatment dates code the first date of the first treatment to the volume and the last date of treatment given after the interruption. This is consistent with the definition of course.

13. Avoid Isotope Confusion

- a. With the exception of electronic brachytherapy (Modality Code 12), most brachytherapy (codes 07-11) is delivered with radioactive isotopes. Generally, this is in the form of seeds or rods of radioactive metal, radium and cobalt historically, cesium and iridium today, that are inserted in to tissue (interstitial) or body cavities (intracavitary).
- b. Codes 13 to 16 are modalities specifically described as radioisotopes but not as brachytherapy. Most commonly these are available in liquid form and inserted into the blood stream or a body cavity.
- c. A common coding mistake is to use modality code 13 – Radioisotopes, NOS, when the record shows, for example, intracavitary treatment to the vagina, cervix, uterine canal, or some combination. Yes, radioisotopes were used but no, that is not the correct code. You should use a brachytherapy code, high dose rate (HDR) if the isotope is iridium, low dose rate if it is cesium or iodine.
- d. Eye plaque brachytherapy is a form of surface brachytherapy and should be coded Brachytherapy, NOS (Modality Code 07).